UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549

                                    FORM SB-2
             REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933
                                ----------------
                            ORTEC INTERNATIONAL, INC.
             (Exact name of registrant as specified in its charter)

         Delaware                                                               11-3068704
         (State or other jurisdiction of                                        (I.R.S. Employer
         incorporation or organization)                                         Identification No.)

                     3960 Broadway, New York, New York 10032
                                 (212) 740-6999
       (Address, including zip code, and telephone number, including area
               code, of registrant's principal executive offices)
                   Alan W. Schoenbart, Chief Financial Officer
                            Ortec International, Inc.
                                  3960 Broadway
                            New York, New York 10032
                                 (212) 740-6999

    (Name, address, including zip code, and telephone number, including area
                      code, of agent for service)

                                    Copy to:

                             Gabriel Kaszovitz, Esq.
           Feder, Kaszovitz, Isaacson, Weber, Skala, Bass & Rhine LLP
                              750 Lexington Avenue
                          New York, New York 10022-1200
                                 (212) 888-8200
                               Fax: (212) 888-7776

Approximate date of proposed sale to the public: As soon as practicable after
the effective date of this Registration Statement.

    If this Form is filed to register additional securities for an offering
pursuant to Rule 462(b) under the Securities Act, please check the following box
and list the Securities Act registration statement number of the earlier
effective registration statement for the same offering.

    If this Form is a post-effective amendment filed pursuant to Rule 462c under
the Securities Act, check the following box and list the Securities Act
registration statement number of the earlier effective registration statement
for the same offering.

    If this Form is a post-effective amendment filed pursuant to Rule 462(d)
under the Securities Act, check the following box and list the Securities Act
registration statement number of the earlier effective registration statement
for the same offering.

If delivery of the prospectus is expected to be made pursuant to Rule 434,
please check the following box.






THE REGISTRANT HEREBY AMENDS THIS REGISTRATION STATEMENT ON SUCH DATE OR DATES
AS MAY BE NECESSARY TO DELAY ITS EFFECTIVE DATE UNTIL THE REGISTRANT SHALL FILE
A FURTHER AMENDMENT WHICH SPECIFICALLY STATES THAT THIS REGISTRATION STATEMENT
SHALL THEREAFTER BECOME EFFECTIVE IN ACCORDANCE WITH SECTION 8 (A) OF THE
SECURITIES ACT OR UNTIL THE REGISTRATION STATEMENT SHALL BECOME EFFECTIVE ON
SUCH DATE AS THE COMMISSION, ACTING PURSUANT TO SAID SECTION 8(A), MAY
DETERMINE.

                         CALCULATION OF REGISTRATION FEE
====================================================================================================================

                                                        Proposed Maximum     Proposed Maximum        Amount of
  Title of Each Class of          Amount to be         Offering Price Per   Aggregate Offering    Registration Fee
Securities To Be Registered       Registered (2)           Share (1)             Price(1)               (3)
--------------------------------------------------------------------------------------------------------------------

     Common Stock, par             201,407,495

   Value $.001 per share             Shares                  $0.22              $44,309,649            $1,000
--------------------------------------------------------------------------------------------------------------------

(1)      Estimated solely for the purpose of computing the amount of the
         registration fee pursuant to Rule 457(c) promulgated under the
         Securities Act of 1933, based upon the average of the high and low sale
         prices of the common stock on June 16, 2006.

(2)      Includes (a) 47,442,080 shares of common stock, (b) 23,794,461 shares
         issuable upon conversion of currently outstanding Series D preferred
         stock, (c) 32,386,665 shares issuable upon conversion of currently
         outstanding Series E preferred stock, (d) 8,096,666 shares if shares
         issuable upon conversion of the Series E preferred stock are more than
         5,000 shares of common stock for one share of Series E preferred stock,
         (e) 176,197 shares issuable upon exercise of currently outstanding
         Series B-1 warrants, (f) 112,798 shares issuable upon exercise of
         currently outstanding Series B-2 warrants, (g) 102,000 shares issuable
         upon exercise of currently outstanding Series C warrants, (h)
         16,740,311 shares issuable upon exercise of currently outstanding
         Series E warrants, (i) 2,746,376 shares issuable upon exercise of
         currently outstanding Series E -PA warrants, (j) 17,443,892 shares
         issuable upon exercise of currently outstanding Series F warrants, (k)
         3,179,618 shares issuable upon exercise of currently outstanding Series
         F - PA warrants, (l) 32,536,665 shares issuable upon exercise of
         currently outstanding Series H warrants, (m) 8,096,666 shares of common
         stock that may be issuable pursuant to the aniti-dilution provision of
         the outstanding Series H warrants, and (n) 8,553,100 shares issuable
         upon other warrants currently outstanding. The additional 16,193,332
         shares referred to in clauses (d) and (m) of the preceding sentence
         constitute 25% of the shares of common stock otherwise required to be
         registered for conversion of the Series E preferred stock and exercise
         of the Series H warrants. Of the 201,407,495 shares of common stock
         being registered, 52,348,991 shares of common stock can be issued by
         the Company only when the Board of Directors of the Company, pursuant
         to authorization by the Company's stockholders, effects prior to
         September 30, 2006, a reverse split of the Company's common stock of
         not less than one share for each five shares outstanding.

(3)      Pursuant to Rule 429 promulgated under the Securities Act of 1933, the
         amount of registration fee does not include amounts previously paid
         relating to 53,350,439 shares of common stock previously registered
         pursuant to registration statement Nos. 333-118300 and 333-102409 of
         which 53,350,439 shares remain unsold as of the date hereof and
         continue to be registered.

Pursuant to Rule 429 under the Securities Act of 1933, as amended, the
prospectus filed as part of this registration statement also constitutes a
prospectus for registration statement Nos. 333-118300 and 333-102409; the
53,350,439 shares of common stock that remain unsold under such registration
statements are being combined with the shares of common stock to be registered
pursuant to this registration statement to enable the Selling Stockholders
listed in the combined prospectus included herein to offer an aggregate of
201,407,495 shares of common stock pursuant to the combined prospectus.


PROSPECTUS

                       201,407,495 Shares of Common Stock

                            ORTEC INTERNATIONAL, INC.

This prospectus relates to 201,407,495 shares of our common stock that may be
sold from time to time by the Selling Stockholders listed under the caption
"Selling Stockholders". We will not receive any of the proceeds from the sale of
the common stock sold. The Selling Stockholders may sell those shares from time
to time in the public securities market. The Selling Stockholders may determine
the prices at which they will sell the common stock, which prices may be at
market prices prevailing at the time of such sale or some other price. See "Plan
of Distribution".


                                 ---------------


We will amend this prospectus (by filing a post-effective amendment to the
registration statement of which this prospectus is a part) to inform you of any
fundamental changes to the information in this prospectus. Our common stock is
traded on the Over the Counter Bulletin Board under the symbol "ORTN". On June
16, 2006, the last reported sale price of our common stock was $0.22 per share.

                                 ---------------

INVESTING IN OUR COMMON STOCK INVOLVES RISKS. SEE "RISK FACTORS" BEGINNING ON PAGE 6.

Neither the Securities and Exchange Commission nor any state securities
commission has approved or determined if this prospectus is truthful and
complete. Any representation to the contrary is a criminal offense.

                                 ---------------

The date of this Prospectus is ____________, 2006





























                                TABLE OF CONTENTS


CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS.................................................................4
PROSPECTUS SUMMARY...................................................................................................4
RISK FACTORS........................................................................................................5

    We do not have  sufficient  funds to bring our  product to market  for use by large  patient  populations.  Unless we secure
    additional financing we will not be able to continue to operate our business.  ..................................5

    Because of our history of ongoing  losses and because we may never  generate a profit and our lack of cash or other  current
    assets,  we have received an opinion from our independent  registered  public  accountants  that there is substantial  doubt
    about our ability to continue as a going concern.................................................................5

    We have  accumulated  obligations  that we are required,  but are unable to pay currently.  This also raises doubt as to our
    ability to continue as a going concern...........................................................................6

    Unless we secure FDA  clearance  for the sale of ORCEL to treat venous stasis ulcers it will be difficult for us to continue
    to operate our business..........................................................................................6

    Unless we later secure FDA  clearance  for the sale of ORCEL in its  cryopreserved  form to treat  diabetic  foot ulcers our
    sales of ORCEL will be more limited and thereby limit our ability to earn profits................................6

    Clinical trials for ORCEL are expensive, time consuming and their outcome is uncertain...........................7

    Even if our ORCEL receives regulatory clearance,  ORCEL will still be subject to extensive post-market regulation which will
    result in significant expense to us..............................................................................7

    Our failure to sell ORCEL on a profitable basis will limit our ability to continue our operations................8

    We may lose our U.S. patents, patent applications and trademarks because of security interests we have granted in them 8

    We are subject to extensive governmental  regulation which increases the costs of manufacturing our product and will thereby
    negatively impact our ability to earn profits ...................................................................8

    The medical  community  may not accept  ORCEL which will prevent us from selling  ORCEL and prevent us from  continuing  our
    business.........................................................................................................8

    Our potential  competitors have greater financial,  sales and marketing  resources than we do so that we may have difficulty
    in competing against them........................................................................................9

    We rely on a limited  number of key suppliers to  manufacture  ORCEL and therefore run the risk or delay in securing  needed
    materials from other suppliers.  We also rely on only one distributor to sell ORCEL in the United States,  Canada and Mexico
    and run the risk that such distributor may not successfully market ORCEL.........................................9

    We  depend  on our  patents  and  proprietary  technology  which  may not  provide  us with  sufficient  protection  against
    technologies  used, or which may be used by our competitors.  We cannot protect our intellectual  property rights throughout
    the world.......................................................................................................9

    We may be subject to product  liability  claims  which we might not be able to pay  thereby  causing us to  discontinue  our
    business........................................................................................................10

     If we lose our key employees we may not be able to continue our business operations............................10

    The market prices of our common stock may be highly volatile  creating  greater  financial risk for the owners of our common
    stock...........................................................................................................10

    Our largest stockholders may take actions that are contrary to your
interests, including selling their stock ...10

    We may have to sell additional equity securities in the future which will dilute the portion of Ortec's equity owned by our
    current stockholders............................................................................................11




                          TABLE OF CONTENTS (continued)

    RISK FACTORS......................................................................................................

    The price  protection  provisions of most of our  outstanding  warrants  might prevent  increases in the market price of our
    common stock ...................................................................................................11

    Because we do not intend to pay any  dividends  on our common  stock,  an investor in our common  stock may only  realize an
    economic gain from an increase, if any, in the market price of our common stock.................................12

    Termination of employment  agreements we have entered into with our executive and other officers could negatively affect the
    market price of our common stock because they discourage  open market  purchases of our common stock by purchasers who might
    seek to secure control of Ortec ................................................................................12

    Our operations might be interrupted by the occurrence of a natural disaster or other catastrophic event ........12

    New laws and  regulations  affecting  corporate  governance  may impede our ability to retain and attract  board members and
    executive officers, and increase the costs associated with being a public company...............................13

USE OF PROCEEDS.....................................................................................................13
MARKET FOR COMMON EQUITY AND RELATED STOCKHOLDER MATTERS............................................................14
DESCRIPTION OF BUSINESS.............................................................................................15
    Overview .......................................................................................................15
    Acquisition of Hapto Biotech ...................................................................................16
    ORCEL ..........................................................................................................17
      Government Regulation ........................................................................................17
    The FDA Clearance Process ......................................................................................17
    Regulatory Strategies ..........................................................................................19
    Sales and Marketing ............................................................................................19
    Production and Supply ..........................................................................................20
    Competition ....................................................................................................21
    Patents and Proprietary Rights .................................................................................22
    Paul Royalty Fund Agreement ....................................................................................23
    Research and Development Expenses ..............................................................................24
    Compliance with Environmental Regulations ......................................................................25
    Employees ......................................................................................................25
    Description of Property ........................................................................................25
PLAN OF OPERATION...................................................................................................26
DIRECTORS AND EXECUTIVE OFFICERS....................................................................................30
EXECUTIVE COMPENSATION..............................................................................................32
SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT......................................................35
CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS......................................................................37
SELLING STOCKHOLDERS................................................................................................38
PLAN OF DISTRIBUTION................................................................................................46
DESCRIPTION OF SECURITIES...........................................................................................47
TRANSFER AGENT......................................................................................................53
EXPERTS.............................................................................................................53
LEGAL MATTERS.......................................................................................................54
AVAILABLE INFORMATION ..............................................................................................54
DISCLOSURE OF COMMISSION POSITION OF INDEMNIFICATION FOR SECURITIES ACT LIABILITIES.................................54
INDEX TO CONSOLIDATED FINANCIAL STATEMENTS........................................................................ F-1


You should rely only on the information contained or incorporated in this
prospectus. We and the Selling Stockholders have not authorized anyone to
provide you with information different from that contained or incorporated in
this prospectus. The Selling Stockholders are offering to sell, and seeking
offers to buy, shares of common stock only in jurisdictions where offers and
sales are permitted. The information contained or incorporated in this
prospectus is accurate only as of the date of this prospectus, regardless of the
time of delivery of this prospectus or any sale of our common stock. In this
prospectus and in documents incorporated in this prospectus, references to the
"Company," "Ortec," "we," "us" and "our" refer to Ortec International, Inc. and
its wholly owned subsidiaries.





              CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

This prospectus includes "forward-looking statements" within the meaning of
Section 27A of the Securities Act of 1933 and Section 21E of the Securities
Exchange Act of 1934. For example, statements included or incorporated in this
prospectus regarding the potential market revenues from the sale of our OrCel
product, the number of patients with medical conditions who can be treated with
OrCel, the clinical trials for OrCel, future approvals or clearances by the
United States Food and Drug Administration (the "FDA") and other plans and
objectives for the future and assumptions and predictions about future supply,
manufacturing, costs and sales and future financing we may secure are all
forward looking statements. When we use words like "intend," "anticipate,"
"believe," "assume," "estimate," "plan" or "expect," we are making forward
looking statements. We believe that the assumptions and expectations reflected
in such forward looking statements are reasonable, based on information
available to us on the date of this prospectus, but we cannot assure you that
these assumptions and expectations will prove to have been correct or that we
will take any action that we may presently be planning. We have disclosed
certain important factors that could cause our actual results to differ
materially from our current expectations under "Risk Factors" elsewhere in this
prospectus. You should understand that forward-looking statements made in
connection with this offering are necessarily qualified by these factors. We are
not undertaking to publicly update or revise any forward-looking statement if we
obtain new information or upon the occurrence of future events or otherwise.


                               PROSPECTUS SUMMARY


The Company

We are a biotechnology company which was organized in 1991 under the laws of the
State of Delaware. We are currently in the development stage, and accordingly,
have no revenues. Our offices are located at 3960 Broadway, New York, New York
10032. Our telephone number is 212-740-6999. Our website address is
www.ortecinternational.com. Our OTC Bulletin Board Symbol is ORTN.

Our company is focused on advancing regenerative medicine and stem cell therapy
through the development and commercialization of innovative products by
combining advanced cell technology and advanced biomaterials. Our lead product
is OrCel (R) (Bilayered Cellular Matrix) (ORCEL). Our current focus is the
application of ORCEL to heal chronic and acute wounds. ORCEL is composed of a
collagen sponge seeded with allogeneic epidermal and dermal cells. These cells
secrete growth factors and cytokines normally found in acute human wounds and
are believed to have a beneficial role in promoting tissue repair.

We have completed a pivotal clinical trial evaluating a cryopreserved version of
ORCEL in the treatment of venous stasis ulcers and we have filed a Pre Market
Approval (PMA) application for commercial sales of ORCEL to treat venous stasis
ulcers. We recently completed patient enrollment in a confirmatory trial
required by the FDA and the data from this confirmatory trial is expected to be
integrated with the results of the completed pivotal clinical trial and
submitted as a clinical supplement to our PMA filing. We already obtained FDA
clearance for use of a non-frozen version of ORCEL in the treatment of
Epidermolysis Bullosa and donor sites in burn patients. In addition, the FDA has
granted us approval to initiate a pivotal (Phase III) trial evaluating ORCEL for
the treatment of diabetic foot ulcers.

We recently acquired two fibrin derived advanced biomaterial technologies,
Fibrin Microbeads (FMB's) and Haptides(TM). FMB's have the potential to play a
significant role in advancing stem cell therapy having demonstrated the ability
to efficiently recover adult stem cells and allow for their growth,
proliferation, and potential reimplantation into the patient. Haptides(TM)
utilize proprietary synthetic peptides that mimic the mechanism of cell
attachment to fibrin. These peptides have demonstrated the ability to
significantly enhance cell attraction and attachment providing the potential to
use Haptides(TM) in the development of products for cosmetic tissue
augmentation, wound healing, orthopedics, and drug delivery markets.

We incurred a net loss applicable to common shareholders of $4.8 million during
the three months ended March 31, 2006, and, as of that date, our current
liabilities exceeded our current assets by $36.2 million, our total liabilities
exceeded our total assets by $35.4 million and we have a deficit accumulated in
the development stage of $161.2 million. These factors, among others, raise
substantial doubt about our ability to continue as a going concern.

Prior to the offering we have 87,072,596 common shares outstanding. We also have
5,948.615 shares of Series D preferred stock equivalent to 23,794,461 common
shares when converted, and 6477.333 shares of Series E preferred stock
equivalent to at least 32,386,665 common shares when converted.






                                  RISK FACTORS

You should carefully consider the risks described below before making an
investment decision. The risks and uncertainties described below are not the
only ones facing us. Additional risks and uncertainties not presently known to
us or that we currently deem immaterial also may impair our business operations.
If any of the following risks actually occur, our business could be harmed. In
such case, the trading price of our common stock could decline, and you may lose
all or part of your investment.

We do not have sufficient  funds to bring our product to market for use by large
patient  populations.  Unless we secure additional financing we will not be able
to continue to operate our business.

We will need to secure additional financing for the approximately $875,000 of
cash we are currently consuming per month. Such 875,000 includes the cash we are
currently using in the operations of Hapto Biotech, Inc. which we acquired in
April 2006. The amount of cash we consume each month fluctuates, depending,
among other things, on whether we are incurring expenses from services provided
by third party suppliers in connection with a clinical trial and what payments
we have to make on our outstanding debt. On April 17, 2006, we completed a
private placement of our equity securities for aggregate proceeds of $6,176,000.
We believe that the proceeds from such private placement will enable us to
continue our operations until approximately August 31, 2006.

After our recent private placement we will still have to obtain additional funds
through the sale of our securities to the public and through private placements,
debt financing or other, including short-term, loans. We may not be able to
secure any additional financing nor may we be able to reach the larger patient
population markets of persons with venous stasis ulcers and diabetic foot
ulcers, with funds that we may be able to raise. We are also likely to continue
to encounter difficulties which are common to development stage companies,
including unanticipated costs relating to development, delays in the testing of
products, regulatory approval and compliance and competition.

Our capital funding requirements depend on numerous factors, including:

o        the progress and magnitude of our research and development programs;
o        the time involved in obtaining regulatory approvals for the
         commercial sale of our ORCEL product in its cryopreserved form
         to treat venous stasis ulcers and, later, diabetic foot
         ulcers;
o        the costs involved in filing and maintaining patent claims;
o        technological advances;
o        competitive and market conditions;
o        the successful  implementation  of the agreements we have entered into
         with Cambrex for  manufacturing  and sales of our ORCEL
         product;
o        our ability to establish and maintain other collaborative arrangements and
o        the cost and effectiveness of commercialization activities and arrangements.

Unless we obtain such additional financing we will not be able to continue to
operate our business after August 2006. We have no current commitments from any
persons that they will provide us with additional financing.

Because of our history of ongoing losses and because we may never generate a
profit and our lack of cash or other current assets, we have received an opinion
from our independent registered public accountants that there is substantial
doubt about our ability to continue as a going concern.

Since our organization in 1991 we have sustained losses each year because, among
other reasons, we have had very limited sales of our product. For the quarter
ended March 31, 2006, we incurred a net loss applicable to common stockholders
of $4,793,894. During the quarter ended March 31, 2006, our current liabilities
exceeded our current assets by $36,171,156, and our total liabilities exceeded
our total assets by $35,351,739, and we have a deficit accumulated in our
development stage of $161,205,615. Included in our current and total liabilities
is the $31,544,000 revenue interest obligation to Paul Royalty Fund. Our
independent registered public accountants advised us that these factors, among
others, raise substantial doubt about our ability to continue as a going
concern. Unless we obtain additional financing we will not be able to continue
as a going concern.




We have accumulated obligations that we are required, but are unable, to pay
currently. This also raises doubt as to our ability to continue as a going
concern.

As of May 31, 2006, payment of approximately $1,394,000 of the approximately
$1,750,000 we owed to our trade creditors was past due. Of this past due amount
$500,725 will be paid in common stock in accordance with agreements entered into
with Cambrex Bio Science of Walkersville, Inc. ("Cambrex").

While we have arranged for payment of some of our obligations over a period of
time, and have to make other payments of past due obligations to our current and
ongoing suppliers, our ability to make payments we have agreed to pay and to
insure continued receipt of needed supplies, and to continue reducing our past
due obligations, will depend on our ability to secure needed financing or our
ability to issue equity in satisfaction of certain obligations.

Unless we secure FDA clearance for the sale of ORCEL to treat venous stasis
ulcers it will be difficult for us to continue to operate our business.

We completed the treatment and follow-up of 136 patients in our pivotal clinical
trial of the use of ORCEL in its cryopreserved form for the treatment of venous
stasis ulcers, and in February 2004 we filed our PMA with the FDA to market
ORCEL for the treatment of venous stasis ulcers. From February 2004 through
March 2005 we responded to various questions from the FDA relating to our
pre-market approval application. On April 25, 2005, the FDA advised us that
although our cryopreserved ORCEL product showed promise for the effective
treatment of venous stasis ulcers, additional clinical data would be required to
demonstrate reasonable assurance of ORCEL's safety and effectiveness before the
FDA would clear ORCEL for commercial sales for such treatment. The clinical data
from the pivotal trial of 136 patients submitted to the FDA showed that in 60
patients who had typical venous ulcers (defined as those ulcers with partial or
full-thickness ulcers in which the wound base is visible and the ulcer extends
through the dermis but not into the subcutaneous tissue to fascia, muscle or
bone), 59% of the ORCEL treated patients achieved wound closure versus 36% of
the patients who received the standard of care treatment. The FDA agreed that
data of these 60 patients would be combined with that of the 60 patients to be
enrolled in a confirmatory clinical trial and the combined results will be
analyzed using Bayesian statistics. We obtained FDA approval for our
confirmatory trial protocol in mid July 2005 and began the confirmatory trial in
mid August 2005. We completed enrollment for this confirmatory clinical trial in
April 2006. When the clinical trial is completed we will work towards obtaining
regulatory clearance for commercial sales of cryopreserved ORCEL to treat venous
stasis ulcers. We may not obtain FDA clearance for the commercial sale of the
cryopreserved form of ORCEL for the treatment of venous stasis ulcers and later
for diabetic foot ulcers. Among the factors which may contribute to those
findings are a negative assessment of our manufacturing processes, raw materials
used in manufacturing our product, our freezing technique, and ORCEL's clinical
results. If we do not obtain FDA clearance for the sale of ORCEL in its
cryopreserved form for the treatment of venous stasis ulcers, it may be
difficult for us to raise capital to continue our business operations.

Unless we later secure FDA clearance for the sale of ORCEL in its cryopreserved
form to treat diabetic foot ulcers our sales of ORCEL will be more limited and
thereby limit our ability to earn profits.

Although we have completed an FDA cleared pilot clinical trial for the use of
the fresh form of ORCEL for the treatment of diabetic foot ulcers, we do not
have the funds available to conduct a pivotal clinical trial for the use of
ORCEL in its cryopreserved form for the treatment of diabetic foot ulcers. The
cryopreserved form of ORCEL has a shelf life of approximately seven months as
opposed to only approximately three days for the fresh form of ORCEL. We expect
to initiate patient enrollment after, and if, we receive clearance for the sale
of cryopreserved ORCEL in the treatment of venous stasis ulcers. We do not
expect to begin the FDA clearance process for a pivotal trial for cryopreserved
ORCEL for the treatment of diabetic foot ulcers until we believe that we can
secure financing for the conduct of that trial. If we are unable to later obtain
FDA clearance for the sale of cryopreserved ORCEL for the treatment of diabetic
foot ulcers, our sales of ORCEL will be more limited and thereby limit our
ability to earn profits.






Clinical trials for ORCEL are expensive, time consuming and their outcome is
uncertain.

Clinical trials are very expensive and difficult to design and implement. The
clinical trial process is also time consuming. Before we can obtain regulatory
clearance for the commercial sale of any product that we wish to develop, we are
required to complete extensive human clinical trials to demonstrate its safety
and efficacy. The timing of the commencement, continuation and completion of
clinical trials may be subject to significant delays relating to various causes,
including:

o delays or inability to manufacture or obtain sufficient quantities of
materials for use in clinical trials; o delays in obtaining regulatory approvals
to commence a study; o delays in identifying and reaching agreement on
acceptable terms with prospective clinical trial sites; o slower than expected
rates of patient recruitment and enrollment; o uncertain dosing issues; o
inability or unwillingness of medical investigators to follow our clinical
protocols; o variability in the number and types of subjects available for each
study and resulting difficulties in identifying and
             enrolling subjects who meet trial eligibility criteria; o
scheduling conflicts with participating clinicians and clinical institutions; o
difficulty in maintaining contact with subjects after treatment, resulting in
incomplete data; o unforeseen safety issues or side effects; o lack of
effectiveness during the clinical trials; or o other regulatory delays.

Even if our ORCEL receives regulatory clearance, ORCEL will still be subject to
extensive post-market regulation which will result in significant expense to us.

If we receive regulatory clearance for ORCEL, we will also be subject to ongoing
FDA obligations and continued regulatory review, such as continued safety
reporting requirements, and we may also be subject to additional FDA
post-marketing obligations, all of which may result in significant expense and
limit our ability to commercialize our product.

If we receive United States regulatory clearance, the FDA may still impose
significant restrictions on the indicated uses for which the product may be
marketed or impose ongoing requirements for potentially costly post-approval
studies. In addition, regulatory agencies subject a product, its manufacturer
and the manufacturer's facilities to continual review and periodic inspections.
The subsequent discovery of previously unknown problems with a product,
including adverse medical effects, or problems with the facility where the
product is manufactured, may result in restrictions on the marketing of that
product, and could include withdrawal of the product from the market. Failure to
comply with applicable regulatory requirements may result in: o issuance of
warning letters by the FDA; o fines and other civil penalties; o criminal
prosecutions; o injunctions, suspensions or revocations of marketing licenses; o
suspension of any ongoing clinical trials; o suspension of manufacturing; o
delays in commercialization; o refusal by the FDA to approve pending
applications or supplements to approved applications filed by us or our
collaborators; o refusals to permit products to be imported or exported to or
from the United States; o restrictions on operations, including costly new
manufacturing requirements; and o product recalls or seizures. The FDA's
policies may change and additional government regulations may be enacted that
could prevent or delay regulatory clearance of our ORCEL or further restrict or
regulate post-clearance activities. We cannot predict the likelihood, nature or
extent of adverse government regulation that may arise from future legislation
or administrative action, either in the United States or abroad. If we are not
able to maintain regulatory compliance, we might not be permitted to market
ORCEL and our business could suffer. In order to market any products outside of
the United States, we and our collaborators must establish and comply with
numerous and varying regulatory requirements of other countries regarding safety
and efficacy. Approval procedures vary among countries and can involve
additional product testing and additional administrative review periods. The
time required to obtain clearance in other countries might differ from that
required to obtain FDA clearance. The regulatory clearance process in other
countries may include all of the risks associated with FDA clearance as well as
additional presently unanticipated risks. Regulatory clearance in one country
does not ensure regulatory clearance in another, but a failure or delay in
obtaining regulatory clearance in one country may negatively impact the
regulatory process in others. Failure to obtain regulatory clearance in other
countries or any delay or setback in obtaining such clearance could have the
same adverse effects associated with regulatory clearance in the United States,
including the risk that our product may not be cleared for all indications
requested and that such clearance may be subject to limitations on the indicated
uses for which ORCEL may be marketed.

Our failure to sell ORCEL on a profitable basis will limit our ability to
continue our operations.

To date ORCEL is the only product that we have developed and for which we have
conducted human clinical trials. In the event we fail to develop additional
products, or if the FDA does not grant us clearance to use ORCEL for the
treatment of venous stasis ulcers and later diabetic foot ulcers, or if ORCEL is
not favorably received by the medical community or it becomes obsolete, we will
be unable to become profitable and we may be required to discontinue our
operations.

We may lose our U.S. patents, patent applications and trademarks because of
security interests we have granted in them.

See the description of our agreement with Paul Royalty Fund (PRF) in
"Description of Business-Paul Royalty Fund Agreement" If in the future PRF
exercised its right to compel us to repurchase its interest in our revenues and
we did not have the funds to do so, PRF could foreclose its security interest in
our U.S. patents, patent applications and trademarks and in such event we will
have to discontinue our business operations.

We are subject to extensive governmental regulation which increases the costs of
manufacturing our product and will thereby negatively impact our ability to earn
profits.

Our business is subject to extensive regulation principally by the FDA in the
United States and corresponding foreign regulatory agencies in each country in
which we intend to sell ORCEL. These regulations affect:

o        Product marketing clearances or approvals;
o        Product standards;
o        Packaging requirements;
o        Design requirements;
o            Manufacturing and quality assurance, including compliance by the
             manufacturing facility with good manufacturing process
             requirements, record keeping, reporting and product testing
             standards;
o        Labeling;
o Periodic FDA inspections of the facility in which ORCEL will be manufactured;
o Import and export restrictions; and o Tariffs and other tax requirements.

Our need to comply with these regulatory requirements will increase the cost of
manufacturing our ORCEL product and negatively impact our ability to earn
profits.

The medical community may not accept ORCEL which will prevent us from selling
ORCEL and prevent us from continuing our business.

Market acceptance for ORCEL will depend upon a number of factors, including:

o            The receipt and timing of FDA regulatory approvals for use of
             ORCEL, in its cryopreserved form, for the treatment of venous
             stasis ulcers and later for diabetic foot ulcers;

o            Acceptance by the medical community of ORCEL for the treatment of
             the medical conditions that it is intended to treat, the
             demonstration of its safety and its cost effectiveness; and

o            Securing approval of third parties, such as Medicare and insurance companies,
             for reimbursement for the cost of ORCEL.

Unless we secure market acceptance for ORCEL we will be unable to sell ORCEL and
as a result we will be unable to conduct any business.

Our potential competitors have greater financial, sales and marketing resources
than we do so that we may have difficulty in competing against them.

See the description of "Description of Business - Competition". As there noted,
sales of Apligraf are now being made directly by Organogenesis. Organogenesis is
substantially larger than we are and has significantly greater resources than we
have. The biomedical field is continually undergoing rapid and significant
technological changes. Other companies may succeed in developing other products
that are more effective than ORCEL. If such new products are accepted by the
medical community, or if those products receive FDA clearance for treatment of
venous stasis and diabetic foot ulcers before ORCEL does, or if other companies
develop products that are more effective than ORCEL, any such developments could
impede our ability to continue our operations.

We rely on a limited number of key suppliers to manufacture ORCEL and therefore
run the risk of delay in securing needed materials from other suppliers. We also
rely on only one distributor to sell ORCEL in the United States, Canada and
Mexico and run the risk that such distributor may not successfully market ORCEL.

See the discussion of "Description of Business-Sales and Marketing" and
"Description of Business-Production and Supply" where we describe our production
and sales distribution agreements with Cambrex and our agreements with other
suppliers. If Cambrex does not produce ORCEL at a per unit price well below the
price at which we can sell ORCEL in North America we may not be able to
continue, or at least would be seriously hampered in continuing, our business
operations. Also, any disruption in the supply of corium or collagen matrix or
other materials from our current suppliers of such materials would have a
significant negative impact on our ability to manufacture and sell ORCEL or at
least would cause us delays and additional expenses in the manufacturing of
ORCEL.

We depend on our patents and proprietary technology which may not provide us
with sufficient protection against technologies used, or which may be used by
our competitors. We cannot protect our intellectual property rights throughout
the world.

The validity and breadth of claims in medical technology patents involves
complex legal and factual questions and, therefore, are highly uncertain.
Although we successfully defended challenges to our United States and European
patents in the respective patent offices where those patents were issued, those
successful defenses do not preclude future challenges in court. We do not know
if any of the patents issued to us will be challenged, invalidated or
circumvented. Patents and patent applications in the United States may be
subject to an interference proceeding brought by the U.S. Patent and Trademark
Office, or to opposition proceedings initiated in a foreign patent office by
third parties. We might incur significant costs defending such proceedings and
we might not be successful. We do not know if any of our patents or any of our
pending patent applications or any future patent application of ours that will
issue as patents, will provide us with the scope of patent protection that will
be enough to exclude competitors. We also do not know that any of our patents
will be held valid if subsequently challenged or that others will not claim
rights in or ownership of the patents and other proprietary rights held by us.
We do not know if others have or will develop similar products, duplicate any of
our products or design around any of our patents issued or that may be issued in
the future. In addition, whether or not patents are issued to us, others may
hold or receive patents which contain claims having a scope that covers aspects
of our products or processes.

Filing patents on our ORCEL technology throughout the world would be
prohibitively expensive. Competitors may use our technology in jurisdictions
where we have not obtained patent protection to develop their own products.
These products may compete with ORCEL and may not be covered by any of our
patent claims or other intellectual property rights.

Patent law outside the United States is also uncertain and many countries are
currently reviewing and revising patent laws, particularly with respect to
biotechnology and pharmaceutical inventions. The laws of some countries do not
protect our intellectual property rights to the same extent as U.S. laws. It may
be necessary or useful for us to participate in proceedings to determine the
validity of our, or our competitors', foreign patents, which could result in
substantial cost and divert our efforts and attention from other aspects of our
business.





We may be subject to product liability claims which we might not be able to pay
thereby causing us to discontinue our business.

ORCEL is designed to be used in the treatment of medical conditions and diseases
where there is a high risk of serious medical complications, amputation of the
leg or death. Although we have obtained product liability insurance coverage in
the amount of $3,000,000, such insurance coverage may not be adequate to protect
us against future product liability claims. In addition, the cost of obtaining
product liability insurance in the future may prevent us from securing such
insurance on terms acceptable to us, if at all. Furthermore there can be no
assurance that we will avoid significant product liability claims and the
attendant adverse publicity. Large product liability claims or other claims with
respect to uninsured or underinsured liabilities could make it impossible for us
to continue our business operations.

If we lose our key employees we may not be able to continue our business
operations.

Messrs. Lipstein and Papastephanou, two of our executive officers, manage our
day-to-day operations. The development and production of our product is managed
by a wide array of scientific personnel, one of whom we consider to be a key
employee. Dr. Melvin Silberklang is our vice president for research and
development and our chief scientific officer. The loss of the services of
Messrs. Lipstein, Papastephanou, or Silberklang could cause delays in our
ongoing business operations, and could have a material adverse effect on our
business, results of operations and financial condition. Except for the
termination of employment agreements we have entered into with Messrs. Lipstein
and Katz and with Alain Klapholz we do not have employment contracts with any of
our key personnel nor any of our other employees nor do we carry key man
insurance policies for any of our employees.

The market price of our common stock may be highly volatile creating greater
financial risk for the owners of our common stock.

The market price of our common stock has ranged from $0.14 to $5.00 during the
past three years. As of June 1, 2006, we had 87,072,596 shares outstanding.
Other factors that may affect the price of our common stock include:

o        our ability to successfully market and sell our ORCEL product,
o        our ability to develop other products for sale,
o        our competitors' announcements concerning technological innovations,
o        new commercial products or procedures,
o        proposed government regulations,
o        developments or disputes relating to patents, trade secrets or proprietary rights,
o        the following substantial number of additional shares of our common stock we would have to issue; or have recently issued :

|X|  an aggregate of 23,794,461 shares upon conversion of our outstanding Series
     D convertible preferred stock;

|X|  an aggregate of at least 32,386,665 shares upon conversion of our
     outstanding Series E convertible preferred stock

|X|  an aggregate of 86,489,804 shares upon the exercise of warrants to purchase
     the shares of our common stock we granted primarily in connection with
     financings during the past three years;

|X|  an aggregate of 8,310,980 shares upon exercise of options we have granted
     to our employees, and particularly to our executive officers, our directors
     and to consultants and vendors.

             Our largest stockholders may take actions that are contrary to your
interests, including selling their stock. A small number of our stockholders
hold a significant amount of our outstanding stock. These stockholders may
support competing transactions and have interests that are different from those
of our other shareholders. In addition, the average number of shares of our
stock that trade each day is generally low. As a result, sales of a large number
of shares of our stock by these large stockholders or other stockholders within
a short period of time could adversely affect our stock price.






We may have to sell additional equity securities in the future which will dilute
the portion of Ortec's equity owned by our current stockholders

In addition to a number of private placements of our equity securities in the
past 4 years, in the future we will probably have to sell even more shares of
our common stock, or other securities convertible into or otherwise entitling
the holder to purchase our common stock. In the future we will also issue
additional options to purchase our common stock to our employees, our executive
officers, and our directors, and to consultants and vendors. All such sales and
issuances of our common stock, other equity securities and warrants and options
to purchase our common stock, will dilute the portion of our equity owned by our
current stockholders.

The price protection provisions of most of our outstanding warrants might
prevent increases in the market price of our common stock.

In 2002 and 2003, we granted to the purchasers of our Series B and Series C
convertible preferred stock, and to the placement agent and to designees of the
placement agent who arranged such preferred stock financings, warrants to
purchase our common stock. In the fourth quarter of 2004 and the first quarter
of 2005, we granted warrants to purchase our common stock to (a) purchasers of
our common stock in the special warrant offering we made in the fourth quarter
of 2004 to holders of our Series B-1, B-2 and C warrants, (b) purchasers of our
common stock in the private placement we closed on January 5, 2005, and one
other purchaser of our common stock later in the first quarter of 2005, (c) to
holders of approximately $9.6 million of our promissory notes upon conversion of
those notes to shares of our common stock, (d) holders of our Series C preferred
stock who exchanged their preferred shares for common stock in the January 5,
2005 private placement, (e) investors who exercised their rights to purchase
additional shares of our common stock not later than 45 days subsequent to the
January 5, 2005 private placement on the same terms and conditions as the sales
in the January 5, 2005 private placement and (f) to the placement agent and its
designees who arranged the private placement financing which closed in the first
quarter of 2005. In the fourth quarter of 2005, we granted warrants to purchase
our common stock to (a) the holders of approximately $3.5 million of our
promissory notes upon conversion of those notes to shares of our common stock on
October 12, 2005, (b) purchasers of our common stock in the private placement we
closed on October 12 and October 31, 2005 and (c) to the placement agent and its
designees who arranged the October 2005 private placement financing. In April
2006 we granted warrants (a) to the purchasers of our Series E convertible
preferred stock and to the placement agents for that financing, and (b) in our
acquisition of Hapto Biotech, Inc. Our Series B-1, B-2, C, E, E PA, F, and F PA,
G, and H warrants to purchase the following number of shares of our common stock
at the following exercise prices are currently outstanding:

o             176,198 shares at $4.00 per share (the "Series B-1 Warrants")
o             112,798 shares at $5.00 per share (the "Series B-2 Warrants")
o             102,000 shares at $3.60 per share (the "Series C Warrants")
o          3,814,189 shares at $0.91 per share (the "Series E Warrants")
o             717,600 shares at $0.79 per share (the "Series E Warrants")
o        14,107,372 shares at $0.001 per share (the "Series E Warrants")
o          2,746,376 shares at $0.35 per share (the "Series E PA Warrants")
o        17,443,892 shares at $0.45 per share (the "Series F Warrants")
o          3,179,618 shares at $0.30 per share (the "Series F PA Warrants")
o          3,000,000 shares at $0.30 per share (the "Series G Warrants")
o        32,536,665 shares at $0.50 per share (the "Series H Warrants")

The Series E and F Warrants provide that if we sell shares of our common stock
at prices below the exercise prices of those warrants, or issue other securities
convertible into, or which entitle the holder to purchase, shares of our common
stock, which could result in the sale of our common stock at a price which in
effect (taking into consideration the price paid for the convertible security or
the warrant or the option) is less than the exercise price of the Series E and F
Warrants, then the exercise price of the Series E and F Warrants is reduced by a
portion of the difference between the exercise price and the lower price at
which the common stock was, or effectively could be, acquired. That percentage
by which the exercise price of the Series E and F Warrants could be reduced
depends not only on the lower price at which our common stock was, or could be,
acquired, but also by the ratio that the number of shares of our common stock
that were, or could be, so acquired bears to the total number of shares of our
common stock that would be outstanding after such sale of our common stock, or
the conversion of securities convertible into, or the exercise of such warrants
or options to purchase, our common stock.

Our Series H Warrants provide that the $0.50 per share exercise price will be
reduced to the price, if lower, at which we sell our common stock in the future,
and, or the effective cost to the purchaser of our common stock upon conversion
of equity securities, or exercise of warrants or options, we may sell or grant
in the future.

Such price protection provisions in our Series E F, and H Warrants could have
the effect of limiting any significant increase in the market value of our
common stock. However, the Series E and F warrants all have provisions that
permit the holders who could acquire the majority of the shares of our common
stock issuable upon exercise of all the warrants in that particular series, to
waive the price protection provisions for that series.

Although our Series B-1, B-2 and C Warrants contain (for our Series C Warrants)
similar or (for our Series B-1 and B-2 Warrants) more severe anti-dilution
provisions, our Series B-1, B-2 and C Warrants were amended (in accordance with
their terms) to provide that, except in situations not here applicable, the
exercise prices would not be reduced below those set forth above.

The closing price for our common stock on June 15, 2006 was $0.21.

Because we do not intend to pay any dividends on our common stock, an investor
in our common stock may only realize an economic gain from an increase, if any,
in the market price of our common stock.

We have never paid, and have no intentions in the foreseeable future to pay, any
dividends on our common stock. Therefore, an investor who purchases our common
stock, in all likelihood, will only realize a profit on his investment if the
market price of our common stock increases in value.

Termination of employment agreements we have entered into with our executive and
other officers could negatively affect the market price of our common stock
because they discourage open market purchases of our common stock by purchasers
who might seek to secure control of Ortec.

We have entered into agreements with Messrs. Steven Katz and Ron Lipstein, two
of our executive officers, and with one other employee, Mr. Alain Klapholz, who
is not an executive officer, that provide for payments to them in the event that
their employment is terminated by us, including "constructive termination" as
defined in those agreements. We will pay to Messrs. Katz and Lipstein an amount
equal to 2.99 times, and to Mr. Klapholz 1.99 times, the average annual
compensation paid by us to such person in the five tax years prior to
termination of his employment. The agreements also provide that (a) in the event
of such termination of employment, the expiration dates of all options and
warrants which have been granted to such persons and which expire less than
three years after such termination of employment, will be extended so that such
options and warrants expire three years after such termination of employment,
and (b) that we will reimburse such persons for any federal excise taxes (and
for taxes on such reimbursements) payable by such persons because of such
termination of employment payments we make to them. The agreements further
provide that in the event of the death or disability of any of Messrs. Katz,
Lipstein or Klapholz, or the voluntary termination by either Messrs. Katz or
Lipstein of their employment with us, we will pay to such person an amount equal
to the compensation received by such officer from us in the previous twelve
months.

Such termination of employment agreements could also discourage persons from
making open market purchases of our common stock for the purpose of securing a
controlling interest in Ortec.

Our operations might be interrupted by the occurrence of a natural disaster or
other catastrophic event. We depend on our collaborators, contractors and
vendors and on our laboratories and other facilities for the continued operation
of our business. Natural disasters or other catastrophic events, including
terrorist attacks, power interruptions, wildfires and other fires, actions of
animal rights activists, earthquakes and wars could disrupt our operations or
those of our collaborators, contractors and vendors. Even though we believe we
carry reasonably adequate business interruption and liability insurance, and
Cambrex and our suppliers may carry liability insurance that protects us in
certain events, we might suffer losses as a result of business interruptions
that exceed the coverage available under our and such other entities' insurance
policies or for which we or such other entities do not have coverage. For
example, we are not insured against a terrorist attack. Any natural disaster or
catastrophic event could have a significant negative impact on our operations
and financial results.






New laws and regulations affecting corporate governance may impede our ability
to retain and attract board members and executive officers, and increase the
costs associated with being a public company.

On July 30, 2002, President George W. Bush signed into law the Sarbanes-Oxley
Act of 2002. The new act is designed to enhance corporate responsibility through
new corporate governance and disclosure obligations, increase auditor
independence, and provide tougher penalties for securities fraud. In addition,
the Securities and Exchange Commission has adopted rules in furtherance of the
act and are considering adopting others. This act and the related new rules and
regulations will likely have the effect of increasing the complexity and cost of
our corporate governance and the time our executive officers spend on such
issues, and may increase the risk of personal liability for our board members,
chief executive officer, chief financial officer and other executives involved
in our corporate governance process. As a result, it may become more difficult
for us to attract and retain board members and executive officers involved in
the corporate governance process. In addition, we have experienced, and will
continue to experience, increased costs associated with being a public company,
including additional professional and independent registered public accountant
fees.

                                 USE OF PROCEEDS

We will not receive any proceeds from the sale by the Selling Stockholders of
the shares of common stock pursuant to this prospectus which are already owned
by them, or which are to be issued to them upon their conversion of shares of
any of our Convertible Preferred Stock or when they exercise any of the warrants
we granted in equity financings in which we sold shares of our convertible
preferred stock if the holders of those warrants use the cashless exercise
provisions in those warrants.






            MARKET FOR COMMON EQUITY AND RELATED STOCKHOLDER MATTERS

Market Information

Our common stock commenced trading on January 19, 1996, under the symbol "ORTC."
The common stock traded on the NASDAQ Small Cap market until August 2002, when
it was delisted from the Small Cap market and commenced trading on the National
Association of Securities Dealers' Bulletin Board, where it presently trades
under the symbol "ORTN.OB." The following table sets forth the high and low
sales prices of our common stock as reported by the Bulletin Board for each full
quarterly period within the two most recent fiscal years and for the first
quarter of 2006.

                                                            HIGH        LOW
2006 Quarter
First                                                     $0.38        $0.14


2005 Quarter
First                                                      1.19         0.63
Second                                                     0.88         0.27
Third                                                      0.40         0.24
Fourth                                                     0.35         0.17

2004 Quarter
First                                                      3.55         1.95
Second                                                     2.95         2.05
Third                                                      2.40         1.35
Fourth                                                     2.30         0.89

Security Holders

To the best of our knowledge, at June 15, 2006, there were 326 record holders of
our common stock. We believe there are more than 1,800 beneficial owners of our
common stock whose shares are held in "street name."

Dividends

We have not paid and have no current plans to pay dividends on our common stock.
Under our Agreement with Paul Royalty Fund we agreed not to issue any new debt
or equity securities that contain cash dividend or mandatory redemption
provisions.

Proposed Reverse Split

At our annual meeting our shareholders voted to grant our directors
discretionary authority to amend our certificate of incorporation to effect a
reverse split of our common stock at a ratio within the range from one for five
to one for fifteen, at any time prior to September 30, 2006. Our management
intends to recommend that our directors amend our certificate of incorporation
to effect a one for fifteen reverse split of our common stock before July 31,
2006.





                             DESCRIPTION OF BUSINESS

Overview

We are a development stage tissue engineering company with core competencies in
cell culturing, biology and biomaterials. We have developed a proprietary and
patented technology that we call OrCel (R) (ORCEL), which is used to stimulate
the repair and regeneration of human skin. ORCEL is a two-layered tissue
engineered dressing that consists of human derived skin cells, both dermal and
epidermal, supported within a porous collagen matrix. The composite matrix is
seeded with keratinocytes (epidermal cells) and fibroblasts (dermal cells). When
ORCEL is applied to the wound site, it produces a mix of growth factors that
stimulates wound closure.

Our primary target patient populations for the use of ORCEL are persons with
venous stasis and diabetic foot ulcers, which we believe are large potential
markets for the use of ORCEL. We also believe that ORCEL may have applications
for cosmetic surgery, and other types of chronic and acute wounds.

We have developed the technology for the cryopreservation of ORCEL without
diminishing its effectiveness. Cryopreservation is the freezing of our product
to give it an extended shelf life. Currently, ORCEL has a shelf life of no less
than seven months, as opposed to only a few days with the non-cryopreserved
product. We believe that the longer shelf life will reduce the cost per unit of
producing ORCEL as well as provide us with a marketing advantage over non-frozen
competitive products.

In 2001, the FDA granted our application for the commercial sale of the fresh
form of ORCEL for the treatment of donor site wounds. A donor site wound is
created in an area of the patient's body from which the patient's skin was taken
to cover a wound at another part of such patient's body. In 2001, the FDA also
granted our application for the commercial sale of the fresh form of ORCEL for
use on patients with recessive dystrophic epidermolysis bullosa undergoing hand
reconstruction, as well as to treat the donor site wounds created during the
surgery. Recessive dystrophic epidermolysis bullosa is a condition in which a
newborn infant's skin instantly blisters and can peel off at the slightest touch
and leave painful ulcerations and permanent scarring resulting in deformity of
the hands and feet.

From December 2001 through December 2002, our gross revenues from the sale of
ORCEL, using a limited contracted sales force, were $265,665. We discontinued
our sales efforts and the manufacture of fresh ORCEL for commercial sale
preferring to use our limited financial resources for the completion of our
clinical trial for the use of cryopreserved ORCEL in the treatment of venous
stasis ulcers. Based on published information we believe that the use of ORCEL
for the treatment of patients suffering from venous stasis ulcers, and of
patients suffering from diabetic foot ulcers, each represents a significantly
larger potential market than the use of ORCEL for the treatment of donor site
wounds or epidermolysis bullosa.

We completed a pivotal clinical trial for the use of ORCEL in its cryopreserved
form for the treatment of venous stasis ulcers. Venous stasis ulcers are open
lesions on the legs which result from the poor circulation of the blood
returning from the legs to the heart. In February 2004, we filed with the Food
and Drug Administration (FDA) our application for clearance to market ORCEL for
the treatment of venous stasis ulcers. In the process of reviewing our
application the FDA requested clarification of the various information provided
by us. After a number of meetings we had with the FDA's staff and additional
submissions we made to the FDA, on April 25, 2005 the FDA advised us that
although our cryopreserved ORCEL showed promise for the effective treatment of
venous stasis ulcers, additional clinical data would be required to demonstrate
reasonable assurance of the safety and effectiveness of cryopreserved ORCEL in
treating patients with venous stasis ulcers, before the FDA would clear ORCEL
for commercial sales for such treatments. The clinical data from the pivotal
trial of 136 patients submitted to the FDA showed that in 60 patients who had
typical venous ulcers (defined as those ulcers with partial or full-thickness
ulcers in which the wound base is visible and the ulcer extends through the
dermis but not into the subcutaneous tissue to fascia, muscle or bone), 59% of
the ORCEL treated patients achieved wound closure versus 36% of the patients who
received the standard of care treatment. The FDA agreed that data of these 60
patients would be combined with that of the 60 patients to be enrolled in a
confirmatory clinical trial and the combined results will be analyzed using
Bayesian statistics. We obtained FDA approval for our confirmatory trial
protocol in mid July 2005 and began the confirmatory trial in mid August 2005.
We completed enrollment for the clinical trial in April 2006. When the clinical
trial is completed we will work towards obtaining regulatory clearance for
commercial sales of cryopreserved ORCEL to treat venous stasis ulcers.

We have deferred conducting a pivotal clinical trial for the use of ORCEL in the
treatment of diabetic foot ulcers until after FDA determination of whether we
may make commercial sales of cryopreserved ORCEL to treat venous stasis ulcers.
We completed a pilot clinical trial for the use of ORCEL, in its fresh, not
cryopreserved, form in the treatment of diabetic foot ulcers in the latter part
of 2001. The results of that clinical trial showed a 75% improvement over the
standard of care as well as a daily healing rate that was twice as fast as the
standard of care, for those patients treated with ORCEL. On January 6, 2005, we
submitted a modified protocol to the FDA for the conduct of a clinical trial of
cryopreserved ORCEL to treat diabetic foot ulcers. In February 2005, the FDA
completed a review of our modified protocol and gave us permission to initiate a
pivotal trial evaluating cryopreserved ORCEL in the treatment of diabetic foot
ulcers. We expect to initiate patient enrollment for the diabetic foot ulcers
pivotal clinical trial shortly after receiving FDA clearance for commercial
sales of ORCEL in the treatment of venous stasis ulcers. We expect that the
diabetic foot ulcers clinical trial will be conducted at up to 25 clinical
centers and involve up to approximately 200 patients.

We have a Cell Therapy Manufacturing Agreement with Cambrex Bio Science
Walkersville, Inc., a subsidiary of Cambrex Corporation (Cambrex), for Cambrex
to produce ORCEL for us in Cambrex' production facilities in Walkersville,
Maryland. Cambrex is experienced in producing cell based medical products such
as ORCEL. Having Cambrex produce ORCEL for us alleviated the need for us to
build and equip our own production and distribution facility, thus avoiding a
large capital outlay, and we believe is otherwise more cost effective for us. We
have also entered into a Sales Agency Agreement with Cambrex for Cambrex to be
the exclusive distributor of ORCEL in the United States, Canada and Mexico. Our
sales agency agreement with Cambrex requires Cambrex to spend $4,000,000 in a
sixteen month period to create a dedicated sales force for, and otherwise to
arrange for the sale of ORCEL. That agreement also provides us with the major
share of revenues from the sale of ORCEL, a dedicated sales force, and an
amendment to our Cell Therapy Manufacturing Agreement with Cambrex resulting in
a $1,500,000 reduction in the amount we were required to contribute to building
a larger production facility. We believe that our production and sales
agreements with Cambrex will enable us to begin commercial sales of ORCEL in the
United States shortly after, and if, we get clearance from the FDA to begin
commercial sales of cryopreserved ORCEL for the treatment of venous stasis
ulcers. During 2005, Cambrex further supported our efforts both through a
$200,000 investment in the January 2005 private placement and in agreeing to
accept 1,030,000 shares of our common stock and warrants to purchase an
additional 1,545,000 shares of our common stock at an exercise price of $1.80
per share in exchange for approximately $800,000 of production suite charges for
the period May through October 2005. Additionally, for the period January
through June 2006, Cambrex has agreed to accept 4,420,398 shares of our common
stock and warrants to purchase an additional 1,105,100 shares of our common
stock at an exercise price of $0.75 per share in exchange for approximately
$800,000 of production suite charges.

While our immediate focus continues to be the commercialization of our core
technology for chronic wounds and wound management, we continue to look at
opportunities in which we can leverage our cell culturing biomaterials and
regulatory knowledge and expertise to broaden our potential sources of revenue.

Acquisition of Hapto Biotech, Inc.

In October 2004 we entered into a collaboration agreement with Hapto Biotech
Inc. (Hapto). Hapto is a privately-held company involved in the field of tissue
engineering focused on the development of two proprietary fibrin derived
platform technologies: Fibrin Micro Beads (FMB's) and Fibrin based peptides
(Haptides(TM)), which have demonstrated the ability to optimize the recovery,
potential delivery and therapeutic value of adult stem cells. Hapto's research
indicates that FMB's have the ability to efficiently recover adult stem cells
from mixed cell populations, as well as allow for their growth, proliferation
and potential reimplantation into the patient. Hapto's research also indicates
that Haptides(TM) have the ability to enhance cell attraction and attachment, as
well as effect cellular internalization of macromolecules and nanoparticles,
allowing for the potential development of products for the stem cell, tissue
regeneration and tissue augmentation, gene therapy and drug delivery markets.
The objective of the collaboration entered into in October 2004 was to combine
our proprietary collagen biomaterial and know how with Haptides(TM) to develop a
non cellular peptide based collagen biomaterial which could promote the
attraction and attachment of healthy cells within the patient's body in
regenerating new tissue or repairing wounds. The collaboration's pre-clinical
animal studies with this biomaterial showed promising results. Based on these
promising results and the potential of the FMB's technology, on December 15,
2005, we executed a non-binding letter of intent to acquire Hapto, and all its
fibrin based technology and intellectual property. On April 14, 2006, we
completed the acquisition of Hapto after the acquisition was approved by Hapto'
shareholders and we received commitments for over $6,000,000 from a private
placement sale of our equity securities. The receipt of such gross proceeds was
a condition for the closing of our acquisition of Hapto. For such acquisition we
issued to the Hapto shareholders a total of 30,860,000 shares of our common
stock and warrants to purchase an additional 3,000,000 shares at $0.30 per
share. Rodman & Renshaw, LLC served as our advisor for this acquisition. On
April 17, 2006, we completed a private placement sale of our equity securities
for aggregate proceeds of $6,176,000.

Research for Hapto's FMB and Haptide technologies is conducted at Hadassah
Hospital facilities in Jerusalem, Israel, pursuant to an agreement between our
Hapto subsidiary and Hadasit Medical Research Services & Development Limited, an
Israeli company. Under that agreement Hadasit provides the facilities where the
research is conducted as well as the services of one of the two senior
scientists who have developed the two Hapto technologies. We pay Hadasit a
monthly fee and other charges currently at the rate of $17,500 per month for the
use of such facilities and the services of that one scientist.

Hapto has not conducted any human clinical trials to determine the safety and
effectiveness in using FMB's or Haptides to treat human medical conditions.
Hapto has performed research on the potential use of FMB's and Haptides in
animal tests and in vitro testing and this data has been published. Hapto's
research is conducted in Israel.

We believe that our experience and knowledge in the areas of cell biology,
biomaterials and tissue regeneration provide a platform from which we can
effectively expand our focus to include the development of stem cell and
regenerative medicine products. In anticipation of receiving FDA approval during
the next year to begin marketing our ORCEL product for the treatment of venous
stasis ulcers, we believe we should identify our future growth opportunities.
Adding Hapto's technologies to our product and technology puts us in the growing
field of stem cells and regenerative medicine. We believe Hapto's technologies
and focus present an attractive opportunity for us and our shareholders.

ORCEL

ORCEL is produced from cells derived from infant foreskins obtained during
routine circumcisions. The immature, neonatal cells are highly reproductive and
provide enhanced proliferation and rapid remodeling of the human skin. We
separate the epidermis from the dermis and treat each of these layers to release
individual keratinocyte (epidermal) and fibroblast (dermal) cells, which are the
primary cellular components of human skin. We grow the fibroblast and
keratinocyte cells in cultures in large quantities, then freeze and store them
as a cell bank, ready for use. Prior to the use of each cell line, we conduct
extensive testing and screening in accordance with current FDA guidelines to
ensure that the cells are free of presence of bacterial contaminants, viruses,
pathogens, tumorigenicity or other transmittable diseases. We then apply the
dermal fibroblast cells to a proprietary, cross-linked bovine collagen sponge to
form the dermal layer matrix and we grow the epidermal keratinocyte cells on a
separate non-porous layer of collagen. We then incubate and supply this
composite matrix with the proper nutrients to allow the cells to multiply and
for the fibroblasts to permeate inside and anchor to the porous collagen sponge.
The top layers of keratinocyte cells and bottom layers of fibroblast cells in
the collagen matrix, together constitute our proprietary ORCEL.

Dr. Mark Eisenberg, a physician in Sydney, Australia, developed our technology.
Dr. Eisenberg is a director and one of our founders. He has been involved in
biochemical and clinical research at the University of New South Wales in
Australia for over twenty-five years, focusing primarily on treating the
symptoms of epidermolysis bullosa. In 1987, through his work on epidermolysis
bullosa, Dr. Eisenberg first succeeded in growing epidermal layers of human
skin, which he successfully applied as an allograft on an epidermolysis bullosa
patient. An allograft is a transplant other than with the patient's own skin.
Dr. Eisenberg continued his research which eventually led to the development of
ORCEL: a tissue-engineered dressing which consists of both the dermal and
epidermal layers.

Government Regulation

We are subject to extensive government regulation. Products for human treatment
are subject to rigorous pre-clinical and clinical testing procedures as a
condition for clearance by the FDA and by similar authorities in foreign
countries prior to commercial sale. Upon the completion of our current
confirmatory clinical trial evaluating ORCEL for treatment of venous stasis
ulcers we will again submit our PMA application to the FDA to determine whether
we may make commercial sales of our product to treat venous stasis ulcers.
However, it is not possible for us to determine whether the results from our
human clinical trial will be sufficient to obtain FDA clearance.

The FDA Clearance Process

Pursuant to the Federal Food Drug and Cosmetic Act and regulations promulgated
thereunder, the FDA regulates the manufacture, distribution and promotion of
medical devices in the United States. ORCEL is considered by the FDA to be a
medical device and is therefore regulated by the Center for Device and
Radiological Health. We must receive pre-market clearance from the FDA for any
commercial sale of our product. Before receiving such clearance we must provide
proof in human clinical trials of the safety and efficacy of ORCEL. Pre-market
clearance is a lengthy and expensive process.

The steps in the FDA clearance process may be summarized as follows:

o    The sponsor (such as Ortec) prepares a protocol which sets forth in detail
     all aspects of the proposed clinical trial. The information includes the
     number of patients to be treated, the number of sites (hospitals and
     clinics) at which the patients in the clinical trial are to be treated, the
     then current standard of care with which the patients in the control group
     (in comparable medical condition as the patients to be treated with the
     medical device which is the subject of the clinical trial) are to be
     treated, the treatment frequency and the statistical plan that will be
     utilized to analyze the data derived from the clinical trial.

o    The protocol also has to establish the safety of the use of the medical
     device to be studied in the trial. Safety can be established in a number of
     ways. One is by showing the results of use of the medical device in
     treatments in other clinical trials, in hospital approved treatments
     elsewhere in the world or by use in animal clinical trials and/or in an FDA
     cleared "pilot" clinical trial in which far fewer patients are treated than
     in the definitive "pivotal" clinical trial.

o    The sponsor submits the protocol to the FDA.

o    The FDA staff gives their comments, objections and requirements on the
     submitted protocol.

o    The sponsor redrafts the protocol and otherwise responds to the FDA's
     comments.

o    The sponsor recruits hospitals and clinics as sites at which the patients
     in the study are to be treated. Such recruitment begins with or prior to
     the preparation of the protocol.

o    After the FDA clears the protocol the trial sites and the sponsor recruit
     the patients to be treated in the study.

o    The patients are treated at not more than the number of trial sites
     specified in the protocol. One half of the patients are treated with the
     medical device being studied and the other half, the control group, with
     the then current standard of care for treatment of the same medical
     condition.

o    The sites follow up each treated patient (for the period and the number of
     times provided in the FDA cleared protocol) to determine the efficacy of
     the medical device being studied in the treatment of the medical condition
     identified in the protocol, as against the efficacy of the standard of care
     used in the study.

o    The sponsor assists and monitors compliance with the protocol's
     requirements in each site's conduct of the study.

o    The sponsor collects the clinical data of each patient's treatment and
     progress from the sites.

o    The data is analyzed by or for the sponsor. The sponsor prepares a report
     of the results of the study and submits the report and the supporting
     clinical data to the FDA staff reviewers for their comments and questions.

o    After staff review of the submitted data, the sponsor responds to the FDA's
     comments and questions.

o    After completion of its review, the FDA staff may submit a report of the
     results of the trial to an advisory medical panel consisting of experts in
     the treatment of the medical condition which the studied medical device is
     intended to treat.

o    The panel submits its advice as to the efficacy and safety of the device to
     the FDA official who is the Director of the FDA Division to which the
     protocol and the results of the pivotal trial were originally submitted. If
     no advisory panel is required, the FDA staff reviewers submit their
     recommendation directly to the Division Director.

o    The FDA Division Director is the FDA official who determines whether or not
     to clear the medical device for commercial sale for treatment of that
     medical condition. The sponsor may appeal a Division Director's negative
     determination through appeal levels within the FDA, up to the Commissioner
     of the FDA.

o    After FDA clearance the sponsor must submit all labeling information for
     the medical device to the FDA to make certain that the claims on the label
     accurately state the uses for which the medical device has been cleared.

We have already discussed our pivotal clinical trial of the use of ORCEL in the
study. There were 136 patients that were treated at 19 clinical sites in that
study. We are currently completing a confirmatory clinical trial involving 60
patients to further test the safety and efficacy of cryopreserved ORCEL to treat
venous stasis ulcers.

Regulatory Strategies

We employ a team of regulatory and clinical professionals, both full time
employees and consultants, with extensive knowledge in strategic regulatory and
clinical trial planning to support our product development efforts through every
stage of the development and FDA clearance process. We also employ persons with
extensive knowledge and experience in the marketing and sale of new FDA approved
products for treatment of many medical conditions, including experience in
securing approval of insurance companies to reimburse their insured patients for
the cost of the use of new medical products used in medical treatments. We have
secured approval for Medicare payments for the use of ORCEL under Medicare's
Outpatient Prospective Payment System (OPPS) for approximately $1,100 per unit
of ORCEL. This approval covers the use of ORCEL in hospitals, other
hospital-owned facilities and for hospital outpatient treatment. However, we
will still need to secure the approval of Medicare designated contractors in
different parts of the country for approval of the different medical conditions
for which Medicare reimbursement of the use of ORCEL will be made. We can only
secure that further approval after we have received FDA clearance for use of
ORCEL for the treatment of that medical condition. We will also seek to secure
approval for private health insurance providers' reimbursement for the cost of
ORCEL. We believe that securing Medicare reimbursement approval for ORCEL will
be of significant assistance to us in securing reimbursement approval by private
health insurance companies.

Sales and Marketing

As noted above, our business strategy is to combine our efforts with Cambrex for
the production and commercial sale of ORCEL. On October 18, 2004, we entered
into a Sales Agency Agreement with Cambrex, providing for Cambrex to be the
exclusive sales agent in the United States for our ORCEL product or any other
future bi-layered cellular matrix product of ours for the treatment of venous
stasis ulcers, diabetic foot ulcers or any other therapeutic indication for
dermatological chronic or acute wound healing. The agreement is for a period of
six years beginning sixty days after we receive clearance from the FDA for the
commercial sale of ORCEL for the treatment of venous stasis ulcers. The
agreement requires us to pay commissions to Cambrex ranging from initially at
40% of net sales and decreasing to 27% of net sales as the amount of sales
increases. The agreement requires Cambrex to spend $4,000,000 for marketing
efforts during the sixteen-month period after the FDA clears our sale of ORCEL
for the treatment of venous stasis ulcers.

Cambrex had the right to terminate the agreement if we did not receive FDA
clearance for commercial sale of ORCEL for the treatment of venous stasis ulcers
by April 1, 2005 and has the right to terminate if for any period of six
consecutive months beginning in 2007, sales are less than 9,000 units. We may
terminate the agreement if sales of ORCEL are less in any twelve month period
than amounts targeted in the agreement for that period (ranging from 10,000
units in the first twelve month period to 100,000 units in the sixth twelve
month period). Although we did not receive FDA clearance by April 1, 2005, we
have received no indication from Cambrex that they plan to terminate our
agreement. During 2005, as noted earlier, Cambrex made equity investments in
cash, and or in exchange for services, of approximately $1,000,000.
Additionally, in 2006 Cambrex agreed to accept our common stock and warrants in
exchange for an additional approximate $800,000 of production suite charges.

Concurrent, and in connection with the Sales Agency Agreement, we entered into a
License Agreement pursuant to which we licensed certain intellectual property
rights to Cambrex. We also entered into a Security Agreement with Cambrex to
secure the performance of our obligations under the Manufacturing, License, and
Sales Agreement. The secured collateral consists of all accounts, cash, contract
rights, payment intangibles, and general intangibles arising out of or in
connection with the sale of products pursuant to the sales agreement and/or
license agreement. The lien and security interests under this security agreement
are subordinate and junior in priority to the perfected lien and security
interest we granted to Paul Royalty Fund under the Paul Royalty Security
Agreement.

In October 2003, we entered into an exclusive License Agreement with Teva
Medical Limited, a subsidiary of Teva Pharmaceutical Industries Ltd. (Teva) for
the sales and marketing of our ORCEL product in Israel. This ten-year agreement,
beginning on the date the product is launched for marketing in Israel, requires
Teva to seek regulatory and reimbursement approval for ORCEL in Israel. We
received an upfront payment of $50,000 in 2003 which we recorded as deferred
income. We will receive an additional $50,000 within thirty days of grant of
reimbursement approval in Israel, and another $100,000 within 30 days of
attainment of aggregate net sales of $3,000,000 in Israel within any period of
twelve consecutive calendar months. The agreement also provides for ORCEL
pricing and terms of payment. Additionally Teva will pay us royalties of 10% of
net sales in Israel up to $5,000,000 per annum. If sales are in excess of
$5,000,000 annually Teva will pay us 10% on the first $5,000,000 of sales in
Israel and a 20% royalty on sales above $5,000,000 in Israel. As of June 1,
2006, regulatory and reimbursement approval have not been achieved.






Production and Supply

On October 29, 2003, we entered into an agreement commencing November 1, 2003,
with Cambrex for Cambrex to manufacture ORCEL in its Walkersville, Maryland
facilities. The Cambrex manufacturing facility is required to meet FDA's good
manufacturing processes standards. Cambrex is experienced in the manufacture of
cell-based medical products such as our ORCEL. On October 18, 2004, in
connection with our Sales Agency Agreement with Cambrex, we amended certain
terms of this manufacturing agreement.

Our manufacturing agreement with Cambrex requires us to currently pay Cambrex
$132,613 per month, or approximately $1,591,350 per year, for the use of a
Cambrex production facility in Walkersville, Maryland. The payments we will make
to Cambrex will increase to $175,000 monthly, or $2,100,000 per year, if we
require Cambrex to build us a larger production facility to meet our
requirements for the production of ORCEL. Such annual payments include some
services and overhead expenses provided and paid for by Cambrex. These annual
payments we are required to make increase 3% per annum on the anniversary of the
commencement date. We are required to pay 50% of the cost of the construction of
that larger production facility up to a maximum payment by us of $1,000,000 (up
to $2,500,000 if we terminate our Sales Agency Agreement with Cambrex). However,
the amount we contribute to the construction of that larger facility will be
repaid to us by credits against a portion of the future annual payments and of
certain other payments we are required to make to Cambrex after the larger
facility is in use. We are also required to pay specified hourly charges for the
Cambrex employees engaged in the production of ORCEL as well as certain other
charges. After construction of the larger production facility we are required to
acquire from Cambrex virtually all of our requirements for ORCEL that Cambrex
can produce. Prior to our election to have Cambrex construct the larger
production facility for us, either we or Cambrex may terminate the agreement on
six months notice by us and twelve months notice by Cambrex. If we elect to have
Cambrex construct the larger production facility for us the agreement will
continue for six years after the larger production facility is constructed.
However, even after such construction we and Cambrex may elect to scale down
over the following three years the portion of our requirements for ORCEL that
Cambrex will produce for us. We may elect the scale down period at any time
after one year after the larger production facility is constructed and in
operation in which event there are additional payments we must make to Cambrex.
If we elect the scale down period after one year we must pay Cambrex $2,625,000
and if we elect the scale down period after two years we must pay Cambrex
$1,050,000. If we elect the scale down periods in either of those two years, we
forfeit our right to receive any further credits (up to the amount of our
contribution to the cost of the larger production facility) against payments we
are thereafter required to make to Cambrex. Either Cambrex or we may elect the
scale down period later than three years after that facility is in operation and
neither of us will be required to make any additional payments to the other
because of that election.

If after the construction of the larger production facility, we breach a
material term of our agreement with Cambrex, or elect to terminate the
agreement, we will have to pay Cambrex the following amounts:


                      If termination occurs after the following          Amount
                      anniversary of the construction of the             of
                      larger production facility                         Payment
                      -----------------------------------------------    --------------
                      6 years                                             $1,050,000
                      5 years, but less than 6 years                       1,575,000
                      4 years, but less than 5 years                       2,625,000
                      3 years, but less than 4 years                       3,675,000
                      2 years, but less than 3 years                       5,250,000
                      1 year, but less than 2 years                        6,300,000

In addition, upon such termination we will forfeit our right to receive any
further credits (up to the amount of our contribution to the cost of the larger
production facility) against future payments we may have to make to Cambrex.

The raw materials that we use to manufacture ORCEL come from a limited number of
suppliers. We currently purchase collagen corium, a component of the collagen
matrix in ORCEL, from a single supplier but we are in the process of securing a
secondary source of supply for that item. The collagen matrix used in ORCEL is
manufactured for us to our specifications by another supplier, and we are in the
process of identifying a secondary source for collagen matrix also. On December
30, 2004 we entered into a two-year supply agreement with the manufacturer of
the collagen matrix. We agreed to purchase a minimum of 3,500 units of finished
collagen sponges within the first twelve-month period. The value of such
commitment is approximately $200,000. Such commitment was not achieved in 2005
and we were released from any resulting liability by the supplier. We also
agreed that subsequent to a written notification from the FDA clearing us to
sell ORCEL commercially for treatment of venous stasis ulcers we will provide
such supplier projections for one or more subsequent quarters and the parties
will be obligated to purchase and sell those projected amounts. While there may
be other sources from where we could purchase such materials, a disruption in
the supply chain for any of those materials would have a significant negative
impact on our ability to manufacture and sell ORCEL and in any event would
likely cause us delays and additional expenses in the manufacturing of ORCEL.

During 2004 we also announced an agreement with ES Cell International Pte, Ltd
(ESI) to collaborate in the development of ESI's human Embryonic Stem Cell (hES)
derived cell therapy products. Under the terms of the agreement, we will supply
ESI with human skin cells generated from cell lines developed and manufactured
by us for our ORCEL product. We have conducted extensive testing for viruses of
the cells we are providing to ESI in accordance with FDA guidelines. ESI will
use the cells we provide in research and development and in commercialization of
their stem cell products. Under the terms of the agreement, we have received
upfront payments and may receive additional payments on the achievement of
milestones in ESI's human hES cell derived cell therapy programs. The agreement
also provides for payment of royalties to us from future commercial sales of
ESI's cell therapy products.

Competition

We are aware of several companies that are actively engaged in the research and
development of products for the repair and regeneration of skin. There are
currently three primary and distinct approaches to the repair and regeneration
of skin: the acellular (no cell) approach, including the use of cadaver based
products; the cell-based unilayered (epidermal or dermal cell) approach, and the
cell-based bi-layered (epidermal and dermal cell) approach. A cell-based
approach makes use of human donor cells. The approach we believe to be the most
advanced and effective is the cell-based bi-layered approach. The production of
ORCEL consists of a top layer of epidermal cells and a bottom layer of dermal
cells in a collagen matrix, that is a bi-layered approach utilizing donor cells.

There are many products available for treating skin wounds. However, as already
noted, we believe that the use of donor cells delivered to the wound on a matrix
is the most effective process for healing skin wounds and in particular hard to
heal skin wounds. Therefore, we believe that only products using donor cells
placed on a matrix will compete with ORCEL.

We consider the Apligraf product manufactured by Organogenesis, Inc. to be our
principal competitor. Apligraf is an FDA cleared product using human dermal and
epidermal cells (bi-layered) placed on a matrix, for the treatment, of both
venous stasis and diabetic foot ulcers. The Apligraf product is not
cryopreserved and has reported it has a shelf life of 10 days. Organogenesis,
Inc. is a private company that markets and sells their own product. Although
financial information has to our knowledge not been publicly disclosed we
believe Organogenesis has greater resources than we have.

The biomedical field is continually undergoing rapid and significant
technological changes. Other companies may succeed in developing other products
that are more effective than ORCEL. If such new products are accepted by the
medical community, or if those products receive FDA approval for treatment of
venous stasis and diabetic foot ulcers before ORCEL does, or if other companies
develop products that are more effective than ORCEL, any such developments could
impede our ability to continue our operations.

We believe that our Haptides product will regenerate human tissues for wound
healing. Currently there are commercial applications of certain materials that
are sold by a number of companies and are used as dermal fillers for cosmetic
purposes and as dental fillers used to try to regenerate the patient's dental
structure to be available for dental implants. We believe that our Haptides, in
addition to regenerating human tissues for wound healing, will also enhance the
use of those other materials as dermal fillers and as dental fillers.

Our FMBs are designed to extract therapeutic stem cells from blood as well as
from fat and from bone marrow. Cytori Therapeutics, Inc., a San Diego based
company, is currently conducting a clinical trial using stem cells extracted
from fat tissue for orthopedic repairs. Aastrom Biosciences, Inc., also an
American based company, is also conducting a clinical trial using stem cells and
progenitor cells extracted from bone marrow for orthopedic repairs. We believe
that our FMB technology will secure stem cells with greater potential for
therapeutic applications. To our knowledge there are currently no commercial
sales of therapeutic stem cells used for therapeutic applications.






Patents and Proprietary Rights

We have four United States patents, one European patent covering thirteen
countries, and ten patents in ten other countries, issued. We also have one
United States and eight international patent applications (filed under the
Patent Cooperation Treaty) pending for our technology and processes:

o                 The first of these patents covers the structure of ORCEL. It
                  is an epidermal layer of cultured epidermal cells and a
                  bilayered collagen sponge structure that includes a layer of
                  highly purified, non-porous collagen on top of a porous
                  cross-linked collagen sponge containing cultured dermal cells.
                  This patent expires on February 1, 2011. This is also the
                  technology covered by the European and other foreign patents
                  which have been issued to us. These foreign patents also
                  expire in 2011.

o                 Another United States patent provides for the extension of the
                  use of the collagen sponge structure described above which may
                  contain cells other than epidermal and/or dermal cells, such
                  as cells for regenerating such organs and tissues as heart
                  muscle, blood vessels, ligaments, cartilage and nerves. This
                  patent also expires on February 1, 2011. We have not
                  performed, nor are we planning to perform in the near future,
                  any clinical trial using our platform technology for use of
                  donor cells other than epidermal and dermal cells.

o                 Another United States patent covers a manufacturing process
                  which, when implemented, can reduce the cost of producing
                  ORCEL. This new manufacturing process creates an improvement
                  over our collagen structures described above in that a third
                  layer of collagen which is hospitable to cell growth is
                  deposited on the non-porous collagen layer. This patent
                  expires on December 28, 2020.

o                 Our fourth United States patent covers a process for the
                  cryopreservation of ORCEL. This patent expires on December 26,
                  2021.

o                 We have filed a divisional patent application of the
                  cryopreservation process patent to add claims to cover the
                  cryopreserved form of ORCEL.

In connection with our recent acquisition of Hapto the FMB's and Haptides(TM)
are covered under various patent applications.

FMB's are derived from fibrinogen through a specific chemical process and
provide a matrix for cell growth and transfer. The FMB technology is covered by
five US patents and one Australian patent. There are also corresponding
European, Japanese and Canadian applications in the prosecution phase.

o        The first USA patent, entitled "Fibrin Microbeads Prepared from
         Fibrinogen, Thrombin and Factor VIII," covers a method for producing
         fibrin microbeads. This patent expires on September 19, 2017.

o        The second USA patent, entitled "Fibrin Microbeads Prepared from
         Fibrinogen, Thrombin and Factor VIII for Binding Cells", covers FMBs
         prepared by a certain method, a composition including cells that are
         bound to such FMBs and a method for culturing cells on such FMBs. This
         patent expires on September 15, 2018.

o        The third USA patent, entitled "Fibrin Microbeads and Uses thereof",
         covers a method for separating cells that bind to FMBs from cell
         culture, a method for transplanting such cells into a patient and a
         method for engineering human tissues. This patent expires on October
         25, 2022. A corresponding patent has been granted in Australia and
         corresponding applications are pending in Canada, Europe and Japan.

o        The fourth USA patent, entitled "Fibrin Nanoparticles and Uses
         thereof", covers isolated fibrin nanoparticles having a mean diameter
         of 200-2000 nm and a method for preparing the fibrin nanoparticles.
         This patent expires on August 30, 2021. Corresponding applications are
         pending in Canada, Europe, Japan and Australia. There is also a USA
         pending application directed to a composition comprising fibrin
         nanoparticles and an agent.

o        The Fifth USA patent, entitled "Fibrin Applicator Pistols", covers an
         applicator that can simultaneously deliver two component solutions,
         fibrinogen and thrombin at precise ratios and provides a method for
         delivering either as a spray or endoscopically FMB suspended within one
         of the solutions. This patent expires on March 27, 2022.

Haptides(TM) are synthetic peptides that mimic the mechanism of cell attachment
to fibrinogen. These haptotactic (cell binding) peptides can be coated to
scaffolds and devices and could also be used for drug delivery and for gene
therapy. In Australia, one patent has been granted and another patent has been
allowed. In the USA, An allowance of claims on a USA patent covering the Haptide
technology was received in May 2006 and two patent applications are in the
prosecution phase in the USA, Europe and PCT countries.

o        The first family of applications, entitled "Novel peptides", covers a
         group of novel peptides homologous to a portion of Fibrinogen, which
         retains certain desired properties of the entire fibrinogen molecule
         including cell adhesive effects. One patent has been granted in
         Australia and corresponding applications are pending in Canada, Europe,
         Israel and Japan.

o        Another USA application, entitled "Novel Haptotactic Peptides", to
         receive allowance of claims in May 2006 covers a novel peptide
         homologous to a specific portion of Fibrinogen and such peptide retains
         certain properties of the fibrinogen molecule including cell adhesive
         effects. .

o        There are is another family of patents, entitled "Novel Haptotactic
         Peptides", that discloses novel peptide sequences homologous to the
         known fibrinogen derived haptotactic peptides Ca and CaE. The novel
         peptides are derived from proteins related to fibrinogen and which
         possess cell attraction activity. One patent has been allowed in
         Australia and patent applications covering these peptides are pending
         in the USA, Canada, Europe, Israel and Japan.

o        Another family of patents, entitled "Liposomal Compositions Comprising
         Haptotactic Peptides and uses thereof " have been filed. These patents
         relate to liposomal compositions comprising peptides that elicit cell
         attachment responses and are internalized by cells and that are capable
         of enhancing the uptake of liposomes by cells. This invention can be
         used in pharmaceutical and cosmetic compositions. These patent
         applications are pending in the USA, Europe, Israel and Japan

Despite such patents our success will depend, in part, on our ability to
maintain trade secret protection for our technologies.

We successfully defended challenges by Organogenesis to our United States patent
and by Advanced Tissue Sciences to our European patent in the respective patent
offices where those patents were issued. However, those successful defenses do
not preclude future challenges in court. We do not know if any of the other
patents issued to us will be challenged, invalidated or circumvented. Patents
and patent applications in the United States may be subject to interference
proceedings brought by the U.S. Patent and Trademark Office, or to opposition
proceedings initiated in a foreign patent office by third parties or to
re-examination proceedings in the United States. We might incur significant
costs defending such proceedings and we might not be successful.

The validity and breadth of claims in medical technology patents involves
complex legal and factual questions and, therefore, are highly uncertain. We do
not know if any pending patent applications or any future patent application
will issue as patents, that the scope of any patent protection obtained will be
enough to exclude competitors or that any of our patents will be held valid if
subsequently challenged in court proceedings. We do not know if others have or
will develop similar products, duplicate any of our products or design around
any of our patents issued or that may be issued in the future. In addition,
whether or not patents are issued to us, others may hold or receive patents
which contain claims having a scope that covers aspects of our products or
processes.

Several of our competitors have been granted patents, including those granted to
Organogenesis and Advanced Tissue Sciences, Inc., relating to their particular
skin technologies which also utilize donor cells on a collagen sponge matrix. To
that extent they may be considered similar to our ORCEL technology.






Paul Royalty Fund Agreement

In August 2001 and in 2002, we entered into agreements with Paul Royalty Fund,
L.P. (PRF) pursuant to which we agreed in consideration of PRF paying us
$10,000,000, to pay to PRF 3.33% of the end user sales prices paid for our ORCEL
product in the United States, Canada and Mexico through the period ending in
2011. Such percentage interest in our revenues in those three countries may be
adjusted upward or downward based on the volume of sales to end users of ORCEL
in those three countries. As security for the performance of our obligations to
PRF, we have granted PRF a security interest in all of our U.S. patents, patent
applications and trademarks. Our agreement with PRF provides that in certain
events PRF may, at its option, compel us to repurchase the interest in our
revenues that we sold to PRF for a price equal to the $10,000,000 PRF paid us
plus an amount that would yield PRF a 30% per annum internal rate of return on
its $10,000,000 investment. Among the events that would entitle PRF to compel us
to repurchase its interest in our revenues at that price is if we are insolvent
or if we are unable to pay our debts as they become due. Our agreement with PRF
provides that in determining such insolvency any amount we owe to PRF is
excluded in calculating our net worth (or negative net worth). In addition,
although we are currently trying to manage our debt we are not paying our debts
as they become due. As defined in our agreement with PRF we are currently
insolvent. As a result of this insolvency our obligation under the revenue
interest assignment is stated at $31,544,000, the amount PRF could compel us to
repurchase their revenue interest at March 31, 2006. In December 2004, PRF
entered into a forbearance agreement with us agreeing that they cannot exercise
their right to compel us to repurchase their interest in our revenues because of
our insolvency prior to July 2006. If PRF exercised its right to compel us to
repurchase its interest in our revenues and we did not have the funds to pay the
purchase price, PRF could foreclose its security interest in our U.S. patents,
patent applications and trademarks and in such event we may have to discontinue
our business operations.

The agreement with PRF is more fully described in Note 10 of the accompanying
December 31, 2005 financial statements. As described in Note 10, in accordance
with accounting promulgated by Statements of Financial Accounting Standards No.
15, "Accounting by Debtors and Creditors for Troubled Debt Restructurings" (SFAS
15) even if we are no longer insolvent as long as our future cash payments
relating to the revenue interest assignment obligation are indeterminate, the
revenue interest assignment obligation would remain at the value that achieves
the 30% internal rate of return for PRF through the last date of our insolvency.
We believe that it is highly improbable we will ever owe PRF the amount of this
obligation.

SFAS 15 allows debtors that can predict with certainty the absolute amounts of
future cash flow payments to record an immediate gain if the maximum future cash
payments are less than the carrying amount of the obligation. In the case where
the future cash payments are indeterminate, as ours are considered, the gain is
not recognized until the end of the term of the outstanding debt, December 31,
2011, or upon termination. We estimate that we would need to achieve a North
American sales level of approximately $1,256,000,000 during the approximate
remaining five sales years under the revenue interest assignment agreement to
offset the principal balance of the $31,544,000 revenue interest obligation. We
are prohibited by SFAS 15 from making a reasonable estimation of our future
sales to assess the amount of our future debt payments and therefore are
precluded from reducing the liability and recognizing a gain at this time. We
believe we will likely record a gain on the revenue interest assignment
obligation to PRF in 2011 or upon termination, if sooner.

Research and Development Expenses

Research and development expenses consist primarily of salaries; amounts paid to
Cambrex, facility costs and laboratory supplies. Research and development
expenses were $7,535,532 for the year ended December 31, 2005, compared to
$7,139,733 for the year ended December 31, 2004.

Compliance with Environmental Regulations

We are subject to regulation under the Occupational Safety and Health Act, the
Environmental Protection Act, the Toxic Substances Control Act, the Resource
Conservation and Recovery Act, the Controlled Substances Act and other present
and potential future federal, state or local regulations. Our research and
development programs involve the controlled use of hazardous materials,
chemicals, biological materials and various radioactive compounds.

Although we believe that our operations comply in all material respects with
applicable environmental laws and regulations, the risk of accidental
contamination or injury from these materials cannot be completely eliminated. In
the event of such an accident, we could be held liable for any damages that
result, and the extent of that liability could exceed our resources. Our
compliance with these laws and regulations did not, and is not expected to, have
a material effect upon our capital expenditures, earnings or competitive
position.

Although our operations in Israel are subject to Israeli environmental laws and
regulations, all our activities in Israel are performed at Hadassah Hospital's
facilities in Jerusalem and we rely upon Hadassah Hospital's compliance with
Israeli environmental laws and regulations.
Employees

We presently employ 36 people on a full-time basis, including four executive
officers in our offices and facilities in New York City. We also have six
part-time employees. We presently employ two people on a full time basis and one
person on a part time basis in Israel. One of our employees in Israel is a
scientist who is employed to develop our FMB and Haptide technologies. Another
scientist who also works on the development of those technologies is employed
by, and his services are provided by, Hadasit Medical Research & Development
Services.

Description of Property

Pursuant to a lease which expires December 31, 2007, we occupy an aggregate of
approximately 14,320 square feet of space in Columbia University's Audubon
Biomedical Science and Technology Park in New York City, for laboratory and
office space. We use our laboratories for assay development, wound healing
research, biomaterial development, bioprocess development, histology, quality
assurance testing and for two clean rooms where we produce ORCEL. Rent for the
entire 14,320 square feet is $60,860 per month.







                                PLAN OF OPERATION

We are a development stage enterprise which had no operating revenue prior to
December 2001. During 2001, we received Food and Drug Administration approval
for the use of the fresh form of our ORCEL product for the treatment of patients
with recessive dystrophic epidermolysis bullosa and for donor sites in burn
patients. We began marketing and selling our product for use on patients with
one of these indications using a contract sales organization. Our sales and
marketing efforts were active only for a brief period and accordingly our
revenues were not significant. We terminated our sales efforts and elected to
focus our attention on completing development of a cryopreserved form of our
product for treatment of chronic wounds affecting larger populations. As a
result, we completed a clinical trial during 2003 for the use of the
cryopreserved form of ORCEL to treat venous stasis ulcers and filed an
application for pre-market approval (PMA) with the FDA in February 2004. In a
letter dated April 25, 2005, although the FDA concluded that cryopreserved ORCEL
showed promise for the effective treatment of venous stasis ulcers, the FDA
determined that additional data would be necessary to confirm cryopreserved
ORCEL's effectiveness and safety treating venous stasis ulcers. The clinical
data from the pivotal trial of 136 patients submitted to the FDA showed that in
60 patients who had typical venous ulcers (defined as those ulcers with partial
or full-thickness ulcers in which the wound base is visible and the ulcer
extends through the dermis but not into the subcutaneous tissue to fascia,
muscle or bone), 59% of the ORCEL treated patients achieved wound closure versus
36% of the patients who received the standard of care treatment. The FDA agreed
that data of these 60 patients would be combined with that of the 60 patients to
be enrolled in a confirmatory clinical trial and the combined results will be
analyzed using Bayesian statistics. We obtained FDA approval for our
confirmatory trial protocol in mid July 2005 and began the confirmatory trial in
mid August 2005. We completed enrollment for this confirmatory clinical trial in
April 2006. Our plan of operation for the next twelve months is to complete such
confirmatory clinical trial and continue to work towards obtaining regulatory
clearance for commercial sales of cryopreserved ORCEL to treat venous stasis
ulcers. In the interim, we are working with Cambrex Bio Science Walkersville,
Inc., a subsidiary of Cambrex Corporation (Cambrex) to limit expenditures under
our manufacturing agreement primarily to those which are essential for
conducting the confirmatory trial. Together, we are working on process
improvements that we expect will drive down the cost of producing ORCEL as we
plan for the potential commercialization of our product. In February 2006,
Cambrex assisted us financially by once again agreeing to accept our common
stock and warrants in exchange for approximately $800,000 of production suite
charges to be incurred during the first half of 2006.

We have deferred conducting a pivotal clinical trial for the use of ORCEL in the
treatment of diabetic foot ulcers until after FDA determination of whether we
may make commercial sales of cryopreserved ORCEL to treat venous stasis ulcers.
We completed a pilot clinical trial for the use of ORCEL, in its fresh, not
cryopreserved, form in the treatment of diabetic foot ulcers in the latter part
of 2001. The results of that clinical trial showed a 75% improvement over the
standard of care as well as a daily healing rate that was twice as fast as the
standard of care, for those patients treated with ORCEL. On January 6, 2005, we
submitted a modified protocol to the FDA for the conduct of a clinical trial of
cryopreserved ORCEL to treat diabetic foot ulcers. In February 2005, the FDA
completed a review of our modified protocol and gave us permission to initiate a
pivotal trial evaluating cryopreserved ORCEL in the treatment of diabetic foot
ulcers. We expect to initiate patient enrollment for the diabetic foot ulcers
pivotal clinical trial shortly, if and after receiving FDA clearance for
commercial sales of ORCEL in the treatment of venous stasis ulcers. We expect
that the diabetic foot ulcers clinical trial will be conducted at up to 25
clinical centers and involve up to approximately 200 patients.

In the past twelve months, in anticipation of commercialization of ORCEL, our
operations were focused towards finalizing the ORCEL production process at Ortec
and transferring the commercial manufacturing operations to Cambrex. During this
time we enhanced and validated the ORCEL production process in our laboratory
facilities allowing for the transfer of the production process and full
validation at Cambrex. Work was also ongoing in the area of process development
to improve the consistency, increase the scale and reduce the cost of producing
ORCEL. To increase scale and reduce the cost of producing ORCEL, we developed a
cell factory process to provide for the ability to accomplish larger scale cell
expansion which will facilitate the production of additional cell inventory.
Development efforts were also ongoing to improve the process, and reduce the
cost of producing our collagen sponge matrix, which included developing a
prelaminated sponge and finding alternative sources of supply of bovine hide
collagen and various grades of sponges that could provide new business
opportunities. We validated several assay methods used to qualify incoming raw
materials and to monitor both the ORCEL production process and the final ORCEL
product, all required by the FDA. Other manufacturing cost reduction projects
may be delayed, or may be accomplished in collaboration with Cambrex.
Preliminary discussions with Cambrex have taken place with respect to the
transfer of our cell expansion processes as well as co-development of other cost
reduction and increased production projects. The costs associated with these
projects will be negotiated with Cambrex.






The following is a listing of the projected development activities on which we
expect to focus during the next twelve months:

o    Transfer to Cambrex of a process which doubles the ORCEL production lot
     size,

o    Production and expansion of cell inventory, o Completion of prelaminated
     sponge project, o Completion of development of the cell factory project, o
     Completion of all FDA required tests and validations, and o Validation of
     "BSE-free" collagen.

Additionally we plan to:

o    Expand our focus to application of our technologies to opportunities in
     regenerative medicine such as stem cells, wound healing, and cosmetic
     tissue augmentation;

o    Further develop our newly acquired Fibrin Micro Beads and Haptides(TM)
     technologies (see next section);

o    Explore opportunities where we can use our FDA approved facility, cell
     culturing biomaterials and regulatory knowledge and expertise as an income
     source or to secure interests in other companies' biotechnology products or
     in their business operations;

o    Examine potential licensing opportunities for use of our biomaterials in
     other tissue engineering applications; o Pursue co-development opportunity
     using growth factor media in development of cosmeceutical products, and o
     Submit proposals to the appropriate agencies for the purpose of securing
     available research grants.

We may invest approximately $125,000 for equipment which will allow us to expand
our collagen sponge manufacturing capacity.

We expect that the above projects will require our current level of staffing. We
periodically review and adjust our staffing levels and operational expenses for
maximum efficiency. We do not presently expect any significant changes in
personnel in 2006.

Acquisition of Hapto Biotech

On December 15, 2005 we executed a non-binding letter of intent to acquire Hapto
Biotech (Hapto), a privately-held company involved in the field of tissue
engineering focused on the development of two proprietary fibrin derived
platform technologies: Fibrin Micro Beads (FMB's) and Fibrin based peptides
(Haptides(TM)), which have demonstrated the ability to optimize the recovery,
potential delivery and therapeutic value of adult stem cells. Hapto's research
indicates that FMB's have the ability to efficiently recover adult stem cells
from mixed cell populations, as well as, allow for their growth, proliferation
and potential reimplantation into the patient. Hapto's research also indicates
that Haptides(TM) have the ability to enhance cell attraction and attachment, as
well as effect cellular internalization of macromolecules and nanoparticles,
allowing for the potential development of products for the stem cell, tissue
regeneration and tissue augmentation, gene therapy and drug delivery markets.
Hapto has not conducted any human clinical trials to determine the safety and
effectiveness in using FMB's or Haptides(TM) to treat human medical conditions.
Hapto has conducted research on the potential use of FMB's and Haptides(TM) in
animal tests and in vitro testing, both conducted in Israel.

We closed our acquisition of Hapto on April 14, 2006. We believe that due to the
early stages of the development of Hapto's technology, that the Hapto assets we
acquired do not constitute a business. For such acquisition we issued a total of
30,860,000 shares of our common stock to the Hapto shareholders and granted them
warrants to purchase an additional 3,000,000 of our common shares at $0.30 per
share. Based on the market price of our common stock on April 14, 2006, and
valuing the warrants using the Black Scholes formula, the value of the shares
and warrants we issued to Hapto's shareholders is approximately $10,100,000. The
purchase price will be allocated to in-process research and development costs,
and accordingly, expensed immediately. The investment banking firm of Rodman &
Renshaw, LLC (R&R) acted as our advisor in this acquisition. R&R received
three-year warrants to purchase 4,000,000 shares of our common stock at $0.30
per share for their advisory services.

Other Liquidity Matters

Our agreement with Paul Royalty Fund (PRF) provides that in certain events PRF
may, at its option, compel us to repurchase the interest in our revenues that we
sold to PRF for a price equal to the $10,000,000 PRF paid us plus an amount that
would yield PRF a 30% per annum internal rate of return on its $10,000,000
investment. Among the events that would entitle PRF to compel us to repurchase
its interest in our revenues at that price is if we are insolvent or if we are
unable to pay our debts as they become due. Our agreement with PRF provides that
in determining such insolvency any amount we owe to PRF is excluded in
calculating our net worth (or negative net worth). In addition, although we are
currently trying to manage our debt we are not paying our debts as they become
due. As defined in our agreement with PRF we are currently insolvent. As a
result of this insolvency our obligation under the revenue interest assignment
is stated at $31,544,000, the amount PRF could compel us to pay to repurchase
their revenue interest at March 31, 2006. Although in December 2004 we entered
into an eighteen-month forbearance agreement providing that PRF would not prior
to July 1, 2006 compel us to repurchase its interest in our revenues because of
our insolvency, as of March 31, 2006 we were still considered insolvent and
therefore were required to record as an obligation we owe PRF the amount to
provide PRF with a 30% internal rate of return on its $10,000,000 investment. If
in the future PRF exercised its right to compel us to repurchase its interest in
our revenues and we did not have the funds to do so, PRF could foreclose its
security interest in our U.S. patents, patent applications and trademarks and in
such event we may have to discontinue our business operations. Outside of a
repurchase event, more fully explained in Note 10 of our consolidated financial
statements for the year ended December 31, 2005, PRF would be entitled to the
applicable royalty percentages of our future revenues in North America. We
estimate that we would need to achieve a North American sales level of
approximately $1,256,000,000 during the approximate remaining five sales years
under the revenue interest assignment agreement to offset the principal balance
of the $31,544,000 revenue interest obligation. We are prohibited by SFAS 15
from making a reasonable estimation of our future sales to assess the amount of
our future debt payments and therefore are precluded from reducing the liability
and recognizing a gain at this time. We believe we will likely record a gain on
the revenue interest assignment obligation to PRF in 2011 or upon termination,
if sooner.

We will need to secure additional financing for the approximately $875,000 of
expenses we are currently incurring on a monthly basis. The amount of cash we
consume each month fluctuates, depending, among other things, on whether we are
incurring expenses from services provided by third party suppliers in connection
with a clinical trial and what payments we have to make on our outstanding debt.

While we have arranged for payment of some of our obligations over a period of
time, and have to make other payments of past due obligations to our current and
ongoing suppliers, our ability to make payments we have agreed to pay and to
insure continued receipt of needed supplies and services, and to continue
reducing our past due obligations, will depend on our ability to secure needed
financing or our ability to issue equity in satisfaction of certain obligations.

We hope to obtain additional funds through the sale of our securities to the
public and through private placements, debt financing or other short-term loans.
We may not be able to secure any financing nor may we be able to reach the
larger patient population markets of persons with venous stasis ulcers and
diabetic foot ulcers, with funds that we may be able to raise. We are also
likely to continue to encounter difficulties which are common to development
stage companies, including unanticipated costs relating to development, delays
in the testing of products, regulatory approval and compliance and competition.

Our capital funding requirements depend on numerous factors, including:

o        the progress and magnitude of our research and development programs;
o                 the time involved in obtaining regulatory approvals for the
                  commercial sale of our ORCEL product in its cryopreserved form
                  to treat venous stasis ulcers and, later, diabetic foot
                  ulcers;
o        the costs involved in filing and maintaining patent claims;
o        technological advances;
o        competitive and market conditions;
o        the successful  implementation  of the agreements we have entered into with Cambrex for  manufacturing  and sales of our ORCEL
                  product;
o        our ability to establish and maintain other collaborative arrangements and
o        the cost and effectiveness of commercialization activities and arrangements.

Unless we obtain additional financing we will not be able to continue to operate
our business.

On March 17, 2006, we settled a vendor liability of approximately $102,000 for
$35,000 cash payable in seven equal monthly installments and a three-year
warrant to purchase 285,000 shares of our common stock at an exercise price of
$0.25 per share. The warrant has piggyback registration rights for the
underlying shares of common stock.

In March 2006, we received $445,000 in short-term loans. We received two loans
for $130,000 and $65,000, respectively, from two of our executive officers.
These loans were non-interest bearing and payable from the proceeds of our
future financings. $35,000 was repaid on April 6, 2006 with the balance paid
from the proceeds of our April 17, 2006 private placement of our equity
securities. The third loan for $250,000 bore interest at 8% per annum and was
from the investor who had committed to provide us with $1,058,000 by the later
of the filing of our pre-market approval application for our confirmatory venous
leg ulcer trial, or March 31, 2006. This $250,000 loan automatically converted
into the equity securities we issued in our recent private placement, at 1.2
times the note's principal and accrued interest amount. Additionally we agreed
that upon conversion of such $250,000 loan to our equity securities, since the
investor provided us with the funds earlier than was required, we would forego
such investor's remaining commitment to provide us with $808,000 of additional
financing, and that the earlier repricing (upon commitment) of our warrants held
by such investor would not be affected.

On April 3, 2006 we received another short-term loan of $45,000 from another of
our executive officers. This loan was also repaid from the proceeds of our
recent private placement. On April 17, 2006, with the completion of our recent
private placement, we converted the $250,000 short-term loan with its then
outstanding loan balance of $301,333 into 301.33 shares of our Series E
preferred stock, and issued a warrant to purchase 1,506,665 shares of our common
stock at an exercise price of $0.50 per share. On April 5, 2006 we received a
$200,000 short-term loan due April 30, 2006 to be repaid at 110% of principal
plus accrued interest at 8% per annum on the original $200,000 principal
balance. We issued a three-year warrant to purchase 50,000 shares of our common
stock at an exercise price of $0.50 per share, to the lender.

On April 17, 2006, we completed a private placement sale for aggregate gross
proceeds of $6,176,000, to accredited investors of our 6% Series E convertible
preferred stock and warrants to purchase our common stock. The Series E
convertible preferred stock is entitled to vote on an "as converted" basis on
all matters submitted to a vote by the holders of our common stock. At any time
these investors can convert their preferred stock into common stock at a $0.20
per common share conversion price. After we complete a reverse split of our
outstanding common stock the investors are obligated to convert their preferred
stock on the later of (i) the date of this prospectus, or (ii) the 21st trading
day following such reverse split, by dividing the amount they paid for such
preferred shares plus dividends at 6% per annum, by the lesser of $0.20, or 90%
of the average of the volume weighted average prices for our common stock for
the twenty trading days following the effective date of such reverse stock
split. We issued to the purchasers of our Series E convertible preferred stock,
five-year warrants to purchase an aggregate of 32,386,665 shares of our common
stock at $0.50 per share. The warrants carry full ratchet price reset provisions
should we sell our common stock or our other securities convertible into, or
exercisable for, our common stock, at an effective price per common share less
than the $0.50 exercise price of the warrants. We are obligated to register,
under the Securities Act of 1933, all of the shares of our common stock issuable
upon conversion of the 6% Series E convertible preferred stock, and upon
exercise of such warrants. We will pay investors 2% per month for any failure to
timely file the registration statement by June 18, 2006 or have it declared
effective by August 17, 2006.

Off-Balance Sheet Arrangements

We had no off-balance sheet arrangements as of March 31, 2006.







                        DIRECTORS AND EXECUTIVE OFFICERS

Name                                       Age       Position
------------------------------------     --------    --------------------------------------------------------
------------------------------------     --------    --------------------------------------------------------

Steven Katz, Ph.D.                         61        Chairman of the Board of Directors
Ron Lipstein                               50        Chief Executive Officer, Vice Chairman of the Board of
                                                     Directors and Secretary
Mark D. Eisenberg, M.D.                    68        Director
Steve Lilien, Ph.D.                        59        Director
Allen I. Schiff, Ph.D.                     60        Director
Gregory B. Brown, M.D.                     52        Director
Raphael Hofstein, Ph.D.                    55        Director
Andreas Vogler                             44        Director

Steven Katz, one of our founders, has been a director since our inception in
1991 and was elected Chairman of the Board of Directors in September 1994. He
has been employed by us since 1991 and served as our chief executive officer
until January 2003. Dr. Katz has also been a professor of Economics and Finance
at Bernard M. Baruch College in New York City since 1972. He has a Ph.D. in
Finance and Statistics as well as an MBA and an MS in Operations Research, both
from New York University.


Ron Lipstein, one of our founders, has been the Secretary and a director since
1991. Mr. Lipstein was elected Vice Chairman of the Board of Directors in
January 2003, and Chief Executive Officer in March 2003. Prior to March 2003,
Mr. Lipstein served as our Chief Financial Officer. He has been employed by us
since 1991. Mr. Lipstein is a Certified Public Accountant.


Dr. Mark Eisenberg, one of our founders, has been a director since 1991. He has
been a physician in private practice in Sydney, Australia, since 1967. He is a
member and co-founder of the dystrophic epidermolysis bullosa clinic at the
Prince of Wales Hospital for children in Sydney, Australia, and has done
extensive research on epidermolysis bullosa disease.


Steven Lilien has been a director since February 1998. He was chairman of the
accounting department of Bernard M. Baruch College in New York City for 15 years
and is currently the Weinstein Professor of Accounting there. He is a certified
public accountant and has a Ph.D. in accounting and finance and an MS, both from
New York University.


Allen I. Schiff was elected a director in June 2001. He is a Professor of
Accounting and is currently the Area Chair of the undergraduate and graduate
accounting departments at Fordham University School of Business. He has also
served as Director of the MBA Consulting Program at Fordham University Graduate
School of Business since 1992. He has a Ph.D. in finance and economics and an MS
in accounting, both from New York University.


Gregory B. Brown has been a director since March 2003. Since January 2003 Dr.
Brown has been a partner at Paul Capital Partners. Pursuant to our agreement
with its affiliate, Paul Royalty Fund, L.P., that entity appointed Dr. Brown as
its designee to the Board. From 1997 to 2002 Dr. Brown served as a managing
director of Adams, Harness & Hill, an investment banking firm, and from April
2001 to December 2002 as head of its healthcare division and co-head of
investment banking. Prior to 1997 Dr. Brown was a thoracic and vascular surgeon.
He received a B.A. degree from Yale University, an M.D. from Upstate Medical
School and an M.B.A. from Harvard Business School.


Raphael Hofstein was elected a director on June 5, 2006. Since 1999, he served
as the managing director of Hadasit, Ltd., a technology holding company for
Hadassah Medical Organization in Jerusalem, Israel. Hadasit holds interests in a
number of companies engaged in developing and marketing medical devices,
biomedicines and medical diagnostic products. Pursuant to the April 14, 2006
agreement whereby we acquired Hapto Biotech, Inc., the former shareholders of
Hapto Biotech have appointed Dr. Hofstein as one of their two designees to serve
as directors of Ortec. From 1997 to 1999 Dr. Hofstein was the president of
Mindsense Biosystems Ltd., an Israeli company engaged in the development of
immune assays for different diagnosis in neuropsychiatry. From 1988 to 1997 he
was employed by Ecogen, Inc. of Langhorne, Pennsylvania, first in Israel as
scientific director of Ecogen Israel Partnership evaluating, funding and
developing products, and from 1997 in Langhorne, Pennsylvania for the commercial
development of novel microbial fungicides. Dr. Hofstein received master and
doctoral degrees in life sciences and chemistry from the Weizman Institute of
Science in Rehovot, Israel in 1976 and 1980, respectively, and post doctoral
research fellowships from Harvard Medical School from 1980 to 1983.


Andreas Vogler was elected a director on June 5, 2006. Since 2002 he has been
the managing general partner of BioMedical Innovations Management Ltd., a
private equity fund that invests primarily in medical technology and healthcare
companies. Pursuant to the April 14, 2006 agreement whereby we acquired Hapto
Biotech, Inc., the former shareholders of Hapto Biotech have appointed Mr.
Vogler as one of their two designees to serve as directors of Ortec. Since
receiving his masters degree in economics at the University of Basle in
Switzerland in 1988, Mr. Vogler was employed until 2002 by UBS Warburg (formerly
Swiss Bank Corporation) as a securities analyst and in investment banking,
primarily in the medical technology and healthcare fields. Mr. Vogler serves as
a chairman of our Israeli subsidiary, Hapto Biotech (Israel) Ltd. Mr. Vogler is
also a director of Orthoscan Ltd. and Bioscan Ltd., both private Israel
technology companies in the development stage, and of Piexon AG, a Swiss
industrial company. From 2002 to 2004 he served as a director of Hirslanden
Group, the largest private hospital chain in Switzerland.

Executive Officers

Officers are appointed annually by the Board of Directors and serve at the
discretion of the Board. Two of our executive officers, Steven Katz and Ron
Lipstein, are also directors of Ortec. Information with regard to such persons
is set forth above. The other executive officers are Costa Papastephanou, our
President, and Alan W. Schoenbart, our Chief Financial Officer.

Costa Papastephanou, 60, has been employed as our President since February 2001.
Prior to joining us, he was employed by Bristol Myers-Squibb for 30 years, the
last 14 of which he was with Bristol Myers' Convatec, a multinational ostomy and
wound care management division. His last position at Convatec was as President
of the global chronic care division, where he was responsible for that
division's sales and marketing, clinical trials, research and development,
manufacturing, quality assurance and regulatory affairs. He holds a Ph.D. in
Biochemistry from the University of Miami, as well as a Master of Science in
Microbial Biochemistry from the University of London.

Alan W. Schoenbart, 47, has been our Chief Financial Officer since December
2004. He had been acting as Director of Finance since joining us in March 2004.
From April 1999 to December 2003, he was Chief Financial Officer of Vizacom
Inc., a publicly traded provider of consumer software and information technology
services and products, and a designer of WiFi networks. From 1997 to 1999, he
was Chief Financial Officer of Windswept Environmental and from 1995 to 1997, he
was Chief Financial Officer of Advanced Media, Inc., both publicly traded
entities. From 1993 to 1995, he was Controller of Goodtimes Entertainment, a
privately held distributor of videos and software to mass merchant chains. From
May 1981 to August 1993, he worked at KMPG as a manager and at other public
accounting firms. Mr. Schoenbart has a BS in accounting from Fairleigh Dickinson
University and is a Certified Public Accountant in New York.

We do not have an employment agreement with either Dr. Papastephanou or Mr. Schoenbart.

Significant Employee

Melvin Silberklang is our vice president for research and development and our
Chief Scientific Officer. He has held those positions for all of the 11 years
that he has been employed by us. Dr. Silberklang is 56 years old.

We do not have an employment agreement with Dr. Silberklang.






                             EXECUTIVE COMPENSATION

The following table sets forth the compensation paid by us for our fiscal years
ended December 31, 2005, 2004 and 2003 to (i) our Chief Executive Officer, (ii)
three other executive officers and (iii) one additional individual for whom
disclosure would have been provided but for the fact that the individual was not
serving as an executive officer at the end of the last completed fiscal year
(the "Named Executive Officers").

                                            SUMMARY COMPENSATION TABLE
                                                                                     Restricted            Securities
                                                                                       Stock               Underlying
 Name and Principal Position                   Salary         Bonus                  Awards ($)            Options /
                                   Year           ($)            ($)                    (5)                 SARs (#)
-------------------------------    --------    -----------    -----------           --------------        --------------
-------------------------------    --------    -----------    -----------           --------------        --------------

Ron Lipstein                        2005         260,000          127,684 (1) (2)      1,190,000   (6)     3,179,619
   CEO, Vice Chairman
    and  Secretary
                                    2004         260,000         80,747   (1) (3)        -                     -
                                    2003         224,366        118,300   (1)            -                    476,431

Steven Katz                         2005         150,000        127,684   (1) (2)        404,600   (7)     3,179,619
 Chairman

                                    2004         150,000         80,747   (1) (2)        -                     -
                                    2003         158,558        118,300   (1) (4)        -                    476,431

Constantin Papastephanou            2005         230,596          -                       83,300   (8)         -
 President
                                    2004         220,500          -                      -                     -
                                    2003         207,493          -                      -                     57,500

Melvin Silberklang                  2005         190,709          -                      -                     -
 VP, Chief Scientific
  Officer
                                    2004         185,000          -                      -                     -
                                    2003         172,735         10,000                  -                       7,500

Alan W. Schoenbart                  2005         150,000          -                       17,000   (9)         -
 Chief Financial Officer
                                    2004         100,000          -                      -                     10,000
                                    2003           -              -                      -                     -

(1) Mr. Lipstein's and Mr. Katz's bonuses are equal to 1% each of the funds
raised on our behalf (whether such funds are raised in equity or debt financings
or as a result of licensing transactions) as well as options to purchase a
number of shares equal to up to 10% of the number of shares issued in any such
financing transaction.

(2) Amount has been deferred.

(3) $49,528 has been deferred.

(4) $13,300 has been deferred.

(5) The allocation of shares for the restricted stock awards was made by the
Board of Directors in 2003, conditioned on achieving specified milestones. The
year in which the restricted stock awards were granted was the year in which the
milestones were achieved. Dollar values denoted for each individual are as of
dates of grant. Pursuant to our agreements with these individuals these shares
will be forfeited by them if at any time prior to January 1, 2007 we no longer
employ such person. The shares may only be sold in five monthly installments
commencing January 1, 2007. No dividends will be paid on the restricted stock
awards.

(6) As of December 31, 2005, 1,000,000 restricted shares valued at $190,000 (The
product of $0.19 (the closing price of our common stock at December 31, 2005, as
reported on the over the counter Bulletin Board) and the number of restricted
shares).

(7) As of December 31, 2005, 340,000 restricted shares valued at $64,600 (The
product of $0.19 (the closing price of our common stock at December 31, 2005, as
reported on the over the counter Bulletin Board) and the number of restricted
shares).

(8) As of December 31, 2005, 245,000 restricted shares valued at $46,500 (The
product of $0.19 (the closing price of our common stock at December 31, 2005, as
reported on the over the counter Bulletin Board) and the number of restricted
shares).

(9) As of December 31, 2005, 50,000 restricted shares valued at $9,500 (The
product of $0.19 (the closing price of our common stock at December 31, 2005, as
reported on the over the counter Bulletin Board) and the number of restricted
shares).


The following tables show for the fiscal year ended December 31, 2005, certain
information regarding options granted to, exercised by, and held at year-end by,
the Named Executive Officers:

Option Grants in Last Fiscal Year

     Option/ SAR Grants in Last Fiscal Year
     -------------------------------------------------------------------------------------------------
     --------------------------- - -------------- -- -------------- -- ------------- -- --------------
                                                      Percent of
                                                         total
                                     Number of          options
                                    securities        granted to
                                    underlying       employees in
                     options fiscal year Exercise Expiration
                Name                  granted                             price             date
     ---------------------------   --------------    --------------    -------------    --------------
     ---------------------------   --------------    --------------    -------------    --------------
     Steven Katz                       3,179,619             49.7%            $0.25        11/01/2012
     Ron Lipstein                      3,179,619             49.7%            $0.25        11/01/2012

                             Aggregated Option Exercises In Last Fiscal Year
                                     and Fiscal Year-End Option Value
     -------------------------------------------------------------------------------------------------
     -------------------------------------------------------------------------------------------------
          Number of Securities Underlying Value of In-the-Money Options
                                        Unexercised Options at
                                             12/31/05 (#)                  at 12/31/05 ($) (1)
                                   --------------------------------- ---------------------------------
                                   --------------  ----------------- ---------------- ----------------
               Exercisable Unexercisable Exercisable Unexercisable
                 Name
     ----------------------------- --------------  ----------------- ---------------- ----------------
     ----------------------------- --------------  ----------------- ---------------- ----------------
     Steven Katz                     3,899,060            -                 -                -
     Ron Lipstein                    3,896,445            -                 -                -
     Constantin Papastephanou           41,250             28,750           -                -
     Melvin Silberklang                 10,630                250           -                -
     Alan W. Schoenbart                  2,500              7,500           -                -

There were no option exercises in the last fiscal year by any of the Named
Executive Officers.

(1)      The product of (x) the difference between $0.19 (the closing price of
         our common stock at December 31, 2005, as reported on the over the
         counter Bulletin Board) and the exercise price of the unexercised
         options, multiplied by (y) the number of exercisable and unexercisable
         options.




The following table shows for the fiscal year ended December 31, 2005, certain
information regarding participation in Long-term incentive plans by the Named
Executive Officers:

                            Long-Term Incentive Plans-Awards in the Last Fiscal Year
-----------------------------------------------------------------------------------------------------------------
-------------------------- -- ----------- -- -------------------- -- --------------------------------------------
                                                                      Estimated Future Payouts under Non- Stock
                                                                                  Price-Based Plans
                                                                     --------------------------------------------
                                                                     -------------- -- --------- -- -------------

                                               Performance or
                                             other period until
                              Number of         maturation or        Threshold          Target        Maximum
          Name                  shares             payout              ($ or #)        ($ or #)       ($ or #)
--------------------------    -----------    --------------------    --------------    ---------    -------------
--------------------------    -----------    --------------------    --------------    ---------    -------------
Melvin  Silberklang           120,000        01/01/05-12/31/07          60,000           60,000       120,000


The issuance of such 120,000 shares is conditioned as follows: 60,000 will be
issued upon doubling the output of the current manufacturing process, and the
remaining 60,000 shares will be issued upon developing a semi-automated cell
culture process.

Compensation of Directors

Drs. Mark Eisenberg, Steven Lilien, Allen I. Schiff and Gregory B. Brown were
all non-employee Directors in 2005. For Dr. Steven Lilien's services in 2005 as
a Director and as Chairman of the Audit Committee, we paid Dr. Lilien $20,000
and for his services in 2005 as a Director and as a member of our Audit
Committee, we paid Dr. Schiff $20,000. In addition to cash compensation we
granted Drs. Lilien and Schiff each a five-year option to purchase 15,000 shares
of our common stock at an exercise price of $0.26. We paid no compensation to
Dr. Eisenberg or Dr. Brown for their services as Directors.

Compensation Committee Interlock and Insider Participation

None of our executive officers serve as a member of the compensation committee
or on the board of directors of another entity, one of whose executive officers
serves on our Board of Directors.

The Compensation Committee of our Board of Directors determines compensation
policies applicable to its executive officers. Messrs. Steven Katz, Allen I.
Schiff and Steven Lilien are the members of the Compensation Committee. Mr. Katz
is an executive officer of ours.







         SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT

The following table sets forth information, as of June 1, 2006, based upon
information obtained from the persons named below, regarding beneficial
ownership of our common stock and our Series E preferred stock by (i) each of
our current directors, (ii) each of our current executive officers and one of
our other employees named in the Summary Compensation Table set forth under the
caption "Executive Compensation", below, (iii) each person who is known by us to
own beneficially more than 5% of the outstanding shares of our common stock or
of our Series E preferred stock and (iv) all executive officers and directors as
a group.


                                   Amount and
                                                               Nature of                           Perce55age of
Name and Address                                              Beneficial                            Outstanding
of Beneficial Owner*                             55           Ownership**            55           Shares Owned***
[GRAPHIC OMITTED]                                          [GRAPHIC OMITTED]                     [GRAPHIC OMITTED]

Common Stock

                                                              4,251,717     (1)              4.7
Steven Katz
                                                              4,914,313     (2)              5.4
Ron Lipstein
                                                                300,800     (3)              ****
Constantin Papastephanou
                                                                 52,500     (4)              ****
Alan W. Schoenbart
                                                                 10,630     (5)              ****
Mel Silberklang
                                                                170,600     (6)              ****
Mark Eisenberg
                                                                 32,140     (7)              ****
Steven Lilien
                                                                 28,500     (8)              ****
Allen I. Schiff
                                                                      0     (9)               0
Gregory B. Brown
Raphael Hofstein                                              6,713,816    (10)              7.7
Hadassah
P.O. Box 12000
Jerusalem 91120
Israel
Andreas Vogler                                               16,743,497    (11)               18.9
BioMedical Innovations, Ltd.
Bleicherweg 45
8002 Zurich, Switzerland
Microdent, Ltd.                                               6,168,996                        7.1
P.O. Box 11, Tefen
24959, Israel
Cambrex Bio Science Walkersville, Inc.                        5,885,498    (12)                6.7
8830 Biggs Ford Road
Walkersville, Maryland 21793
North Sound Capital LLC                                       9,066,134    (13)                9.9
53 Forest Avenue
Old Greenwich, CT  06870
SDS Capital Group SPC, Ltd.                                   8,994,885    (14)                9.9
c/o SDS Management LLC
53 Forest Avenue, 2nd Floor
Old Greenwich, CT 06870
All Executive Officers and Directors as a Group              33,207,883    (15)               34.2






                                                                               Percentage of
Name and Address                                  Amount and Nature of       Outstanding Shares
of Beneficial Owner*                              Beneficial Ownership            Owned***
--------------------------------------------- ----------------------------- ---------------------
-------------------------------------------------------------------------------------------------

Series E Convertible Preferred Stock*****


Jacob Gottlieb and Dimitri Balyasny              1,284          (16)              19.8
   650  Madison  Avenue,   20th  Floor,  New
   York, NY 10022
Dimitri Balyasny                                   156          (17)               0.2
   650 Madison Avenue
   19th Floor
   New York, NY 10022
The Phoenix Insurance  Company                     500                             7.7
   53 Derech Hashalom
   Givatayim 53454
   Israel



[GRAPHIC OMITTED]
                                       55

*    Unless otherwise noted, the address of each person is c/o Ortec
     International, Inc., 3960 Broadway, New York, NY 10032.

**   The number of shares of common stock beneficially owned by each person or
     entity is determined under rules promulgated by the Securities and Exchange
     Commission. Under these rules, beneficial ownership includes any shares as
     to which the person or entity has sole or shared voting power or investment
     power. Included among the shares owned by such person are any shares which
     such person or entity has the right to acquire within 60 days after June 1,
     2006. Unless otherwise indicated, each person or entity referred to above
     has sole voting and investment power with respect to the shares listed. The
     inclusion herein of any shares deemed beneficially owned does not
     constitute an admission of beneficial ownership of such shares.

***       For purposes of calculating the percentages of outstanding common
          stock owned by each person, the total number of issued and outstanding
          shares is 87,072,596, which includes 154,397 shares that had not been
          processed for issuance on June 1, 2006. For purposes of calculating
          the percentages of outstanding Series E preferred stock owned by each
          person, the total number of issued and outstanding shares of such
          Series E preferred stock is 6,477.333.

**** Less than 1%, based upon information available to us. ***** Each share of

Series E preferred stock is entitled to cast 5,000 votes.

      (1) Includes 3,899,060 shares of common stock underlying stock options.
          Does not include shares owned by Dr. Katz's children, their spouses
          and his grandchildren. Dr. Katz disclaims any beneficial interest in
          such shares. In addition, does not include shares issuable upon the
          exercise of options that Dr. Katz is entitled to but that to date he
          has elected not to receive. Pursuant to Dr. Katz's agreement with us,
          the number of shares that may be issued upon the exercise of such
          options represents up to 10% of the number of shares issued in
          financing transactions entered into by us.
      (2) Includes 3,896,445 shares of common stock underlying stock options.
          Does not include 3,360 shares owned by Mr. Lipstein's children. Mr.
          Lipstein disclaims any beneficial interest in these shares. Does not
          include shares issuable upon the exercise of options that Mr. Lipstein
          is entitled to but that to date he has elected not to receive.
          Pursuant to Mr. Lipstein's agreement with us, the number of shares
          that may be issued upon the exercise of such options represents up to
          10% of the number of shares issued in financing transactions entered
          into by us.
      (3) Includes 55,625 shares of common stock underlying stock options.
      (4) Includes 2,500 shares of common stock underlying stock options..
      (5) Consists of 10,630 shares of common stock underlying stock options.
      (6)  Includes 111,000 shares of common stock underlying stock options.
      (7) Includes 32,100 shares of common stock underlying stock options.
      (8) Includes 28,500 shares of common stock underlying stock options.
      (9) Does not include 321,502 shares owned by Paul Royalty Fund L.P., an
          affiliate of Paul Capital Partners,  of which
          Dr. Brown is a partner.  Dr. Brown was selected by Paul Royalty Fund
          to serve as a director of Ortec  pursuant to
          our agreement giving Paul Royalty Fund the right to name one director.
     (10) Consists of 6,560,730 shares, and warrants to purchase an additional
          153,086 shares, owned by HBL Hadasit BioHoldings Limited, of which
          company Mr. Hofstein is a director and the chief executive officer.
     (11) Includes 12,013,863 shares and warrants to purchase an additional
          1,717,692 shares owned by Denkaria B.V. Mr. Vogler is the managing
          general partner of Denkaria.
     (12) Includes 1,225,100 shares issuable upon exercise of outstanding warrants.
     (13) Includes 4,225,000 shares issuable upon exercise of outstanding
          warrants. According to a Schedule 13G filed by North Sound Capital LLC
          on February 13, 2005, the managing member of that entity is Thomas
          McAuley. North Sound Capital LLC may be deemed the beneficial owner of
          the shares in its capacity as the managing member of North Sound
          Legacy Institutional Fund LLC and North Sound Legacy International
          Ltd., which funds are the registered owners of such shares. As the
          managing member of these funds, North Sound Capital LLC has voting and
          investment control with respect to the shares of common stock held by
          these funds.
     (14) Includes 3,500,000 shares issuable upon exercise of outstanding
          warrants. According to a Schedule 13G filed jointly on February 6,
          2005, by SDS Capital Group SPC, Ltd., SDS Management LLC, its
          investment advisor, and Steve Derby, the sole manager of the
          investment advisor, all three persons share voting and dispositive
          power over these shares.
     (15) Includes 8,025,230 shares underlying stock options. Includes warrants
          to purchase an additional 1,870,778 shares of which 153,086 are owned
          by HBL Hadasit BioHoldings Limited, and 1,717,692 are owned by
          Denkaria B.V. See notes (10) and (11) above.
     (16) Consists of shares owned by the four Visium Funds of which Visium
          Asset Management LLC is the Investment Advisor and Balyasny Asset
          Management LP is the Sub-advisor. Mr. Gottlieb is the managing member
          of Visium Asset Management and Mr. Balyasny is a partner of Balyasny
          Asset Management. Messrs. Gottlieb and Balyasny share voting and
          dispositive power over these shares.
     (17) Consists of shares owned by Atlas Master Fund, Ltd., of which Balyasny
          Asset Management is the Investment Advisor and therefore Mr. Balyasny
          has sole voting and dispositive power over these shares.

                 CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS

Special Compensation to Executive Officers

Pursuant to a resolution adopted by our Board of Directors in 2001, we are
required to pay to Mr. Ron Lipstein, our chief executive officer, and to Dr.
Steven Katz, the chairman of our Board of Directors, one percent each of all
moneys received by us from investors in our equity securities or certain
lenders. We are also required to issue to each of them options to purchase such
number of shares of our common stock equal to ten percent of the shares issued
by us in an equity financing, which options are exercisable at the prices paid
by the investors for the shares we sell in the equity financing. During the past
three years we have paid $149,519 of the amount owed by us to Mr. Lipstein and
$105,000 of the amount owed by us to Dr. Katz, pursuant to such directors'
resolution, but payment of the balance of $177,212 owed by us to Mr. Lipstein
and $221,732 owed by us to Dr. Katz, has been deferred with the agreement of
Messrs. Katz and Lipstein. Pursuant to such resolution, in October and November
2005 we granted to Messrs. Katz and Lipstein seven-year options entitling each
of them to purchase 3,179,619 shares of our common stock at an exercise price of
$0.25 per share as a result of our sale of 31,796,190 shares of our common stock
in a private placement in the latter part of 2005. We expect to grant to each of
Dr. Katz and Mr. Lipstein options to purchase ten percent of the number of
shares of our common stock that the purchasers of our Series E convertible
preferred stock receive upon conversion of their Series E preferred stock, with
the exercise price of such options being the price per share of common stock
such purchasers will have paid for our common stock they receive. We have not,
with Messrs. Katz's and Lipstein's consent, granted them options because of
private placement sales of our equity securities prior to October 2005.


Termination of Employment Agreements


We have entered into agreements with Messrs. Katz and Lipstein that provide for
payments to them in the event that their employment is terminated by us,
including "constructive termination" as defined in those agreements. We will pay
to such terminated individuals an amount equal to 2.99 times the average annual
compensation paid by us to such person in the five tax years prior to
termination of his employment. The agreements also provide that in the event of
a termination of employment, the expiration dates of all options and warrants
which have been granted to such persons and which expire less than three years
after such termination of employment, will be extended so that such options and
warrants expire three years after such termination of employment. The agreements
further provide that in the event of the death, disability or voluntary
termination of employment of each individual, we will pay to such executive an
amount equal to the compensation received by such executive from us in the
previous 12 months.


The Internal Revenue Code provides that in the event that payments to an
executive officer resulting from a change of control of a company exceeds three
times the average annual compensation paid by such company to such executive
officer in the five year period prior to such change of control (a) such excess
will not be able to be deducted by the company in calculating its income for
income tax purposes and (b) a special excise tax equal to 20% of such excess
will have to be paid by the executive officer receiving such excess payments.
Such agreements are commonly referred to as "golden parachutes." The agreements
with Messrs. Katz and Lipstein provide that we will pay such excise tax payable
by such executive officer, as well as income taxes payable by such executive
officer as a result of our payment of such excise tax.

Obligation to Elect Directors

Dr. Gregory B. Brown, one of our directors, was selected by Paul Royalty Fund,
L.P. as its board designee, as provided by an amendment, entered into in
February 2003, to an agreement between us and Paul Royalty Fund.

The April 14, 2006 agreement whereby we acquired Hapto provides that if our
shareholders do not elect two designees of the former shareholders of as
directors of Ortec for the earlier of (i) the next two years, or (ii) until such
time as the number of shares of our common stock acquired by the former
shareholders of Hapto in our acquisition of Hapto amount to less than 5% of our
common stock then outstanding, we will be required to issue an additional
1,750,000 shares of our common stock to the former shareholders of Hapto for
each such Hapto designee that is not elected as a director of Ortec. The former
shareholders of Hapto have selected Raphael Hofstein and Andreas Vogler as their
designees to serve as directors of Ortec.






                              SELLING STOCKHOLDERS


The prospectus includes an aggregate of 185,214,063 shares to be offered for
sale by the Selling Stockholders named below, including (a) 47,442,080 shares of
common stock, (b) 23,794,461 shares issuable upon conversion of currently
outstanding Series D preferred stock, (c) 32,386,665 shares issuable upon
conversion of currently outstanding Series E preferred stock, (d) 176,197 shares
issuable upon exercise of currently outstanding Series B-1 warrants, (e) 112,798
shares issuable upon exercise of currently outstanding Series B-2 warrants, (g)
102,000 shares issuable upon exercise of currently outstanding Series C
warrants, (f) 16,740,311 shares issuable upon exercise of currently outstanding
Series E warrants, (g) 2,746,376 shares issuable upon exercise of currently
outstanding Series E -PA warrants, (h) 17,443,892 shares issuable upon exercise
of currently outstanding Series F warrants, (i) 3,179,618 shares issuable upon
exercise of currently outstanding Series F - PA warrants, (j) 32,536,665 shares
issuable upon exercise of currently outstanding Series H warrants, and (k)
8,553,100 shares issuable upon exercise of other warrants currently
outstanding.. The shares are to be offered by and for the respective accounts of
the Selling Stockholders and any pledgees or donees or other assignees of the
Selling Stockholders. We have agreed to register all of the shares under the
Securities Act and to pay all of the expenses in connection with such
registration and sale of the shares, other than underwriting discounts and
selling commissions and the fees and expenses of advisors to the Selling
Stockholders. We will not receive any proceeds from the sale of the shares by
the Selling Stockholders, except for the exercise price, if any, paid in
connection with the exercise of the warrants.

Information with respect to the Selling Stockholders and the shares is set forth
in the footnotes to the following table. None of the Selling Stockholders has
had any material relationship with us within the past three years, except as
noted in such footnotes.

We do not know when or in what amounts the Selling Stockholders may offer shares
for sale. The Selling Stockholders may not sell any or all of the shares offered
by this prospectus. Because the Selling Stockholders may offer all or some of
the shares pursuant to this offering, and because there are currently no
agreements, arrangements or understandings with respect to the sale of any of
the shares, we cannot estimate the number of shares that will be held by the
Selling Stockholders after completion of the offering. For purposes of this
table, however, we have assumed that, after completion of the offering, none of
the shares covered by this prospectus will be held by the Selling Stockholders.

Beneficial ownership is determined in accordance with the rules of the SEC, and
includes voting or investment power with respect to shares. All calculations
assume the conversion of all shares of Series D and Series E preferred stock
outstanding at June 1, 2006. Pursuant to the terms of the Certificates of
Designation for both the Series D and Series E preferred stock, the holders of
shares of Series D and Series E preferred stock do not have the right to convert
their shares of Series D and Series E preferred stock to common stock to the
extent that after giving effect to such conversion, the stockholder together
with the stockholder's affiliates would have beneficial ownership of more than
9.99% of our outstanding common stock immediately after the conversion. Unless
otherwise indicated below, to our knowledge, all stockholders named in the table
have sole voting and investment power with respect to their shares of common
stock, except to the extent authority is shared by spouses under applicable law.
The inclusion of any shares in this table does not constitute an admission of
beneficial ownership for the stockholders named below. Holders of Series E
preferred stock are obligated to convert their preferred stock on the later of
(a) the date of this prospectus, or (b) 21st trading day following a reverse
split of our common stock, by dividing the amount they paid for such preferred
shares plus dividends at 6% per annum, by the lesser of $0.20, or 90% of the
average of the volume weighted average prices for our common stock for the
twenty trading days following the effective date of such reverse stock split
providing this registration statement is then effective. In calculating the
number of shares of common stock offered for sale we have assumed a conversion
price of $0.20 per common share for the Series E preferred stock, or 5,000
common shares for each Series E preferred share.















                                     Shares
                                                                 Owned        Shares                                Shares
                                                                Prior to      Being                           Beneficially Owned
                 Name of Selling Stockholder                    Offering     Offered          Type            After the Offering
--------------------------------------------------------------------------------------------------------------------------------------
                                                                                                              Number        Percent
A.4Y. Investments and Holdings Ltd.                                                                                   -
                                                              -           250,000              (1)                        -
Alan Cohen                                                                                                            -
                                                              79,641      138,157            (2) (3)                      -
Alan E. Ennis / SEP-IRA                                                                                               -
                                                              26,000      39,000               (2)                        -
Alan J. Rubin                                                                                                         -
                                                              521,182     635,182           (2) - (4)                     -
Albert Poliak                                                                                                         -
                                                              -           14,000             (9) (12)                     -
Allen Weiss                                                                                                           -
                                                              129,245     155,245            (2) (3)                      -
Alpha Capital AG                                                                                                      -
                                                              800,000     1,224,991          (2) (8)                      -
Anat Pinhas Green                                                                                                     -
                                                              -           500,000              (1)                        -
Annabel Lukens                                                                                                        -
                                                              3,000       36,600             (9) (12)                     -
ARC Securities Bvi Ltd                                                                                                -
                                                              -           1,000,000            (1)                        -
Ark Financial Services Inc.                                                                                           -
                                                              2,400       2,400              (9) (13)                     -
Arthur & Gail Gronbach                                                                                                -
                                                              66,962      86,962               (4)                        -
Arthur Gronbach                                                                                                       -
                                                              30,356      30,356             (2) (3)                      -
Atlas Master Fund, Ltd.                                                                                               -
                                                              -           1,560,000            (1)                        -
Avi Geffen                                                                                                            -
                                                              -           100,000              (1)                        -
Avitan Ami                                                                                                            -
                                                              -           100,000              (1)                        -
Azriel Wiederkehr                                                                                                     -
                                                              -           600,000              (1)                        -
Bay Star Capital II, L.P.                                                                                             -
                                                              219,900     377,214           (4) - (6)                     -
Ben Ari Gadi                                                                                                          -
                                                              -           760,000              (1)                        -
Bernard & Faith Marks                                                                                                 -
                                                              60,000      90,000               (4)                        -
Bernard McElhone                                                                                                      -
                                                              60,000      90,000               (4)                        -
Boaz Schwartz                                                                                                         -
                                                              -           400,000              (1)                        -
Brad Reifler                                                                                                          -
                                                              92,789      362,207            (9) (12)                     -
Brian Judge & Diana Garchitorena                                                                                      -
                                                              61,200      91,800               (4)                        -
Brian M Herman                                                                             (2) (3) (9)                -
                                                              209,922     624,062             (12)                        -
Bridges & Pipes, LLC                                                                                                  -
                                                              175,463     293,195          (4) (5) (8)                    -
Bristol Investment Fund, Ltd.
                                                              2,190,567   6,727,616         (1) - (6)            1,715       0.0%*
Bruce Falkin                                                                                                          -
                                                              1,082       1,407                (6)                        -
Byron Rosenstein                                                                                                      -
                                                              100,000     150,000              (2)                        -
Cambrex Bio Science Walkersville, Inc.                                                                                -
                                                              4,660,398   5,885,498          (4) (10)                     -
CGA Resources LLC                                                                                                     -
                                                              722,080     1,113,120          (2) (12)                     -
Charles Dollar
                                                              506,560     104,843            (9) (12)         506,560        0.6%*
Chattanooga Ventures, LLC                                                                                             -
                                                              100,000     150,000              (2)                        -
Christopher Choma                                                                                                     -
                                                              285,868     352,868            (2) (3)                      -
Christopher Shufeldt                                                                                                  -
                                                              -           89,375             (9) (12)                     -
Claude Ware                                                                                                           -
                                                              9,500       84,377             (9) (12)                     -
Commitment, Excellence & Business                                                                                     -
                                                              289,875     389,875            (2) (4)                      -
Cranshire Capital, L.P.                                                                                               -
                                                              -           2,500,000            (1)                        -
Crestview Capital Fund I, L.P.                                                                                        -
                                                              92,118      92,118             (3) (4)                      -
Crestview Capital Fund II, L.P.                                                                                       -
                                                              718,875     718,875            (3) (4)                      -
Crestview Capital Master LLC                                                                                          -
                                                              1,986,583   2,937,245            (2)                        -
Crestview Capital Offshore Fund Inc.                                                                                  -
                                                              13,160      13,160             (3) (4)                      -
Daldila LTD                                                                                                           -
                                                              -           250,000              (1)                        -
Dan Ly                                                                                                                -
                                                              -           125,000            (9) (12)                     -
Dan Volpert                                                                                                           -
                                                              -           500,000              (1)                        -
Dana Bowler                                                                                                           -
                                                              40,000      60,000               (2)                        -
Dana Paul Bowler                                                                                                      -
                                                              60,084      60,084               (3)                        -
Daniel Foley                                                                                                          -
                                                              137,741     167,741            (2) (3)                      -
Daniel Pietro                                                                                                         -
                                                              1,050       26,090               (9)                        -
Daniel Schneiderman                                                                                                   -
                                                              -           125,000            (9) (12)                     -
                                                                                                                    Shares
                                                                                                              Beneficially Owned
                                                                 Shares                                       After the Offering
                                                                 Owned        Shares
                                                                Prior to      Being
                 Name of Selling Stockholder                    Offering     Offered          Type
--------------------------------------------------------------------------------------------------------------------------------------
--------------------------------------------------------------------------------------------------------------------------------------
                                                                                                              Number        Percent
Daryl Demsko                                                                                                          -
                                                              130,157     156,157            (2) (3)                      -
David & Caren Garmus Trust                                                                                            -
                                                              64,000      96,000               (2)                        -
David Brill                                                                                                           -
                                                              116,045     136,045            (2) (3)                      -
David Grossman                                                                                                        -
                                                              -           150,000              (1)                        -
David Israel                                                                                                          -
                                                              323,976     638,952              (3)                        -
David Kostman                                                                                                         -
                                                              -           400,000              (1)                        -
David M. & Iry Ricci, Jt.                                                                                             -
                                                              1,803       2,344                (6)                        -
David P Garmus & Caren Garmus TTEEs FBO Garmus Living Trust                                                           -
                                                              102,164     102,164            (3) (4)                      -
David Prescott                                                                                                        -
                                                              137,165     167,165            (2) (3)                      -
David Snyder                                                                                                          -
                                                              344,955     494,955            (2) (4)                      -
David Wiener Revocable Trust                                                                                          -
                                                              40,000      60,000               (2)                        -
David Wiener Revocable Trust-96                                                                                       -
                                                              39,193      77,261               (3)                        -
David Wilstein & Sue Wilstein, Trustees of the Century Trust                                                          -
                                                              175,000     262,500            (2) (4)                      -
Dawson James Securities, Inc.                                                                                         -
                                                              -           59,400             (9) (13)                     -
Dennis Wells                                                                                                          -
                                                              100,000     150,000              (2)                        -
Double U Master Fund LP                                                                                               -
                                                              -           500,000              (1)                        -
Douglas Kaiser                                                                                                        -
                                                              -           14,000             (9) (12)                     -
Edge Investments Ltd.                                                                                                 -
                                                              -           200,000              (1)                        -
Ehud Lurie                                                                                                            -
                                                              -           250,000              (1)                        -
Eliahu Zahavi                                                                                                         -
                                                              -           1,000,000            (1)                        -
Eli-Peri & Moran Gotchlack                                                                                            -
                                                              -           100,000              (1)                        -
Elite Financial Communcations Group, LLC                                                                              -
                                                              -           75,000             (8) (13)                     -
Eric Singer                                                                                                           -
                                                              100,586     241,336          (8) (9) (12)                   -
Eurocom Investments L.P.                                                                                              -
                                                              -           2,000,000            (1)                        -
Fiserv Securities c/f Nathaniel Orme IRA                                                                              -
                                                              30,000      45,000               (4)                        -
Formula Investment House                                                                                              -
                                                              -           250,000              (1)                        -
Frances E. Belmont                                                                                                    -
                                                              85,000      105,000            (2) (4)                      -
Francisco J. Santiago                                                                                                 -
                                                              12,000      18,000               (4)                        -
Frank Salvatore                                                                                                       -
                                                              -           14,000          (9) (12)+D286                   -
Frederic M. Bauthier                                                                                                  -
                                                              234,173     274,173            (2) (3)                      -
Gal Ehrlich                                                                                                           -
                                                              -           300,000              (1)                        -
George F Manos Rollover IRA                                                                                           -
                                                              160,000     240,000              (2)                        -
George Manos                                                                                                          -
                                                              180,485     180,485              (3)                        -
Gerald Ferro                                                                                                          -
                                                              135,900     167,900            (2) (4)                      -
Gibralt Capital Corporation                                                                                           -
                                                              -           380,680              (3)                        -
Gilead Otensoser                                                                                                      -
                                                              7,500       7,500              (9) (12)                     -
Gmul Barak Market Making LTD.                                                                                         -
                                                              -           1,600,000          (1) (3)                      -
Greg Downes                                                                                                           -
                                                              275,163     335,163              (2)                        -
Grenfal J. Beachler                                                                                                   -
                                                              222,177     282,177            (2) (3)                      -
Haim Givon                                                                                                            -
                                                              -           300,000              (1)                        -
Hanoch Dovrath                                                                                                        -
                                                              -           300,000              (1)                        -
Harry Fallterbauer IRA                                                                                                -
                                                              18,000      27,000               (2)                        -
Harry Falterbauer                                                                                                     -
                                                              426,195     546,195            (2) (3)                      -
Helena Curtis IRA                                                                                                     -
                                                              2,525       3,283                (6)                        -
Hilary Bergman                                                                                                        -
                                                              92,789      362,207            (9) (12)                     -
HSBC Private Bank (Suisse) SA                                                                                         -
                                                              -           500,000              (1)                        -
Hudson Bay Fund LP                                                                                                    -
                                                              -           2,500,000          (1) (12)                     -
Hudson Valley Capital Management LLC                                                       (2) (3) (9)                -
                                                              246,428     506,560             (12)                        -
I. Allon Holdings                                                                                                     -
                                                              -           200,000              (1)                        -
Icon Capital Partners LP                                                                                              -
                                                              -           1,000,000          (1) (12)                     -
                                     Shares
                                                                                                                    Shares
                                                                                                              Beneficially Owned
                                                                 Owned        Shares                          After the Offering
                                                                Prior to      Being
                 Name of Selling Stockholder                    Offering     Offered          Type
--------------------------------------------------------------------------------------------------------------------------------------
--------------------------------------------------------------------------------------------------------------------------------------
                                                                                                              Number        Percent
Ilan Vinner                                                                                                           -
                                                              -           250,000              (1)                        -
Ilan Zajonts                                                                                                          -
                                                              -           100,000              (1)                        -
Insiders Trend Fund LP                                                                                                -
                                                              120,000     180,000              (4)                        -
Iron Grid Ltd.                                                                                                        -
                                                              118,157     138,157            (2) (3)                      -
Iroquois Master Fund Ltd.                                                                                             -
                                                              -           1,250,000            (1)                        -
Itzchak Keinan                                                                                                        -
                                                              -           600,000              (1)                        -
Jacob Shinkind                                                                                                        -
                                                              -           200,000              (1)                        -
James Doolan                                                                                                          -
                                                              -           6,635              (8) (12)                     -
James Lehman                                                                                                          -
                                                              233,170     273,170            (2) (3)                      -
James R Fisher & Diane R Fisher Living Trust                                                                          -
                                                              152,887     188,887            (2) (4)                      -
James St. Clair                                                                                                       -
                                                              1,552       12,913             (9) (12)                     -
Jason Adelman                                                                                                         -
                                                              1,340,000   5,146,262        (8) (9) (12)                   -
Jeffrey R. Bossert                                                                                                    -
                                                              85,000      105,000            (2) (4)                      -
Jerdan Enterprises, Inc.                                                                                              -
                                                              1,216,378   1,471,378         (2) - (4)                     -
Jerome L. Dreyfuss                                                                                                    -
                                                              84,938      104,938            (2) (4)                      -
JHF Ventures L.P.                                                                                                     -
                                                              -           13,091               (8)                        -
Joe Nahome                                                                                                            -
                                                              -           600,000              (1)                        -
John Bossert                                                                                                          -
                                                              85,000      105,000            (2) (4)                      -
John Green                                                                                                            -
                                                              -           20,592             (9) (12)                     -
John Jay Gephardt                                                                                                     -
                                                              47,600      58,800             (2) (4)                      -
John Keyser                                                                                                           -
                                                              1,800       1,800              (9) (12)                     -
John M. Somody                                                                                                        -
                                                              231,554     271,554            (2) (3)                      -
John O Johnston                                                                                                       -
                                                              60,084      60,084               (3)                        -
John O Johnston Trust U/A DTD 5/17/93                                                                                 -
                                                              32,000      48,000             (2) (4)                      -
John Simonelli                                                                                                        -
                                                              50,962      62,962             (2) (4)                      -
Johnathan Rand                                                                                                        -
                                                              30,000      45,000               (4)                        -
Jonathan M. Levine                                                                                                    -
                                                              -           250,000              (1)                        -
Jonathan Nassie                                                                                                       -
                                                              -           200,000              (1)                        -
Joseph Hoch                                                                                                           -
                                                              -           4,364                (8)                        -
Joseph McCandless                                                                                                     -
                                                              39,641      78,157               (3)                        -
Judith Ellen Olinger Rev Trust                                                                                        -
                                                              38,617      76,109               (3)                        -
Julie L. Michael                                                                                                      -
                                                              141,959     279,868              (3)                        -
Kanyas Yosi                                                                                                           -
                                                              -           250,000              (1)                        -
Kate Wiener                                                                                                           -
                                                              79,193      137,261            (2) (3)                      -
Kelda M. Sledz                                                                                                        -
                                                              207,365     243,365            (2) (3)                      -
Ken Pilot                                                                                                             -
                                                              -           157,488              (3)                        -
Kenneth Greif                                                                                                         -
                                                              1,172,450   1,372,450          (2) (3)                      -
Kenneth L. Gaspar                                                                                                     -
                                                              120,000     180,000              (2)                        -
Kimball Cross Investment Management Corp.                                                                             -
                                                              2,300       62,878             (9) (13)                     -
Kobi Gershoni                                                                                                         -
                                                              -           300,000              (1)                        -
Leah Kovitz                                                                                                           -
                                                              -           500,000              (1)                        -
Lednim Property Associates                                                                                            -
                                                              60,000      90,000               (4)                        -
Legend Merchant Group, Inc.                                                                                           -
                                                              2,500       32,500             (9) (13)                     -
Leo Mindel Non-GST Exempt Family Trust II                                                                             -
                                                              60,000      90,000               (4)                        -
Lester B. Boelter                                                                                                     -
                                                              100,000     150,000              (2)                        -
Louis & Kathy Cristan                                                                                                 -
                                                              318,169     410,169           (2) - (4)                     -
Lyle E. Cherbonneau                                                                                                   -
                                                              100,000     150,000              (2)                        -
M.R.C. Investments Ltd.                                                                                               -
                                                              -           842,750            (1) (9)                      -
Margaret & Donald Wisnasky                                                                                            -
                                                              140,000     210,000              (2)                        -
Maria Molinsky
                                                              66,106      3,972                (6)              63,051       0.1%*
                                     Shares
                                                                                                                    Shares
                                                                                                              Beneficially Owned
                                                                 Owned        Shares                          After the Offering
                                                                Prior to      Being
                 Name of Selling Stockholder                    Offering     Offered          Type
--------------------------------------------------------------------------------------------------------------------------------------
--------------------------------------------------------------------------------------------------------------------------------------
                                                                                                              Number        Percent
Marietta Dermatology Associates PSP FBO Myles Jerden                                                                  -
                                                              42,500      52,500             (2) (4)                      -
Mark & Andrea Yap JTE                                                                                                 -
                                                              175,800     217,800            (2) (4)                      -
Mark A. Hoffbauer                                                                                                     -
                                                              100,000     150,000              (2)                        -
Mark Ford                                                                                                             -
                                                              6,546       40,675             (9) (12)                     -
Mark J Gillis
                                                              506,560     130,856            (9) (12)         506,560        0.6%
Martin & Linda Mennes                                                                                                 -
                                                              235,950     335,950            (2) (4)                      -
Martin B. Margulies                                                                                                   -
                                                              1,803       2,344                (6)                        -
Martin Glassman                                                                                                       -
                                                              36,000      54,000               (4)                        -
Martin Mennes                                                                                                         -
                                                              91,029      91,029               (3)                        -
Martin P. Gerberg                                                                                                     -
                                                              200,000     300,000              (2)                        -
Martin P. Gerberg Trust                                                                                               -
                                                              60,000      90,000               (4)                        -
Mathew Balk                                                                                                           -
                                                              251,911     938,488          (8) (9) (12)                   -
Meir Marcovich                                                                                                        -
                                                              -           250,000              (1)                        -
Menachem & Sarah Genack                                                                                               -
                                                              -           18,955               (8)                        -
Michael J. Leja TTEE/ FBO Michael J. Leja Trust                                                                       -
                                                              230,213     270,213            (2) (3)                      -
Michael Liss                                                                              (2) -(5) , (8)              -
                                                              380,218     465,818             (12)                        -
Michael P. Rucker                                                                                                     -
                                                              45,000      45,000               (4)                        -
Michael P. Rucker Trust                                                                                               -
                                                              40,000      60,000             (2) (3)                      -
Michael Pokel                                                                                                         -
                                                              117,741     137,741              (2)                        -
Michael R. MacDonald                                                                                                  -
                                                              189,910     239,910            (2) (4)                      -
Michael Rapp                                                                                                          -
                                                              2,000       12,000             (9) (12)                     -
MLA Capital                                                                                                           -
                                                              -           150,000              (8)                        -
Monarch Capital Goup, LLC                                                                                             -
                                                              -           29,820             (9) (13)                     -
N.F.S., LLC, FBO Phil Clark IRA R/O                                                                                   -
                                                              183,600     226,800            (2) (4)                      -
Nancy Cymbala                                                                                                         -
                                                              85,000      105,000            (2) (4)                      -
Nancy Cymbala IRA                                                                                                     -
                                                              85,000      105,000            (2) (4)                      -
National Financial Services, LLC, Julius H. Roma IRA Rollover                                                         -
                                                              105,000     135,000            (2) (4)                      -
NFS LLC FBO: Randall M Tuggle IRA R/O                                                                                 -
                                                              60,000      90,000               (2)                        -
Nicolandra Properties, Inc.                                                                                           -
                                                              100,000     150,000              (2)                        -
Nir Nimrodi                                                                                                           -
                                                              -           100,000              (1)                        -
Nite Capital LP                                                                                                       -
                                                              -           3,000,000            (1)                        -
Norbert Olinger                                                                                                       -
                                                              38,617      76,109               (3)                        -
North American Spine Society / Eric Muehlbauer                                                                        -
                                                              100,000     150,000              (2)                        -
North Metropolitan Radiology Associates, LLP 401k PSP FBO:
Stuart Jacobson                                               883,981     135,900            (2) (4)          778,081        0.9%*
North Sound Legacy Institutional Fund LLC                                                                     137,206
                                                              1,557,354   13,264,613        (2) - (7)                     -
North Sound Legacy International Fund Ltd.                                                                    161,303
                                                              3,283,780   25,728,904        (2) - (7)                     -
Ori Ackerman                                                                                                          -
                                                              -           300,000              (1)                        -
Oscar Garza                                                                                                           -
                                                              202,165     242,165         (2) - (4) (13)                  -
Ota LLC                                                                                                               -
                                                              -           22,602               (8)                        -
P. Savyon Holdings Ltd.                                                                                               -
                                                              -           100,000              (1)                        -
Paradigm Group II, LLC
                                                              122,808     17,446               (6)            109,388        0.1%*
Paradigm Millenium Fund, L.P.                                                                                         -
                                                              203,548     302,959        (2) (4) (5) (6)                  -
Paragon Capital LP                                                                                                    -
                                                              -           1,300,000            (1)                        -
Paul Blizman                                                                                                          -
                                                              67,950      83,950             (2) (4)                      -
Paul Royalty Fund, LP
                                                              248,425     36,111             (6) (11)         220,647        0.3%*
Paul Scharfer                                                                                                         -
                                                              -           710,204          (3) (4) (8)                    -
Pequot Healthcare Fund, L.P.                                                                                          -
                                                              -           4,713                (8)                        -
Pequot Healthcare Offshore Fund, Inc.                                                                                 -
                                                              -           5,542                (8)                        -
Pequot International Fund, L.P.                                                                                       -
                                                              -           67,787               (8)                        -
Pequot Partners Fund, L.P.                                                                                            -
                                                              -           68,223               (8)                        -
                                     Shares
                                                                                                                    Shares
                                                                                                              Beneficially Owned
                                                                 Owned        Shares                     After the Offering
                                                                Prior to      Being
                 Name of Selling Stockholder                    Offering     Offered          Type
--------------------------------------------------------------------------------------------------------------------------------------
--------------------------------------------------------------------------------------------------------------------------------------
                                                                                                              Number        Percent
Peter Yaskowitz                                                                                                       -
                                                              275,163     335,163            (2) (3)                      -
Phil Wagenheim                                                                                                        -
                                                              2,000       12,000             (9) (12)                     -
Philip C Bird                                                                                                         -
                                                              139,200     163,200            (2) (3)                      -
Piper Jaffray C/F Bruce Kurchack IRA                                                                                  -
                                                              76,930      151,610            (3) (5)                      -
ProMed Offshore Fund II, Ltd.                                                                                         -
                                                              -           715,546              (3)                        -
ProMed Offshore Fund, Ltd.                                                                                            -
                                                              -           34,413               (3)                        -
ProMed Partners II, L.P.                                                                                              -
                                                              -           54,035               (3)                        -
ProMed Partners,L.P.                                                                                                  -
                                                              -           213,230              (3)                        -
Quality ReSolve, Inc.                                                                                                 -
                                                              -           285,000              (8)                        -
R&R Biotech Partners, LLC                                                                                             -
                                                              -           2,500,000          (1) (12)                     -
RA Schafer                                                                                                            -
                                                              87,900      108,900            (2) (4)                      -
Ralph Rybacki                                                                                                         -
                                                              103,089     123,089            (2) (3)                      -
RHP Master Fund, Ltd.                                                                                                 -
                                                              590,000     790,000            (2) (4)                      -
Richard L. Feldman IRA                                                                                                -
                                                              7,215       9,379                (6)                        -
Richard Molinsky
                                                              206,647     266,304            (2) (3)            53,495       0.1%*
Robert Cymbala                                                                                                        -
                                                              170,000     210,000            (2) (4)                      -
Robert Cymbala IRA                                                                                                    -
                                                              190,000     240,000            (2) (4)                      -
Robert D. Keyser Jr.                                                                                                  -
                                                              1,800       15,800             (9) (12)                     -
Robert Dombrowski                                                                                                     -
                                                              -           10,148             (9) (12)                     -
Robert Ilanit                                                                                                         -
                                                              -           250,000              (1)                        -
Robert J. Neborsky                                                                                                    -
                                                              80,000      196,136            (2) (3)                      -
Robert Kinney                                                                                                         -
                                                              89,900      111,900            (2) (4)                      -
Robert Klein & Myriam Gluck                                                                                           -
                                                              223,641     273,641           (2) - (4)                     -
Robert L. Hermanos                                                                                                    -
                                                              68,000      84,000             (2) (4)                      -
Robert Nathan                                                                                                         -
                                                              -           7,899              (8) (12)                     -
Robert W. Duggan                                                                                                      -
                                                              -           389,317           (3) - (6)                     -
Robin Burton                                                                                                          -
                                                              -           100,000              (1)                        -
Rodman & Renshaw, LLC                                                                                                 -
                                                              -           6,295,250          (9) (13)                     -
Ronald H. Wise                                                                                                        -
                                                              117,458     138,458            (2) (3)                      -
Ronald Suster                                                                                                         -
                                                              100,000     150,000              (2)                        -
Ronen Givon                                                                                                           -
                                                              -           400,000              (1)                        -
ROO, LLC                                                                                                              -
                                                              15,428      30,406               (3)                        -
Rosa Maria Lukens                                                                                                     -
                                                              16,000      24,000             (2) (12)                     -
Rosa Maria Lukens IRA                                                                                                 -
                                                              17,975      17,975               (4)                        -
Rose E. Snyder Trust                                                                                                  -
                                                              170,000     210,000            (2) (4)                      -
Roy                                                                                                                   -
Korins                                                        60,000      90,000               (4)                        -
Rucker Family Charitable Foundation Trust                                                                             -
                                                              56,000      84,000               (2)                        -
Rucker Family Charitable Lead Annuity Trust                                                                           -
                                                              80,000      120,000              (2)                        -
Rucker Family Charitable Lead Annuity Trust Dtd 1/1/03                                                                -
                                                              151,866     151,866              (3)                        -
Rudolf Treitel                                                                                                        -
                                                              -           8,727                (8)                        -
Russell A. Libby                                                                                                      -
                                                              100,000     150,000              (2)                        -
Salvatore Fazio                                                                                                       -
                                                              100,000     150,000              (2)                        -
Samuel Rapaport                                                                                                       -
                                                              -           500,000              (1)                        -
SDIRA FBO Alan E Ennis                                                                                                -
                                                              46,242      46,242               (3)                        -
SDIRA FBO Harry Faltenbauer Roth IRA                                                                                  -
                                                              17,975      17,975               (4)                        -
SDS Capital Group SPC, Ltd.
                                                              5,494,885   16,994,275        (1) - (7)         445,591        0.5%*
Sean Callahan & George Callahan                                                                                       -
                                                              84,938      104,938          (2) (4) (12)                   -
Sean M Callahan                                                                                                       -
                                                              4,175       81,768           (3) (9) (12)                   -
Sean M Callahan/ Sep IRA                                                                                              -
                                                              114,077     134,077            (2) (12)                     -
Selwyn Partners L.P.                                                                                                  -
                                                              276,804     489,108            (3) (13)                     -
                                     Shares
                                                                                                                    Shares
                                                                                                              Beneficially Owned
                                                                 Owned        Shares                          After the Offering
                                                                Prior to      Being
                 Name of Selling Stockholder                    Offering     Offered          Type
--------------------------------------------------------------------------------------------------------------------------------------
--------------------------------------------------------------------------------------------------------------------------------------
                                                                                                              Number        Percent
Shlomo Shefi                                                                                                          -
                                                              -           200,000              (1)                        -
Spectra Capital Management LLC                                                                                        -
                                                              -           2,500,000            (1)                        -
SR. Horn Assets LTD                                                                                                   -
                                                              -           200,000              (1)                        -
Stephen Rupp                                                                                                          -
                                                              30,000      45,000               (4)                        -
Stephen Swiatliewicz                                                                                                  -
                                                              30,000      45,000               (4)                        -
Steven Fields                                                                                                         -
                                                              120,000     180,000              (4)                        -
Stine Family Trust                                                                                                    -
                                                              100,000     150,000              (2)                        -
Stonestreet Limited Partnership                                                                                       -
                                                              114,728     149,147              (6)                        -
Stuart Jacobson
                                                              783,981     778,081              (2)            135,900        0.2%*
Sun West Holdings, Inc. Defined Benefit Pension Plan                                                                  -
                                                              100,000     150,000            (2) (3)                      -
Suzanne Downes                                                                                                        -
                                                              40,000      60,000               (2)                        -
SXJE, LLC                                                                                                             -
                                                              967,571     1,131,571          (2) (3)                      -
TCMP3 Partners
                                                              -           1,000,000            (1)
The Phoenix Insurance Company Ltd.                                                                                    -
                                                              -           5,000,000            (1)                        -
The Rucker Family Charitable Trust                                                                                    -
                                                              63,000      63,000               (4)                        -
Thomas Corona                                                                                                         -
                                                              3,600       27,175             (9) (12)                     -
Thomas Hands                                                                                                          -
                                                              -           2,500              (9) (12)                     -
Thomas J. Franco                                                                                                      -
                                                              307,163     383,163            (2) (3)                      -
Thomas K. Beard                                                                                                       -
                                                              365,732     465,732           (2) - (4)                     -
Tim V. Shea                                                                                                           -
                                                              40,000      60,000               (2)                        -
Timothy Sledz                                                                                                         -
                                                              247,850     317,850            (2) (4)                      -
Tom Leonard                                                                                                           -
                                                              12,000      18,000               (4)                        -
Tuggle Family LP                                                                                                      -
                                                              45,900      45,900               (4)                        -
Two River Group Holdings                                                                                              -
                                                              -           1,000,000            (1)                        -
Vestal Venture Capital                                                                                                -
                                                              329,000     797,128              (3)                        -
ViewTrade Financial                                                                                                   -
                                                              5,017       41,592             (9) (13)                     -
Vincent Vaiano                                                                                                        -
                                                              100,000     150,000              (2)                        -
Visium Balanced Fund, LP                                                                                              -
                                                              -           3,950,000            (1)                        -
Visium Balanced Offshore Fund, Ltd                                                                                    -
                                                              -           5,600,000            (1)                        -
Visium Long Bias Fund, LP                                                                                             -
                                                              -           820,000              (1)                        -
Visium Long Bias Offshore Fund, Ltd                                                                                   -
                                                              -           3,070,000            (1)                        -
Walter Chojnacki                                                                                                      -
                                                              136,045     166,045            (2) (3)                      -
Walter H. Brent Revocable Trust                                                                                       -
                                                              100,000     150,000              (2)                        -
Walter Kuharchik                                                                                                      -
                                                              296,713     396,713           (2) - (4)                     -
Wesley Eng                                                                                                            -
                                                              100,000     150,000              (2)                        -
Whalehaven Capital Fund Limited                                                                                       -
                                                              1,400,000   2,100,000            (2)                        -
Whalehaven Fund Ltd.                                                                                                  -
                                                              -           210,000              (4)                        -
William & Roxanne Blade                                                                                               -
                                                              40,000      60,000               (2)                        -
William Fox                                                                                                           -
                                                              -           2,500              (9) (12)                     -
William Konigsberg                                                                                                    -
                                                              1,803       2,344                (6)                        -
William M. Levin                                                                                                      -
                                                              18,000      27,000               (4)                        -
Wolfe, L.P.                                                                                                           -
                                                              42,500      52,500             (2) (4)                      -
Yehuda Dachs                                                                                                          -
                                                              476,500     694,500            (2) (4)                      -
Yom Tov Sidi                                                                                                          -
                                                              -           200,000              (1)                        -
YS TAMI Trade LTD                                                                                                     -
                                                              -           600,000              (1)                        -
* Less than 1%




Type:

(1)      Represents or includes common shares issuable to these Selling
         Stockholders upon (a) conversion of their Series E preferred stock
         acquired through purchases of those preferred shares in our April 17th,
         2006 private placement. The Selling Stockholders may convert their
         Series E preferred shares into shares of our common stock by dividing
         the stated value of the Series E preferred shares by the lesser of
         $0.20 (that is, 5,000 shares of common stock for a $1,000 Series E
         preferred share) or such lower amount determined by taking 90% of the
         twenty-day volume weighted average price after the later of the date of
         this prospectus or the date after we have effected a reverse split of
         our common stock of one new share for not less than five old shares.
         For purposes of calculating the number of shares issuable upon
         conversion of our Series E preferred stock, we have assumed a
         conversion rate of $0.20 per share of common stock., and (b) exercise
         of Series H warrants acquired in our April 17, 2006 private placement.

         Although not included in the shares listed for these persons in the
         above table, we have also registered for sale by them additional shares
         of our common stock equal to 25% of the number of shares included in
         the table and described in the first paragraph of this footnote 1. We
         registered such additional shares, the sales of which may be made
         pursuant to this prospectus, to qualify for public sale shares issuable
         (i) as dividends on our Series E preferred stock, (ii) in the event
         that the conversion rate of the Series E preferred stock is les than
         $0.20 per common share and (iii) as additional common shares that may
         be issuable by us as a result of the anti-dilution provisions of our
         Series E preferred stock and/or our Series H warrants. We are obligated
         to register such 25% additional shares pursuant to our agreements with
         the investors in our April 17, 2006 private placement.
(2)      Represents or includes shares (a) purchased by these Selling  Stockholders
         in our private  placements in October 2005 and (b)
         issuable to them upon exercise of their Series F warrants acquired in that private placement.
(3)      Represents or includes shares issued to these Selling Stockholders in
         connection with (a) their extension of the due dates of our promissory
         notes held by them to December 31, 2004 and (b) their subsequent
         conversion of their promissory notes upon our completion of a private
         placement of our equity securities in excess of $5,000,000 on January
         5, 2005 and /or (c) issuable to them upon exercise of their Series E
         warrants which they also received for the conversion of their
         promissory notes.
(4)      Represents or includes shares (a) purchased by these Selling
         Stockholders in our private placements on January 5, 2005 and in
         February 2005 and /or (b) issuable to them upon exercise of their
         Series E warrants acquired in those private placements.
(5)      Represents or includes shares (a) issued to these Selling Stockholders
         in connection with their exchange of our Series C preferred stock for
         common stock and concurrent purchases by them of our common stock in
         our January 5, 2005 private placement, and / or (b) issuable to them
         upon their exercise of their Series E warrants acquired in that private
         placement.
(6)      Includes shares (a) purchased by these Selling Stockholders in our
         December 2004 private placement sale of our common stock to holders of
         our Series B-1, B-2, and C warrants and / or (b) issuable to them upon
         exercise of their Series E warrants acquired in that private placement.
(7)      Includes shares issuable to these Selling Stockholders upon conversion
         of our Series D preferred stock received by them in lieu of our common
         stock in the various private placements of our equity securities.
(8)      Represents  or includes  shares  issuable to these  Selling  Stockholders
         upon exercise of their Series B-1, B-2, C, or other
         warrants.
(9)      Represents or includes shares issued (some of which were transferred to
         these Selling Stockholders) that were originally issued as fees for
         finders or, placement agents for (a) our promissory note financings,
         (b) our October 2005 private placement, (c) our acquisition of Hapto
         Biotech, Inc, (d) in lieu of cash financial advisory fees, and (e) our
         April 2006 private placement of our Series E preferred stock.
(10)     This Selling Stockholder has entered into material manufacturing and
         sales agreements with us more fully described in "Description of
         Business -Sales and Marketing" and "Descrption of Business-Production
         and Supply." See also Note 14 to our financial statements for the year
         ended December 31, 2005 elsewhere in the prospectus. . Includes shares
         and shares issuable upon exercise of warrants, both in lieu of cash
         payment for production suite fees.
(11)     This Selling Stockholder has entered into a material agreement with us
         in which it acquired an interest in our future revenues. This agreement
         is more fully described in "Description of Business- Sales and
         Marketing" and "Description of Business-Production and Supply". See
         also Note 9 to our financial statements for the year ended December 31,
         2005 elsewhere in the prospectus.
(12)     This Selling Stockholder is an affiliate of a broker-dealer. (13) This
         Selling Stockholder is a broker-dealer.








                              PLAN OF DISTRIBUTION

Each Selling Stockholder of the common stock and any of their pledgees,
assignees and successors-in-interest may, from time to time, sell any or all of
their shares of common stock on the Over the Counter Bulletin Board or any other
stock exchange, market or trading facility on which the shares are traded or in
private transactions. These sales may be at fixed or negotiated prices. A
Selling Stockholder may use any one or more of the following methods when
selling shares:

o    ordinary brokerage transactions and transactions in which the broker-dealer
     solicits purchasers;

o    block trades in which the broker-dealer will attempt to sell the shares as
     agent but may position and resell a portion of the block as principal to
     facilitate the transaction;

o    purchases by a broker-dealer as principal and resale by the broker-dealer
     for its account;

o    an exchange distribution in accordance with the rules of the applicable
     exchange;

o    privately negotiated transactions;

o        settlement of short sales entered into after the effective date of the registration statement of which this prospectus is a
                  part;

o        broker-dealers may agree with the Selling Stockholders to sell a specified number of such shares at a stipulated price per
                  share;

o        through the writing or settlement of options or other hedging transactions, whether through an options exchange or
                  otherwise;

o        a combination of any such methods of sale; or

o        any other method permitted pursuant to applicable law.

The Selling Stockholders may also sell shares under Rule 144 under the
Securities Act of 1933, as amended (the "Securities Act"), if available, rather
than under this prospectus.

Broker-dealers engaged by the Selling Stockholders may arrange for other
brokers-dealers to participate in sales. Broker-dealers may receive commissions
or discounts from the Selling Stockholders (or, if any broker-dealer acts as
agent for the purchaser of shares, from the purchaser) in amounts to be
negotiated, but, except as set forth in a supplement to this prospectus, in the
case of an agency transaction not in excess of a customary brokerage commission
in compliance with NASDR Rule 2440; and in the case of a principal transaction a
markup or markdown in compliance with NASDR IM-2440.

In connection with the sale of the common stock or interests therein, the
Selling Stockholders may enter into hedging transactions with broker-dealers or
other financial institutions, which may in turn engage in short sales of the
Common Stock in the course of hedging the positions they assume. The Selling
Stockholders may also sell shares of the common stock short and deliver these
securities to close out their short positions, or loan or pledge the common
stock to broker-dealers that in turn may sell these securities. The Selling
Stockholders may also enter into option or other transactions with
broker-dealers or other financial institutions or the creation of one or more
derivative securities which require the delivery to such broker-dealer or other
financial institution of shares offered by this prospectus, which shares such
broker-dealer or other financial institution may resell pursuant to this
prospectus (as supplemented or amended to reflect such transaction).

The Selling Stockholders and any broker-dealers or agents that are involved in
selling the shares may be deemed to be "underwriters" within the meaning of the
Securities Act in connection with such sales. In such event, any commissions
received by such broker-dealers or agents and any profit on the resale of the
shares purchased by them may be deemed to be underwriting commissions or
discounts under the Securities Act. No Selling Stockholder has informed us that
it has any written or oral agreement or understanding, directly or indirectly,
with any person to distribute the common stock. In no event shall any
broker-dealer receive fees, commissions and markups which, in the aggregate,
would exceed eight percent (8%).

We are required to pay certain fees and expenses incurred by us incident to the
registration of the shares. We have agreed to indemnify the Selling Stockholders
against certain losses, claims, damages and liabilities, including liabilities
under the Securities Act.

Because Selling Stockholders may be deemed to be "underwriters" within the
meaning of the Securities Act, they will be subject to the prospectus delivery
requirements of the Securities Act including Rule 172 thereunder. In addition,
any securities covered by this prospectus which qualify for sale pursuant to
Rule 144 under the Securities Act may be sold under Rule 144 rather than under
this prospectus. There is no underwriter or coordinating broker acting in
connection with the proposed sale of the shares by the Selling Stockholders.

We agreed to keep this prospectus effective until the earlier of (i) the date on
which the shares may be resold by the Selling Stockholders without registration
and without regard to any volume limitations by reason of Rule 144(k) under the
Securities Act or any other rule of similar effect or (ii) all of the shares
have been sold pursuant to this prospectus or Rule 144 under the Securities Act
or any other rule of similar effect. The shares will be sold only through
registered or licensed brokers or dealers if required under applicable state
securities laws. In addition, in certain states, the shares may not be sold
unless they have been registered or qualified for sale in the applicable state
or an exemption from the registration or qualification requirement is available
and is complied with.

Under applicable rules and regulations under the Securities Exchange Act of
1934, as amended (the "Exchange Act"), any person engaged in the distribution of
the shares may not simultaneously engage in market making activities with
respect to the common stock for the applicable restricted period, as defined in
Regulation M, prior to the commencement of the distribution. In addition, the
Selling Stockholders will be subject to applicable provisions of the Exchange
Act and the rules and regulations thereunder, including Regulation M, which may
limit the timing of purchases and sales of shares of the common stock by the
Selling Stockholders or any other person. We will make copies of this prospectus
available to the Selling Stockholders and have informed them of the need to
deliver a copy of this prospectus to each purchaser at or prior to the time of
the sale (including by compliance with Rule 172 under the Securities Act).

                            DESCRIPTION OF SECURITIES

General

We are authorized to issue 200,000,000 shares of common stock, par value $.001
per share, and 1,000,000 shares of preferred stock, par value $.001 per share.
As of June 1, 2006, 87,072,596 shares of our common stock were outstanding and
owned of record by approximately 300 persons, 5,948.615 shares of our Series D
convertible preferred stock were outstanding and owned of record by two
entities, and 6477.333 shares of our Series E convertible preferred stock were
outstanding and were owned of record by approximately 60 persons or entities. We
estimate that there are more than 1,800 beneficial owners of our common stock.

Common Stock

Holders of our common stock are entitled to one vote for each share on all
matters submitted to a vote of our stockholders, including the election of
directors. Our certificate of incorporation does not provide for cumulative
voting. Accordingly, holders of our common stock and of our Series E convertible
preferred stock(which are entitled to vote on all matters submitted to
stockholders on an as if fully converted basis) may elect all of the directors
standing for election if they choose to do so. Holders of common stock will be
entitled to receive ratably dividends, if any, declared from time to time by our
Board of Directors, and will be entitled to receive ratably all of our assets
available for distribution to them upon liquidation. All currently outstanding
shares of our common stock are, and all shares of our common stock offered
hereby, upon issuance and sale, will be, fully paid and nonassessable.

Preferred Stock

Our certificate of incorporation currently provides that we are authorized to
issue up to 1,000,000 shares of "blank check" preferred stock. Without any
further approval by our stockholders, our Board of Directors may designate and
authorize the issuance, upon the terms and conditions the directors may
determine, of one or more classes or series of preferred stock with prescribed
preferential dividend and liquidation rights, voting, conversion, redemption and
other rights. The issuance of preferred stock, while providing flexibility for
securing needed financing and for possible acquisitions and other corporate
purposes, could, among other things, adversely affect the voting power of the
holders of the common stock. Under certain circumstances, the issuance of
preferred stock could also make it more difficult for a third party to gain
control of Ortec, discourage bids for the common stock at a premium or otherwise
adversely affect the market price of our common stock.

Series D Convertible Preferred Stock

Designation and Rank

On August 19, 2003, in connection with our board of director's authority to
issue "blank check" preferred stock, we filed an amendment to our certificate of
incorporation in which amendment we designated the relative rights and
preferences of our Series D preferred stock pursuant to which our board of
directors authorized the issuance of 2,000 shares of Series D preferred stock,
par value $0.001 per share. The Series D preferred stock shall rank prior to the
common stock for purposes of liquidation preference and to all other classes and
series of our equity securities that by their terms do not rank senior to the
Series D preferred stock, except that the Series D preferred stock shall be
subordinate to and rank junior to all other classes of our preferred stock
outstanding as of the date hereof or hereafter created unless any series of
preferred stock hereafter created by its terms ranks junior to the Series D
preferred stock. The Series D preferred stock shall be subordinate to and rank
junior to all our indebtedness now or hereafter outstanding. The Series D
preferred stock has a stated value of $10,000 per share. As of the date of this
prospectus there are 5,948.615 shares of Series D preferred stock outstanding.

Dividends

In the event we declare a cash dividend on our common stock we will be required
to pay a dividend on each share of our Series D preferred stock in an amount
equal to the cash dividend paid on one share of our common stock multiplied by
the number of shares of our common stock into which such one share of our Series
D preferred stock can be converted.

Voting Rights

Except as described below and otherwise required by Delaware law, the Series D
preferred stock has no voting rights.

As long as any shares of the Series D preferred stock remain outstanding, we
will not, without the affirmative vote or consent of the holders of at least 75%
of the shares of the Series D preferred stock outstanding at the time, voting
separately as a class:

o                 amend, alter or repeal the provisions of the Series D
                  preferred stock so as to adversely affect any right,
                  preference, privilege or voting power of the Series D
                  preferred stock;

o                 effect any distribution with respect to junior stock except
                  that we may effect a distribution on our common stock if we
                  make a like kind distribution on each share of our Series D
                  preferred stock outstanding in an amount equal to the
                  distribution on one share of our common stock multiplied by
                  the number of shares of our common stock into which one share
                  of our Series D preferred stock can be converted at such time.

Liquidation Preference

In the event of our liquidation, dissolution or winding up, the holders of
shares of the Series D preferred stock then outstanding shall be entitled to
receive, out of our assets, a Series D Liquidation Preference Amount equal to
$10,000 per share of the Series D preferred stock before any payment shall be
made or any assets distributed to the holders of our common stock or any other
junior stock. However, no Series D Liquidation Preference Amount shall be paid
on any Series D preferred stock unless we have first finished paying all
liquidation preference amounts on all other classes of our outstanding preferred
stock which do not by their terms rank junior to the Series D preferred stock.
If our assets can pay some of, but are not sufficient to pay in full, the Series
D Liquidation Preference Amount to the holders of the Series D preferred stock,
then all of our assets available to pay any portion of the Series D Liquidation
Preference Amount will be distributed among the holders of the Series D
preferred stock ratably on a per share basis. After payment of the full Series D
Liquidation Preference Amount, the holders of shares of Series D preferred stock
will not be entitled to any further participation as such in any distribution of
our assets.

Conversion

Voluntary Conversion

Each holder of Series D preferred stock may, at such holder's option, subject to
certain limitations described below, elect to convert all or any portion of the
shares of Series D preferred stock held by such holder into a number of fully
paid and nonassessable shares of our common stock equal to the quotient of (i)
the Series D liquidation preference amount divided by (ii) the Series D
conversion price (as defined below).

Conversion Restrictions

At no time may a holder of shares of Series D preferred stock convert shares of
the Series D preferred stock if the number of shares of common stock to be
issued pursuant to such conversion would exceed, when aggregated with all other
shares of our common stock owned by such holder at such time, the number of
shares of common stock which would result in such holder beneficially owning in
excess of 9.99% of all of our common stock outstanding at such time; provided,
however, that upon a holder of Series D preferred stock providing us with
sixty-one days notice that such holder would like to waive this provision with
regard to any or all shares of common stock issuable upon conversion of his
Series D preferred stock, this provision shall be of no force or effect with
regard to those shares of Series D preferred stock designated in such notice.

Mandatory Conversion

Upon our written request a holder of Series D preferred stock shall advise us in
writing as to the number of shares of our common stock that are beneficially
owned by such holder. If the shares of our common stock beneficially owned by
such holder amount to less than 9.99% of the shares of our common stock
outstanding at such time, we may, at our option, compel such holder to convert
such portion of the Series D preferred stock owned by him into so many shares of
our common stock so that the total number of shares of our common stock
beneficially owned by such holder after such conversion shall equal 9.99%, but
not more, of the shares of our common stock outstanding after such conversion.

Series D Conversion Price

The Series D preferred stock is subject to a fixed conversion price equal to
$2.50 per share, subject to customary adjustments to the Series D conversion
price in the event of stock splits, combinations, dividends, distributions,
reclassifications and other corporate events.

Reservation of Shares of Common Stock

As long as any shares of Series D preferred stock are outstanding, we are
required to reserve and keep available out of our authorized and unissued common
stock, solely for the purpose of effecting the conversion of the Series D
preferred stock, 100% of such number of shares of common stock that will be
sufficient to effect the conversion of all of the Series D preferred stock then
outstanding.

Series E 6% Convertible Preferred Stock

Designation and Rank

On April 6, 2006, in connection with our board of director's authority to issue
"blank check" preferred stock, we filed an amendment to our certificate of
incorporation in which amendment we designated the relative rights and
preferences of our Series E 6% convertible preferred stock pursuant to which our
board of directors authorized the issuance of 8,000 shares of Series E 6%
convertible preferred stock, par value $0.001 per share. The Series E 6%
convertible preferred stock shall rank prior to the common stock for purposes of
liquidation preference and to all other classes and series of our equity
securities that by their terms do not rank senior to the Series E 6% convertible
preferred stock, except that the Series E 6% convertible preferred stock shall
be subordinate to and rank junior to all other classes of our preferred stock
outstanding as of the date hereof or hereafter created unless any series of
preferred stock hereafter created by its terms ranks junior to the Series E 6%
convertible preferred stock. The Series E 6% convertible preferred stock shall
be subordinate to and rank junior to all our indebtedness now or hereafter
outstanding. The Series E 6% convertible preferred stock has a stated value of
$1,000 per share. As of the date of this prospectus there are 6477.333 shares of
Series E 6% convertible preferred stock outstanding.

Dividends

6% per annum.

Voting Rights

The Series E convertible preferred stock has the right to vote on an "as
converted" basis on all matters to be voted on by the holders of the common
stock.

Liquidation Preference

In the event of our liquidation, dissolution or winding up, the holders of
shares of the Series E 6% convertible preferred stock then outstanding shall be
entitled to receive, out of our assets, a Series E Liquidation Preference Amount
equal to the stated value, plus any accrued and unpaid dividends and any other
fees or liquidated damages owing thereon, before any payment shall be made or
any assets distributed to the holders of our common stock or any other junior
stock. However, no Series E Liquidation Preference Amount shall be paid on any
Series E preferred stock unless we have first finished paying all liquidation
preference amounts on all other classes of our outstanding preferred stock which
do not by their terms rank junior to the Series E preferred stock. If our assets
can pay some of, but are not sufficient to pay in full, the Series E Liquidation
Preference Amount to the holders of the Series E preferred stock, then all of
our assets available to pay any portion of the Series E Liquidation Preference
Amount will be distributed among the holders of the Series E preferred stock
ratably on a per share basis. After payment of the full Series E Liquidation
Preference Amount, the holders of shares of Series E preferred stock will not be
entitled to any further participation as such in any distribution of our assets.

Conversion

Voluntary Conversion

Each holder of Series E preferred stock may, at such holder's option, subject to
certain limitations described below, elect to convert all or any portion of the
shares of Series E preferred stock held by such holder into a number of fully
paid and nonassessable shares of our common stock equal to the quotient of (i)
the Series E stated value amount divided by (ii) $0.20.

Conversion Restrictions

At no time may a holder of shares of Series E preferred stock convert shares of
the Series E preferred stock if the number of shares of common stock to be
issued pursuant to such conversion would exceed, when aggregated with all other
shares of our common stock owned by such holder at such time, the number of
shares of common stock which would result in such holder beneficially owning in
excess of 9.99% of all of our common stock outstanding at such time; provided,
however, that upon a holder of Series E preferred stock providing us with
sixty-one days notice that such holder would like to waive this provision with
regard to any or all shares of common stock issuable upon conversion of his
Series E preferred stock, this provision shall be of no force or effect with
regard to those shares of Series E preferred stock designated in such notice.

Mandatory Conversion

Notwithstanding anything to the contrary, on the 21st trading day (the
"Automatic Conversion Date") following the later of (a) the effective date of
reverse split of our outstanding common stock in a ratio of one new share for
not less than five old shares and (b) the date of the prospectus, the Series E
preferred stock plus all accrued but unpaid dividends and all liquidated damages
and other amounts due in respect of the preferred stock shall automatically
convert into common stock at a conversion price equal to the lesser of (i) $0.20
(subject to adjustment for the reverse split) or (ii) 90% of the average of the
volume weighted average price of our common stock for the 20 trading days
immediately following the effective date of the reverse split. Provided,
however, that a holder may voluntarily convert its preferred stock prior to the
date set for the mandatory conversion.

 Reservation of Shares of Common Stock

As long as any shares of Series E preferred stock are outstanding, we are
required to reserve and keep available out of our authorized and unissued common
stock, solely for the purpose of effecting the conversion of the Series E
preferred stock, 100% of such number of shares of common stock that will be
sufficient to effect the conversion of all of the Series E preferred stock then
outstanding.

Warrants

We issued the following warrants to the purchasers of our Series B preferred
stock and our Series C preferred stock and to the designees of the placement
agent who arranged our Series B preferred stock financings in 2002 and 2003, and
to purchasers of our Series C preferred stock financing in 2003. We also issued
our Series E warrants to participants in a series of private placement and debt
financing transactions that we completed in December 2004 and in January and
February 2005.






Series B-1 Warrants

Exercisable for the purchase of 176,198 shares of our common stock.

Exercise price:  $4.00 per share.

Expiration date: November 13, 2009.

Series B-2 Warrants

Exercisable for the purchase of 112,798 shares of our common stock.

Exercise price:  $5.00 per share.

Expiration date: November 13, 2009.


Both the Series B-1 and the Series B-2 warrants contain customary provisions
with respect to adjustments to the exercise price and the number of shares of
our common stock issuable upon exercise of the warrants in the event we are a
party to any recapitalization, reorganization, reclassification, consolidation,
merger, sale, stock dividend, stock split or reverse stock split involving our
common stock

Series C Warrants

Exercisable for the purchase of 102,000 shares of our common stock.

Exercise price:  $3.60 per share

Expiration dates:

         May 22, 2008 for warrants to purchase 42,000 shares July 28, 2008 for
         warrants to purchase 60,000 shares

The Series C warrants contain customary provisions with respect to adjustments
to the exercise price and the number of shares of our common stock issuable upon
exercise of the warrants in the event we are a party to any recapitalization,
reorganization, reclassification, consolidation, merger, sale, stock dividend,
stock split or reverse stock split involving our common stock

Series E Warrants

Exercisable for the purchase of 21,385,537 shares of our common stock.

Exercise price: $0.91, $0.79, and $0.001 with respect to 3,814,189, 717,600, and
14,107,372, respectively, shares of our common stock underlying Series E
warrants, and $0.35 with respect to 2,746,376 shares underlying our Series E-PA
warrants.

Expiration date: January 5, 2010

The Series E warrants contain customary provisions with respect to adjustments
to the exercise price and the number of shares of our common stock issuable upon
exercise of the Series E warrants in the event we are a party to any
recapitalization, reorganization, reclassification, consolidation, merger, sale,
stock dividend, stock split or reverse stock split involving our common stock

The Series E warrants also provide that if we sell shares of our common stock at
prices below the exercise prices of those warrants, or issue other securities
convertible into, or which entitle the holder to purchase, shares of our common
stock, which could result in the sale of our common stock at a price which in
effect (taking into consideration the price paid for the convertible security or
the warrant or the option) is less than the exercise price of the Series E
warrants, then the exercise price of the Series E warrants is reduced by a
portion of the difference between the exercise price and the lower price at
which the common stock was, or effectively could be, acquired. That percentage
by which the exercise price of the Series E warrants could be reduced depends
not only on the lower price at which our common stock was, or could be,
acquired, but also by the ratio that the number of shares of our common stock
that were, or could be, so acquired bears to the total number of shares of our
common stock that would be outstanding after such sale of our common stock, or
the conversion of securities convertible into, or the exercise of such warrants
or options to purchase, our common stock.

Commencing on January 5, 2007, subject to a registration statement then being
effective with respect to the common stock underlying the Series E warrants, the
Series E warrants may be redeemed by us if trading in our common stock closes
above $3.60 for ten consecutive trading days. We have no right to redeem any of
the E-PA warrants.

Series F Warrants

Exercisable for the purchase of 20,623,510 shares of our common stock.

Exercise price: $0.45 with respect to 17,443,892 shares Series F warrants and;
$0.30 with respect to 3,179,618 Series F-PA warrants.

Expiration date: October 12, 2012

The Series F warrants contain customary provisions with respect to adjustments
to the exercise price and the number of shares of our common stock issuable upon
exercise of the Series F warrants in the event we are a party to any
recapitalization, reorganization, reclassification, consolidation, merger, sale,
stock dividend, stock split or reverse stock split involving our common stock

The Series F warrants also provide that if we sell shares of our common stock at
prices below the exercise prices of those warrants, or issue other securities
convertible into, or which entitle the holder to purchase, shares of our common
stock, which could result in the sale of our common stock at a price which in
effect (taking into consideration the price paid for the convertible security or
the warrant or the option) is less than the exercise price of the Series F
warrants, then the exercise price of the Series F warrants is reduced by a
portion of the difference between the exercise price and the lower price at
which the common stock was, or effectively could be, acquired. That percentage
by which the exercise price of the Series F warrants could be reduced depends
not only on the lower price at which our common stock was, or could be,
acquired, but also by the ratio that the number of shares of our common stock
that were, or could be, so acquired bears to the total number of shares of our
common stock that would be outstanding after such sale of our common stock, or
the conversion of securities convertible into, or the exercise of such warrants
or options to purchase, our common stock.

Commencing on January 5, 2007, subject to a registration statement then being
effective with respect to the common stock underlying the Series F warrants, the
Series F warrants may be redeemed by us if trading in our common stock closes
above $3.60 for ten consecutive trading days. We have no right to redeem any of
the F-PA warrants.

Series G Warrants

Exercisable for the purchase of 3,000,000 shares of our common stock.

Exercise price:  $0.30 per share

Expiration date:  April 10, 2009

The Series G warrants contain customary provisions with respect to adjustments
to the exercise price and the number of shares of our common stock issuable upon
exercise of the Series G warrants in the event we are a party to any
recapitalization, reorganization, reclassification, consolidation, merger, sale,
stock dividend, stock split or reverse stock split involving our common stock.

Series H Warrants

Exercisable for the purchase of 32,536,665 shares of our common stock.

Exercise price:  $0.50

Expiration date: April 11, 2011.

The Series H warrants contain customary provisions with respect to adjustments
to the exercise price and the number of shares of our common stock issuable upon
exercise of the warrants in the event we are a party to any recapitalization,
reorganization, reclassification, consolidation, merger, sale, stock dividend,
stock split or reverse stock split involving our common stock.

The Series H warrants also provide that if we sell shares of our common stock at
prices below the exercise prices of those warrants, or issue other securities
convertible into, or which entitle the holder to purchase, shares of our common
stock, which could result in the sale of our common stock at a price which in
effect (taking into consideration the price paid for the convertible security or
the warrant or the option) is less than the exercise price of the Series H
warrants, then the exercise price of the Series H warrants is reduced to the
lower price at which the common stock was, or effectively could be, acquired.

Other Warrants and Options

We also have other warrants outstanding which entitle the holders to purchase an
aggregate of 8,553,100 shares of our common stock, of which three year warrants
expiring March 17, 2009 to purchase 285,000 shares are exercisable at $0.25 per
share, of which three year warrants expiring April 14, 2009 to purchase
4,000,000 shares are exercisable at $0.30 per share, of which five year warrants
expiring April 17, 2011 to purchase 2,888,000 shares are exercisable at $0.40
per share, of which warrants expiring July 18, 2008 to purchase 25,000 shares
are exercisable at $0.50 per share, warrants to purchase 25,000 shares expiring
December 1, 2008 are exercisable at $0.50 per share, warrants to purchase 50,000
shares expiring April 5, 2009 are exercisable at $0.50 per share, of which three
year warrants to purchase 1,105,100 shares expiring February 13, 2009 are
exercisable at $0.75 per share, of which three year warrants to purchase 25,000
shares expiring October 18, 2008 are exercisable at $1.00 per share, of which
three year warrants expiring July 22, 2006 to purchase 150,000 shares are
exercisable at $2.00 per share. We have granted options under our employee stock
option plan, and options outside the plan, to our employees, directors,
consultants and vendors, to purchase an aggregate of 8,310,980 shares of our
common stock at exercise prices ranging from $0.20 to $2.25 per share for
7,432,999 shares, and at exercise prices in excess of $2.25 per share for
877,981 shares.

Requirements to file registration statements

During the past four years we have completed a number of private placements of
our equity securities which have provided us with the funds we needed to
continue our business operations. In April 2006 we issued our equity securities
to acquire Hapto Biotech, Inc. Our securities described above which we sold in
such private placements and issued for such acquisition include our common
stock, our Series D and E convertible preferred stock and our Series B-1, B-2,
C, E, F, G and H warrants. In all of the agreements we signed with the investors
in those private placements and with the former shareholders of Hapto Biotech we
undertook obligations to file registration statements with the Securities and
Exchange Commission to enable those investors and former Hapto Biotech
shareholders to sell in the public securities markets the shares of our common
stock which those investors (a) acquired, (b) could acquire upon conversion of
the preferred stock they acquired, or (c) could acquire upon exercise of the
warrants they acquired. The registration statement of which this prospectus is a
part was filed by us pursuant to those obligations we undertook. Some of our
agreements with those investors and former Hapto Biotech shareholders also
provide for penalties we have to pay if we fail to timely file, or fail to have
the registration statement declared effective, in the periods provided in those
agreements. Those penalties range from 1% to 2% per month (for 18 to 24 months)
of the purchase prices paid by the investors in the private placements for those
securities for which registration deadline filing and effectiveness dates have
not been met. Although in the past we have not incurred any of those penalties
(often securing waivers in accordance with the provisions in those agreements),
we can give no assurance that we will not incur those penalties in the future.
Furthermore, the pendency of a registration statement before it is declared
effective by the Securities and Exchange Commission, may, because of the
Commission's general solicitation rule, prevent us from simultaneously raising
funds from future private placement sales of our securities when we need such
funds to continue our business operations.

                                 TRANSFER AGENT

The transfer agent for our common stock is Registrar and Transfer Company,
Cranford, New Jersey.

                                     EXPERTS

Our consolidated financial statements as of December 31, 2005 and for the two
years then ended and for the period from March 12, 1991 (inception) to December
31, 2005, (except for the consolidated statements of operations, shareholders'
deficit and cash flows for the period from March 12, 1991 (inception) to
December 31, 2003, which were audited by Grant Thornton LLP,) included in this
prospectus and in the registration statement of which this prospectus is a part,
have been audited by BDO Seidman, LLP, an independent registered public
accounting firm, to the extent and for the period set forth in their report. BDO
Seidman's report which contains an explanatory paragraph regarding our ability
to continue as a going concern, is incorporated herein in reliance upon the
authority of said firm as experts in auditing and accounting.

The consolidated financial statements for the period from March 12, 1991
(inception) to December 31, 2003, have been audited by Grant Thornton LLP, a
registered independent public accounting firm, to the extent and for the periods
set forth in their report. Their report, which also contains an explanatory
paragraph regarding our ability to continue as a going concern, is incorporated
herein in reliance upon the authority of said firm as experts in auditing and
accounting.

                                  LEGAL MATTERS

The legality of the common stock offered hereby will be passed upon for us by
Feder, Kaszovitz, Isaacson, Weber, Skala, Bass & Rhine LLP, New York, New York.

                              AVAILABLE INFORMATION

Our annual reports on Form 10-KSB, quarterly reports on Form 10-QSB, current
reports on Form 8-K and all amendments to those reports filed or furnished
pursuant to Section 13(a) or 15(d) of the Securities Exchange Act of 1934 are
available free of charge on our website (www.ortecinternational.com) as soon as
reasonably practicable after they are filed with, or furnished to, the
Securities and Exchange Commission.

                          DISCLOSURE OF COMMISSION POSITION ON INDEMNIFICATION FOR SECURITIES ACT LIABILITIES

Our certificate of incorporation provides that the personal liability of our
directors shall be limited to the fullest extent permitted by the provisions of
Section 102(b)(7) of the General Corporation Law of the State of Delaware (the
"DGCL"). Section 102(b)(7) of the DGCL generally provides that no director shall
be liable personally to us or our shareholders for monetary damages for breach
of fiduciary duty as a director, provided that our certificate of incorporation
does not eliminate the liability of a director for (i) any breach of the
director's duty of loyalty to us or our shareholders; (ii) acts or omissions not
in good faith or that involve intentional misconduct or a knowing violation of
law; (iii) acts or omissions in respect of certain unlawful dividend payments or
stock redemptions or repurchases; or (iv) any transaction from which such
director derives improper personal benefit. The effect of this provision is to
eliminate our rights and the rights of our shareholders through stockholders'
derivative suits on our behalf, to recover monetary damages against a director
for breach of her or his fiduciary duty of care as a director, including
breaches resulting from negligent or grossly negligent behavior except in the
situations described in clauses (i) through (iv) above. The limitations
summarized above, however, do not affect our or our shareholders ability to seek
non-monetary remedies, such as an injunction or rescission, against a director
for breach of her or his fiduciary duty.

In addition, our certificate of incorporation provides that we shall, to the
fullest extent permitted by Section 145 of the DGCL, indemnify all persons who
we may indemnify pursuant to Section 145 of the DGCL. Section 145 of the DGCL
permits a company to indemnify an officer or director who was or is a party or
is threatened to be made a party to any proceeding because of his or her
position, if the officer or director acted in good faith and in a manner he or
she reasonably believed to be in or not opposed to the best interests of such
company and, with respect to any criminal action or proceeding, had no
reasonable cause to believe his or her conduct was unlawful.

We maintain a directors' and officers' liability insurance policy covering
certain liabilities that may be incurred by our directors and officers in
connection with the performance of their duties. The entire premium for such
insurance is paid by us.

Insofar as indemnification for liabilities arising under the Securities Act may
be permitted to our directors and officers, and to persons controlling Ortec
pursuant to the foregoing provisions, we have been informed that in the opinion
of the Securities and Exchange Commission, such indemnification is against
public policy as expressed in the Securities Act and is therefore unenforceable.








                            ORTEC INTERNATIONAL, INC.
                        (A DEVELOPMENT STAGE ENTERPRISE)
                      CONDENSED CONSOLIDATED BALANCE SHEETS


                                                                                                                                                                                                                                   March 31,
                                                                                                                                                                                                                                     2006
                                                                                                                                                                                                                       ----------------------------------
                                                                                                                                                                                                                       ----------------------------------
                                                                                                  ASSETS                                                                                                                          (Unaudited)

Current assets:
  Cash and cash equivalents                                                                                                                                                                                        $                               7,479
   Prepaid and other current assets                                                                                                                                                                                                              364,215
                                                                                                                                                                                                                       ----------------------------------
                                                                                                                                                                                                                       ----------------------------------
Total current assets                                                                                                                                                                                                                             371,694
  Property and equipment, net                                                                                                                                                                                                                    171,908
  Patent application costs, net                                                                                                                                                                                                                  537,407
  Deposits and other assets                                                                                                                                                                                                                      155,388
                                                                                                                                                                                                                       ----------------------------------
                                                                                                                                                                                                                       ----------------------------------
Total assets                                                                                                                                                                                                       $                           1,236,397
                                                                                                                                                                                                                       ==================================
                                                                                                                                                                                                                       ==================================

                                                                                   LIABILITIES AND SHAREHOLDERS' DEFICIT

Current liabilities:
  Accounts payable and accrued expenses                                                                                                                                                                            $                           4,329,667
  Insurance premium financing payable                                                                                                                                                                                                            157,253
  Current maturities of loan payable                                                                                                                                                                                                52,306
  Capital lease obligation - current                                                                                                                                                                                                              14,624
  Current maturity of promissory notes                                                                                                                                                                                                           445,000
  Obligation under revenue interest assignment                                                                                                                                                                                                31,544,000
                                                                                                                                                                                                                       ----------------------------------
Total current liabilities                                                                                                                                                                                                                     36,542,850
  Promissory notes - noncurrent                                                                                                                                                                                                                   39,411
  Capital lease obligation - noncurrent                                                                                                                                                                                                            5,875
                                                                                                                                                                                                                       ----------------------------------
                                                                                                                                                                                                                       ----------------------------------
Total liabilities                                                                                                                                                                                                                             36,588,136

COMMITMENTS AND CONTINGENCIES

Temporary equity-common stock,$.001 par value,
    2,210,199 shares issued and outstanding                                                                                                                                                                                                      523,080

Shareholders' deficit:
Preferred stock, $.001 par value; authorized, 1,000,000 shares: Series D, stated
  value $10,000 per share; authorized 2,000 shares;
   6,272.0156 shares issued and outstanding; liquidation preference $62,720,156                                                                                                                                                               15,911,331
 Common stock, $.001 par value; authorized 200,000,000 shares;
   53,473,894 issued and 51,471,894 outstanding (including shares subject to
   registration rights classified as temporary equity)                                                                                                                                                                                            51,265
 Additional paid-in capital                                                                                                                                                                                                                  109,911,395
 Deficit accumulated during the development stage                                                                                                                                                                                          (161,205,615)
 Treasury stock, 2,000 shares at cost                                                                                                                                                                                                          (177,645)
 Deferred compensation                                                                                                                                                                                                                         (365,550)
                                                                                                                                                                                                                       ----------------------------------
                                                                                                                                                                                                                       ----------------------------------
 Total shareholders' deficit                                                                                                                                                                                                                (35,874,819)
                                                                                                                                                                                                                       ----------------------------------
                                                                                                                                                                                                                       ----------------------------------
 Total liabilities and shareholders' deficit                                                                                                                                                                       $                           1,236,397
                                                                                                                                                                                                                       ==================================

See accompanying notes to condensed unaudited financial statements.












                                                                                                              ORTEC INTERNATIONAL, INC.
                                                                                                          (A DEVELOPMENT STAGE ENTERPRISE)
                                                                                                   CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
                                                                                                                   (Unaudited)




                                                                                                                                                                                                                       Cumulative
                                                                                                                                                                                                                          From
                                                                                                                                                                                                         March 12, 1991
                                                                                                                                                                                                                     (inception) to
                                                                                                                                             Three Months Ended March 31,                                              March 31,
                                                                                                                     -----------------------------------------------------------------------------
                                                                                                                                                        ----
                                                                                                                                   2006                                      2005                                         2006
                                                                                                                     ---------------------------------        ------------------------------------       ---------------------------------------
                                                                                                                     ---------------------------------        ------------------------------------       ---------------------------------------

     Product revenue                                                                                           $                    -                     $                    -                     $                                  265,665
                                                                                                                     ---------------------------------        ------------------------------------       ---------------------------------------
                                                                                                                     ---------------------------------        ------------------------------------       ---------------------------------------

     Expenses
       Product and laboratory costs                                                                                                         1,325,509                                   1,222,044                                    32,112,657
       Personnel                                                                                                                              924,819                                   1,138,028                                    42,006,374
       General and administrative                                                                                                             391,979                                     518,294                                    21,296,436
       Rent                                                                                                                                   182,580                                     117,422                                     4,628,887
       Consulting                                                                                                                                   -                                           -                                     5,702,651
       Interest and other expense                                                                                                           1,981,870                                   1,550,164                                    29,080,479
       Interest and other income                                                                                                             (12,863)                                      28,130                                   (2,567,081)
       Loss on settlement of promissory notes                                                                                                       -                                  10,328,199                                    13,081,453
       Lease termination costs                                                                                                                      -                                           -                                     1,119,166
       Loss on extinguishments of debt and
          Series A preferred shares                                                                                                                 -                                           -                                     1,004,027
                                                                                                                     ---------------------------------        ------------------------------------       ---------------------------------------
                                                                                                                     ---------------------------------        ------------------------------------       ---------------------------------------
                                                                                                                                            4,793,894                                  14,902,281                                   147,465,049
                                                                                                                     ---------------------------------        ------------------------------------       ---------------------------------------
                                                                                                                     ---------------------------------        ------------------------------------       ---------------------------------------

     Net loss                                                                                                                             (4,793,894)                                (14,902,281)                                 (147,199,384)

     Preferred stock dividend                                                                                                                       -                                    (17,891)                          3,011,574
     Preferred stock and warrants
       deemed dividends and discounts                                                                                                               -                                   2,125,974                           6,725,657
     Accretion of discount                                                                                                                          -                                           -                           4,269,000
                                                                                                                     ---------------------------------        ------------------------------------       ---------------------------------------
                                                                                                                     ---------------------------------        ------------------------------------       ---------------------------------------
     Net loss applicable to common shareholders                                                                $                          (4,793,894)     $                          (17,010,364)    $                            (161,205,615)
                                                                                                                     =================================        ====================================       =======================================
                                                                                                                     =================================        ====================================       =======================================

     Net loss per share

        Basic and diluted                                                                                      $                                (.07)     $                                 (.76)
                                                                                                                     =================================        ====================================
                                                                                                                     =================================        ====================================

     Weighted average shares outstanding

        Basic and diluted                                                                                                                  66,105,695                                  22,305,534
                                                                                                                     =================================        ====================================
                                                                                                                     =================================        ====================================


See accompanying notes to condensed unaudited financial statements.






                                                                                          ORTEC INTERNATIONAL INC.
                        (A DEVELOPMENT STAGE ENTERPRISE)
            CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY (DEFICIT)
                                   (Unaudited)

                                                                                                                                                                                                 Deficit
                                                                                                                                                                                               accumulated
                                                                                                                                                                         Additional            during the                                                         Total
                                                                                   Common Stock                                     Preferred Stock                       paid-in              development           Treasury             Deferred            shareholders'
                                                                                   ------------
                                                                                                             -----------------------------------------------------
                                                                            Shares             Amount           Series B          Series C           Series D             capital                 stage               stock             compensation        equity (deficit)
                                                                        ----------------  -----------------  ----------------  ----------------  -----------------  ---------------------  --------------------  -----------------  ---------------------  --------------------
                                                                        ----------------  -----------------  ----------------  ----------------  -----------------  ---------------------  --------------------  -----------------  ---------------------  --------------------
March 12, 1991 (inception) to December 31, 1991
Founders                                                                        155,382              $ 155          -                 -                 -                 $          715            -                   -                    -                    $ 870
First private placement ($3.00 per share)                                        21,744                 22          -                 -                 -                  64,978                   -                   -                    -                   65,000
The Director ($11.50 and $53.00 per share)                                       14,902                 15          -                 -                 -                 249,985                   -                   -                    -                   250,000
Second private placement ($94.25 per share)                                       5,302                  5          -                 -                 -                 499,995                   -                   -                    -                   500,000
Share issuance expense                                                                -                  -          -                 -                 -                 (21,118)                  -                   -                    -                  (21,118)
Net loss                                                                              -                  -          -                 -                 -                    -                                (281,644) -                    -                  (281,644)
                                                                        ----------------  -----------------  ----------------  ----------------  -----------------  ---------------------  --------------------  -----------------  ---------------------  --------------------
                                                                        ----------------  -----------------  ----------------  ----------------  -----------------  ---------------------  --------------------  -----------------  ---------------------  --------------------
Balance at December 31, 1991                                                    197,330                197          -                 -                 -                 794,555               (281,644)               -                    -                   513,108
Second private placement ($94.25 per share)                                       2,646                  3          -                 -                 -                 250,003                   -                   -                    -                   250,006
Second private placement ($94.25 per share)                                       2,286                  2          -                 -                 -                 215,465                   -                   -                    -                   215,467
Stock purchase agreement with the Director
     ($94.25 per share)                                                           3,182                  3          -                 -                 -                 299,995                   -                   -                    -                   299,998
Share issuance expense                                                                -                  -          -                 -                 -                 (35,477)                  -                   -                    -                  (35,477)
Net loss                                                                              -                  -          -                 -                 -                    -                  (785,941)               -                    -                  (785,941)
                                                                        ----------------  -----------------  ----------------  ----------------  -----------------  ---------------------  --------------------  -----------------  ---------------------  --------------------
                                                                        ----------------  -----------------  ----------------  ----------------  -----------------  ---------------------  --------------------  -----------------  ---------------------  --------------------
Balance at December 31, 1992                                                    205,444                205          -                 -                 -                1,524,541             (1,067,585)              -                    -                   457,161
Third private placement ($100.00 per share)                                      10,965          11                 -                 -                 -                1,096,489                  -                   -                    -                  1,096,500
Third private placement ($100.00 per share)                                       2,250          2                  -                 -                 -                 224,998                   -                   -                    -                   225,000
Stock purchase agreement with Home
  Insurance Company ($90.00 per share)                                           11,112          11                 -                 -                 -                 999,988                   -                   -                    -                   999,999
Stock purchase agreement with the Director
  ($94.25 per share)                                                              2,122          2                  -                 -                 -                 199,998                   -                   -                    -                   200,000
Shares issued in exchange for commission                                             60          1                  -                 -                 -                  5,999                    -                   -                    -                    6,000
Share issuance expenses                                                               -          -                  -                 -                 -                (230,207)                  -                   -                    -                  (230,207)
Net loss                                                                              -          -                  -                 -                 -                    -                 (1,445,624)              -                    -                 (1,445,624)
                                                                        ----------------  -----------------  ----------------  ----------------  -----------------  ---------------------  --------------------  -----------------  ---------------------  --------------------
                                                                        ----------------  -----------------  ----------------  ----------------  -----------------  ---------------------  --------------------  -----------------  ---------------------  --------------------
Balance at December 31, 1993                                                    231,953                232          -                 -                 -                3,821,806             (2,513,209)              -                    -                  1,308,829
Fourth private placement ($100.00 per share)                                      3,946                  4          -                 -                 -                 397,708                   -                   -                    -                   397,712
Stock purchase agreement with Home
Insurance Company ($100.00 per share)                                             5,000                  5          -                 -                 -                 499,995                   -                   -                    -                   500,000
Share issuance expense                                                         -                 -                  -                 -                 -                     (8,697)               -                   -                    -                   (8,697)
Net loss                                                                       -                 -                  -                 -                 -                    -                 (1,675,087)              -                    -                 (1,675,087)
                                                                        ----------------  -----------------  ----------------  ----------------  -----------------  ---------------------  --------------------  -----------------  ---------------------  --------------------
                                                                        ----------------  -----------------  ----------------  ----------------  -----------------  ---------------------  --------------------  -----------------  ---------------------  --------------------
Balance at December 31, 1994                                                    240,899                241                                                               4,710,812             (4,188,296)              -                    -                   522,757
Rent forgiveness                                                               -                 -                  -                 -                 -                  40,740                   -                   -                    -                   40,740
Net loss                                                                       -                 -                  -                 -                 -                    -                 (1,022,723)              -                    -                 (1,022,723)
                                                                        ----------------  -----------------  ----------------  ----------------  -----------------  ---------------------  --------------------  -----------------  ---------------------  --------------------
                                                                        ----------------  -----------------  ----------------  ----------------  -----------------  ---------------------  --------------------  -----------------  ---------------------  --------------------
Balance at December 31, 1995                                                    240,899         241                 -                 -                 -                4,751,552             (5,211,019)              -                    -                  (459,226)
Initial public offering                                                         120,000         120                 -                 -                 -                5,999,880                  -                   -                    -                  6,000,000
Exercise of warrants                                                              3,389          3                  -                 -                 -                  33,882                   -                   -                    -                   33,885
Fifth private placement ($64.90 per share)                                       95,911              96             -                 -                 -                6,220,701                  -                   -                    -                  6,220,797
Share issuance expenses                                                        -                 -                  -                 -                 -               (1,580,690)                 -                   -                    -                 (1,580,690)
Stock options issued for services                                              -                 -                  -                 -                 -                 152,000                   -                   -                    -                   152,000
Net loss                                                                       -                 -                  -                 -                 -                    -                 (2,649,768)              -                    -                 (2,649,768)
                                                                        ----------------  -----------------  ----------------  ----------------  -----------------  ---------------------  --------------------  -----------------  ---------------------  --------------------
                                                                        ----------------  -----------------  ----------------  ----------------  -----------------  ---------------------  --------------------  -----------------  ---------------------  --------------------
Balance at December 31, 1996                                                    460,199         460                 -                 -                 -                15,577,325            (7,860,787)              -                    -                  7,716,998
Exercise of warrants                                                            115,878         116                 -                 -                 -                10,822,675                 -                   -                    -                 10,822,791
Share issuance expenses                                                        -                 -                  -                 -                 -                (657,508)                  -                   -                    -                  (657,508)
Stock options and warrants issued for services                                 -                 -                  -                 -                 -                 660,000                   -                   -                    -                   660,000
Net loss                                                                       -                 -                  -                 -                 -                    -                 (4,825,663)              -                    -                 (4,825,663)
                                                                        ----------------  -----------------  ----------------  ----------------  -----------------  ---------------------  --------------------  -----------------  ---------------------  --------------------
                                                                        ----------------  -----------------  ----------------  ----------------  -----------------  ---------------------  --------------------  -----------------  ---------------------  --------------------
Balance at December 31, 1997                                                    576,077         576                 -                 -                 -                26,402,492           (12,686,450)              -                    -                 13,716,618
Exercise of warrants                                                             22,149          22                 -                 -                 -                1,281,935                  -                   -                    -                  1,281,957
Stock options and warrants issued for services                                 -                 -                  -                 -                 -                1,920,111                  -                   -                    -                  1,920,111
Sixth private placement                                                          20,000                 20          -                 -                 -                1,788,678                  -                   -                    -                  1,788,698
Sixth private placement - warrants issued                                      -                 -                  -                 -                 -                 211,302                   -                   -                    -                   211,302
Share issuance expenses                                                        -                 -                  -                 -                 -                 (48,000)                  -                   -                    -                  (48,000)
Purchase of 660 shares of treasury stock  (at cost)                            -                 -                  -                 -                 -                    -                      -                         (67,272)       -                  (67,272)
Net loss                                                                       -                 -                  -                 -                 -                    -                 (8,412,655)                                   -                 (8,412,655)
                                                                        ----------------  -----------------  ----------------  ----------------  -----------------  ---------------------  --------------------  -----------------  ---------------------  --------------------
                                                                        ----------------  -----------------  ----------------  ----------------  -----------------  ---------------------  --------------------  -----------------  ---------------------  --------------------
Balance at December 31, 1998                                                    618,226                618          -                 -                 -                31,556,518           (21,099,105)           (67,272)                -                 10,390,759
Exercise of warrants                                                              1,410                  1          -                 -                 -                  14,102                   -                   -                    -                   14,103
Stock options and warrants issued for services                                 -                 -                  -                 -                 -                         64,715            -                   -                    -                                    64,715
Seventh private placement ($87.50 per share)                                     38,916                 39          -                 -                 -                      3,168,746            -                   -                    -                                 3,168,785
Seventh private placement - investor warrants                                  -                 -                  -                 -                 -                        236,291            -                   -                    -                                   236,291
Seventh private placement - placement agent warrants                           -                 -                  -                 -                 -                        232,000            -                   -                    -                                   232,000
Eighth private placement ($55.00 per share)                                     163,637                164          -                 -                 -                      8,999,838            -                   -                    -                                 9,000,002
Share issuance expenses                                                        -                 -                  -                 -                 -                (619,908)                  -                   -                    -                  (619,908)
Purchase of 910 shares of treasury stock (at cost)                             -                 -                  -                 -                 -                    -                      -                (75,518)                -                  (75,518)
Net loss                                                                       -                 -                  -                 -                 -                    -                (10,040,509)              -                    -                (10,040,509)
                                                                        ----------------  -----------------  ----------------  ----------------  -----------------  ---------------------  --------------------  -----------------  ---------------------  --------------------
                                                                        ----------------  -----------------  ----------------  ----------------  -----------------  ---------------------  --------------------  -----------------  ---------------------  --------------------
Balance at December 31, 1999                                                    822,189                822          -                 -                 -                43,652,302           (31,139,614)              (142,790)            -                 12,370,720
Exercise of options and warrants                                                 17,554                 17          -                 -                 -                 327,265                   -                   -                    -                   327,282
Stock options and warrants issued for services                                 -                 -                  -                 -                                           56,265            -                   -                    -                                    56,265
Ninth private placement ($150.00 per share)                                       6,667                  7          -                 -                 -                        999,998            -                   -                    -                                 1,000,005
Ninth private placement - placement agent warrants                             -                 -                  -                 -                 -                  23,000                   -                   -                    -                   23,000
Tenth private placement ($67.50 per share)                                      124,757                125          -                 -                 -                8,420,946                  -                   -                    -                  8,421,071
Share issuance expenses                                                        -                 -                  -                 -                 -                (641,500)                  -                   -                    -                  (641,500)
Purchase of 430 shares of treasury stock (at cost)                             -                 -                  -                 -                 -                    -                      -                         (34,855)       -                                   (34,855)
Net loss                                                                       -                 -                  -                 -                 -                    -                (12,129,663)              -                    -                (12,129,663)
                                                                        ----------------  -----------------  ----------------  ----------------  -----------------  ---------------------  --------------------  -----------------  ---------------------  --------------------
                                                                        ----------------  -----------------  ----------------  ----------------  -----------------  ---------------------  --------------------  -----------------  ---------------------  --------------------
Balance at December 31, 2000                                                    971,167                971          -                 -                 -                     52,838,276      (43,269,277)          (177,645)                -                  9,392,325
Stock options issued for services                                              -                 -                  -                 -                 -                        188,080            -                   -                    -                   188,080
Net loss                                                                       -                 -                  -                 -                 -                    -                (15,885,377)              -                    -                (15,885,377)
                                                                        ----------------  -----------------  ----------------  ----------------  -----------------  ---------------------  --------------------  -----------------  ---------------------  --------------------
                                                                        ----------------  -----------------  ----------------  ----------------  -----------------  ---------------------  --------------------  -----------------  ---------------------  --------------------
Balance at December 31, 2001                                                    971,167                971          -                 -                 -                     53,026,356      (59,154,654)          (177,645)                -                 (6,304,972)
Exercise of options and warrants                                                 35,720          36                 -                 -                 -                            321            -                   -                    -                     357
Stock options and warrants issued for services                                 -                 -                  -                 -                 -                        113,060            -                   -                    -                   113,060
Warrants issued with convertible debentures                                    -                 -                  -                 -                 -                        440,523            -                   -                    -                   440,523
Warrants issued with convertible redeemable                                                                                                                                                                                                  -
   preferred stock                                                             -                 -                  -                 -                 -                        559,289            -                   -                    -                   559,289
Convertible debenture conversion benefit                                       -                 -                  -                 -                 -                      1,042,663            -                   -                    -                  1,042,663
Redeemable convertible preferred stock                                                                                                                                                                                                       -
   conversion benefit                                                          -                 -                  -                 -                 -                      1,097,886            -                   -                    -                  1,097,886
Issuance of series B preferred stock (938                                                                                                                                                                                                    -
shares)   ($10,000 per share)                                                  -                 -               9,382,742            -                 -                    -                      -                   -                    -                  9,382,742
Warrants issued and exercised with preferred stock                              938,275                  938                (3,479,043-                 -                      3,485,443            -                   -                    -                    7,338
Shares issuance costs - preferred stock                                        -                 -              (866,612)             -                 -                        304,615            -                   -                    -                  (561,997)
Preferred stock dividends                                                       375,315         375                 -                 -                                        1,125,559       (1,125,934)              -                    -                      -
Net loss                                                                       -                 -                  -                 -                 -                    -                (21,578,021)              -                    -                (21,578,021)
                                                                        ----------------  -----------------  ----------------  ----------------  -----------------  ---------------------  --------------------  -----------------  ---------------------  --------------------
                                                                        ----------------  -----------------  ----------------  ----------------  -----------------  ---------------------  --------------------  -----------------  ---------------------  --------------------
Balance at December 31, 2002 (carried forward)                                2,320,477        2,320            5,037,087             -                 -                     61,195,715      (81,858,609)         (177,645)                 -                (15,801,132)





                                                                                               ORTEC INTERNATIONAL INC.
                        (A DEVELOPMENT STAGE ENTERPRISE)
            CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY (DEFICIT)
                                                                                                            (Unaudited)

                                                                                                                                                                                                  Deficit
                                                                                                                                                                                                accumulated
                                                                                                                                                                          Additional            during the                                                        Total
                                                                                 Common Stock                                       Preferred Stock                        paid-in              development         Treasury              Deferred            shareholders'
                                                                                 ------------
                                                                                                           --------------------------------------------------------
                                                                           Shares            Amount           Series B          Series C            Series D               capital                 stage               Stock            compensation        equity (deficit)
                                                                       ----------------  ----------------  ----------------  ----------------  --------------------  ---------------------  --------------------  ----------------  ---------------------  --------------------
                                                                       ----------------  ----------------  ----------------  ----------------  --------------------  ---------------------  --------------------  ----------------  ---------------------  --------------------
Balance at December 31, 2002 (brought forward)                               2,320,477        2,320           5,037,087             -                   -                      61,195,715      (81,858,609)          (177,645)               -                (15,801,132)
Exercise of options and warrants                                               398,750         399                -                 -                   -                          12,567            -                   -                   -                   12,966
Issuance of preferred stock: series B (200                                                                                                                                                                                                   -
   shares), series C (948 shares)                                             -                 -             2,000,000            5,690,000            -                     -                      -                   -                   -                  7,690,000
Warrants issued with preferred stock                                          -                 -             (490,567)          (1,225,632)            -                       1,716,199            -                   -                   -                      -
Warrants issued for services                                                  -                 -                 -                                     -                          87,000            -                   -                   -                   87,000
Share issuance costs - preferred stock                                        -                 -             (393,488)            (797,327)            -                         359,078            -                   -                   -                  (831,737)
Conversion of series B preferred stock (605                                                                                                                                                                                                  -
   shares) into common stock                                                 2,421,556        2,422          (3,253,571)            -                   -                       3,251,149            -                   -                   -                      -
Conversion of series B  preferred stock into                                                                                                                                                                                                 -
   series D preferred stock (483 shares)                                      -                 -            (2,628,602)            -                    2,628,602            -                      -                   -                   -                      -
Preferred stock deemed dividends and discounts                                -                 -                 -                 -                   -                       4,269,000       (4,269,000)              -                   -                      -
Preferred stock dividends                                                       92,308         92                 -                 -                   -                         922,985        (923,077)               -                   -                      -
Common stock dividend to be distributed on                                                                                                                                                                                                   -
   series C preferred stock                                                   -                 -                 -                 -                   -                         336,550        (336,550)               -                   -                      -
Common stock to be issued in connection with                                                                                                                                                                                                 -
  promissory notes                                                            -                 -                 -                 -                   -                         287,000            -                   -                   -                         287,000
Adjustment for one for ten reverse stock split                                      74          -                 -                 -                   -                     -                      -                   -                   -                      -
Net loss                                                                      -                 -                 -                 -                   -                     -                (15,920,504)              -                   -                (15,920,504)
                                                                       ----------------  ----------------  ----------------  ----------------  --------------------  ---------------------  --------------------  ----------------  ---------------------  --------------------
                                                                       ----------------  ----------------  ----------------  ----------------  --------------------  ---------------------  --------------------  ----------------  ---------------------  --------------------
Balance at December 31, 2003                                                 5,233,165             5,233           270,859         3,667,041             2,628,602             72,437,243         (103,307,740)         (177,645)            -                    (24,476,407)
Common stock issued in connection with                                                                                                                                                                                                       -
  previously issued notes                                                   157,000                     157       -                 -                   -                           (157)            -                   -                   -                      -
Common stock issued in                                                                                                                                                                                                                       -
  connection with promissory notes                                             331,831               332          -                 -                   -                         745,870            -                   -                   -                         746,202
Common stock (277,020) and 34.31 shares of                                                                                                                                                                                                   -
  series D preferred to be issued in connection                                                                                                                                                                                              -
  with agreements which extended due date of                                                                                                                                                                                                 -
  promissory notes                                                            -                 -                 -                 -                   -                         828,540            -                   -                   -                         828,540
Common stock issued in connection with exercise                                                                                                                                                                                              -
  of warrants                                                                   32,460                32          -                 -                   -                             293            -                   -                   -                             325
Conversion of 35.62 shares of series C preferred                                                                                                                                                                                             -
  stock into common stock                                                      106,872               107          -                (137,752)            -                         137,645            -                   -                   -                      -
Payment of dividends on 35.62 shares of series C                                                                                                                                                                                             -
  preferred stock in common stock                                               13,743                14          -                 -                   -                          30,085              (30,099)          -                   -                      -
Common stock and series D preferred (233.83                                                                                                                                                                                                  -
    shares) issued in connection with special                                                                                                                                                                                                -
    warrant offer                                                              496,981               497          -                 -                      939,050                498,472            -                   -                   -                       1,438,019
Common stock dividend to be distributed on                                                                                                                                                                                                   -
  series B and series C preferred stock                                       -                 -                 -                 -                   -                         613,805            (613,805)           -                   -                      -
Option issued to director for services                                        -                 -                 -                 -                   -                         398,574            -                   -                   -                         398,574
Warrant issued for services                                                   -                 -                 -                 -                   -                          94,393            -                   -                   -                          94,393
Warrant issued in connection with lease                                       -                 -                 -                 -                   -                          18,500            -                   -                   -                          18,500
Share issuance expenses                                                       -                 -                 -                 -                   -                        (26,600)            -                   -                   -                        (26,600)
Special warrant offer deemed dividends                                        -                 -                 -                 -                   -                       1,123,000           (1,123,000)          -                   -                      -
Net loss                                                                      -                 -                 -                 -                   -                     -                    (15,377,900)          -                   -                    (15,377,900)
                                                                       ----------------  ----------------  ----------------  ----------------  --------------------  ---------------------  --------------------  ----------------  ---------------------  --------------------
                                                                       ----------------  ----------------  ----------------  ----------------  --------------------  ---------------------  --------------------  ----------------  ---------------------  --------------------
Balance at December 31, 2004                                                 6,372,052             6,372           270,859         3,529,289             3,567,652             76,899,663         (120,452,544)         (177,645)            -                    (36,356,354)
Common stock and series D preferred (34.31 shares)
  issued in connection with agreements which extended
  due date of promissory notes                                                 277,020               277          -                 -                      274,500              (274,777)            -                   -                   -                      -
January 2005 Private Placement:
  Common stock issued in connection with private
    placement                                                                6,483,962             6,484          -                 -                   -                       4,769,616            -                   -                   -                       4,776,100
  Common stock and series D preferred (1,720.16 shares)
    issued in connection with  promissory note conversion                    7,953,123             7,953          -                 -                    5,733,853             14,887,606            -                   -                   -                      20,629,412
  Common stock and series D preferred (1,086.21 shares)
    issued in connection with Series C preferred exchange                    3,283,682             3,284          -              (3,529,289)             3,620,702              2,011,770           (2,106,467)          -                   -                      -
  Common stock issued in connection with exercise of
  additional investment right from private placement                           153,263               153          -                 -                   -                         114,794            -                   -                   -                         114,947
Common stock issued in connection with February 2005
  private placement                                                            120,000               120          -                 -                   -                          86,153            -                   -                   -                          86,273
Common stock issued in connection with exchange for
   series B preferred stock                                                    220,647               221         (270,859)          -                   -                         272,254               (1,616)          -                   -                      -
Common stock issued to officers                                              1,645,000             1,645          -                 -                   -                         749,939            -                   -                   (462,445)                 289,139
Common stock issued upon exercise of warrants                              3,658,513              3,659           -                 -                   -                     -                      -                   -                   -                           3,659
October 2005 Private Placement:
 Common stock issued                                                     14,590,764             14,591            -                 -                   -                     3,159,025              -                   -                   -                       3,173,616
 Common stock and Series D preferred (2,714.62 shares)
 and warrants issued for promissory notes                                  6,346,925             6,347            -                 -                   2,714,624             3,616,746              -                   -                   -                       6,337,717
Modifications of Series E warrant prices                                      -                 -                 -                 -                   -                     3,490,140            (3,476,683)           -                   -                          13,457
Warrant issued for services                                                   -                 -                 -                 -                   -                          7,189             -                   -                   -                           7,189
Share issuance expenses                                                       -                 -                 -                 -                   -                       (14,234)             -                   -                   -                        (14,234)
Net loss                                                                      -                 -                 -                 -                   -                     -                    (30,374,411)          -                   -                    (30,374,411)
                                                                       ----------------  ----------------  ----------------  ----------------  --------------------  ---------------------  --------------------  ----------------  ---------------------  --------------------
                                                                       ----------------  ----------------  ----------------  ----------------  --------------------  ---------------------  --------------------  ----------------  ---------------------  --------------------
Balance at December 31, 2005 (carried forward)                              51,104,951           $51,106          -                 -                  $15,911,331           $109,775,884        $(156,411,721)        $(177,645)             $(462,445)         $(31,313,490)






                            ORTEC INTERNATIONAL INC.
                        (A DEVELOPMENT STAGE ENTERPRISE)
            CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY (DEFICIT)
                                                                                                            (Unaudited)

                                                                                                                                                                                                  Deficit
                                                                                                                                                                                                accumulated
                                                                                                                                                                          Additional            during the                                                        Total
                                                                                 Common Stock                                       Preferred Stock                        paid-in              development         Treasury              Deferred            shareholders'
                                                                                 ------------
                                                                                                           --------------------------------------------------------
                                                                           Shares            Amount           Series B          Series C            Series D               capital                 stage               Stock            compensation        equity (deficit)
                                                                       ----------------  ----------------  ----------------  ----------------  --------------------  ---------------------  --------------------  ----------------  ---------------------  --------------------
Balance at December 31, 2005 (brought forward)                              51,104,951           $51,106          -                 -                  $15,911,331           $109,775,884        $(156,411,721)        $(177,645)             $(462,445)         $(31,313,490)
Exercise of Series E warrants                                                  158,644               159          -                 -                   -                     -                      -                   -                   -                             159
Warrant issued for vendor settlement                                          -                 -                 -                 -                   -                          54,982            -                   -                   -                          54,982
Common stock and warrant issued for production suite
  Charges                                                                    2,210,299          -                 -                 -                   -                          67,505            -                   -                   -                          67,505
Share-based compensation                                                      -                 -                 -                 -                   -                          13,024            -                   -                   -                          13,024
Amortization of deferred compensation                                         -                 -                 -                 -                   -                     -                      -                   -                        96,895                96,895
Net loss                                                                      -                 -                 -                 -                   -                     -                     (4,793,894)          -                   -                     (4,793,894)
                                                                       ----------------  ----------------  ----------------  ----------------  --------------------  ---------------------  --------------------  ----------------  ---------------------  --------------------
                                                                       ----------------  ----------------  ----------------  ----------------  --------------------  ---------------------  --------------------  ----------------  ---------------------  --------------------
Balance at March 31, 2006                                                   53,473,894           $51,265          -                 -                  $15,911,331           $109,911,395        $(161,205,615)        $(177,645)             $(365,550)         $(35,874,819)
                                                                       ================  ================  ================  ================  ====================  =====================  ====================  ================  =====================  ====================

The accompanying notes are an integral part of these statements.






                                       F-8
                                                                                                              ORTEC INTERNATIONAL INC.
                                                                                                          (A DEVELOPMENT STAGE ENTERPRISE)
                 CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
                                   (Unaudited)
                                                                                                                                                                                                                              Cumulative from
                                                                                                                                                                                                                              March 12, 1991
                                                                                                                                                            Three months ended March 31,                                      (inception) to
                                                                                                                                         --------------------------------------------------------------------
                                                                                                                                         --------------------------------  ----  ----------------------------
                                                                                                                                                      2006                                  2005                              March 31, 2006
                                                                                                                                         --------------------------------        ----------------------------        ----------------------------------
                                                                                                                                         --------------------------------                                            ----------------------------------
Cash flows from operating activities
Net loss                                                                                                                           $                         (4,793,894)   $                    (14,902,281)   $                        $(147,199,384)
Adjustments to reconcile net loss to net cash used in operating activities
   Depreciation and amortization                                                                                                                                  51,742                              84,814                                 5,618,589
   Allowance for doubtful accounts                                                                                                                                     -                                   -                                     5,374
   Unrealized loss on marketable securities                                                                                                                            -                                   -                                    11,404
   Realized loss on marketable securities                                                                                                                              -                                   -                                     5,250
   Gain on sale of property and equipment                                                                                                                              -                                   -                                  (58,642)
   Loss on settlement of promissory note                                                                                                                               -                          10,328,199                                13,081,453
   Cost to terminate lease on New Jersey facility                                                                                                                      -                                   -                                   836,032
   Amortization of deferred compensation                                                                                                                          96,895                              68,360                                 3,721,265
   Non-cash interest                                                                                                                                               3,030                               3,029                                 1,986,253
   Non-cash imputed interest                                                                                                                                   1,975,000                           1,521,890                                24,897,150
   Non-cash production suite charges                                                                                                                             590,585                                   -                                   826,085
   Share-based compensation                                                                                                                                       13,024                                   -                                    13,024
   Gain on loan adjustment                                                                                                                                             -                                   -                                 (236,000)
   Gain on vendor settlement                                                                                                                                    (11,710)                                   -                                  (11,710)
   Loss on extinguishment of debt and series A preferred stock                                                                                                         -                                   -                                 1,004,027
   Purchase of marketable securities                                                                                                                                   -                                   -                              (19,075,122)
   Sales of marketable securities                                                                                                                                      -                                   -                                19,130,920
   Other                                                                                                                                                               -                                   -                                    20,646
   Changes in operating assets and liabilities
      Prepaid and other current assets                                                                                                                         (212,243)                           (160,029)                                 (273,334)
      Accounts payable and accrued liabilities                                                                                                                 1,037,036                           (912,663)                                 6,084,399
                                                                                                                                         --------------------------------        ----------------------------        ----------------------------------
                                                                                                                                         --------------------------------        ----------------------------        ----------------------------------
Net cash used in operating activities                                                                                                                        (1,250,535)                         (3,968,681)                              (89,612,321)
                                                                                                                                         --------------------------------        ----------------------------        ----------------------------------
                                                                                                                                         --------------------------------        ----------------------------        ----------------------------------

Cash flows from investing activities
   Purchases of property and equipment                                                                                                                           (1,799)                            (39,056)                               (4,615,676)
   Proceeds from sale of property and equipment                                                                                                                        -                                   -                                   145,926
   Payments for patent applications                                                                                                                             (13,591)                            (15,876)                               (1,083,464)
   Organization costs                                                                                                                                                  -                                   -                                  (10,238)
   Deposits                                                                                                                                                            -                                   -                                 (790,273)
   Purchases of marketable securities                                                                                                                                  -                                   -                                 (594,986)
   Sale of marketable securities                                                                                                                                       -                                   -                                   522,532
                                                                                                                                         --------------------------------        ----------------------------        ----------------------------------
                                                                                                                                         --------------------------------        ----------------------------        ----------------------------------
Net cash used in investing activities                                                                                                                           (15,390)                            (54,932)                               (6,426,179)
                                                                                                                                         --------------------------------        ----------------------------        ----------------------------------
                                                                                                                                         --------------------------------        ----------------------------        ----------------------------------

Cash flows from financing activities
   Proceeds from issuance of notes payable                                                                                                                       445,000                      -                                             14,093,126
   Proceeds from issuance of common stock                                                                                                                              -                           5,004,741                                61,701,458
   Proceeds from exercise of warrants                                                                                                                                159                                   -                                 1,362,822
   Proceeds from insurance premium financing                                                                                                                     220,500                             220,000                                   720,500
   Share issuance expenses and other financing costs                                                                                                                   -                                   -                               (5,384,247)
   Purchase of treasury stock                                                                                                                                          -                                   -                                 (177,645)
   Proceeds from issuance of loan payable                                                                                                                              -                                   -                                 1,446,229
   Proceeds from obligations under revenue interest assignment                                                                                                         -                                   -                                10,000,000
   Proceeds from issuance of convertible debentures                                                                                                                    -                                   -                                 5,908,000
   Proceeds from issuance of preferred stock-
     Series A                                                                                                                                                          -                                   -                                 1,200,000
     Series B                                                                                                                                                          -                                   -                                 3,070,000
     Series C                                                                                                                                                          -                                   -                                 5,690,000
   Advances received                                                                                                                                                   -                                   -                                   130,000
   Repayment of capital lease obligations                                                                                                                        (4,397)                            (23,578)                                 (589,191)
   Repayment of loan payable                                                                                                                                           -                            (49,333)                               (1,239,161)
   Repayment of obligations under revenue interest assignment                                                                                                          -                                   -                                  (11,414)
   Repayment of insurance premium financing payable                                                                                                             (63,247)                            (23,861)                                 (563,247)
   Repayment of promissory notes                                                                                                                                       -                           (127,911)                                 (795,751)
   Repayment of notes payable                                                                                                                                          -                                   -                                 (515,500)
                                                                                                                                         --------------------------------        ----------------------------        ----------------------------------
                                                                                                                                         --------------------------------        ----------------------------        ----------------------------------
Net cash provided by financing activities                                                                                                                        598,015                           5,000,058                                96,045,979
                                                                                                                                         --------------------------------        ----------------------------        ----------------------------------
                                                                                                                                         --------------------------------        ----------------------------        ----------------------------------

Net Increase (Decrease) In Cash And Cash Equivalents                                                                                                           (667,910)                             976,445                                     7,479
CASH AND CASH EQUIVALENTS
   Beginning of period                                                                                                                                           675,389                             227,370                                         -
                                                                                                                                         --------------------------------        ----------------------------        ----------------------------------
                                                                                                                                         --------------------------------        ----------------------------        ----------------------------------
   End of period                                                                                                                                                 $ 7,479                         $ 1,203,815                                   $ 7,479
                                                                                                                                         ================================        ============================        ==================================






                            ORTEC INTERNATIONAL, INC.
                        (A DEVELOPMENT STAGE ENTERPRISE)
                 CONDENSED STATEMENTS OF CASH FLOWS (continued)
                                   (Unaudited)

                                                                                                                                                                                                                               Cumulative from
                                                                                                                                                                                                                               March 12, 1991
                                                                                                                                                                    Three months ended March 31,                               (inception) to
                                                                                                                                                      ---------------------------------------------------------
                                                                                                                                                                2006                            2005                           March 31, 2006
                                                                                                                                                      -------------------------        ------------------------        --------------------------------
                                                                                                                                                      -------------------------                                        --------------------------------
Supplemental disclosures of cash flow information:
 Noncash investing and financing activities
  Assets acquired under capital leases                                                                                                          $                            -   $                           -   $                             628,523
  Deferred offering costs included in accrued professional fees                                                                                                              -                               -                                 314,697
  Financing costs - other long-term obligations                                                                                                                              -                               -                                  59,500
  Forgiveness of rent payable                                                                                                                                                -                               -                                  40,740
  Share issuance expenses - warrants                                                                                                                                         -                               -                                 255,000
  Deferred compensation                                                                                                                                                      -                         660,814                                 751,584
  Dividends on series B preferred stock paid in common shares                                                                                                                -                               -                               2,099,011
  Dividends on series C preferred stock paid in common shares                                                                                                                -                        (17,891)                                 576,013
  Accretion of discount on preferred stock and warrants                                                                                                                      -                       2,125,974                              10,994,657
  Series B preferred stock converted to common stock                                                                                                                         -                         270,859                                 270,859
  Series C preferred stock exchanged for common stock                                                                                                                        -                       3,529,289                               3,529,289
  Issuance of series D preferred stock in lieu of common stock                                                                                                               -                       9,629,055                              12,343,678
  Share issuance expenses for series B preferred
   stock incurred through issuance of warrants                                                                                                                               -                               -                                 391,307
  Share issuance expenses for series C preferred
   stock incurred through issuance of warrants                                                                                                                               -                               -                                 272,386
  Share issuance of series D preferred stock in
   exchange for series B preferred stock                                                                                                                                     -                               -                               2,628,602
  Equipment transferred in satisfaction of deposit                                                                                                                           -                               -                                 100,000
  Discount on promissory notes                                                                                                                                               -                               -                               1,033,202
  Discount on advances payable                                                                                                                                               -                               -                                       -
  Accounts payable converted to promissory notes                                                                                                                             -                               -                                 837,468
  Advances converted to promissory notes                                                                                                                                     -                               -                                 130,000
  Accrued deferred financing costs                                                                                                                                           -                               -                                       -
  Warrant issued in connection with lease                                                                                                                                    -                               -                                  18,500
  Warrant issued in connection with liability settlement                                                                                                                54,982                               -                                  54,982
  Promissory notes forgiven for warrant participation                                                                                                                        -                               -                                 100,000
  Promissory notes repaid with common stock                                                                                                                                  -                       9,626,626                              13,112,626
  Promissory notes interest due repaid with common stock                                                                                                                     -                         674,587                                 658,776
  Conversion of series C preferred stock into common stock                                                                                                                   -                               -                                 137,645
  Contribution of capital of amount due to founder                                                                                                                           -                               -                                 398,967


Cash paid for interest                                                                                                                          $                        2,072   $                      24,610   $                             862,698
                                                                                                                                                      =========================        ========================        ================================
                                                                                                                                                      =========================        ========================        ================================


Cash paid for income taxes                                                                                                                      $                            -   $                           -   $                             203,411
                                                                                                                                                      =========================        ========================        ================================

See accompanying notes to condensed unaudited financial statements.




                            ORTEC INTERNATIONAL, INC.
                        (A DEVELOPMENT STAGE ENTERPRISE)
              NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
                                   (Unaudited)


NOTE 1 - FINANCIAL STATEMENTS

The condensed consolidated balance sheet as of March 31, 2006, and the condensed
consolidated statements of operations and cash flows for the three-month periods
ended March 31, 2006 and 2005, and for the period from March 12, 1991
(inception) to March 31, 2006, and condensed consolidated statements of
shareholders' equity (deficit) for the period from March 12, 1991 (inception) to
March 31, 2006, have been prepared by the Company and are unaudited. In the
opinion of management, all adjustments (consisting of normal recurring accruals)
necessary to present fairly the financial position as of March 31, 2006, results
of operations and cash flows for the three-month periods ended March 31, 2006
and 2005, and from March 12, 1991 (inception) through March 31, 2006, and
statements of shareholders' equity (deficit) for the period from March 12, 1991
(inception) to March 31, 2006, have been made. Certain information and footnote
disclosures normally included in the annual financial statements prepared in
accordance with accounting principles generally accepted in the United States of
America have been condensed or omitted. It is suggested that these condensed
consolidated financial statements be read in conjunction with the financial
statements and notes thereto in the Company's December 31, 2005 annual report on
Form 10-KSB filed with the Securities and Exchange Commission. The results of
operations for the three-month period ended March 31, 2006, are not necessarily
indicative of the operating results for the full year or any other interim
period.

NOTE 2 - FORMATION OF THE COMPANY AND BASIS OF PRESENTATION

Formation of the Company

Ortec International, Inc. ("Ortec" or the "Company") was incorporated in March
1991 as a Delaware corporation to secure and provide funds for the further
development of the technology developed by Dr. Mark Eisenberg of Sydney,
Australia, to replicate in the laboratory, a tissue engineered skin substitute
for use in skin regeneration procedures (the "Technology"). Pursuant to a
license agreement dated September 7, 1991, Dr. Eisenberg had granted Ortec a
license for a term of ten years, with automatic renewals by Ortec for two
additional ten-year periods, to commercially use and exploit the Technology for
the development of products. In April 1998, Dr. Eisenberg assigned his patent
for the Technology to Ortec.

Basis of Presentation

We are a development stage enterprise which had no operating revenue prior to
December 2001. During 2001, we received Food and Drug Administration approval
for the use of the fresh form of our ORCEL product for the treatment of patients
with recessive dystrophic epidermolysis bullosa and for donor sites in burn
patients. We began marketing and selling our product for use on patients with
one of these indications using a contract sales organization. Our sales and
marketing efforts were active only for a brief period and accordingly our
revenues were not significant. We terminated our sales efforts and elected to
focus our attention on completing development of a cryopreserved form of our
product for treatment of chronic wounds affecting larger populations. As a
result, we completed a clinical trial during 2003 for the use of the
cryopreserved form of ORCEL to treat venous stasis ulcers and filed an
application for pre-market approval (PMA) with the FDA in February 2004. In a
letter dated April 25, 2005, although the FDA concluded that cryopreserved ORCEL
showed promise for the effective treatment of venous stasis ulcers, the FDA
determined that additional data would be necessary to confirm cryopreserved
ORCEL's effectiveness and safety treating venous stasis ulcers. The clinical
data from the pivotal trial of 136 patients submitted to the FDA showed that in
60 patients who had typical venous ulcers (defined as those ulcers with partial
or full-thickness ulcers in which the wound base is visible and the ulcer
extends through the dermis but not into the subcutaneous tissue to fascia,
muscle or bone), 59% of the ORCEL treated patients achieved wound closure versus
36% of the patients who received the standard of care treatment. The FDA agreed
that data of these 60 patients would be combined with that of the 60 patients to
be enrolled in a confirmatory clinical trial and the combined results will be
analyzed using Bayesian statistics. We obtained FDA approval for our
confirmatory trial protocol in mid July 2005 and began the confirmatory trial in
mid August 2005. We completed enrollment for this clinical trial in April 2006.
Our plan of operation for the next twelve months is to complete such clinical
trial and continue to work towards obtaining regulatory clearance for commercial
sales of cryopreserved ORCEL to treat venous stasis ulcers. In the interim, we
are working with Cambrex Bio Science Walkersville, Inc., a subsidiary of Cambrex
Corporation (Cambrex) to limit expenditures under our manufacturing agreement
primarily to those which are essential for conducting the trial. Together, we
are working on process improvements that we expect will drive down the cost of
producing ORCEL as we plan for the potential commercialization of our product.
In February 2006, Cambrex assisted us financially by agreeing to accept our
common stock and warrants in exchange for approximately $800,000 of production
suite charges to be incurred during the first half of 2006. See Note 8.





The accompanying financial statements have been prepared assuming that we will
continue as a going concern. We incurred a net loss applicable to common
shareholders of $4.8 million during the three months ended March 31, 2006, and,
as of that date, our current liabilities exceeded our current assets by $36.2
million, our total liabilities exceeded our total assets by $35.4 million and we
have a deficit accumulated in the development stage of $161.2 million. These
factors, among others, raise substantial doubt about our ability to continue as
a going concern.

In the first quarter of 2006, we received an aggregate of $445,000 in short-term
bridge loans: $195,000 was from two of our executive officers repayable without
interest and $250,000 was a convertible note from an outside investor. In early
April 2006 we received an additional $45,000 bridge loan from another of our
executive officers and a $200,000 bridge note from an outside investor. In mid
April 2006, we completed a convertible preferred stock offering in which we
raised gross proceeds of approximately $6.2 million. Out of these proceeds we
repaid all of the executive officer loans without interest, repaid the $200,000
bridge note, and converted the $250,000 loan into the preferred stock offering.

We expect to incur obligations of approximately $875,000 per month primarily for
personnel and rent, insurance, fees to Cambrex for a production suite and
technology transfer activities, various research and development activities, and
payment of past due obligations. We will require substantial funding to enable
us to continue our research and development activities, pay a portion of our
past due obligations, complete the additional clinical trial necessary to obtain
PMA for our ORCEL to treat venous stasis ulcers, and provide for our general and
corporate working capital requirements for 2006.

While we have arranged for payment of some of our obligations over a period of
time, and have to make other payments of past due obligations to our current and
ongoing suppliers, our ability to make payments we have agreed to pay and to
insure continued receipt of needed supplies, and to continue reducing our past
due obligations, will depend on our ability to secure needed financing or our
ability to issue our equity securities in satisfaction of certain obligations.

We hope to obtain additional funds through the sale of our securities to the
public and through private placements, debt financing or other short-term loans.
We may not be able to secure any financing nor may we be able to reach the
larger patient population markets of persons with venous stasis ulcers and
diabetic foot ulcers, with funds that we may be able to raise. We are also
likely to continue to encounter difficulties which are common to development
stage companies, including unanticipated costs relating to development, delays
in the testing of products, regulatory approval and compliance and competition.

Our capital funding requirements depend on numerous factors, including:

o                 the progress and magnitude of our research and development programs;
o                 the time involved in obtaining regulatory approvals for the commercial sale of our ORCEL product in its cryopreserved form to treat venous stasis ulcers and, later, diabetic foot ulcers;
o                 the costs involved in filing and maintaining patent claims;
o                 technological advances;
o                 competitive and market conditions;
o                 the successful implementation of the agreements we have entered into with Cambrex for manufacturing and sales of our ORCEL product;
o                 our ability to establish and maintain other collaborative arrangements and
o                 the cost and effectiveness of commercialization activities and arrangements.

We believe that our cash and cash equivalents on hand at March 31, 2006, $7,479,
as well as funds received in the April 2006 private placement of our equity
securities, and the additional funds we will need to raise in 2006, may enable
us to continue our operations for the next twelve months. There can be no
assurances that we can raise additional funds.

These financial statements have been prepared assuming that we will continue as
a going concern. Successful future operations depend upon the successful
development and marketing of our ORCEL product. Historically we have funded our
operating losses by periodically raising additional sources of capital. If
additional funding is not available to us when needed, we may not be able to
continue operations. No adjustments have been made to the accompanying
financials as a result of this uncertainty.






Reclassifications

Certain reclassifications have been made to the 2005 amounts to conform to the
2006 presentation.

NOTE 3 - RECENT PRONOUNCEMENTS

In November 2004, the Financial Accounting Standards Board (FASB) issued
Statement of Financial Accounting Standard No. 151, "Inventory Costs, an
amendment of ARB No. 43, Chapter 4" (SFAS 151). SFAS 151 clarifies that abnormal
amounts of idle facility expense, freight, handling costs and spoilage should be
recognized as current-period charges and requires the allocation of fixed
production overheads to inventory based on the normal capacity of the production
facilities. SFAS 151 was effective for us on January 1, 2006. The adoption of
SFAS 151 did not have a material impact on our consolidated financial position
and results of operations.

In May 2005, the FASB issued SFAS No. 154, "Accounting Changes and Error
Corrections" (SFAS 154) which replaces APB No. 20, "Accounting Changes," and
SFAS No. 3, "Reporting Accounting Changes in Interim Financial Statements - An
Amendment of APB Opinion No. 28." SFAS 154 provides guidance on the accounting
for and reporting of accounting changes and error corrections. It establishes a
retrospective application, or the latest practicable date, as the required
method for reporting a change in accounting principle and the reporting of a
correction of an error. SFAS 154 was effective for us on January 1, 2006. The
adoption of SFAS 154 did not have a material impact on our consolidated
financial position and results of operations.

NOTE 4 - SHARE BASED COMPENSATION

Effective January 1, 2006, we adopted Statement of Financial Accounting
Standards No. 123 (revised 2004), "Share-Based Payment," (SFAS 123(R)). We
adopted SFAS 123(R) using the modified prospective method of adoption, and
accordingly, financial statement amounts for prior periods presented have not
been restated to reflect the fair value method of recognizing compensation cost
relating to stock options. Compensation expense was recognized during the
quarter ended March 31, 2006, for all share-based option awards granted after
January 1, 2006, based on the grant date fair value in accordance with the
provisions of SFAS 123(R). The effect of the adoption in the first quarter of
2006 was an additional expense of $13,204 related to stock options.

The fair value of stock options granted during the quarter ended March 31, 2006
was estimated at $0.12, using the Black-Scholes option-pricing model. This model
used the following assumptions:
----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
Dividend yield                                                                                                                                                                                                                                      0.00%
Volatility                                                                                                                                                                                                                                         86.00%
Risk-free rate of return                                                                                                                                                                                                                      4.41- 4.63%
Expected life                                                                                                                                                                                                                                    5 years
----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

The fair value of each of our stock option awards is expensed on a straight-line
basis over the vesting period of the options, which is generally four years.
Expected volatility is based on the historical volatility of our stock with
reasonable assumptions regarding projected future events. The risk-free rate of
interest for periods within the contractual life of the stock option award is
based on the yield curve of a zero-coupon U.S. Treasury bond on the date the
award is granted with a maturity equal to the expected term of the award. We use
historical data to estimate forfeitures within its valuation model. The expected
life of our stock option awards is derived from historical experience and
represents the period of time that awards are expected to be outstanding.

Under the recognition and measurement principles of APB 25, we estimated the
fair value of stock options granted during the quarter ended March 31, 2005, to
be $0.73 using the Black-Scholes option-pricing model. The assumptions used in
the model were a dividend yield of 0.00%, volatility of 82%, risk-free rate of
return of 3.87% and expected life of 7 years. The following table illustrates
the effect on net loss applicable to common shareholders and loss per share had
we applied the fair value recognition provisions of SFAS 123, "Accounting for
Stock-Based Compensation," for the quarter ended March 31, 2005:






Net loss applicable to common shareholders, as reported                                                                                                                                                                 $                 (17,010,364)
Deduct: Total stock-based employee compensation expense
         determined under fair value based method for all awards                                                                                                                                                                               (1,813)
----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
Pro forma net loss                                                                                                                                                                                                      $                 (17,012,177)
----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Basic and diluted loss per share:
         As reported                                                                                                                                                                                                    $                        (.76)
         Pro forma                                                                                                                                                                                                                               (.76)

Changes in options outstanding under the plans were as follows:
                                                                                                                            Shares                           Weighted-                          Aggregate                          Weighted-
                                                                                                                           subject                            average                           intrinsic                           average
                                                                                                                          to option                        exercise price                         value                         remaining life
----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
December 31, 2005                                                                                                                    8,168,180     $                         1.41
Granted                                                                                                                                146,000                                .21
Cancelled                                                                                                                               (3,200)                              1.71
----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
Outstanding March 31, 2006                                                                                                           8,310,980     $                         1.39     $                      332,542                               6.0
==========================================================================================================================================================================================================================================================
Exercisable March 31, 2006                                                                                                           8,098,655     $                         1.37     $                      319,162                               5.8
----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

7,733,638 of the above outstanding stock options were granted outside of our
employee stock option plan.

The following table summarizes information concerning currently outstanding and
exercisable options:
                                                                                                       Options outstanding                                                                             Options exercisable
    ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                                                                       Number                               Weighted-                             Weighted-                               Number                               Weighted-
                      Range of                                       outstanding                             average                               average                              exercisable                             average
                   exercise price                                    at 03/31/06                         remaining life                         exercise price                          at 03/31/06                         exercise price
----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
$             0.20             -      $          0.99                              6,568,738                                   6.5      $                           0.25                              6,419,863      $                           0.25
              1.80             -                 2.25                                864,261                                   4.0                                  1.90                                803,011                                  1.76
              3.00             -                 8.75                                793,675                                   3.7                                  3.65                                791,550                                  3.64
             34.90             -                60.50                                 52,835                                   2.5                                 50.43                                 52,760                                 50.38
             62.00             -               100.00                                 31,471                                   1.4                                 84.03                                 31,471                                 84.03
----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
$             0.20             -      $        100.00                              8,310,980                                   6.0      $                           1.39                              8,098,655      $                           1.37
----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

In April 1996, the Board of Directors and stockholders approved the adoption of
a stock option plan (the "Plan"). The Plan provided for the grant of options to
purchase up to 35,000 shares of our common stock. These options may be granted
to employees, our officers, our non-employee directors, consultants, and
advisors. The Plan provides for granting of options to purchase our common stock
at not less than the fair value of such shares on the date of the grant. Some of
the options generally vest ratably over a four-year period, while others vest
immediately. The options generally expire after seven years.

In August 1998, the stockholders and Board of Directors ratified and approved an
amended and restated 1996 Stock Option Plan increasing the maximum number of
shares of our common stock for which stock options may be granted from 35,000 to
155,000 shares. In August 2000, the stockholders and Board of Directors ratified
and approved the second amendment to our Amended and Restated 1996 Stock Option
Plan increasing the number of shares of our common stock for which options have
been or could be granted under the Plan from 155,000 to 300,000 shares.

In February 2003, the stockholders and Board of Directors ratified and approved
an amended and restated Stock Option Plan, increasing the maximum number of
shares of our common stock for which stock options may be granted from 300,000
to 450,000 shares. As of March 31, 2006 no options were available for grant
under the Plan.





In July 2005, the Board of Directors and stockholders approved the adoption of
the 2005 Stock Option Plan (the "2005 Plan"). The 2005 Plan provides for the
grant of options to purchase up to 1,000,000 shares of our common stock. These
options may be granted to employees, our officers, our non-employee directors,
consultants, and advisors. The 2005 Plan provides for granting of options to
purchase our common stock at not less than the fair value of such shares on the
date of the grant. As of March 31, 2006, all of the 872,658 options were
available for grant under the 2005 Plan.

Our Board of Directors or its Stock Option Committee has determined the exercise
price for all stock options awarded.

Share-based compensation expense is included in personnel expense.

NOTE 5 - NET LOSS PER SHARE

As of March 31, 2006, an aggregate of 37,370,152 outstanding warrants and
options and an aggregate of 25,088,062 shares of common stock issuable upon the
conversion of our Series D preferred stock outstanding were excluded from the
weighted average share calculations, as the effect was antidilutive. Basic and
diluted loss per share for the quarter ended March 31, 2006 includes warrants to
purchase 14,107,367 shares of common stock, exercisable at $.001 per share
reflected as outstanding from the date of grant. The weighted average share
calculations include those common shares subject to registration rights and
potential liquidated damages classified on the balance sheet as temporary
equity.

As of March 31, 2005, an aggregate of 27,566,558 outstanding warrants and
options and an aggregate of 14,229,566 shares of common stock issuable upon the
conversion of Series D preferred stock outstanding were excluded from the
weighted average share calculations, as the effect was antidilutive.

NOTE 6 - WARRANTS

The following represents warrant activity during the three months ended March
31, 2006:


                                                                    Balance at December 31, 2005                                                                                41,949,135
                                                                    Granted                                                                                                      1,390,100
                                                                    Exercised                                                                                                     (158,644)
                                                                    Expired or cancelled                                                                                           (14,052)
                                                                                                                                                        ----------------------------------
                                                                                                                                                        ----------------------------------
                                                                    Balance at March 31, 2006                                                                                   43,166,539
                                                                                                                                                        ==================================


NOTE 7 - ACCOUNTS PAYABLE AND ACCRUED EXPENSES

Accounts payable and accrued expenses consist of the following at March 31,
2006:


Accounts payable                                                                     $                              2,964,257
Accrued professional fees                                                                                             557,623
Due to officers                                                                                                       498,219
Accrued expenses                                                                                                      178,565
Accrued compensation                                                                                                   50,525
Bank overdraft                                                                                                         30,478
Deferred income                                                                                                        50,000
                                                                                           ----------------------------
                                                                                     $                              4,329,667
                                                                                           ============================
                                                                                           ============================







NOTE 8 - FINANCING TRANSACTIONS

Modification of Registration Rights Agreement: In October 2005 we closed a
private placement in which we sold our common stock and Series F warrants to a
group of accredited investors. In connection with such sales we entered into an
agreement with such investors whereby we undertook to register all of the shares
of our common stock they purchased, and the shares of our common stock issuable
upon exercise of our Series F warrants they acquired, in that private placement.
We agreed that if we did not file that registration statement by January 6,
2006, or have that registration statement declared effective by March 14, 2006,
we would pay liquidated damages to the purchasers. Our agreement with those
purchasers provided that the holders of a majority of the shares of our common
stock we were required to register pursuant to that agreement (the "majority
holders") could modify and/or waive our obligations under that agreement and
such modification and/or waiver would be binding on all the purchasers in that
private placement. On January 30, 2006 the majority holders (i) waived our
obligation to pay any liquidated damages for our failure to file the
registration statement by January 6, 2006; (ii) extended to June 7, 2006 the
time by which the registration statement had to be declared effective before we
had to pay any liquidated damages and (iii) permitted us to include in such
registration statement shares of our common stock we may issue, or that will be
issuable, in (x) a transaction in which we acquire by merger another
biotechnology company and/or (y) a new private placement of our securities in
which we raise up to $10,000,000. Such modification and waiver enabled us to
pursue such acquisition and private placement without incurring those liquidated
damages expenses.

Availability of Authorized Shares: On January 30 and 31, 2006, North Sound
Capital, LLC (North Sound) and SDS Capital Group SPC, Ltd. (SDS) entered into
agreements with us whereby they agreed not to convert any of the aggregate of
6,272.0156 shares of our Series D Convertible Preferred Stock owned by them, nor
exercise any of our Series F warrants held by them, until such time that we are
able to obtain approval from our stockholders to amend our certificate of
incorporation to increase the number of shares of our common stock we are
authorized to issue, or take such other corporate action, which will enable us
to have sufficient number of shares of our common stock which we are authorized
to issue, to issue in a private placement of our securities and in the
acquisition of a biotechnology company. See Note 10 for a description of those
transactions. These agreements provided us with the ability to use the
approximately 33,000,000 shares which North Sound and SDS have agreed not to
acquire, together with our available authorized shares, in such private
placement and acquisition transactions. We agreed that after the completion of
the proposed private placement and/or acquisition we would proceed promptly to
file a proxy statement for a meeting of our stockholders at which we expect to
increase the number of shares of our common stock we are authorized to issue, or
take such other corporate action, to have available for issuance enough shares
of our common stock upon conversion of North Sound's and SDS's Series D
Convertible Preferred Stock and upon exercise of their warrants. We filed that
proxy statement on May 2, 2006.

Reduction of Liquidation Preference: All 6,272.0156 outstanding shares of our
Series D Convertible Preferred Stock are owned by North Sound and SDS. On
January 30 and 31, 2006 North Sound and SDS entered into agreements with us
agreeing to exchange all of their shares of our Series D Convertible Preferred
Stock into an equal number of shares of our new Series D-1 Convertible Preferred
Stock. The only difference between our Series D Preferred shares and our Series
D-1 Preferred shares is that the liquidation preference of the Series D
Preferred shares is $10,000 per share and that of the Series D-1 Preferred
shares is $10 per share. Each Series D-1 Preferred share will be convertible (as
is each Series D Preferred share) into 4,000 shares of our common stock. As of
May 15, 2006 we had not yet exchanged the Series D Preferred shares for Series
D-1 Preferred shares.

We have no material relationship with any of the persons who signed the
modification and waiver agreements referred to above.

Cambrex Suite Deal II: On February 13, 2006 we entered into an agreement with
our manufacturing and marketing partner, Cambrex, whereby for the six-month
period January 1 to June 30, 2006 the $132,612 monthly charges we incur for
rental of a production suite used to produce ORCEL at their Maryland facility,
Cambrex has agreed to accept 736,733 shares of our common stock monthly in lieu
of cash payment. Accordingly, we issued 2,210,199 shares for three months of
suite fees during the first quarter of 2006. The shares were valued at $523,080
using the closing market price of our common stock at the end of each monthly
performance period. We also issued to Cambrex a three-year warrant exercisable
July 1, 2006 to purchase 1,105,100 shares of our common stock at $0.75 per
share. The warrant was valued at $67,505 on the date of agreement utilizing a
Black Scholes model with the following assumptions: expected life of 3 years,
volatility factor of 86%, risk free rate of 4.66%, and no expected dividend
yield. The warrant is being amortized over the six-month period of the
agreement. Each of these securities carry certain registration rights. The
common shares issued to Cambrex were subject to registration rights and
potential liquidated damages and have been classified on the balance sheet as
temporary equity.

Vendor Settlement: On March 17, 2006, we settled a vendor liability of
approximately $102,000 for $35,000 cash payable in seven equal monthly
installments and a three-year warrant to purchase 285,000 shares of our common
stock at an exercise price of $0.25 per share. The warrant was valued at $54,982
utilizing a Black Scholes model with the following

assumptions: expected life of 3 years, volatility factor of 86%, risk free rate
of 4.64%, and no expected dividend yield. The warrant has piggyback registration
rights for the underlying shares of common stock.

Bridge Financing: In March 2006, we received $445,000 in short-term loans. We
received two loans for $130,000 and $65,000, respectively, from two of our
executive officers. These loans were non-interest bearing and payable from the
proceeds of our future financings. $35,000 was repaid on April 6, 2006 with the
balance paid from the proceeds of our April 17th private placement of our equity
securities. The third loan for $250,000 bore interest at 8% per annum and was
from the investor who had committed to provide us with $1,058,000 by the later
of the filing of our pre-market approval application for our confirmatory venous
leg ulcer trial, or March 31, 2006. This $250,000 loan automatically converted
into the equity securities we issued in our recent private placement at 1.2
times the note's principal and accrued interest amount. See Note 10. We will
need to measure whether any beneficial conversion feature exists on the date of
conversion as a result of this transaction. Additionally we agreed that since
the investor provided us with the funds earlier than was required, upon
conversion of such $250,000 loan to our equity securities, we would forego such
investor's remaining commitment to provide us with $808,000 of additional
financing, and that the earlier repricing (upon commitment) of our warrants held
by such investor would not be affected.

NOTE 9 - COMMITMENTS & CONTINGENCIES

Legal Challenge Withdrawn: In January 2006 we were informed that Advanced Tissue
Sciences withdrew its appeal against the grant of our European patent for our
ORCEL product. We were originally granted the European patent in December 1997
and received notification in November 1998 that it was being challenged by
Advanced Tissue Sciences. In March 2002, we announced that we had successfully
defended Advanced Tissue Sciences' opposition filed with the European Patent
office and, subsequently, Advanced Tissue Sciences appealed the patent offices'
decision, but is now withdrawing that appeal. Withdrawal of the appeal by
Advanced Tissue Sciences concludes this litigation and our European patent
remains as originally issued.

Third Amendment of Lease: On March 16, 2006 we agreed to a two-year extension of
our lease for our 14,320 square foot New York City laboratory and office
facility, effective January 1, 2006. We agreed to a monthly rental of $60,860 or
$730,320 per annum. We have the option to renew the lease for an additional two
years after 2007 at the rate of $63,843 per month, or $766,120 annually.

Letter of Intent: In December 2005 we executed a non-binding letter of intent to
acquire Hapto Biotech (Hapto), a privately-held company focused on the
development of two proprietary fibrin derived platform technologies: Fibrin
Micro Beads (FMB's) and Fibrin based peptides, (Haptides(TM)). Hapto's research
indicates that FMB's have the ability to optimize the recovery, potential
delivery and therapeutic value of adult stem cells. In October 2004, we
initiated our relationship with Hapto by forming a joint venture to combine our
proprietary collagen biomaterial technology and Hapto's Haptide(TM) peptide
technology to develop non cellular, biologically active enhanced biomaterials to
promote the attraction and attachment of cells for wound healing,
reconstructive, cosmetic, tissue regeneration and dental applications. See Note
10.

NOTE 10 - SUBSEQUENT EVENTS

Bridge Financing: On April 3, 2006 we received a non-interest bearing short-term
loan of $45,000 from another of our executive officers which was repaid from our
April 17th private placement with a $500 transaction fee. On April 5, 2006 we
received a $200,000 short-term loan from a third party due April 30, 2006 to be
repaid at 110% of principal plus accrued interest at 8% per annum on the
original $200,000 principal balance. We issued a three-year warrant to purchase
50,000 shares of our common stock at an exercise price of $0.50 per share to the
lender. On April 17, 2006, with the completion of our recent private placement,
we converted the $250,000 (see Note 8) short-term loan with its then outstanding
loan balance of $301,333 into 301.33 shares of Series E Preferred Stock, and
issued a warrant to purchase 1,506,665 shares of our common stock at an exercise
price of $0.50 per share.

Acquisition of Hapto: On April 14, 2006, we closed our acquisition of Hapto. We
believe that due to the early stages of the development of Hapto's technology,
that the Hapto assets we acquired do not constitute a business. For such
acquisition we issued a total of 30,860,000 shares of our common stock to the
Hapto shareholders and granted them warrants to purchase an additional 3,000,000
of our common shares at $0.30 per share. Based on the market price of our common
stock on April 14, 2006, and valuing the warrants using the Black Scholes
formula, the value of the shares and warrants we issued to Hapto's shareholders
is approximately $10,100,000. The purchase price will be allocated to in-process
research and development costs, and accordingly, expensed immediately. The
investment banking firm of Rodman & Renshaw, LLC (R&R) acted as our advisor in
this acquisition. R&R received three-year warrants to purchase 4,000,000 shares
of our common stock at $0.30 per share for their advisory services.

Private Placement: On April 17, 2006, we completed a private placement sale for
aggregate gross proceeds of $6,176,000 to accredited investors of our 6% Series
E Convertible Preferred Stock and warrants to purchase our common stock. The
Series E Convertible Preferred Stock is entitled to vote on an "as converted"
basis on all matters submitted to a vote by the holders of our common stock. At
any time these investors can convert their preferred stock into common stock at
a $0.20 conversion price. After we complete a reverse split of our outstanding
common stock the investors are obligated to convert their preferred stock on the
21st trading day following such reverse split by dividing the amount they paid
for such preferred shares plus dividends at 6% per annum, by the lesser of
$0.20, or 90% of the average of the volume weighted average prices for our
common stock for the twenty trading days following the effective date of such
reverse stock split. We issued five-year warrants to purchase 32,386,650 shares
of our common stock at $0.50 per share. The warrants carry full ratchet price
reset provisions should we sell our common stock or our other securities
convertible into, or exercisable for, our common stock, at an effective price
per common share less than the $0.50 exercise price of the warrants. We are
obligated to register, under the Securities Act of 1933, all of the shares of
our common stock issuable upon conversion of the 6% Series E Convertible
Preferred Stock and upon exercise of such warrants. We will pay investors 2% per
month for any failure to timely file the registration statement by June 18, 2006
or have it declared effective by August 17, 2006.








REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

Board of Directors and Stockholders
Ortec International, Inc.
New York, New York

We have audited the accompanying consolidated balance sheet of Ortec
International, Inc. (a development stage enterprise) as of December 31, 2005 and
the related consolidated statements of operations, shareholders' deficit, and
cash flows for the years ended December 31, 2005 and 2004 and for the period
from March 12, 1991 (inception) to December 31, 2005. These consolidated
financial statements are the responsibility of the Company's management. Our
responsibility is to express an opinion on these consolidated financial
statements based on our audit. We did not audit the consolidated statements of
operations, shareholders' deficit and cash flows for the period from March 12,
1991 (inception) to December 31, 2003, which reflect product revenue of
approximately $.3 million, expenses of approximately $96.9 million, preferred
stock dividends and discounts of approximately $6.7 million, cash used in
operating activities of $69.9 million, cash used in investing activities of
approximately $6.2 million and cash provided by financing activities of $77.4
million. Those financial statements were audited by another auditor whose report
has been furnished to us, and our opinion, insofar as it relates to the amounts
included for such period, is based solely on the report of the other auditor.

We conducted our audit in accordance with the standards of the Public Company
Accounting Oversight Board (United States). Those standards require that we plan
and perform the audit to obtain reasonable assurance about whether the financial
statements are free of material misstatement. The Company is not required to
have, nor were we engaged to perform, an audit of its internal control over
financial reporting. Our audit included consideration of internal control over
financial reporting as a basis for designing audit procedures that are
appropriate in the circumstances, but not for the purpose of expressing an
opinion on the effectiveness of the Company's internal control over financial
reporting. Accordingly, we express no such opinion. An audit also includes
examining, on a test basis, evidence supporting the amounts and disclosures in
the financial statements, assessing the accounting principles used and
significant estimates made by management, as well as evaluating the overall
financial statement presentation. We believe that our audit and the report of
the other auditor provide a reasonable basis for our opinion.

In our opinion, based on our audit and the report of the other auditor, the
consolidated financial statements referred to above present fairly, in all
material respects, the financial position of Ortec International, Inc. at
December 31, 2005, and the results of the Company's operations and cash flows
for the years ended December 31, 2005 and 2004 and for the period from March 12,
1991 (inception) to December 31, 2005, in conformity with accounting principles
generally accepted in the United States.

The accompanying consolidated financial statements have been prepared assuming
that the Company will continue as a going concern. As discussed in Note 1, the
Company incurred a net loss applicable to common shareholders of $36 million
during the year ended December 31, 2005, and, as of that date, the Company's
current liabilities exceeded its current assets by $32.2 million, its total
liabilities exceeded its total assets by $31.3 million and the Company has a
deficit accumulated in the development stage of $156.4 million. These factors,
among others, as discussed in Note 1 to the consolidated financial statements,
raise substantial doubt about the Company's ability to continue as a going
concern. Management's plans in regard to these matters are also described in
Note 1. The consolidated financial statements do not include any adjustments
that might result from the outcome of this uncertainty.

/s/ BDO Seidman, LLP

New York, New York
March 30, 2006, except for Notes 14 and 18 to the consolidated financial
    statements, as to which the dates are April 14 and 17, 2006







                            ORTEC INTERNATIONAL, INC.
                        (A DEVELOPMENT STAGE ENTERPRISE)

                           CONSOLIDATED BALANCE SHEET





                                                                                                                                                                                                                                            December 31,
                                                                                                                                                                                                                                                  2005
                                                                                                                                                                                                                                ----------------------------------
                                                                                                                                                                                                                                ----------------------------------
                                                                                                        ASSETS

Current assets:
  Cash and cash equivalents                                                                                                                                                                                                 $                             675,389
   Prepaid and other current assets                                                                                                                                                                                                                       151,973
                                                                                                                                                                                                                                ----------------------------------
                                                                                                                                                                                                                                ----------------------------------
Total current assets                                                                                                                                                                                                                                      827,362
Property and equipment, net                                                                                                                                                                                                                               198,331
Patent application costs, net                                                                                                                                                                                                                             547,335
Deposits and other assets                                                                                                                                                                                                                                 156,876
                                                                                                                                                                                                                                ----------------------------------
Total assets                                                                                                                                                                                                                $                           1,729,904
                                                                                                                                                                                                                                ==================================
                                                                                                                                                                                                                                ==================================

                                                                                         LIABILITIES AND SHAREHOLDERS' DEFICIT

Current liabilities:
  Accounts payable and accrued expenses                                                                                                                                                                                     $               3,359,323
  Capital lease obligation - current                                                                                                                                                                                                         13,405
  Current maturities of promissory notes                                                                                                                                                                                                     41,635
  Obligation under revenue interest assignment                                                                                                                                                                                             29,569,000
                                                                                                                                                                                                                                ----------------------------------
                                                                                                                                                                                                                                ----------------------------------
Total current liabilities                                                                                                                                                                                                                  32,983,363
  Promissory notes, less current portion                                                                                                                                                                                                     50,082
  Capital lease obligation, less current portion                                                                                                                                                                                                        9,949
                                                                                                                                                                                                                                ----------------------------------
                                                                                                                                                                                                                                ----------------------------------
Total liabilities                                                                                                                                                                                                                          33,043,394

COMMITMENTS AND CONTINGENCIES

Shareholders' deficit:
Preferred stock, $.001 par value; authorized, 1,000,000 shares:
   Convertible
       Series D, stated value $10,000 per share; authorized 10,000 shares; 6,272 shares
       issued and outstanding; liquidation preference of $62,720,156 *                                                                                                                                                                     15,911,331
Common stock, $.001 par value; authorized, 200,000,000 shares; 51,104,951 shares
   issued and 51,102,951 outstanding                                                                                                                                                                                                         51,106
Additional paid-in capital                                                                                                                                                                                                                        109,775,884
Deficit accumulated during the development stage                                                                                                                                                                                          (156,411,721)
Treasury stock, 2,000 shares at cost                                                                                                                                                                                                           (177,645)
Deferred compensation                                                                                                                                                                                                                       (462,445)
                                                                                                                                                                                                                                ----------------------------------
                                                                                                                                                                                                                                ----------------------------------
Total shareholders' deficit                                                                                                                                                                                                               (31,313,490)
                                                                                                                                                                                                                                ----------------------------------
                                                                                                                                                                                                                                ----------------------------------
Total liabilities and shareholders' deficit                                                                                                                                                                                 $                 1,729,904
                                                                                                                                                                                                                                ==================================

The accompanying notes are an integral part of these statements.

*Corrected amount - See Note 11.








                            ORTEC INTERNATIONAL, INC.
                        (A DEVELOPMENT STAGE ENTERPRISE)

                      CONSOLIDATED STATEMENTS OF OPERATIONS

                                                                                                                                                                                                               Cumulative
                                                                                                                                                                                                                  From
                                                                                                                                                                                                  March 12, 1991
                                                                                                                                                                                                            (inception) to
                                                                                                                       Year ended December 31,                                                                December 31,
                                                                                                                 -------------------------------------------------------------------------
                                                                                                                                                   ----
                                                                                                                              2005                                     2004                                       2005
                                                                                                                 --------------------------------        ---------------------------------        --------------------------------------
                                                                                                                 --------------------------------        ---------------------------------        --------------------------------------

Product Revenue                                                                                            $                    -                    $                  -                     $                                 265,665
                                                                                                                 --------------------------------        ---------------------------------        --------------------------------------
                                                                                                                 --------------------------------        ---------------------------------        --------------------------------------

Expenses
  Product and laboratory costs                                                                                                         3,620,562                                3,014,461                                    30,787,148
  Personnel                                                                                                                            3,896,068                                3,857,052                                    41,081,555
  General and administrative                                                                                                           1,869,106                                1,664,294                                    20,904,457
  Rent                                                                                                                                   474,013                                  481,782                                     4,446,307
  Consulting                                                                                                                    -                                                  13,045                                     5,702,651
  Interest expense                                                                                                                     7,316,780                                6,745,928                                    27,098,609
  Other (income) expense                                                                                                                 116,429                                (398,662)                                   (2,554,218)
  Loss on settlement of promissory notes                                                                                     13,081,453                                 -                                          13,081,453
  Lease termination costs                                                                                                       -                                       -                                                     1,119,166
  Loss on extinguishments of debt
    and series A preferred shares                                                                                               -                                       -                                                     1,004,027
                                                                                                                 --------------------------------        ---------------------------------        --------------------------------------
                                                                                                                                      30,374,411                               15,377,900                                   142,671,155
                                                                                                                 --------------------------------        ---------------------------------        --------------------------------------
                                                                                                                 --------------------------------        ---------------------------------        --------------------------------------

Net loss                                                                                                                            (30,374,411)                             (15,377,900)                                 (142,405,490)

Preferred stock dividends                                                                                                               (17,891)                                  643,904                                     3,011,574
Preferred stock and warrants
  deemed dividends and discounts                                                                                                       5,602,657                                1,123,000                                    10,994,657

                                                                                                                 --------------------------------        ---------------------------------        --------------------------------------
                                                                                                                 --------------------------------        ---------------------------------        --------------------------------------

Net loss applicable to common shareholders                                                                 $                        (35,959,177)     $                       (17,144,804)     $                           (156,411,721)
                                                                                                                 ================================        =================================        ======================================
                                                                                                                 ================================        =================================        ======================================

Net loss per share

   Basic and diluted                                                                                       $                              (0.93)     $                             (3.03)
                                                                                                                 ================================        =================================
                                                                                                                 ================================        =================================

Weighted average shares outstanding

   Basic and diluted                                                                                                                  38,534,706                                5,655,406
                                                                                                                 ================================        =================================
                                                                                                                 ================================        =================================


The accompanying notes are an integral part of these statements.





                            ORTEC INTERNATIONAL INC.
                        (A DEVELOPMENT STAGE ENTERPRISE)

            CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY (DEFICIT)


                                                                                                                                                                                                 Deficit
                                                                                                                                                                                               accumulated
                                                                                                                                                                         Additional            during the                                                         Total
                                                                                   Common Stock                                     Preferred Stock                       paid-in              development           Treasury             Deferred            shareholders'
                                                                                   ------------
                                                                                                             -----------------------------------------------------
                                                                            Shares             Amount           Series B          Series C           Series D             capital                 stage               stock             compensation        equity (deficit)
                                                                        ----------------  -----------------  ----------------  ----------------  -----------------  ---------------------  --------------------  -----------------  ---------------------  --------------------
                                                                        ----------------  -----------------  ----------------  ----------------  -----------------  ---------------------  --------------------  -----------------  ---------------------  --------------------
March 12, 1991 (inception) to December 31, 1991
Founders                                                                        155,382              $ 155          -                 -                 -                 $          715            -                   -                    -                    $ 870
First private placement ($3.00 per share)                                        21,744                 22          -                 -                 -                  64,978                   -                   -                    -                   65,000
The Director ($11.50 and $53.00 per share)                                       14,902                 15          -                 -                 -                 249,985                   -                   -                    -                   250,000
Second private placement ($94.25 per share)                                       5,302                  5          -                 -                 -                 499,995                   -                   -                    -                   500,000
Share issuance expense                                                                -                  -          -                 -                 -                 (21,118)                  -                   -                    -                  (21,118)
Net loss                                                                              -                  -          -                 -                 -                    -                                (281,644) -                    -                  (281,644)
                                                                        ----------------  -----------------  ----------------  ----------------  -----------------  ---------------------  --------------------  -----------------  ---------------------  --------------------
                                                                        ----------------  -----------------  ----------------  ----------------  -----------------  ---------------------  --------------------  -----------------  ---------------------  --------------------
Balance at December 31, 1991                                                    197,330                197          -                 -                 -                 794,555               (281,644)               -                    -                   513,108
Second private placement ($94.25 per share)                                       2,646                  3          -                 -                 -                 250,003                   -                   -                    -                   250,006
Second private placement ($94.25 per share)                                       2,286                  2          -                 -                 -                 215,465                   -                   -                    -                   215,467
Stock purchase agreement with the Director
     ($94.25 per share)                                                           3,182                  3          -                 -                 -                 299,995                   -                   -                    -                   299,998
Share issuance expense                                                                -                  -          -                 -                 -                 (35,477)                  -                   -                    -                  (35,477)
Net loss                                                                              -                  -          -                 -                 -                    -                  (785,941)               -                    -                  (785,941)
                                                                        ----------------  -----------------  ----------------  ----------------  -----------------  ---------------------  --------------------  -----------------  ---------------------  --------------------
                                                                        ----------------  -----------------  ----------------  ----------------  -----------------  ---------------------  --------------------  -----------------  ---------------------  --------------------
Balance at December 31, 1992                                                    205,444                205          -                 -                 -                1,524,541             (1,067,585)              -                    -                   457,161
Third private placement ($100.00 per share)                                      10,965          11                 -                 -                 -                1,096,489                  -                   -                    -                  1,096,500
Third private placement ($100.00 per share)                                       2,250          2                  -                 -                 -                 224,998                   -                   -                    -                   225,000
Stock purchase agreement with Home
  Insurance Company ($90.00 per share)                                           11,112          11                 -                 -                 -                 999,988                   -                   -                    -                   999,999
Stock purchase agreement with the Director
  ($94.25 per share)                                                              2,122          2                  -                 -                 -                 199,998                   -                   -                    -                   200,000
Shares issued in exchange for commission                                             60          1                  -                 -                 -                  5,999                    -                   -                    -                    6,000
Share issuance expenses                                                               -          -                  -                 -                 -                (230,207)                  -                   -                    -                  (230,207)
Net loss                                                                              -          -                  -                 -                 -                    -                 (1,445,624)              -                    -                 (1,445,624)
                                                                        ----------------  -----------------  ----------------  ----------------  -----------------  ---------------------  --------------------  -----------------  ---------------------  --------------------
                                                                        ----------------  -----------------  ----------------  ----------------  -----------------  ---------------------  --------------------  -----------------  ---------------------  --------------------
Balance at December 31, 1993                                                    231,953                232          -                 -                 -                3,821,806             (2,513,209)              -                    -                  1,308,829
Fourth private placement ($100.00 per share)                                      3,946                  4          -                 -                 -                 397,708                   -                   -                    -                   397,712
Stock purchase agreement with Home
Insurance Company ($100.00 per share)                                             5,000                  5          -                 -                 -                 499,995                   -                   -                    -                   500,000
Share issuance expense                                                         -                 -                  -                 -                 -                     (8,697)               -                   -                    -                   (8,697)
Net loss                                                                       -                 -                  -                 -                 -                    -                 (1,675,087)              -                    -                 (1,675,087)
                                                                        ----------------  -----------------  ----------------  ----------------  -----------------  ---------------------  --------------------  -----------------  ---------------------  --------------------
                                                                        ----------------  -----------------  ----------------  ----------------  -----------------  ---------------------  --------------------  -----------------  ---------------------  --------------------
Balance at December 31, 1994                                                    240,899                241                                                               4,710,812             (4,188,296)              -                    -                   522,757
Rent forgiveness                                                               -                 -                  -                 -                 -                  40,740                   -                   -                    -                   40,740
Net loss                                                                       -                 -                  -                 -                 -                    -                 (1,022,723)              -                    -                 (1,022,723)
                                                                        ----------------  -----------------  ----------------  ----------------  -----------------  ---------------------  --------------------  -----------------  ---------------------  --------------------
                                                                        ----------------  -----------------  ----------------  ----------------  -----------------  ---------------------  --------------------  -----------------  ---------------------  --------------------
Balance at December 31, 1995                                                    240,899         241                 -                 -                 -                4,751,552             (5,211,019)              -                    -                  (459,226)
Initial public offering                                                         120,000         120                 -                 -                 -                5,999,880                  -                   -                    -                  6,000,000
Exercise of warrants                                                              3,389          3                  -                 -                 -                  33,882                   -                   -                    -                   33,885
Fifth private placement ($64.90 per share)                                       95,911              96             -                 -                 -                6,220,701                  -                   -                    -                  6,220,797
Share issuance expenses                                                        -                 -                  -                 -                 -               (1,580,690)                 -                   -                    -                 (1,580,690)
Stock options issued for services                                              -                 -                  -                 -                 -                 152,000                   -                   -                    -                   152,000
Net loss                                                                       -                 -                  -                 -                 -                    -                 (2,649,768)              -                    -                 (2,649,768)
                                                                        ----------------  -----------------  ----------------  ----------------  -----------------  ---------------------  --------------------  -----------------  ---------------------  --------------------
                                                                        ----------------  -----------------  ----------------  ----------------  -----------------  ---------------------  --------------------  -----------------  ---------------------  --------------------
Balance at December 31, 1996                                                    460,199         460                 -                 -                 -                15,577,325            (7,860,787)              -                    -                  7,716,998
Exercise of warrants                                                            115,878         116                 -                 -                 -                10,822,675                 -                   -                    -                 10,822,791
Share issuance expenses                                                        -                 -                  -                 -                 -                (657,508)                  -                   -                    -                  (657,508)
Stock options and warrants issued for services                                 -                 -                  -                 -                 -                 660,000                   -                   -                    -                   660,000
Net loss                                                                       -                 -                  -                 -                 -                    -                 (4,825,663)              -                    -                 (4,825,663)
                                                                        ----------------  -----------------  ----------------  ----------------  -----------------  ---------------------  --------------------  -----------------  ---------------------  --------------------
                                                                        ----------------  -----------------  ----------------  ----------------  -----------------  ---------------------  --------------------  -----------------  ---------------------  --------------------
Balance at December 31, 1997                                                    576,077         576                 -                 -                 -                26,402,492           (12,686,450)              -                    -                 13,716,618
Exercise of warrants                                                             22,149          22                 -                 -                 -                1,281,935                  -                   -                    -                  1,281,957
Stock options and warrants issued for services                                 -                 -                  -                 -                 -                1,920,111                  -                   -                    -                  1,920,111
Sixth private placement                                                          20,000                 20          -                 -                 -                1,788,678                  -                   -                    -                  1,788,698
Sixth private placement - warrants issued                                      -                 -                  -                 -                 -                 211,302                   -                   -                    -                   211,302
Share issuance expenses                                                        -                 -                  -                 -                 -                 (48,000)                  -                   -                    -                  (48,000)
Purchase of 660 shares of treasury stock  (at cost)                            -                 -                  -                 -                 -                    -                      -                         (67,272)       -                  (67,272)
Net loss                                                                       -                 -                  -                 -                 -                    -                 (8,412,655)                                   -                 (8,412,655)
                                                                        ----------------  -----------------  ----------------  ----------------  -----------------  ---------------------  --------------------  -----------------  ---------------------  --------------------
                                                                        ----------------  -----------------  ----------------  ----------------  -----------------  ---------------------  --------------------  -----------------  ---------------------  --------------------
Balance at December 31, 1998                                                    618,226                618          -                 -                 -                31,556,518           (21,099,105)           (67,272)                -                 10,390,759
Exercise of warrants                                                              1,410                  1          -                 -                 -                  14,102                   -                   -                    -                   14,103
Stock options and warrants issued for services                                 -                 -                  -                 -                 -                         64,715            -                   -                    -                                    64,715
Seventh private placement ($87.50 per share)                                     38,916                 39          -                 -                 -                      3,168,746            -                   -                    -                                 3,168,785
Seventh private placement - investor warrants                                  -                 -                  -                 -                 -                        236,291            -                   -                    -                                   236,291
Seventh private placement - placement agent warrants                           -                 -                  -                 -                 -                        232,000            -                   -                    -                                   232,000
Eighth private placement ($55.00 per share)                                     163,637                164          -                 -                 -                      8,999,838            -                   -                    -                                 9,000,002
Share issuance expenses                                                        -                 -                  -                 -                 -                (619,908)                  -                   -                    -                  (619,908)
Purchase of 910 shares of treasury stock (at cost)                             -                 -                  -                 -                 -                    -                      -                (75,518)                -                  (75,518)
Net loss                                                                       -                 -                  -                 -                 -                    -                (10,040,509)              -                    -                (10,040,509)
                                                                        ----------------  -----------------  ----------------  ----------------  -----------------  ---------------------  --------------------  -----------------  ---------------------  --------------------
                                                                        ----------------  -----------------  ----------------  ----------------  -----------------  ---------------------  --------------------  -----------------  ---------------------  --------------------
Balance at December 31, 1999                                                    822,189                822          -                 -                 -                43,652,302           (31,139,614)              (142,790)            -                 12,370,720
Exercise of options and warrants                                                 17,554                 17          -                 -                 -                 327,265                   -                   -                    -                   327,282
Stock options and warrants issued for services                                 -                 -                  -                 -                                           56,265            -                   -                    -                                    56,265
Ninth private placement ($150.00 per share)                                       6,667                  7          -                 -                 -                        999,998            -                   -                    -                                 1,000,005
Ninth private placement - placement agent warrants                             -                 -                  -                 -                 -                  23,000                   -                   -                    -                   23,000
Tenth private placement ($67.50 per share)                                      124,757                125          -                 -                 -                8,420,946                  -                   -                    -                  8,421,071
Share issuance expenses                                                        -                 -                  -                 -                 -                (641,500)                  -                   -                    -                  (641,500)
Purchase of 430 shares of treasury stock (at cost)                             -                 -                  -                 -                 -                    -                      -                         (34,855)       -                                   (34,855)
Net loss                                                                       -                 -                  -                 -                 -                    -                (12,129,663)              -                    -                (12,129,663)
                                                                        ----------------  -----------------  ----------------  ----------------  -----------------  ---------------------  --------------------  -----------------  ---------------------  --------------------
                                                                        ----------------  -----------------  ----------------  ----------------  -----------------  ---------------------  --------------------  -----------------  ---------------------  --------------------
Balance at December 31, 2000                                                    971,167                971          -                 -                 -                     52,838,276      (43,269,277)          (177,645)                -                  9,392,325
Stock options issued for services                                              -                 -                  -                 -                 -                        188,080            -                   -                    -                   188,080
Net loss                                                                       -                 -                  -                 -                 -                    -                (15,885,377)              -                    -                (15,885,377)
                                                                        ----------------  -----------------  ----------------  ----------------  -----------------  ---------------------  --------------------  -----------------  ---------------------  --------------------
                                                                        ----------------  -----------------  ----------------  ----------------  -----------------  ---------------------  --------------------  -----------------  ---------------------  --------------------
Balance at December 31, 2001                                                    971,167                971          -                 -                 -                     53,026,356      (59,154,654)          (177,645)                -                 (6,304,972)
Exercise of options and warrants                                                 35,720          36                 -                 -                 -                            321            -                   -                    -                     357
Stock options and warrants issued for services                                 -                 -                  -                 -                 -                        113,060            -                   -                    -                   113,060
Warrants issued with convertible debentures                                    -                 -                  -                 -                 -                        440,523            -                   -                    -                   440,523
Warrants issued with convertible redeemable                                                                                                                                                                                                  -
   preferred stock                                                             -                 -                  -                 -                 -                        559,289            -                   -                    -                   559,289
Convertible debenture conversion benefit                                       -                 -                  -                 -                 -                      1,042,663            -                   -                    -                  1,042,663
Redeemable convertible preferred stock                                                                                                                                                                                                       -
   conversion benefit                                                          -                 -                  -                 -                 -                      1,097,886            -                   -                    -                  1,097,886
Issuance of series B preferred stock (938                                                                                                                                                                                                    -
shares)   ($10,000 per share)                                                  -                 -               9,382,742            -                 -                    -                      -                   -                    -                  9,382,742
Warrants issued and exercised with preferred stock                              938,275                  938                (3,479,043-                 -                      3,485,443            -                   -                    -                    7,338
Shares issuance costs - preferred stock                                        -                 -              (866,612)             -                 -                        304,615            -                   -                    -                  (561,997)
Preferred stock dividends                                                       375,315         375                 -                 -                                        1,125,559       (1,125,934)              -                    -                      -
Net loss                                                                       -                 -                  -                 -                 -                    -                (21,578,021)              -                    -                (21,578,021)
                                                                        ----------------  -----------------  ----------------  ----------------  -----------------  ---------------------  --------------------  -----------------  ---------------------  --------------------
                                                                        ----------------  -----------------  ----------------  ----------------  -----------------  ---------------------  --------------------  -----------------  ---------------------  --------------------
Balance at December 31, 2002 (carried forward)                                2,320,477        2,320            5,037,087             -                 -                     61,195,715      (81,858,609)         (177,645)                 -                (15,801,132)





                                                                                               ORTEC INTERNATIONAL INC.
                        (A DEVELOPMENT STAGE ENTERPRISE)

            CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY (DEFICIT)


                                                                                                                                                                                                  Deficit
                                                                                                                                                                                                accumulated
                                                                                                                                                                          Additional            during the                                                        Total
                                                                                 Common Stock                                       Preferred Stock                        paid-in              development         Treasury              Deferred            shareholders'
                                                                                 ------------
                                                                                                           --------------------------------------------------------
                                                                           Shares            Amount           Series B          Series C            Series D               capital                 stage               Stock            compensation        equity (deficit)
                                                                       ----------------  ----------------  ----------------  ----------------  --------------------  ---------------------  --------------------  ----------------  ---------------------  --------------------
                                                                       ----------------  ----------------  ----------------  ----------------  --------------------  ---------------------  --------------------  ----------------  ---------------------  --------------------
Balance at December 31, 2002 (brought forward)                               2,320,477        2,320           5,037,087             -                   -                      61,195,715      (81,858,609)          (177,645)               -                (15,801,132)
Exercise of options and warrants                                               398,750         399                -                 -                   -                          12,567            -                   -                   -                   12,966
Issuance of preferred stock: series B (200                                                                                                                                                                                                   -
   shares), series C (948 shares)                                             -                 -             2,000,000            5,690,000            -                     -                      -                   -                   -                  7,690,000
Warrants issued with preferred stock                                          -                 -             (490,567)          (1,225,632)            -                       1,716,199            -                   -                   -                      -
Warrants issued for services                                                  -                 -                 -                                     -                          87,000            -                   -                   -                   87,000
Share issuance costs - preferred stock                                        -                 -             (393,488)            (797,327)            -                         359,078            -                   -                   -                  (831,737)
Conversion of series B preferred stock (605                                                                                                                                                                                                  -
   shares) into common stock                                                 2,421,556        2,422          (3,253,571)            -                   -                       3,251,149            -                   -                   -                      -
Conversion of series B  preferred stock into                                                                                                                                                                                                 -
   series D preferred stock (483 shares)                                      -                 -            (2,628,602)            -                    2,628,602            -                      -                   -                   -                      -
Preferred stock deemed dividends and discounts                                -                 -                 -                 -                   -                       4,269,000       (4,269,000)              -                   -                      -
Preferred stock dividends                                                       92,308         92                 -                 -                   -                         922,985        (923,077)               -                   -                      -
Common stock dividend to be distributed on                                                                                                                                                                                                   -
   series C preferred stock                                                   -                 -                 -                 -                   -                         336,550        (336,550)               -                   -                      -
Common stock to be issued in connection with                                                                                                                                                                                                 -
  promissory notes                                                            -                 -                 -                 -                   -                         287,000            -                   -                   -                         287,000
Adjustment for one for ten reverse stock split                                      74          -                 -                 -                   -                     -                      -                   -                   -                      -
Net loss                                                                      -                 -                 -                 -                   -                     -                (15,920,504)              -                   -                (15,920,504)
                                                                       ----------------  ----------------  ----------------  ----------------  --------------------  ---------------------  --------------------  ----------------  ---------------------  --------------------
                                                                       ----------------  ----------------  ----------------  ----------------  --------------------  ---------------------  --------------------  ----------------  ---------------------  --------------------
Balance at December 31, 2003                                                 5,233,165             5,233           270,859         3,667,041             2,628,602             72,437,243         (103,307,740)         (177,645)            -                    (24,476,407)
Common stock issued in connection with                                                                                                                                                                                                       -
  previously issued notes                                                   157,000                     157       -                 -                   -                           (157)            -                   -                   -                      -
Common stock issued in                                                                                                                                                                                                                       -
  connection with promissory notes                                             331,831               332          -                 -                   -                         745,870            -                   -                   -                         746,202
Common stock (277,020) and 34.31 shares of                                                                                                                                                                                                   -
  series D preferred to be issued in connection                                                                                                                                                                                              -
  with agreements which extended due date of                                                                                                                                                                                                 -
  promissory notes                                                            -                 -                 -                 -                   -                         828,540            -                   -                   -                         828,540
Common stock issued in connection with exercise                                                                                                                                                                                              -
  of warrants                                                                   32,460                32          -                 -                   -                             293            -                   -                   -                             325
Conversion of 35.62 shares of series C preferred                                                                                                                                                                                             -
  stock into common stock                                                      106,872               107          -                (137,752)            -                         137,645            -                   -                   -                      -
Payment of dividends on 35.62 shares of series C                                                                                                                                                                                             -
  preferred stock in common stock                                               13,743                14          -                 -                   -                          30,085              (30,099)          -                   -                      -
Common stock and series D preferred (233.83                                                                                                                                                                                                  -
    shares) issued in connection with special                                                                                                                                                                                                -
    warrant offer                                                              496,981               497          -                 -                      939,050                498,472            -                   -                   -                       1,438,019
Common stock dividend to be distributed on                                                                                                                                                                                                   -
  series B and series C preferred stock                                       -                 -                 -                 -                   -                         613,805            (613,805)           -                   -                      -
Option issued to director for services                                        -                 -                 -                 -                   -                         398,574            -                   -                   -                         398,574
Warrant issued for services                                                   -                 -                 -                 -                   -                          94,393            -                   -                   -                          94,393
Warrant issued in connection with lease                                       -                 -                 -                 -                   -                          18,500            -                   -                   -                          18,500
Share issuance expenses                                                       -                 -                 -                 -                   -                        (26,600)            -                   -                   -                        (26,600)
Special warrant offer deemed dividends                                        -                 -                 -                 -                   -                       1,123,000           (1,123,000)          -                   -                      -
Net loss                                                                      -                 -                 -                 -                   -                     -                    (15,377,900)          -                   -                    (15,377,900)
                                                                       ----------------  ----------------  ----------------  ----------------  --------------------  ---------------------  --------------------  ----------------  ---------------------  --------------------
                                                                       ----------------  ----------------  ----------------  ----------------  --------------------  ---------------------  --------------------  ----------------  ---------------------  --------------------
Balance at December 31, 2004                                                 6,372,052             6,372           270,859         3,529,289             3,567,652             76,899,663         (120,452,544)         (177,645)            -                    (36,356,354)
Common stock and series D preferred (34.31 shares)
  issued in connection with agreements which extended
  due date of promissory notes                                                 277,020               277          -                 -                      274,500              (274,777)            -                   -                   -                      -
January 2005 Private Placement:
  Common stock issued in connection with private
    placement                                                                6,483,962             6,484          -                 -                   -                       4,769,616            -                   -                   -                       4,776,100
  Common stock and series D preferred (1,720.16 shares)
    issued in connection with  promissory note conversion                    7,953,123             7,953          -                 -                    5,733,853             14,887,606            -                   -                   -                      20,629,412
  Common stock and series D preferred (1,086.21 shares)
    issued in connection with Series C preferred exchange                    3,283,682             3,284          -              (3,529,289)             3,620,702              2,011,770           (2,106,467)          -                   -                      -
  Common stock issued in connection with exercise of
  additional investment right from private placement                           153,263               153          -                 -                   -                         114,794            -                   -                   -                         114,947
Common stock issued in connection with February 2005
  private placement                                                            120,000               120          -                 -                   -                          86,153            -                   -                   -                          86,273
Common stock issued in connection with exchange for
   series B preferred stock                                                    220,647               221         (270,859)          -                   -                         272,254               (1,616)          -                   -                      -
Common stock issued to officers                                              1,645,000             1,645          -                 -                   -                         749,939            -                   -                   (462,445)                 289,139
Common stock issued upon exercise of warrants                              3,658,513              3,659           -                 -                   -                     -                      -                   -                   -                           3,659
October 2005 Private Placement:
 Common stock issued                                                     14,590,764             14,591            -                 -                   -                     3,159,025              -                   -                   -                       3,173,616
 Common stock and Series D preferred (2,714.62 shares)
 and warrants issued for promissory notes                                  6,346,925             6,347            -                 -                   2,714,624             3,616,746              -                   -                   -                       6,337,717
Modifications of Series E warrant prices                                      -                 -                 -                 -                   -                     3,490,140            (3,476,683)           -                   -                          13,457
Warrant issued for services                                                   -                 -                 -                 -                   -                          7,189             -                   -                   -                           7,189
Share issuance expenses                                                       -                 -                 -                 -                   -                       (14,234)             -                   -                   -                        (14,234)
Net loss                                                                      -                 -                 -                 -                   -                     -                    (30,374,411)          -                   -                    (30,374,411)
                                                                       ----------------  ----------------  ----------------  ----------------  --------------------  ---------------------  --------------------  ----------------  ---------------------  --------------------
                                                                       ----------------  ----------------  ----------------  ----------------  --------------------  ---------------------  --------------------  ----------------  ---------------------  --------------------
Balance at December 31, 2005                                                51,104,951           $51,106          -                 -                  $15,911,331           $109,775,884        $(156,411,721)        $(177,645)             $(462,445)         $(31,313,490)
                                                                       ================  ================  ================  ================  ====================  =====================  ====================  ================  =====================  ====================

The accompanying notes are an integral part of these statements.







                            ORTEC INTERNATIONAL, INC.
                        (A DEVELOPMENT STAGE ENTERPRISE)

                      CONSOLIDATED STATEMENTS OF CASH FLOWS
                                                                                                                                                                                                              Cumulative from
                                                                                                                                                                                                               March 12, 1991

(inception) to
                                                                                                                                             Year ended December 31,                                                    December 31,
                                                                                                                                ----------------------------------------------------------------------
                                                                                                                                ------------------------------  ----  --------------------------------
                                                                                                                                               2005                                   2004                                  2005
                                                                                                                                ------------------------------        --------------------------------        ----------------------------------
                                                                                                                                ------------------------------        --------------------------------        ----------------------------------
Cash flows from operating activities
  Net loss                                                                                                              $               (30,374,411)            $                        (15,377,900)   $               (142,405,490)
  Adjustments to reconcile net loss to net cash
   used in operating activities
     Depreciation and amortization                                                                                                         291,975                                         466,966                        5,566,847
     Allowance for doubtful accounts                                                                                                              -                                              -                          5,374
     Unrealized loss on marketable securities                                                                                                     -                                      -                                 11,404
     Realized loss on marketable securities                                                                                                       -                                      -                                  5,250
     (Gain) / loss on sale of property and equipment                                                                                              -                                (26,802)                               (58,642)
     Loss on settlement of promissory notes                                                                                                 13,081,453                                           -                       13,081,453
     Cost to terminate lease on New Jersey facility                                                                                               -                                              -                         836,032
     Non-cash stock compensation                                                                                                           289,139                                  94,000                                3,624,370
     Non cash interest                                                                                                                     126,391                                   1,856,832                            1,983,223
     Non-cash imputed interest                                                                                                            6,830,890                              4,184,254                               22,922,150
     Non-cash production suite charges                                                                                                         235,500                               -                                            235,500
     Gain on loan adjustment                                                                                                                      -                                   (236,000)                                (236,000)
     Loss on extinguishments of debt & series A preferred stock                                                                                   -                                      -                                1,004,027
     Purchase of marketable securities                                                                                                            -                                      -                              (19,075,122)
     Sales of marketable securities                                                                                                               -                                      -                               19,130,920
     Other                                                                                                                                       20,646                                  -                                         20,646
     Change in operating assets and liabilities
        Other current assets and other assets                                                                                             (23,036)                                 (96,665)                               (61,090)
        Accounts payable and accrued liabilities                                                                                         (1,129,595)                              1,298,208                               5,047,362
                                                                                                                                ------------------------------        --------------------------------        ----------------------------------
   Net cash used in operating activities                                                                                                (10,651,048)                             (7,837,107)                            (88,361,786)
                                                                                                                                ------------------------------        --------------------------------        ----------------------------------
                                                                                                                                ------------------------------        --------------------------------        ----------------------------------

Cash flow from investing activities
     Purchases of property and equipment                                                                                                  (66,535)                                 (81,622)                              (4,613,877)
     Proceeds from sale of property and equipment                                                                                                 -                                 14,025                                 145,926
     Payments for patent applications                                                                                                     (49,167)                                 (48,975)                              (1,069,873)
     Organization costs                                                                                                                           -                                      -                                (10,238)
     (Security deposit) Security deposits refunded                                                                                              16,000                                           -                        (790,273)
     Purchases of marketable securities                                                                                                           -                                      -                                (594,986)
     Sale of marketable securities                                                                                                                -                                      -                                 522,532
                                                                                                                                ------------------------------        --------------------------------        ----------------------------------
   Net cash used in investing activities                                                                                                  (99,702)                                (116,572)                              (6,410,789)
                                                                                                                                ------------------------------        --------------------------------        ----------------------------------
                                                                                                                                ------------------------------        --------------------------------        ----------------------------------

Cash flows from financing activities
     Proceeds from issuance of notes payable                                                                                              3,486,000                               6,506,626                              13,648,126
     Proceeds from issuance of common stock                                                                                                   8,150,936                                  -                               61,701,458
     Proceeds from exercise of warrants                                                                                                     3,659                                 1,338,344                               1,362,663
     Proceeds from insurance premium financing                                                                                             220,000                                 280,000                                 500,000
     Share issuance expenses and other financing costs                                                                                         (14,234)                            (26,600)                              (5,384,247)
     Purchase of treasury stock                                                                                                                   -                                      -                                (177,645)
     Proceeds from issuance of loan payable                                                                                                       -                                      -                                1,446,229
     Proceeds from obligation under revenue interest assignment                                                                                   -                                      -                               10,000,000
     Proceeds from issuance of convertible debentures                                                                                             -                                      -                                5,908,000
     Proceeds from issuance of preferred stock -
       Series A                                                                                                                                   -                                      -                                1,200,000
       Series B                                                                                                                                   -                                      -                                3,070,000
       Series C                                                                                                                                   -                                      -                                5,690,000
     Advances received                                                                                                                            -                                      -                                 130,000
     Repayment of insurance premium financing                                                                                             (220,000)                                       (280,000)                       (500,000)
     Repayment of capital lease obligations                                                                                               (66,065)                                        (154,079)                       (584,794)
     Repayment of loan payable                                                                                                            (203,462)                                       (173,943)                      (1,239,161)
     Repayment of obligation under revenue interest assignment                                                                                    -                                      -                                (11,414)
     Repayment of notes payable                                                                                                                   -                                      -                                (515,500)
     Repayment of promissory notes                                                                                                        (158,065)                                   (637,686)                           (795,751)
                                                                                                                                ------------------------------        --------------------------------        ----------------------------------
                                                                                                                                ------------------------------        --------------------------------        ----------------------------------
   Net cash provided by financing activities                                                                                             11,198,769                               6,852,662                              95,447,964
                                                                                                                                ------------------------------        --------------------------------        ----------------------------------
                                                                                                                                ------------------------------        --------------------------------        ----------------------------------

   Net Increase/(Decrease) in Cash And Cash Equivalents                                                                                    448,019                               (1,101,017)                               675,389
CASH AND CASH EQUIVALENTS:
   Beginning of year                                                                                                                       227,370                                1,328,387                                       -
                                                                                                                                ------------------------------        --------------------------------        ----------------------------------
                                                                                                                                ------------------------------        --------------------------------        ----------------------------------
   End of year                                                                                                          $                  675,389              $                  227,370              $                  675,389
                                                                                                                                ==============================        ================================        ==================================





                                                                                          ORTEC INTERNATIONAL, INC.
                        (A DEVELOPMENT STAGE ENTERPRISE)

                CONSOLIDATED STATEMENTS OF CASH FLOWS (continued)

                                                                                                                                                                                                                         Cumulative
                                                                                                                                                                                                                            From
                                                                                                                                                                                                              March 12, 1991
                                                                                                                                                                                                                          (inception) to
                                                                                                                                           Year ended December 31,                                                      December 31,
                                                                                                                                        --------------------------------------------------------------
                                                                                                                                        --------------------------  ----  ----------------------------
                                                                                                                                                  2005                               2004                                   2005
                                                                                                                                        --------------------------        ----------------------------        ----------------------------------
                                                                                                                                        --------------------------        ----------------------------        ----------------------------------

Supplemental disclosures of cash flow information:
  Non-cash financing and investing activities
    Capital lease obligations                                                                                                     $                         7,717   $                   52,462          $                  628,523
    Deferred offering costs included in accrued professional fees                                                                                   -                                  -                                   314,697
    Financings costs  - other long-term obligations                                                                                                 -                                  -                                   59,500
    Forgiveness of rent payable                                                                                                                     -                                  -                                   40,740
    Share issuance expenses - warrants                                                                                                              -                                  -                                   255,000
    Deferred compensation                                                                                                                        751,584                               -                                   751,584
    Dividends on preferred stock paid in common shares -
       Series B                                                                                                                                     -                               50,000                                2,099,011
       Series C                                                                                                                                           (17,891)                     593,904                              576,013
    Accretion of discount on preferred stock and warrants                                                                                       5,602,657                          1,123,000                             10,994,657
    Series B preferred stock converted to common stock                                                                                             270,859                             -                                   270,659
    Series C preferred stock exchanged for common stock                                                                                          3,529,289                             -                                  3,529,289
    Issuance of Series D preferred stock in lieu of common stock                                                                               12,343,679                              -                                 12,343,679
    Share issuance expenses for preferred stock
       incurred through issuance of warrants -
       Series B                                                                                                                                     -                                  -                                   391,307
       Series C                                                                                                                                     -                                  -                                   272,386
    Share issuance of series D preferred stock in
      exchange from series B preferred stock                                                                                                        -                                  -                                  2,628,602
      Promissory notes repaid with common stock                                                                                                13,112,626                              -                                 13,112,626
      Promissory note interest paid in common stock                                                                                              658,776                               -                                   658,776
      Promissory notes forgiven for warrant participation                                                                                           -                               100,000                                100,000
    Warrant issued in connection with lease                                                                                                         -                               18,500                                 18,500
    Conversion of series C preferred stock into common stock                                                                                        -                                       137,645                          137,645
    Contribution of capital of amount due to founder                                                                                                -                               398,967                                398,967
    Equipment transferred in satisfaction of deposit                                                                                                -                                        25,000                        100,000
   Discount on promissory notes                                                                                                                     -                               746,202                               1,033,202
   Accounts payable converted to promissory notes                                                                                                   -                               837,468                                837,468
   Advances converted to promissory notes                                                                                                           -                               130,000                                130,000


   Cash paid for interest                                                                                                         $              142,770            $               69,975              $                  860,626
                                                                                                                                        ==========================        ============================        ==================================
                                                                                                                                        ==========================        ============================        ==================================

   Cash paid for income taxes                                                                                                     $                 -               $                2,835              $                  203,411
                                                                                                                                        ==========================        ============================        ==================================

The accompanying notes are an integral part of these statement.




                            ORTEC INTERNATIONAL, INC.
                        (A DEVELOPMENT STAGE ENTERPRISE)

                   NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

1 - FORMATION OF THE COMPANY AND BASIS OF PRESENTATION

Formation of the Company

Ortec International, Inc. ("Ortec" or the "Company") was incorporated in March
1991 as a Delaware corporation to secure and provide funds for the further
development of the technology developed by Dr. Mark Eisenberg of Sydney,
Australia, to replicate in the laboratory, a tissue engineered skin substitute
for use in skin regeneration procedures (the "Technology"). Pursuant to a
license agreement dated September 7, 1991, Dr. Eisenberg had granted us a
license for a term of ten years, with automatic renewals by us for two
additional ten-year periods, to commercially use and exploit the Technology for
the development of products. In April 1998, Dr. Eisenberg assigned his patent
for the Technology to us.

The Skin Group, Ltd. (the "Skin Group") also was formed as a Delaware
corporation in March 1991, to raise funds for the development of the Technology.
On July 27, 1992, the Skin Group was merged with and into Ortec. Owners of Skin
Group shares were given .83672 of an Ortec share for each Skin Group share. The
merger was accounted for as if it were a pooling of interests and, accordingly,
the accompanying financial statements include the accounts of the Skin Group for
all periods presented.

Basis of Presentation

We are a development stage enterprise which had no operating revenue prior to
December 2001. During 2001, we received Food and Drug Administration (FDA)
approval for the use of the fresh form of OrCel (R) (ORCEL) for the treatment of
patients with recessive dystrophic epidermolysis bullosa and for donor sites in
burn patients. We then began marketing and selling our product for use on
patients with those medical conditions. Revenues were not significant. We
terminated our selling efforts and elected to focus our efforts on developing a
cryopreserved form of our product for treating medical conditions with
considerably larger patient populations. Venous stasis ulcers is a medical
condition with a larger patient population. We completed a clinical trial during
2003 for the use of a cryopreserved form of ORCEL to treat venous stasis ulcers.
In February 2004, we filed an application with the FDA for pre-market approval
(PMA). On April 25, 2005 the FDA advised us that we had to have additional
clinical data from a confirmatory clinical trial to demonstrate reasonable
assurance of safety and effectiveness of ORCEL in treating patients with venous
stasis ulcers. In late June 2005, the FDA approved our conducting a 60 patient
confirmatory clinical trial. We obtained FDA approval for the trial protocol in
mid July 2005 and began the confirmatory clinical trial in mid August 2005. Our
plan of operation for the next twelve months is to complete such clinical trial
and continue to work towards obtaining regulatory clearance for commercial sales
of cryopreserved ORCEL to treat venous stasis ulcers. In the interim, we are
working with Cambrex Bio Science Walkersville, Inc., a subsidiary of Cambrex
Corporation (Cambrex) to limit our expenditures under our manufacturing
agreement with Cambrex primarily to those which are essential for conducting the
clinical trial.

The accompanying financial statements have been prepared assuming that we will
continue as a going concern. We incurred a net loss applicable to common
shareholders of $36 million during the year ended December 31, 2005, and, as of
that date, our current liabilities exceeded our current assets by $32.2 million,
our total liabilities exceeded our total assets by $31.3 million and we have a
deficit accumulated in the development stage of $156.4 million. These factors,
among others, raise substantial doubt about our ability to continue as a going
concern.

During 2005 we raised gross proceeds of $9.3 million through private placements
of our common stock and approximately $3.5 million from a convertible note
offering. Additionally we converted $13.1 million of promissory notes and
$773,000 of accrued interest into, and all of the outstanding shares of our
Series B and C preferred stock were exchanged by the holders for, our common
stock.

We expect to incur obligations of approximately $850,000 per month primarily for
personnel and rent, insurance, fees to Cambrex for a production suite and
technology transfer activities, various research and development activities, and
payment of past due obligations. We will require substantial funding to enable
us to continue our research and development activities, pay a portion of our
past due obligations, complete the additional clinical trial necessary to obtain
PMA for our ORCEL to treat venous stasis ulcers, and provide for our general and
corporate working capital requirements for 2006.

As of December 31, 2005, payment of approximately $1,354,000 of the
approximately $1,980,000 we owed to our trade creditors was past due. We have
entered into agreements with creditors to whom we owe an aggregate of $736,000
(as of December 31, 2005) to pay $471,000 in 2006 and $265,000 in 2007.

While we have arranged for payment of some of our obligations over a period of
time, and have to make other payments of past due obligations to our current and
ongoing suppliers, our ability to make payments we have agreed to pay and to
insure continued receipt of needed supplies, and to continue reducing our past
due obligations, will depend on our ability to secure needed financing or our
ability to issue equity in satisfaction of certain obligations.

We hope to obtain additional funds through the sale of our securities to the
public and through private placements, debt financing or other short-term loans.
We may not be able to secure any financing nor may we be able to reach the
larger patient population markets of persons with venous stasis ulcers and
diabetic foot ulcers, with funds that we may be able to raise. We are also
likely to continue to encounter difficulties which are common to development
stage companies, including unanticipated costs relating to development, delays
in the testing of products, regulatory approval and compliance and competition.

Our capital funding requirements depend on numerous factors, including:


o    the progress and magnitude of our research and development programs;

o    the time involved in obtaining regulatory approvals for the commercial sale
     of our ORCEL product in its cryopreserved form to treat venous stasis
     ulcers and, later, diabetic foot ulcers;

o    the costs involved in filing and maintaining patent claims;

o    technological advances;

o    competitive and market conditions;

o    the successful implementation of the agreements we have entered into with
     Cambrex for manufacturing and sales of our ORCEL product;

o    our ability to establish and maintain other collaborative arrangements and

o    the cost and effectiveness of commercialization activities and
     arrangements.

We believe that our cash and cash equivalents on hand at December 31, 2005,
approximately $675,000, as well as the additional funds we will need to raise in
2006, may enable us to continue our operations for the next twelve months. There
can be no assurances that we can raise additional funds. See Note 18 regarding
funding made subsequent to December 31, 2005.

These financial statements have been prepared assuming that we will continue as
a going concern. Successful future operations depend upon the successful
development and marketing of our ORCEL product. Historically we have funded our
operating losses by periodically raising additional sources of capital. If
additional funding is not available to us when needed, we may not be able to
continue operations. No adjustments have been made to the accompanying
financials as a result of this uncertainty.

Principles of Consolidation

The consolidated financial statements include the accounts of the Company and
its wholly owned subsidiary. All intercompany balances and transactions have
been eliminated.

Common Stock Reserve Split

On June 24, 2003, we effected a reverse stock split of our common shares
outstanding, whereby every stockholder, warrant and option holder, was granted
one new common share or warrant or option to purchase common shares, for every
ten outstanding common shares (or its equivalent). The par value of the common
shares remained unchanged at $.001 per share. The exercise prices of all
warrants and options outstanding were adjusted as a result of this reverse
split. The conversion rates of the preferred stock outstanding were also
adjusted.






2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Revenue Recognition

Product revenue is recognized upon shipment of ORCEL when title and risk of loss
pass to the customer, which occurs when the end user customer receives the
product. Royalties from licensees will be based on third-party sales of licensed
products and will be recorded in accordance with contract terms when third-party
results are reliably measurable and collectibility is reasonable assured. Fees
paid to us upon entering a license agreement are recognized when earned as
defined by the terms of the agreement.

In accordance with EITF Issue No. 00-21, Revenue Arrangements with Multiple
Deliverables, we review each contract to determine if there are multiple
revenue-generating activities that constitute more than one unit of accounting.
Revenue is recognized for each unit of accounting based on revenue recognition
criteria relevant to that unit. Up-front payments are deferred, if appropriate,
and recognized into revenues over the obligation period.

Research and Development Costs

We are in the business of research and development and therefore, all research
and development costs, including payments relating to products under
development, research, consulting agreements and personnel costs, are expensed
when incurred. Research and Development costs aggregated $7,535,532 and
$7,139,733, for the years ending 2005 and 2004, respectively. Research and
Development costs are comprised of production and laboratory costs, rent,
consulting, personnel, and depreciation and amortization expenses.

Depreciation and Amortization

Property and equipment are carried at cost, less any grants received for
construction. In 1996, we received a $400,000 grant toward the construction of
our new laboratory and office facilities and we received an additional grant of
$130,000 in 1998.

Office furniture and equipment and laboratory equipment are depreciated on the
straight-line basis over the estimated lives of the assets (5 years). Leasehold
improvements are amortized over the shorter of the term of the related lease or
the life of the asset.

Intangible Assets

Our intangible assets consist of patent application costs. We amortize these
separately identifiable assets over their estimated useful lives. Patent
application costs relate to our U.S. patent application and application fees in
foreign jurisdictions and consist of legal and other direct fees. The
recoverability of the patent application costs is dependent upon, among other
matters, obtaining further FDA approvals for the use of the underlying
technology.

Impairment of Long-Lived Assets

We review long-lived assets, which consist of fixed assets and patent
application costs, for possible impairment whenever events or changes in
circumstances indicate that the carrying amount of an asset may not be
recoverable. We have determined, based on estimated future cash flows, that no
provision is necessary for the impairment of long-lived assets at December 31,
2005.

Foreign Currency Translation

We conducted some of our research and development at our laboratory in Sidney,
Australia. However, because all Australian expenditures were funded from the
United States, we determined that the functional currency of our Australian
office was the U.S. dollar. Accordingly, current assets and current liabilities
are remeasured into the functional currency using current exchange rates and
non-current assets and liabilities are remeasured using historical exchange
rates. Expense accounts are measured using the average rate in effect for the
year. As of December 31, 2002, we terminated all of our research and development
activities at our laboratory in Sidney.






Use of Estimates

In preparing financial statements in conformity with accounting principles
generally accepted in the United States of America, management is required to
make estimates and assumptions that affect the reported amounts of assets and
liabilities and disclosure of contingent assets and liabilities at the date of
the financial statements, as well as the reported amounts of revenues and
expenses during the reporting period. Actual results could differ from those
estimates.

Income Taxes

Deferred tax assets and liabilities are recognized for the estimated future tax
consequences attributable to differences between the financial statement
carrying amounts of existing assets and liabilities and their respective tax
bases. Deferred tax assets and liabilities are measured using enacted tax rates
in effect for the years in which those temporary differences are expected to be
recovered or settled. The effect on deferred tax assets and liabilities of a
change in tax rates is recognized in income in the period that includes the
enactment date. A valuation allowance is provided for as it is more likely than
not that the deferred tax assets will not be realized.

Cash and Cash Equivalents

For purposes of the statement of cash flows, we consider all highly liquid debt
instruments purchased with original maturities of three months or less to be
cash equivalents. Cash equivalents consist principally of money market funds.
The fair value of cash and cash equivalents approximates the recorded amount
because of the short-term maturity of such instruments.

Net Loss Per Share

Net loss per common share is based on the weighted-average number of common
shares outstanding during the periods.

Basic net loss per share is computed by dividing the net loss by the
weighted-average common shares outstanding for the period. Diluted net loss per
share reflects the weighted-average common shares outstanding plus the potential
dilutive effect of securities or contracts which are convertible to common
shares, such as options, warrants and convertible preferred stock.

Options and warrants to purchase shares of common stock were not included in the
computation of diluted net loss per share in each of the years presented because
to do so would have been antidilutive for the periods presented.

The amount of options and warrants excluded are as follows:

                                                                                            Year ended December 31,
                                                                                          ----------------------------------------------------------------
                                                                                          ---------------------------  ----
                                                                                          2005                               2004
                                                                                          ---------------------------        -----------------------------
                                                                                          ---------------------------        -----------------------------

Warrants                                                                                                  41,949,135                            988,603
                                                                                          ===========================        =============================
                                                                                          ===========================        =============================

Stock Options - in plan                                                                                      434,542                                      428,324
                                                                                          ===========================        =============================
                                                                                          ===========================        =============================

Stock Options - outside of plan                                                                            7,733,638                                    1,374,400
                                                                                          ===========================        =============================
                                                                                          ===========================        =============================


Additionally, the effects of conversion of the preferred stock were excluded
from the weighted average share calculation, as the effect would be
antidilutive. An aggregate of 25,088,062 and 5,804,977 shares of common stock
would be issuable upon conversion of the preferred stock outstanding at December
31, 2005 and December 31, 2004, respectively.






Employee Stock Option Plan

We account for our employee stock options under the recognition and measurement
principles of APB Opinion No. 25 (APB 25), Accounting for Stock Issued to
Employees, and related Interpretations. No stock-based employee compensation
cost is reflected in net income, as all options granted under these plans had an
exercise price equal to the market value of the underlying common stock on the
date of grant.

The following table illustrates the effect on net income and earnings per share
if we had applied the fair value recognition provisions of FASB Statement (SFAS)
No.123, "Accounting for Stock-Based Compensation".

                                                                                                                                                              Year ended December 31,
                                                                                                                                                        --------------------------------------------------------------------------
                                                                                                                                                        ---------------------------------  ---  ----------------------------------
                                                                                                                                                        2005                                    2004
                                                                                                                                                        ---------------------------------       ----------------------------------
                                                                                                                                                        ---------------------------------

Net loss applicable to common shareholders, as reported                                                                                           $                        (35,959,177)    $                       (17,144,804)
Deduct:  Total stock-based employee compensation
 income (expense) determined under fair value based method                                                                                              (1,143,889)                                                    425,801
                                                                                                                                                        ---------------------------------       ----------------------------------
                                                                                                                                                        ---------------------------------       ----------------------------------
Pro forma net loss                                                                                                                                $                        (37,103,066)    $                       (16,719,003)
                                                                                                                                                        =================================       ==================================
                                                                                                                                                        =================================       ==================================

Net loss applicable to common shareholders per share:
  Basic and Diluted - as reported                                                                                                                 $       (0.93)                           $    (3.03)
  Basic and Diluted - pro forma                                                                                                                   $       (0.96)                           $      (2.96)

We utilized the Black-Scholes option-pricing model to quantify the expense of
options and warrants granted to non-employees and the pro forma effects on net
loss and net loss per share of the fair value of the options and warrants
granted to employees during the years ended December 31, 2005 and 2004. The
following weighted average assumptions were made in estimating fair value.

                                                                                      Years ended December 31,
                                                                                    ---------------------------------------------------------------
                                                                                    -----------------------------  ---  ---------------------------
                                                                                    2005                                2004
                                                                                    -----------------------------       ---------------------------
                                                                                    -----------------------------
Risk-free interest rate                                                                                      4.2 %                               3.1 %
Expected option life                                                                                         3.8 years                           5 years
Expected volatility                                                                                         85.9 %                              80.9 %

The weighted average fair value at the date of grant for options granted during
the year ended December 31, 2005 and 2004 was $0.33 and $1.92, respectively.

Effect of New Accounting Standards

In December 2004, the FASB issued SFAS No. 123(R), "Share-Based Payment" which
establishes accounting standards for all transactions in which an entity
exchanges its equity instruments for goods and services. This statement is a
revision to SFAS No. 123, "Accounting for Stock-Based Compensation", supersedes
APB 25and amends SFAS No. 95, "Statement of Cash Flows." SFAS No. 123(R)
eliminates the ability to account for share-based compensation using the
intrinsic value method allowed under APB 25 and will require us to recognize
share-based compensation as compensation expense in the statement of operations
based on the fair values of such equity on the date of the grant, with the
compensation expense recognized over the period in which the recipient is
required to provide service in exchange for the equity award. This statement
will also require us to adopt a fair value-based method for measuring the
compensation expense related to share-based compensation. SFAS No. 123(R) must
be adopted no later than periods beginning after December 15, 2005 and we will
adopt SFAS No. 123(R) on January 1, 2006. We believe the adoption of SFAS No.
123(R) will have a material impact on our results of operations and earnings per
share.

3 - CONCENTRATION OF CREDIT RISK

We maintain cash and money market accounts primarily at two financial
institutions located in New York City. The FDIC insures cash accounts for
amounts up to $100,000. At times, our balances exceed such FDIC limits.

We have not experienced any losses in such accounts.





4 - PROPERTY AND EQUIPMENT

Property and equipment consist of the following at December 31, 2005:


Laboratory equipment                                                                                     $                              1,769,967
Office furniture and equipment                                                                                                          1,118,481
Leasehold improvements                                                                                                                  1,372,097
                                                                                                               -------------------------------
                                                                                                               -------------------------------
                                                                                                                                        4,260,545
Accumulated depreciation and amortization                                                                                               4,062,214
                                                                                                               -------------------------------
                                                                                                               -------------------------------
                                                                                                         $                                198,331
                                                                                                               ===============================
                                                                                                               ===============================


Depreciation and amortization expense for the years ended December 31, 2005 and
2004 was approximately $203,000 and $385,000, respectively.

As of December 31, 2005 and 2004, included above was $543,000 and $535,000 in
equipment purchased under capital leases and $519,000 and $460,000 in
accumulated amortization, respectively.

5 - PATENTS

Patent application costs are stated at cost less amortization computed by the
straight-line method over the useful life of the patent. As of December 31,
2005, patents, net of accumulated amortization, were as follows:

                                                                                                             Expiration
Patents subject to Amortization                                                                              Date
-----------------------------------------------------------------------------------------------------        ----------------------------
-----------------------------------------------------------------------------------------------------        ----------------------------

Composite Culture Skin (CCS)                                                                                     2/1/2011                  $                                959,857
Manufacturing of Bi-layered Collagen Sponge                                                                  12/28/2020                                                      33,037
Cryopreservation Process                                                                                     12/26/2021                                                      78,759
                                                                                                                                                 ---------------------------
                                                                                                                                                 ---------------------------
                                                                                                                                                                          1,071,653
Accumulated amortization                                                                                                                                                    524,318
                                                                                                                                                 ---------------------------
                                                                                                                                                 ---------------------------
                                                                                                                                           $                                547,335
                                                                                                                                                 ===========================

Amortization expense for the years ended December 31, 2005 and 2004, was $89,000
and $82,000, respectively. The estimated annual amortization expense expected,
based on current intangible balances, for the years 2006 through 2009 is $93,000
per year.

Our U.S. patent for CCS was issued in 1994. During 2002 and 2003 we were issued
two patents by the United States Patent Office. The first patent covers unique
manufacturing processes for our tissue-engineered product, ORCEL. These
processes specifically relate to the manufacturing of our bi-layered collagen
sponge structure and when implemented, can reduce the current manufacturing
costs of ORCEL. This patent was issued on December 31, 2002. The second patent
covers the freezing process for ORCEL. This process, referred to as
cryopreservation, gives our product a minimum shelf life of seven months, as
opposed to only a few days when our product is not cryopreserved. This second
patent was issued on October 28, 2003.

There can be no assurance that any patent will provide commercial benefits to
us. We have determined that no provision for impairment is necessary at December
31, 2005.

We have granted a security interest in our United States and Canadian patents
and trademarks relating to ORCEL to collateralize payments we will be required
to make to satisfy our obligation under a Revenue Interest Assignment Agreement
(see Note 10).






6 - ACCOUNTS PAYABLE AND ACCRUED EXPENSES

Accounts payable and accrued expenses consist of the following at December 31,
2005:


Accounts payable                                                                     $                              1,980,425
Accrued compensation                                                                                                  591,082
Accrued professional fees                                                                                             570,800
Accrued expenses                                                                                                      167,016
Deferred income                                                                                                        50,000
                                                                                           ----------------------------
                                                                                     $                              3,359,323
                                                                                           ============================
                                                                                           ============================


7 - LEASES

In March 1996, we entered into a five-year lease with Columbia University for
our laboratory and offices in Columbia's Audubon Biomedical Science and
Technology Park in New York City. Construction of the laboratory and office
facility was completed in July 1996 and became fully operational in November
1996. We utilize our laboratory facilities to produce ORCEL for research and
development activities including cell expansion and biomaterial research. On
December 18, 2003, we amended the lease agreement with Columbia University,
extending the lease term to December 2005. With this amendment, we agreed to pay
Columbia $25,588 a month for past due rent commencing on February 1, 2004 and
ending on December 31, 2005. In March 2006 we signed the Third Lease Amendment
which extended the existing lease until December 31, 2007. See Note 18.

On August 5, 2002, we reached an agreement with the New Jersey Economic
Development Authority (NJEDA) to terminate a 2001 lease and to enter into a new
lease covering production and office space. Monthly payments under such lease
began on January 1, 2003. On June 9, 2003 NJEDA and we executed an agreement to
terminate this lease. Based on the terms of this settlement, a termination cost
of $978,000 was agreed upon. This termination costs was settled by applying the
$623,000 security deposit, plus accrued interest thereon, with the balance of
$340,000 paid on June 11, 2003. In 2003, we recorded a lease termination cost of
$1,119,166 consisting of the aforementioned $978,000 together with $141,166 of
other costs that we incurred in connection with the build-out of the leasehold.
We continued to rent space in North Brunswick, New Jersey pursuant to a lease
until its expiration on July 31, 2004, at a rent of $2,300 per month.

Future minimum lease payments under a noncancellable operating lease primarily
for office and laboratory space and the present value of future minimum lease
payments under capital leases as of December 31, 2005 are as follows:

                                                                                                                                     Leases
                                                                                                                                     ---------------------------------------------------------
                                                                                                                                     --------------------------  ----  -----------------------
Year ending December 31,                                                                                                             Operating                         Capital
                                                                                                                                     --------------------------        -----------------------
                                                                                                                                     --------------------------        -----------------------
       2006                                                                                                                                                     730,320                           $23,525
       2007                                                                                                                                                     730,320                             8,694
       2008                                                                                                                          -                                                              2,188
                                                                                                                                     --------------------------        -----------------------
       Total                                                                                                                                                  1,460,640                            34,407
                                                                                                                                     ==========================
                                                                                                                                     ==========================
       Less amounts representing interest                                                                                                                                                          11,053
                                                                                                                                                                       -----------------------
                                                                                                                                                                       -----------------------
       Present value of net minimum capital lease payments                                                                                                                                         23,354
       Less: current portion                                                                                                                                                                       13,405
                                                                                                                                                                       -----------------------
       Long-term portion                                                                                                                                                                          $ 9,949
                                                                                                                                                                       =======================


In connection with a lease agreement dated February 27, 2004, we issued a
two-year warrant to purchase 14,052 shares of our common stock at $3.25 per
share. We valued the warrant utilizing a Black-Scholes valuation model at
$18,500. On November 2, 2004 the Board of Directors approved the issuance of the
aforementioned warrant.






8 - NOTES PAYABLE

Promissory notes at December 31, 2005 consists of:


Promissory notes - CUH2A, 4%, due through February 2008                                                                                                                                         91,717
Current portion                                                                                                                                                                                 41,635
                                                                                                                                                             --------------------------
                                                                                                                                                             --------------------------
Noncurrent portion                                                                                                                                                                             $50,082
                                                                                                                                                             ==========================
                                                                                                                                                             ==========================


The CUH2A promissory note was a structured payout of a previous vendor
obligation. We pay them $3,712 monthly.

Minimum payments to be made under the terms of the promissory notes are as
follows:

Year ending December 31,
   2006                                                                                                                                                                                             $44,546
   2007                                                                                                                                                                                              44,546
   2008                                                                                                                                                                                               6,783
                                                                                                                                                                  -------------------------
                                                                                                                                                                  -------------------------
                                                                                                                                                                                                     95,875
   Less amount representing interest                                                                                                                                                                  4,158
                                                                                                                                                                  -------------------------
   Net present value of future loan payments                                                                                                                                                        $91,717
                                                                                                                                                                  =========================


On February 2, 2005, we entered into a commercial premium finance agreement with
First Insurance Funding Corp. of New York in the amount of $220,000. The
financing agreement bore interest at 7.23% and required nine monthly payments of
$25,187 beginning March 2005. The financing was utilized to fund the premium
payments for our directors and officers insurance policy and has been repaid as
of December 31, 2005.

9 - OBLIGATION UNDER REVENUE INTEREST ASSIGNMENTS

On August 29, 2001, as amended February 2003, we entered into a Revenue Interest
Assignment Agreement with Paul Royalty Fund L.P. (PRF), which terminates on
December 31, 2011. Under such agreement we were eligible to receive $10,000,000
during 2001. We received $6,000,000 during 2001 and the remaining $4,000,000 in
January 2002.

In February 2003, PRF and the Company signed an amendment to the agreement,
restating and updating certain provisions of the original agreement, including
removing requirements for additional funding to be provided by PRF. In
connection therewith, PRF purchased 50 shares of our Series B convertible
preferred stock investing $500,000, and for which we issued to PRF 73,077 shares
of our common stock and granted PRF warrants to purchase an aggregate of 50,000
shares of our common stock, at exercise prices of $15.00 per share for 25,000
shares and at $20.00 per share for the other 25,000 shares. The February 2003
amendments to our agreements with PRF provided, among other things, for (a) the
election of one director designated by PRF, (b) the right of one observer (other
than such director) selected by PRF to attend and observe all meetings of our
Board of Directors and (c) for us to use our best efforts to have independent
directors who are acceptable to both us and PRF, including a director designated
by PRF, as a majority of our Board of Directors.

In consideration for the $10,000,000, PRF will receive a minimum of 3.33% of the
first $100,000,000 of annual sales plus 1.99% of annual sales in excess of
$100,000,000 of ORCEL in the United States, Canada and Mexico. Such percentage
may be further adjusted upward or downward, based on the volume of net sales to
end users of our products in those three countries. Beginning on January 1,
2003, PRF was entitled to receive each year the first proceeds to us from end
user sales of our products in North America. The annual amounts that PRF will be
able to draw in advance against the end user sales of our products are
$7,500,000 in 2005 through 2011. The agreement provides for quarterly and annual
accountings between PRF and us for those advance payments. The purpose of these
accountings is to reconcile the advances paid against the actual amount we are
required to pay computed on the basis of the aforementioned percentages of sales
volume. Based on this reconciliation of the actual calculated amounts versus the
advances paid, we will either be required to pay additional amounts or receive a
refund of all or a portion of the advances we paid to PRF. We have not paid PRF
any advances, as there were no sales during 2003, 2004 and 2005. The amounts
received from PRF have been classified as debt in accordance with our
interpretation of Emerging Issues Task Force (EITF) Issues No. 88-18, "Sales of
Future Revenue". PRF bears the risk of revenue interest paid being significantly
less than the current revenue interest obligation, as well as the reward of
revenue interest paid to it being significantly greater than the current revenue
interest obligation. Therefore we are under no obligation to make any other
payments to PRF in the scenario when no repurchase right (as defined) is
triggered and no significant interest payments are made. Conversely, we will be
obligated to continue to make revenue interest payments in the scenario where
sales are sufficiently high to result in amounts due under the Revenue Interest
Assignment Agreement being in excess of the current revenue interest obligation.

We granted PRF a security interest in our United States and Canadian patents and
trademarks relating to our technology for our ORCEL product (collectively, the
"Pledged Assets"), to secure payments required to be made by us to PRF under
this agreement. Pursuant to the default provisions under the agreement PRF may
require us to repurchase their revenue interest at the put option exercise price
which is defined as a price which would yield an internal rate of return to PRF
of 30%.

The events that could require us to repurchase our revenue interest include:

o    any change of control of our company;

o    a transfer of substantially all of our assets;

o    a transfer of our interests in our products;

o    a judicial decision that has a material adverse effect on our business,
     operations, assets, or financial condition;

o    the occurrence of any event that has a material adverse effect on our
     ability to perform our obligations to repurchase the revenue interest
     obligation;

o    the acceleration of our obligations or the exercise of default remedies by
     a secured lender under certain debt instruments; a funding termination
     event (as defined) such as a bankruptcy event (as defined);

o    our insolvency (as defined);

o    the breach of representations, warranties or certifications made by us in
     the agreements with PRF that, individually or in the aggregate, would
     reasonably be expected to have a material adverse effect on our business,
     operations, assets or financial condition, and such breach is not cured
     within 30 days after notice thereof from PRF.

Additionally we agreed not to issue any new debt or equity securities that
contain mandatory cash dividend or redemption provisions through the revenue
interest period, or December 31, 2011.

On December 13, 2004 PRF entered into a forbearance agreement with us agreeing
that they cannot exercise their right to compel us to repurchase their interest
in our revenues because of our insolvency prior to July 1, 2006 (which is
defined as (a) our liabilities, excluding our revenue interest assignment
obligation, exceeding the fair market value of our assets or (b) our inability
to pay our debts as they become due).

As defined in our agreement with PRF we are currently insolvent. As a result of
this insolvency our obligation under the revenue interest assignment is stated
at $29,569,000, the amount PRF could compel us to repurchase their interest in
our revenues at December 31, 2005, had they not entered into a forbearance
agreement with us. This amount represents the amount that would give PRF a 30%
internal rate of return on their $10,000,000 from the dates of their original
investments. Should we continue to be insolvent we will need to continue to
incur non-cash interest charges for this obligation. At such time when the
default provisions are no longer applicable, the effective interest rate imputed
on the obligation will be determined using the interest method and payments to
PRF will be recorded as a reduction of our obligation under the revenue interest
assignment.

In accordance with accounting promulgated by Statements of Financial Accounting
Standards No. 15, "Accounting by Debtors and Creditors for Troubled Debt
Restructurings" (SFAS 15) even if we are no longer insolvent as long as our
future cash payments relating to the revenue interest assignment obligation are
indeterminate, the revenue interest assignment obligation would remain at the
value that achieves the 30% internal rate of return for PRF through the last
date of our insolvency. However, we would no longer have to accrue any
additional interest to achieve a 30% internal rate of return related to
insolvency. That is, we would not reverse the accrual for the insolvency
repurchase event even when we are no longer insolvent. At December 31, 2005 the
amount attributed to the insolvency is $19,569,000. Our revenue stream is
considered indeterminate since we cannot predict with certainty the payments we
will be required to make on this obligation since theoretically our sales are
not limited in amount and payments under our agreement with PRF are determined
based on future sales. We estimate that we would need to achieve a North
American sales level of approximately $1,160,000,000 over the approximate
remaining five sales years under the agreement to offset the principal balance
of the $29,569,000 revenue interest obligation.

SFAS 15 allows debtors that can predict with certainty the absolute amounts of
future cash flow payments to record an immediate gain if the maximum future cash
payments are less than the carrying amount of the obligation. In the case where
the future cash payments are indeterminate, as ours are considered, the gain is
not recognized until the end of the term of the outstanding debt, December 31,
2011, or upon termination. As such, we believe we will likely record a gain on
the revenue interest assignment obligation to PRF in 2011 or upon termination,
if sooner.

If we were unable to repurchase the revenue interest upon a repurchase event,
PRF could foreclose on the Pledged Assets, and we could be forced into
bankruptcy. PRF can also foreclose on the Pledged Assets if we remain insolvent
(waived until July 1, 2006) or are involved in a voluntary or involuntary
bankruptcy proceeding. No repurchase events or foreclosures have occurred as of
December 31, 2005.

We also have the option to repurchase PRF's interest upon the occurrence of a
change in control of the Company or a complete divestiture by us of our
interests in our products, for an amount of cash flows that will generate a 35%
internal rate of return to PRF.

On December 16, 2004, pursuant to a Special Warrant Offer which reduced the
exercise prices of a portion of the 50,000 warrants that PRF received in
February 2003 to $1.00 in exchange for the surrender of the balance, warrants to
purchase 27,778 shares of our common stock were exercised for which we received
$27,889, and warrants to purchase 22,222 shares of our common stock were
surrendered to us. As a result of the Special Warrant Offer PRF was considered
to have received a deemed dividend of approximately $2,500 based on a Black
Scholes calculation considering the valuation of the warrants prior to the
December 16, 2004 offering and subsequent to the offering (see Note 10).

10 - EQUITY TRANSACTIONS

Each share of our common stock is entitled to one vote.

In September 2001, we, with shareholder approval, increased the authorized
amount of our common stock to 35,000,000 shares and authorized the issuance of
up to 1,000,000 shares of preferred stock.

In February 2003, we, with shareholder approval, increased the authorized amount
of our common stock to 200,000,000 shares.

On June 24, 2003, we effected a one for ten reverse stock split for each
outstanding share of common stock. This reverse stock split was retroactively
reflected in the accompanying financial statements and all references to shares
are to the new shares with per share amounts appropriately adjusted.

Founders: Pursuant to an agreement between Dr. Eisenberg and the other founders
(the "Other Founders"), a business relationship was formed by the founders for
the manufacture and sale of products derived from the Technology (the "Business
Agreement"). Under the terms of the Business Agreement, Dr. Eisenberg, who was
the owner of all the capital stock of Ortec (60,000 shares) agreed to license
the Technology to Ortec and sell 70% of Ortec's shares for a purchase price of
$1,000,000 to the Skin Group. Dr. Eisenberg was paid $85,000 in connection with
this agreement as reimbursement for his expenses ($35,000 during the period from
inception (March 12, 1991) to December 31, 1991 and $50,000 during the year
ended December 31, 1992). The Other Founders initially owned all of the stock of
the Skin Group (95,382 shares). On July 27, 1992, the Skin Group was merged with
and into Ortec.

First private placement: In March 1991, the Skin Group issued, in a private
placement, 21,744 shares for $65,000. In June and October 1991, the Skin Group
issued an aggregate 14,902 shares, to a then director of ours (the "Director")
for an aggregate gross proceeds of $250,000.

Second private placement: Commencing in November 1991, the Skin Group issued
7,948 shares under a second private placement for $750,006. The 7,948 shares
consisted of 5,302 shares issued during 1991 and 2,646 issued shares during 1992
for $500,000 and $250,006, respectively. Under the second private placement an
additional 2,286 of our shares were issued for $215,467. In addition, the
Director was granted warrants to purchase 736 of our shares at $94.25 per share.

Stock purchase agreement entered into with the Director: In June 1992, 5,304 of
our shares were sold to the Director for a total purchase price of $499,998. The
purchase price was payable in installments and shares and warrants were issued
in installments pro rata with the payment of the purchase price. During the
years ended December 31, 1992 and 1993, the Director paid $299,998 and $200,000,
respectively, and was issued 3,182 and 2,122 shares, respectively. In addition,
the Director was granted warrants to purchase 7,957 shares (4,774 and 3,183 of
which were granted in 1992 and 1993, respectively) at an exercise price of
$94.25 per share; such warrants were exercised on December 29, 1998.

Further, in connection with the Director's purchase of the 5,304 shares, in
1993, the Other Founders granted to the Director options to purchase from them
an aggregate of 7,400 of our shares, at a price of $50 per share. In 1993, the
Director exercised such option in part, and purchased 4,900 shares from the
Other Founders at the option price of $50 per share. The remaining balance of
such options expired April 15, 1994.

Third private placement: Pursuant to a third private placement that commenced on
January 13, 1993, and concluded on March 31, 1993, we sold an aggregate of
10,965 shares at $100 per share for $1,096,500. Subsequent to such offering, in
1993, we sold an additional 2,250 shares at $100 per share for $225,000. In
connection with such purchases, all purchasers received certain registration
rights.

Stock Purchase Agreement with Home Insurance Company dated July 19, 1993:
Pursuant to a Stock Purchase Agreement dated July 19, 1993, by and between us
and the Home Insurance Company (Home Insurance), we sold to Home Insurance
11,112 shares of common stock for an aggregate purchase price of $999,999, or
$90 per share. In connection with such purchase, Home Insurance received certain
registration rights.

Shares issued in exchange for commission: In 1993, we issued 60 shares to an
individual as compensation for commissions in connection with the sale of our
shares. Such commissions are included in share issuance expenses. The stock
issued was valued at $100 per share.

In August 1993, the Director entered into a stock option agreement with Dr.
Eisenberg and the Other Founders, pursuant to which he received the right to
purchase an aggregate of 10,000 shares owned by such persons in various amounts
and at various times, at a purchase price of $100 per share. As of December 31,
1993, the Director had exercised options and purchased 500 shares under such
agreement at $100 per share. The remaining balance of such options has expired.

Fourth private placement: Pursuant to a fourth private placement consummated in
July 1994, we sold an aggregate of 3,946 shares at between $100 and $125 per
share for aggregate proceeds of $397,712.

Stock Purchase Agreement with Home Insurance dated July 22, 1994: Pursuant to a
Stock Purchase Agreement dated July 22, 1994, between Ortec and Home Insurance,
we sold to Home Insurance 5,000 shares of common stock for an aggregate purchase
price of $500,000, or $100 per share. In connection with such purchase, Home
Insurance received certain registration rights and warrants to purchase 1,000
shares of common stock at $120 per share, which expired on July 21, 1997.

Rent Forgiveness: During the year ended December 31, 1995, Dr. Eisenberg's
father waived the rights to $40,740 of unpaid rent which was accounted for as
additional paid-in capital.

Initial Public Offering: On January 19, 1996, we completed an initial public
offering of 120,000 units for aggregate proceeds of $6,000,000. Each unit
consisted of one share of our common stock, one Class A warrant to purchase one
share of common stock at $100 and one Class B warrant to purchase one share of
common stock at $150. As of December 31, 1998, 108,378 Class A warrants were
exercised and the balance expired unexercised. The Class B warrants were
originally set to expire in January 1999. We extended the expiration date to
March 31, 2000. The Class B warrants were subject to redemption by us at $.10
per warrant. We received gross proceeds of approximately $1,282,000 and
$10,823,000 and net proceeds of approximately $1,262,000 and $10,165,000 as a
result of the exercise of warrants in 1998 and 1997, respectively.

Fifth private placement: In November 1996, we completed a private placement of
our securities from which we received gross proceeds of $6,220,797 and net
proceeds of approximately $5,733,000 (after deducting approximately $487,000 in
placement fees and other expenses of such private placement). We sold 95,911
shares of common stock in such private placement at average prices of $64.90 per
share. In addition, we granted five-year warrants to placement agents to
purchase such number of shares equal to 10% of the number of shares of common
stock sold by such placement agents, exercisable at prices equal to 120% of the
prices paid for such shares. Pursuant to the purchasers' request, we registered
all 95,911 shares.

Options and warrants issued for services: During 1992 and 1993, we issued
warrants to purchase 666 shares at $94.25 per share, and during 1995 we issued
warrants to purchase 2,000 shares at $100 per share to members of our Scientific
Advisory Board. During 1996 and 1997, we issued warrants to purchase 24,210
shares at $60 to $120 per share to the Director and certain others. These
warrants expired at various dates through November 2001.

On January 20, 1996, we granted "lock-up warrants" entitling shareholders to
purchase an aggregate of 38,905 shares of our common stock at a price of $10 per
share. All unexercised warrants expired on January 18, 2000. At different times
during 1996, seven persons exercised such warrants and purchased 3,389 shares of
common stock at the $10 per share exercise price. The issuance of such lock-up
warrants was in consideration for such shareholders signing lock-up agreements
agreeing not to sell or transfer shares of our common stock purchased at prices
of $90 or more per share until January 20, 1997. At different times during the
third quarter of 1997, eight persons exercised such warrants and purchased an
aggregate of 2,121 shares of common stock at the $10 per share exercise price.
During 1998, nine persons exercised such warrants and purchased an aggregate of
9,608 shares of common stock at the $10 per share exercise price. During 1999,
five persons exercised such warrants and purchased an aggregate of 1,410 shares
of common stock at the $10 per share exercise price. There were no underwriting
discounts or commissions given or paid in connection with any of the foregoing
warrant exercises.

During the third quarter of 1997, we granted to one person and its seven
designees four-year warrants to purchase an aggregate of 3,750 shares of common
stock, at an exercise price of $120 per share. Such warrants were not
exercisable until July 18, 1998 and were granted in consideration for consulting
services rendered to us.

During the fourth quarter of 1997, we granted to one person and its six
designees four-year warrants to purchase an aggregate of 3,750 shares of common
stock, at an exercise price of $120 per share. Such warrants were not
exercisable until July 18, 1998 and were granted in consideration for consulting
services rendered to us.

During 1998, warrants for 1,870 shares, mentioned in the two previous
paragraphs, were exercised utilizing the cashless exercise option of the warrant
agreement. We issued 620 shares upon this exercise.

During the third quarter of 1997, we granted to one person a one-year warrant to
purchase an aggregate of 63 shares of common stock, at an exercise price of $120
per share. Such warrants were granted in consideration for consulting services
rendered to us. The warrant was exercised during 1998.

We recorded consulting expense of approximately $65,000 as a result of these
grants during the year ended December 31, 1998.

During the fourth quarter of 1997, we granted five-year warrants to our three
executive officers to purchase an aggregate of 24,000 shares of common stock, at
an exercise price of $120 per share. Such warrants were granted in consideration
for services rendered to us. The exercise of such warrants was contingent upon
the occurrence of certain events, which were considered probable at December 31,
1997. As of December 31, 1998, five of the six events had occurred so that
18,500 of those warrants became vested. As a result, we recorded compensation
expense of approximately $80,000 in December 1997 and $1,185,000 for the year
ended December 31, 1998. The balance of the warrants became vested upon the
exercise of warrants owned by a director in December 1998 in accordance with the
terms of certain compensation provisions as approved by our Board of Directors.

In consideration for services rendered by him as our director in the five-year
period from 1992 to 1996 for which he never received compensation, we extended
by one year to December 31, 1998 the expiration date of warrants owned by a
director to purchase an aggregate of 8,693 shares, exercisable at $94.25 per
share. As a result, we recorded compensation expense of approximately $420,000,
during the fourth quarter of 1997. All of these warrants were exercised on
December 29, 1998.

During the fourth quarter of 1998, we granted five-year options to our three
executive officers to purchase an aggregate of 52,075 shares of common stock, at
exercise prices ranging from $121.30 to $124.40 per share. The exercise of such
options was contingent upon the occurrence of certain events. All of these
options became vested upon the exercise of warrants owned by a director in
December 1998 in accordance with the terms of certain compensation provisions as
approved by our Board of Directors. As a result, we recorded compensation
expense of approximately $495,000 in December 1998.

Sixth private placement: In December 1998, we completed a private placement of
our securities from which we received proceeds of $2,000,000. In addition, we
granted three-year warrants to the purchaser to purchase 5,000 shares at $120
per share. We sold 20,000 shares of common stock in such private placement. We
allocated the $2,000,000 proceeds amongst the common stock and warrants based
upon the relative fair market value of the stock at the date of issuance and the
estimated fair value of the warrants using the Black-Scholes option pricing
model. We assigned values to the common stock and warrants issued of $1,788,698
and $211,302, respectively.

Seventh private placement: In March 1999, we completed a private placement of
38,916 shares of our common stock to twenty investors from which we received
proceeds of $3,405,076. In addition, each investor also received a three-year
warrant to purchase 20% of the number of shares of our common stock such
investors purchased in such private placement. The prices at which such warrants
were exercisable was $125 per share for one half, and $145 per share for the
other half, of the number of shares issuable upon exercise of such warrants. We
allocated the $3,405,076 proceeds amongst the common stock and warrants based
upon the relative fair market value of the stock at the date of issuance and the
estimated fair market value of the warrants using the Black-Scholes option
pricing model. We assigned values to the common stock and warrants issued to the
investors of $3,168,785 and $236,291, respectively. Oscar Gruss & Son,
Incorporated (Gruss) acted as placement agent in such private placement. For its
services as placement agent, we paid Gruss $272,406 and granted Gruss a
five-year warrant to purchase an aggregate of 3,892 shares of our common stock
at an exercise price of $105 per share. The value assigned to the Gruss warrants
was $232,000. Other share issuance costs amounted to $106,002.

Eighth private placement: In December 1999, we completed a private placement of
163,637 shares of our common stock to two institutional funds from which we
received proceeds of approximately $9,000,000. Share issuance costs amounted to
approximately $9,500.

Ninth private placement: In March 2000, we completed a private placement of
6,667 shares of our common stock to one fund from which we received proceeds of
approximately $1,000,000. In addition, we paid a placement agent who introduced
us to the fund a fee of approximately $43,400 and granted such placement agent a
five year warrant to purchase 267 shares of our common stock at an exercise
price of $150 per share. The value assigned to the warrant was $23,000, which
was reflected as share issuance costs. Other share issuance costs amounted to
$3,200.

Tenth private placement: In September 2000, we completed a private placement of
124,757 shares of our common stock to ten investors from which we received
approximately $8,421,000. In addition, we paid the placement agent who
introduced us to the investors a fee of approximately $525,400. Other share
issuance costs amounted to approximately $46,500.

Options issued for services: In April 2001, we issued options to purchase 6,000
shares of our common stock, at $69.50 per share, to certain professionals. The
estimated fair value of $188,080 for such options was charged to general and
administrative expenses.

During 2002, we completed a private placement with several investors, in which
we raised cash proceeds of $8,200,000, issued convertible preferred shares,
issued warrants to purchase common shares and granted common stock as dividends.
(See Note 12).

During July 2003, we granted a warrant to purchase 150,000 shares at an exercise
price of $2.00 per share to a vendor in consideration for twelve months of
consulting services. In accordance with the agreement, 50% of the shares, or
75,000 shares, vested immediately, with the balance vesting upon the six-month
anniversary in January 2004. As a result, we recorded expense of $87,000 in 2003
and $94,393 during 2004 representing the value of the additional 75,000 shares
which had vested.

Restricted Share Grant: During 2003, an allocation of 1,800,000 restricted
shares of common stock were granted to officers and certain employees. The
issuance of these shares was contingent on our achieving certain milestones.

On January 5, 2005, we issued 1,000,000 and 340,000 of these shares to our chief
executive officer and chairman, respectively, for having achieved a milestone of
raising in excess of $15,000,000 over a specified period. On June 27, 2005, we
allocated the remaining 460,000 shares of our common stock to certain executive
officers and other employees. We issued an aggregate of 295,000 shares to our
Chief Operating and Chief Financial Officers. Grants of the remaining 165,000
shares allocated to three employees were conditioned on meeting certain
performance criteria. One of those employees met such performance criteria at
December 31, 2005 and 10,000 shares were issued. Until such time as the three
employees meet the balance of their performance criteria, the fair value of the
155,000 shares will be adjusted at each reporting period. The related charges
will be reflected as additional paid in capital and deferred compensation in the
statement of shareholders' deficit. The shares will vest in five equal monthly
installments commencing January 1, 2007. However, the portion of the shares
granted to such officer or employee which are not vested will be forfeited if
the officer or employee is then no longer employed by us at any time after
January 1, 2007. The shares may only be sold in five monthly installments
commencing January 1, 2007. We recorded a charge to deferred compensation of
$751,584 based on the fair value of these restricted shares. The deferred
compensation for the 1,645,000 issued shares is being amortized over the
29-month vesting period. Included in general and administrative expense is a
charge of $289,139 for the year ended December 31, 2005 reflecting the
amortization of this deferred compensation amount. These shares have certain
registration rights. In lieu of a direct cash payment, these individuals may
transfer a portion of their shares back to us to satisfy their minimum future
personal tax withholding liability arising from the receipt of these shares for
which we will pay their tax obligation.

Promissory Note Transactions: In connection with the issuance of $9,776,626 of
promissory notes to investors placed in 2003 and 2004, we paid our placement
agent a fee equivalent to 50 shares for every $1,000 of the promissory notes and
recorded this as deferred debt issuance cost which was then amortized over the
life of the note to interest expense. 488,831 shares were issued in 2004
consisting of 157,000 shares valued at $287,000 (in 2003) relating to notes
placed in 2003 and 331,831 shares valued at $746,202 relating to notes placed in
2004.

On October 27, 2004 holders of $9,206,000 of investor promissory notes agreed to
extend the maturity date of their notes from November 5, 2004 to December 31,
2004. In consideration of this extension we increased the interest rate for the
fourth quarter of the calendar year to 12% and issued 45,000 common shares for
each $1,000,000 of principal amount held, or 414,270 common shares, which we
issued in 2005. The modification was not considered significant and thus these
shares were valued at $2.00 per share, or $828,540 in the aggregate, and was
charged to interest expense in the fourth quarter. These shares were issued in
2005 upon our confirmation of each noteholders' accredited investor status. In
connection therewith, we issued 277,020 shares of common shares and 34.31 shares
of our Series D preferred stock (equivalent to 137,250 common shares).

As provided in the promissory notes, if we received $5,000,000 of gross proceeds
from a qualified financing, we may elect to prepay the notes and any accrued and
unpaid interest in cash or in our stock. See January 5, 2005 private placement
discussion below.






Special Warrant Offer: On November 16, 2004, we made a Special Warrant Offer
(SWO) to all holders of our Series B-1, B-2 and C warrants. Such warrants were
originally issued in connection with our Series B and Series C preferred stock
financings in November and December 2002 and in February, May and July 2003 (See
Note 13). At the time of the SWO there were outstanding and eligible for the
SWO: 667,989 and 25,000 Series B-1 warrants exercisable to purchase our common
stock at $4.00 and $15.00 per common share, respectively; 544,138 and 25,000
Series B-2 warrants exercisable to purchase our common stock at $5.00 and $20.00
per common share, respectively, and 1,707,000 Series C warrants to purchase our
common stock at $3.60 per common share. Under the terms of the SWO, the holders
were entitled to purchase 1/3 of such shares they could otherwise purchase at a
reduced exercise price of $1.67 per common share. Concurrently with such
exercise they would receive 2/9 of such shares they could otherwise purchase at
the reduced exercise price of $0.01 per common share, and they would surrender
the right to purchase their remaining 4/9 of such shares they could otherwise
purchase. Each warrant holder participating in the SWO received a new warrant to
purchase 30% of the common shares acquired by such purchaser in the SWO.

The SWO was concluded December 3, 2004. Holders of 491,791 of our Series B-1
warrants, 431,341 of our Series B-2 warrants, and 1,605,000 of our Series C
warrants participated in the SWO.

Participation in the offering resulted in aggregate gross proceeds of $1,438,019
consisting of cash proceeds of $1,338,019 and $100,000 relating to the
settlement of an existing promissory note obligation. There were no fees paid to
our placement agent in connection with the SWO. We issued 496,981 shares of our
common stock and 233.8274 shares of Series D convertible preferred stock, which
are equivalent to 935,310 shares of common stock. We also issued five-year
Series E warrants to the investors to purchase an additional 429,689 shares of
our common stock for $1.80 per share.

As a result of the SWO, the warrant holders who participated in the offering
were considered to have received a deemed dividend aggregating $1,120,500 based
upon a Black Scholes calculation considering the valuation of the warrants prior
to the November 16, 2004 offering and subsequent to the offering. We recorded an
aggregate deemed dividend of $1,123,000 inclusive of Paul Royalty Fund's SWO
described in Note 9.

January 2005 private placement: On January 5, 2005 we entered into a number of
agreements with institutional and accredited investors (collectively, the
"purchasers") that provided us with:

o    Gross aggregate cash proceeds of $5,403,302 from the sale of our common
     stock (the "private placement") to former holders of our Series C preferred
     shares and other purchasers at $0.833 per share (the "purchase price") with
     each receiving a five year warrant to purchase one share of common stock at
     $1.80 per share for every two shares purchased;

o    The exchange of all our outstanding Series C preferred shares at January 5,
     2005, or approximately 913 Series C preferred shares, with a liquidation
     preference of $5,476,256 plus accrued and unpaid dividends, an aggregate
     value of $6,357,104, for shares of our common stock at the $0.833 per share
     purchase price and five-year warrants to purchase our common stock at $1.80
     per share. Upon the exchange, the holders of the Series C preferred shares
     received a warrant to purchase one share of common stock for each two
     shares of our common stock they received in the exchange. This exchange was
     offered to Series C preferred shareholders if they participated in the
     private placement sale of our common stock for an amount equal to 30% of
     the liquidation preference amounts of their Series C preferred shares
     exchanged for our common stock. The Series C holders provided gross cash
     proceeds of $1,642,877 (30% of $5,476,256) of the $5,403,302 aggregate
     gross proceeds received by us in the private placement. We recorded a
     deemed dividend of $2,125,974 related to the value of warrants issued in
     the exchange of the Series C preferred shares for common shares.

o    As a result of our receipt of over $5,000,000 in the private placement we
     elected to repay $9,626,626 (principal balance outstanding at January 5,
     2005) of our outstanding promissory notes, accrued interest of $674,587 and
     an added 20% premium, in all $12,361,456, by issuing to each noteholder so
     many shares of common stock equal to the principal, accrued interest and
     premium of each divided by the $0.833 purchase price. Each noteholder also
     received a five-year warrant to purchase one share of our common stock at
     $1.80 per share for each common share received, or approximately 15,000,000
     Series E warrants. We recorded a loss on settlement of $10,328,199 in
     connection with this transaction representing the beneficial conversion
     feature and discount on the notes from issuance of the warrants and the
     final conversion terms. This amount was expensed immediately upon
     conversion of the notes.

o    Purchasers, Series C Holders and holders of the Notes whose participation
     in these transactions would result in ownership of common stock in excess
     of 9.99% of our issued and outstanding shares of common stock could elect
     to receive instead of our common stock, shares of our Series D convertible
     preferred stock convertible into the same number of shares of our common
     stock.

We issued an aggregate 17,720,767 shares of common stock, 2,806.37 shares of
Series D preferred stock (convertible into 11,225,466 shares of common stock),
and five-year Series E warrants to purchase 21,889,989 shares of our common
stock at an exercise price of $1.80 per share, as a result of these
transactions.

We granted each of the purchasers in the $5,403,302 private placement the right
to purchase, within 45 days after the closing date, additional shares of our
common stock and our Series E warrants on the same terms as in the private
placement in an amount not to exceed 25% of their original cash investment in
the private placement. Four investors exercised this right and we received gross
proceeds of $127,719. We issued 153,263 shares and five year warrants to
purchase 76,632 shares of our common stock at an exercise price of $1.80 per
share for such additional investments by these four investors.

The Series E Warrants, with certain exceptions, provide that if we sell shares
of our common stock at prices below the exercise prices of those warrants, or
issue other securities convertible into, or which entitle the holder to
purchase, shares of our common stock, which could result in the sale of our
common stock at a price which in effect (taking into consideration the price
paid for the convertible security or the warrant or the option) is less than the
exercise price of the Series E Warrants, then the exercise price of the Series E
Warrants will be reduced by a portion of the difference between the exercise
price and the lower price at which the common stock was, or effectively could
be, acquired. That percentage by which the exercise price of the Series E
Warrants could be reduced depends not only on the lower price at which our
common stock was, or could be, acquired, but also by the ratio that the number
of shares of our common stock that were, or could be, so acquired bears to the
total number of shares of our common stock that would be outstanding after such
sale of our common stock, or the conversion of securities convertible into, or
the exercise of such warrants or options to purchase, our common stock.

After January 5, 2007, subject to a registration statement then being effective
for the common stock underlying the warrants, the warrants may be redeemed by
us, through expiration, if our common stock closes above $3.60 for ten
consecutive trading days. The warrants contain cashless exercise as well as
other customary anti-dilution provisions.

In connection with these transactions, we paid Burnham Hill Partners, a division
of Pali Capital ("BHP"), our placement agent, commissions consisting of cash
equaling 10% of the $5,403,302 of gross cash proceeds we received from the
private placement. The placement agent and his assigns received warrants to
purchase 2,728,376 shares of our common stock exercisable at $0.95 per share. We
paid $86,872 in legal and accounting expenses in connection with the private
placement. At any time in the next three years, we will pay the placement agent
cash equal to 6% of the gross proceeds received by us from the exercise of the
warrants issued to the investors who purchased shares of common stock for cash
in the private placement. We also entered into an agreement under which the
placement agent provided financial advisory services to us through September 30,
2005, for a fee of $250,000. The fee was amortized over the period of service.
The agreement provided that payment of such fee would be deferred until our cash
balance exceeds $10,000,000. Pursuant to a new advisory agreement dated
September 23, 2005, we agreed that the placement agent may apply all or a
portion of the $250,000 Advisory Fee as purchase price for the common stock and
common stock purchase warrants sold in the financing which we closed October 12,
2005.

Series B conversion: In accordance with an agreement dated May 23, 2003 amongst
the holders of Series B preferred stock which provided for conversion of our
outstanding Series B preferred stock should all of the holders of Series C
preferred stock convert their preferred shares to common stock (which occurred
at the January 5, 2005 closing as described above), Paul Royalty Fund, the sole
remaining holder of Series B preferred stock converted their 50 shares of Series
B preferred stock into 220,647 shares of common stock, which included common
shares for $51,616 in accrued dividends.

February 2005 private placement On February 9, 2005, we completed a private
placement with one investor from which we received aggregate gross proceeds of
$100,000. We issued to the investor 120,000 shares of our common stock and a
five-year warrant to purchase 60,000 shares of our common stock at $1.80 per
share. We paid our placement agent 10% of the gross proceeds and a five-year
warrant to purchase 18,000 shares of our common stock exercisable at $0.95 per
share. We incurred legal expenses of $3,727 for this transaction.

We had undertaken to register all shares of our common stock in our January 5
and February 9, 2005 private offerings as well as all shares of our common stock
issuable upon exercise of all the warrants and conversion of Series D preferred
stock issued in the January 5, 2005 offering, within 10 days after filing of our
Annual Report on Form 10-KSB with the Securities and Exchange Commission, which
Form 10-KSB we filed on March 31, 2005. In April 2005, in consideration for the
waiving of penalties we would have to pay for failure to file our registration
statement at a date no later than April 13, 2005, we entered into agreements
with our Series E Warrant holders who purchased our common stock and received
registration rights in our January 5 and February 9, 2005 private offerings, to
modify the price of their Series E Warrants from $1.80 to $1.50. Utilizing a
Black Scholes valuation model we recorded a deemed dividend to these warrant
holders of $67,217.

2005 Convertible Promissory Note Financing: Beginning May 27, 2005 and
thereafter, we received gross proceeds of $3,186,000 through the issuance of 8%
promissory notes due December 31, 2005. The outstanding principal together with
all unpaid and accrued interest would automatically convert into equity
securities issued by us in an equity financing or a combination of equity
financings with gross proceeds of at least $5,000,000, such conversion to be at
the same price per equity security as the equity securities sold in the equity
financing; provided, however, that for purposes of determining the number of
equity securities including warrants to be received upon such conversion, the
dollar amount due the noteholder will first be multiplied by a factor of 1.2
times. In consideration of such financing the exercise price of the noteholders'
Series E warrants to purchase 11,983,445 shares of common stock received in our
January 5, 2005 private placement where we sold stock at $.833 per share, were
reduced from an exercise price of $1.80 and $1.50 per share to an exercise price
of $.001 per share. Utilizing a Black Scholes valuation model we recorded a
deemed dividend to these warrant holders of $2,212,436. Additionally, an
investor holding in excess of 9.99% of our shares on a fully diluted basis who
purchased $150,000 of those promissory notes, entered into a funding commitment
for an additional $1,208,000. The exercise of such investor's repriced warrants
to purchase 3,618,797 shares of our common stock is limited to an amount
determined by multiplying the 3,618,797 warrants by the percentage of the
$1,358,000 commitment actually funded. Such investor must provide us with such
additional $1,208,000 by the later of the filing of our pre-market approval
application for our confirmatory venous leg ulcer trial, or March 31, 2006. We
received $150,000 towards this amount on September 14, 2005 in the form of a
loan for which we issued an 8% promissory note (to be automatically converted
into our equity securities the same as our other promissory notes, described
above). That left a balance to be paid to us under that commitment of
$1,058,000. We paid a cash fee of 5% of the gross loan proceeds to our financial
advisor in connection with all such loans. See Note 18 regarding a further
advance against the outstanding loan commitment.

On September 29, 2005 we received an additional $150,000 in the form of an 8%
promissory note due December 31, 2005 with similar terms to the $3,186,000 of
promissory notes issued in the prior quarter.

On October 12, 2005, the terms of all of the $3,486,000 of outstanding
promissory notes at September 30, 2005 were amended to reduce the amount of
gross proceeds we had to receive in equity financings to trigger the conversion
of the notes to our equity securities, from the original $5,000,000 to
$2,514,000. In consideration of this amendment the holders received 20,000
seven-year Series F warrants to purchase our common stock at $0.50 per common
share for each $100,000 of outstanding principal amount of the note that is
being converted into our equity securities, or 697,200 Series F warrants. As a
result of our receipt of gross proceeds of approximately $2,650,000 from the
sale of our equity securities on October 12, 2005, all of the promissory notes
we issued after May 26, 2005, including accrued interest of $98,463 and an added
20% premium, in all $4,301,355 were converted into an aggregate of 17,205,421
shares of our common stock. We actually issued 6,346,925 shares of our common
stock and 2,714.624 Series D Preferred (equivalent to 10,858,496 shares of
common stock), and Series F warrants to purchase an additional aggregate
9,299,910 shares of common stock at $0.50 per share. We recorded a loss on
settlement of $2,753,254 in connection with this transaction representing the
beneficial conversion feature and discount on the notes from issuance of the
warrants and the final conversion terms. This amount was expensed immediately
upon conversion of the notes.

Cambrex Suite Deal: On July 12, 2005, we entered into an agreement with our
manufacturing and marketing partner, Cambrex Bio Science Walkersville, Inc.
whereby for the six-month period May 1 to October 31, 2005 the $128,750 monthly
charges we incur for rental of a production suite used to produce ORCEL at their
Maryland facility will be accrued by them for later conversion into shares of
our common stock and warrants. The aggregate accrued charge during the six-month
period of $772,500 will be converted at $0.75 per common share, or 1,030,000
shares of common stock. Concurrently with the conversion we will also issue
three year warrants to purchase an amount representing 1.5 times the number of
shares of our common stock, or 1,545,000 shares, at $1.80 per share. Each of
these securities will carry certain registration rights. At December 31, 2005,
we have accrued a charge for the six month period from May 1 to October 31, 2005
based on the fair value of the 1,030,000 shares and warrants to purchase
1,545,000 shares of our common stock at $1.80 per share. Accordingly, we have
recorded a liability of $235,500 to reflect the fair value of our common stock
and warrants to be issued as payment for the production suite. We entered into a
similar arrangement in 2006. See Note 18, Cambrex Suite Deal II.

Service Agreement: On July 18, 2005, we entered into a three-month service
agreement with a financial communications group whereby we agreed to grant it a
warrant to purchase 50,000 shares, exercisable as follows: (i.) 25,000 shares
exercisable at $0.50 per share, which vested immediately, and (ii.) 25,000
shares exercisable at $1.00 per share, which vested upon the Company and the
financial communications group extending the term of the service agreement.
Utilizing a Black-Scholes valuation model we recorded a general and
administrative charge of $4,903 for these warrants.

On December 1, 2005, in partial consideration for services rendered by it to us
we granted one company three-year warrants to (i) purchase 25,000 shares of our
common stock at an exercise price of $0.50 per share, which will vest on March
31, 2006 immediately, and (ii) to purchase an additional 25,000 shares of our
common stock at an exercise price of $1.00 per share, which vest only if we and
the service provider extend the original three-month term of the service
agreement beyond March 31, 2006. Utilizing a Black-Scholes valuation model we
recorded a general and administrative charge of $2,286 for the initial warrant
to purchase 25,000 shares at $0.50 per share.

October 2005 Private Placement: On October 12th and 31st, 2005, in a private
placement in which we agreed to issue common stock at a purchase price of $0.25
per share we received aggregate gross proceeds of $3,647,691 (approximately
$2,650,000 of which was received on October 12, 2005) for which we issued
14,590,764 shares and each purchaser received our Series F common stock purchase
warrants to purchase 50% of the number of common shares purchased, or an
aggregate of 7,295,382 shares. The Series F warrants are exercisable at $0.50
per share. Investors holding an aggregate 5,881,079 Series E warrants who
purchased our common stock and Series F warrants in this most recent private
placement in an amount equal to at least 40% of their past cash investments in
our January 5, 2005 equity private placement (which was completed at $0.833
cents per share and in which they purchased our common stock and our Series E
warrants), or who converted our promissory notes on that January 5, 2005 date to
shares of our common stock and Series E warrants, had the exercise price of
their Series E warrants held by them reduced to $.001 from $1.80 and $1.50 per
share. The modification of the warrant value was recorded as a deemed dividend
of $1,053,088 based on a Black Scholes valuation.

Purchasers whose participation in our most recent private placement whose
holdings would result in ownership in excess of 9.99% of our outstanding common
stock were given the option to receive our Series D preferred shares which will
be convertible to the same number of shares of our common stock they would
otherwise acquire in this current private placement.

The Series F warrants contain certain anti-dilution provisions. We may redeem
the Series F warrants at any time after twelve months after their issuance
should our common stock trade above $1.00 for ten consecutive trading days.

We are required to file a registration statement registering the shares of the
common stock and the shares of our common stock issuable upon exercise of our
Series F warrants, which we sold in our most recent private placement. That
registration statement was required to be filed no later than January 6, 2006.
We are required to use our best efforts to have the registration statement
declared effective within 60 business days thereafter. Such registration rights
agreement provided, before it was modified, that if the registration statement
was not filed by January 6, 2006, or was not declared effective within 90
business days of its filing we must pay the investors cash liquidated damages
equal to 1.5% of the amount they invested in the current private placement for
the first 30 days of our default, and 1% of the amount invested for each 30 days
thereafter. See Note 19 regarding modification of the registration rights
agreement.

BHP received a cash fee equal to 10% of the gross proceeds (including cash
received for our promissory notes issued since May 2005, approximately half of
which we paid to BHP upon placement of the notes) received by us in this most
recent private placement. BHP received warrants to purchase 3,179,619 shares of
our common stock at an exercise price of $0.30 per common share. BHP has the
option to take $174,300 of their fee to purchase our common stock and our Series
F warrants at the same price as paid by the investors in this most recent
private placement for those securities. Additionally, as a result of such
private placements and sale of our promissory notes, pursuant to our agreement
with BHP, placement agent warrants for the purchase of 2,746,376 shares of our
common stock at an exercise price of $0.95 per share, which we issued to BHP and
its designees in connection with the private placement of our common stock and
our Series E warrants which closed on January 5, 2005, had their exercise price
reduced to $0.35 per share. The modification of the warrant value was recorded
as a deemed dividend of $143,942 based on a Black Scholes valuation. We paid
$109,306 in legal and accounting expenses in connection with the private
placement. For a period of 36 months ending in October 2008 we shall pay BHP a
cash fee of 6% of the proceeds we receive from the exercise of any of our
warrants issued to investors who paid cash for our securities.

For a period of nine months ending July 31, 2006, BHP had the right to act as
our exclusive placement agent in connection with our subsequent financings.
During that period, BHP would have been entitled to an industry standard fee for
completion of a strategic transaction by us. BHP has waived its right to act as
placement agent with respect to a proposed private placement financing we have
to complete and has waived its fee for a proposed strategic transaction we are
negotiating. Pursuant to rights granted to it BHP has applied the $250,000
advisory fee it earned under the advisory agreement between us and BHP dated
January 4, 2005 and $174,300 of commissions owed by us to BHP, to purchase our
common stock and Series F warrants at the same price as paid by the investors in
this most recent private placement for these securities.

Purchasers in our most recent private placement, both those who purchased on
October 12, 2005 and on October 31, 2005, have the right for a period which ends
on the earlier of six months after their purchase of our common stock and our
Series F warrants, or upon our announcement of a transaction in which we will
issue at least 20,000,000 shares of our common stock (a "Material Transaction"),
to participate in any equity financing by us in connection with or relating to
such Material Transaction, so that each purchaser can maintain its percentage
ownership of our common stock as of the date immediately prior to the date of
such equity financing.

The exercise prices of our Series F warrants issued to the purchasers in our
most recent private placement on October 12, 2005 and on October 31, 2005, and
to the note holders, will be adjusted if during the earlier of (a) the six-month
period after the date of issuance of the Series F warrants, or (b) when we
announce a Material Transaction,

                  (i)               we sell our equity securities in a financing
                                    at a price equal to or greater than $0.25
                                    per share, the exercise price of our Series
                                    F warrants held by such persons will be
                                    reduced (or increased but not beyond the
                                    current $0.50 per share exercise price of
                                    our Series F warrants) to the exercise price
                                    of the warrants issued in such equity
                                    financing, or

                  (ii.)             we sell our equity securities in a financing
                                    for less than $0.25 per share
                                    (notwithstanding that such equity financing
                                    is consummated following the announcement of
                                    the Material Transaction), the exercise
                                    price of our Series F warrants held by such
                                    persons will be reduced to the price per
                                    share for which we sell our equity
                                    securities in such financing.

In a press release dated December 15, 2005, we announced our letter of intent to
acquire Hapto Biotech (see Note 14). We considered this a Material Transaction.
The sale of our common stock and our Series F warrants in our most recent
private placement is exempt from the registration requirements of the Securities
Act of 1933, as amended (the "Act") pursuant to the provisions of Regulation D
promulgated under the Act, since all the purchasers were accredited investors,
as that term is defined in Rule 501 in Regulation D.

In October and November 2005, we issued seven-year options to purchase an
aggregate of 3,179,619 shares of our common stock at $0.25 per common share, the
fair value of our common stock on the date of the grant, to each of our chairman
and our chief executive officer. These options represent the bonus due them
under their compensation arrangement with us for the completion of the October
2005 private placement. See Note 12.

The following table summarizes warrant activity during the period from March 12,
1991 (inception) through December 31, 2005 (excluding the Class A and B warrants
which were issued during the IPO):





                            ORTEC INTERNATIONAL, INC.
                        (A DEVELOPMENT STAGE ENTERPRISE)

                   NOTES TO CONSOLIDATED FINANCIAL STATEMENTS


                                                                                Price Range ($)                                        Warrants
                                                                                -----------------------------------------------        ----------------------------------------
                                                                                -------------------  ----  --------------------        ----------------------------------------
March 12, 1991 (inception)
       Granted                                                                                              94.25                                                        736
                                                                                                                                       ----------------------------------------
                                                                                                                                       ----------------------------------------
Balance, December 31, 1991                                                                                  94.25                                                        736
       Granted                                                                                              94.25                                                      5,508
                                                                                                                                       ----------------------------------------
                                                                                                                                       ----------------------------------------
Balance, December 31, 1992                                                                                  94.25                                                      6,244
       Granted                                                                  94.25                -     120.00                                                      4,823
                                                                                                                                       ----------------------------------------
                                                                                                                                       ----------------------------------------
Balance, December 31, 1993                                                      94.25                -     120.00                                                     11,067
       Granted                                                                                             120.00                                                      1,000
                                                                                                                                       ----------------------------------------
                                                                                                                                       ----------------------------------------
Balance, December 31, 1994                                                      94.25                -     120.00                                                     12,067
       Granted                                                                                             100.00                                                        400
       Expired                                                                                              94.25                                                      (268)
                                                                                                                                       ----------------------------------------
                                                                                                                                       ----------------------------------------
Balance, December 31, 1995                                                      94.25                -     120.00                                                     12,199
       Granted                                                                  10.00                -     100.00                                                     51,161
       Exercised                                                                                           100.00                                                    (3,389)
       Expired                                                                                             120.00                                                      (245)
                                                                                                                                       ----------------------------------------
                                                                                                                                       ----------------------------------------
Balance, December 31, 1996                                                      10.00                -     120.00                                                     59,726
       Granted                                                                  120.00               -     142.50                                                     33,063
       Expired                                                                                             120.00                                                    (1,000)
                                                                                                                                       ----------------------------------------
                                                                                                                                       ----------------------------------------
Balance, December 31, 1997                                                      10.00                -     142.50                                                     91,789
       Granted                                                                  120.00               -     140.00                                                      7,500
       Exercised                                                                10.00                -     120.00                                                   (20,585)
       Expired                                                                                             120.00                                                   (10,843)
                                                                                                                                       ----------------------------------------
                                                                                                                                       ----------------------------------------
Balance, December 31, 1998                                                      10.00                -     142.50                                                     67,861
     Granted                                                                    125.00               -     145.00                                                     11,674
     Exercised                                                                                             10.00                                                     (1,410)
     Expired                                                                    60.00                -     94.25                                                     (1,716)
                                                                                                                                       ----------------------------------------
Balance, December 31, 1999                                                      10.00                -     142.50                                                     76,409
     Granted                                                                                               150.00                                                        267
     Exercised                                                                                             120.00                                                      (200)
     Expired                                                                    10.00                -     100.00                                                   (15,499)
                                                                                                                                       ----------------------------------------
                                                                                                                                       ----------------------------------------
Balance, December 31, 2000                                                      77.00                -     150.00                                                     60,977
     Expired                                                                    77.00                -     120.00                                                   (21,436)
                                                                                                                                       ----------------------------------------
                                                                                                                                       ----------------------------------------
Balance, December 31, 2001                                                      77.00                -     150.00                                                     39,541
     Granted                                                                    .01                  -     62.48                                                   2,221,015
     Exercised                                                                                             .01                                                     (973,997)
     Expired                                                                    .01                  -     145.00                                                  (169,348)
                                                                                                                                       ----------------------------------------
                                                                                                                                       ----------------------------------------
Balance, December 31, 2002                                                      .01                  -      150.00                                                 1,117,211
     Granted                                                                    .01                  -     15.00                                                   2,369,212
     Exercised                                                                  .01                  -     4.00                                                    (398,750)
     Expired                                                                                               140.00                                                    (2,500)
                                                                                                                                       ----------------------------------------
                                                                                                                                       ----------------------------------------
Balance, December 31, 2003                                                      .01                  -     120.00                                                  3,085,173
     Granted                                                                    .01                  -     15.00                                                     518,741
     Exercised                                                                  .01                  -      20.00                                                (1,464,759)
     Surrendered                                                                3.60                 -     20.00                                                 (1,145,836)
     Expired                                                                                               140.00                                                    (4,716)
                                                                                                                                       ----------------------------------------
                                                                                                                                       ----------------------------------------
Balance, December 31, 2004                                                      2.00                 -     120.00                                                    988,603
     Granted                                                                    0.001                      1.80                                                   44,622,911
     Exercised                                                                                             0.001                                                 (3,658,513)
     Expired                                                                    45.00                      120.00                                                    (3,866)
                                                                                                                                       ----------------------------------------
                                                                                                                                       ----------------------------------------
Balance, December 31, 2005                                                                                                                                          41,949,135
                                                                                                                                       ========================================







The following table summarizes warrant data as of December 31, 2005:

                                                                                       Weighted
                                                                                        Average                Weighted
                                                                                       Remaining               Average
Range of                                                Number                        contractual              Exercise                                Number
exercise prices                            outstanding                               Life (years)              Price                                 exercisable
-----------------------------------------  ------------------------------  ----------------------------------  -------------------------  --------------------------------------
-----------------------------------------  ------------------------------  ----------------------------------  -------------------------  --------------------------------------
$.001 to $1.00                                            36,862,298                    5.50                                            $.28             36,862,298
$1.50 to $1.80                                             4,531,789                    4.01                                           $1.75              4,531,789
$2.00 to $5.00                                               555,048                    2.63                                           $3.57                555,048
                                           ------------------------------                                                                 --------------------------------------
                                           ------------------------------                                                                 --------------------------------------
                                                          41,949,135                                                                                     41,949,135
                                           ==============================                                                                 ======================================

11 - SERIES A, B, C, & D PREFERRED STOCK, 12% CONVERTIBLE DEBENTURES

Series A Convertible Preferred Stock: On June 25, 2002, our board of directors
unanimously adopted an amendment to our certificate of incorporation designating
2,000 shares out of the 1,000,000 shares of preferred stock that we are
authorized to issue, as Series A convertible preferred stock, and designating
the relative rights and preferences of the Series A convertible preferred stock.
The stated value, which is also the liquidation preference of the Series A
convertible preferred stock, was $10,000 per share. We were required to pay
dividends on the Series A preferred shares, at the rate of 6% per annum of the
$10,000 liquidation preference per share, through June 30, 2003; at the rate of
9% per annum thereafter until June 30, 2004; and thereafter at the rate of 12%
per annum. At our option such dividends could be paid in our common stock at the
"conversion price" for the conversion of such dividends if such shares of common
stock had been registered under the Securities Act of 1933 for sale in the
public securities markets. The conversion price was fixed initially at $15.00
per share of our common stock. There are no shares of Series A convertible
preferred stock outstanding. In November 2004, the designation establishing the
rights and preferences of the Series A convertible preferred stock was
eliminated from our certificate of incorporation so that we are no longer
authorized to issue any more Series A convertible preferred stock.

Series B Convertible Preferred Stock: On November 7, 2002, our board of
directors adopted an amendment to our certificate of incorporation designating
1,200 shares out of the 1,000,000 shares of preferred stock that we are
authorized to issue, as Series B convertible preferred stock at a stated value
of $10,000 per share. Dividends on the Series B preferred shares were payable at
the rate of 12% per annum, in cash or shares of common stock, at our option,
except that in the first year, dividends were payable, in advance, in shares of
common stock.

The Series B preferred stock was convertible into common shares at any time at
the option of the investor, based on a fixed conversion rate of not less than
$3.00, or commencing after February 1, 2003, based on an alternative conversion
rate equal to 90% of the average of the five lowest volume weighted average
prices for our common stock for the twenty trading days immediately prior to
conversion, subject to a floor price of $2.50.

Series C Convertible Preferred Stock: On May 23, 2003, our board of directors
adopted an amendment to our certificate of incorporation designating 2,000
shares out of the 1,000,000 shares of preferred stock that we are authorized to
issue, as Series C convertible preferred stock at a stated value of $6,000 per
share. Dividends on the Series C preferred shares are payable at the rate of 10%
per annum, in cash or shares of common stock, at our option.

The Series C preferred stock was convertible into common shares at any time at
the option of the investor, based on a fixed conversion rate of $2.00 per share.

Series B & C - Elimination of Designation: On June 16, 2005, the designations
establishing the rights and preferences of our Series B and C convertible
preferred stock, of which no shares were any longer outstanding, were eliminated
from our certificate of incorporation so that we are no longer authorized to
issue any more Series B or C convertible preferred stock.

Series D Convertible Preferred Stock: On August 19, 2003, our board of directors
adopted an amendment to our certificate of incorporation designating 2,000
shares out of the 1,000,000 shares of preferred stock that we are authorized to
issue, as Series D convertible preferred stock at a stated value of $10,000 per
share. In the event we declare a cash dividend on our common stock we will be
required to pay a dividend on each share of our Series D preferred stock in an
amount equal to the cash dividend paid on one share of our common stock
multiplied by the number of shares of our common stock into which such one share
of our Series D preferred stock can be converted. Each holder of Series D
preferred stock may, at such holder's option, subject to certain limitations,
elect to convert all or any portion of the shares of Series D preferred stock
held by such holder into a number of fully paid and nonassessable shares of our
common stock equal to the quotient of (i) the Series D liquidation preference
($10,000 per Series D preferred share previously reported on the balance sheet
as $25,088,062 and corrected to properly reflect aggregate liquidation
preference of $62,720,156) divided by (ii) the Series D conversion price of
$2.50 per share. The conversion price is subject to customary adjustments to the
Series D conversion price in the event of stock splits, stock combinations,
stock dividends, distributions and reclassifications and other corporate events.

Issuance of 12% Convertible Debentures: In March 2002, we engaged an
investment-banking firm to act as our advisor and to assist in raising capital
for us in the form of either debt or equity financing.

On May 13, 2002, we issued $2,333,000 of 12% convertible debentures, which were
convertible into common shares at the lesser of $3.36 or the price per share of
the equity securities to be issued in a subsequent financing. These debentures,
payable April 10, 2003, bore interest at the rate of 12% per annum, up to
October 10, 2002 and 18% thereafter. We also issued 291,000 stock purchase
warrants as part of this May 13, 2002 financing, exercisable at $4.50 per share
for up to five years from the date of grant. The warrants had price protection
features whereby the price of the warrants can be reduced to the prices at which
common stock or common stock equivalents are thereafter sold by us.

On June 28, 2002, $600,000 of these debentures sold on May 13, 2002 were
converted into Series A preferred stock at 110% of face value. Additionally, on
June 28, 2002, we issued an additional $250,000 of 12% convertible debentures
and $1,200,000 in Series A convertible preferred stock. The total face value of
the preferred stock issued was $1,870,000 which consisted of the $1,200,000 of
cash proceeds received, the $600,000 face value of converted debentures and the
$70,000 of additional conversion face value. Additionally, the Series A
preferred stock was convertible into common shares at a rate of $1.50 per share.
The Series A preferred stock had provisions whereby redemption was out of our
control; therefore, the preferred stock was classified as temporary equity.

On June 28, 2002, we also issued 654,624 common stock purchase warrants, at an
exercise price of $1.875 per common share for a five-year period. Of the
654,624, an aggregate of 31,250 warrants were issued with the convertible
debentures, with the remainder issued with the Series A preferred stock. The
warrants also had similar price protection features, whereby the price of the
warrants can be reduced to the prices at which common stock or common stock
equivalents were thereafter sold by us.

During the third quarter 2002, we issued $1,425,000 in convertible debentures,
with terms comparable to those issued in the second quarter. Additionally,
178,127 warrants were issued with similar terms to warrants issued on May 13,
2002. In October and November 2002, prior to our Series B preferred stock
financing, we issued an additional $1,900,000 in convertible debentures and
237,503 warrants, with terms comparable to those issued earlier in 2002.

We deferred the payment of interest due on June 30 and September 30, 2002,
pending the completion of our Series B preferred stock financing. These
debentures along with the accrued interest were convertible into equity
securities if we completed the sale of at least $5,000,000 in equity securities
by July 12, 2002, which date was extended through November 13, 2002. On November
13, 2002, these debentures and accrued interest were converted into Series B
preferred stock with the closing of the Series B preferred stock financing.
These were converted at the rate of 110% of the debentures plus accrued interest
into $10,000 par value Series B convertible preferred shares.

The relative estimated fair value of the warrants issued in connection with the
debentures of $440,523 was recorded as debt discount, as well as the estimated
fair value of the beneficial conversion features of $1,042,663. Both of these
values were being amortized over the remaining life of the convertible
debentures, or through April 10, 2003. Upon conversion, the remaining
unamortized beneficial conversion features were charged to interest expense.

The relative estimated fair value of the warrants issued in connection with the
Series A preferred stock of $797,919 was recorded as a discount to the preferred
stock and was reflected as interest expense, on the date of issuance.
Additionally, the estimated fair value of the beneficial conversion feature of
$859,256 has been recorded as an additional discount and reflected as interest
expense. The Series A preferred stock had no redemption date, and therefore the
charge to interest expense was reflected immediately as the conversion privilege
was exercisable immediately.






First Sale of Series B Convertible Preferred Stock: In November and December
2002, we issued 938.2742 shares of Series B convertible preferred stock to
several investors in a private placement for an aggregate of $8,178,000, which
included $1,070,000 of new Series B preferred stock and the conversion of the
aforementioned convertible debentures and convertible Series A preferred stock.
We recorded a loss on extinguishment of debentures and preferred shares of
$1,004,027, principally due to the additional buying power granted to the
investors resulting from the difference between the present value of the
original debt and the revised present value. The convertible debentures and
convertible Series A preferred stock were converted at 110% of face value plus
accrued interest. In addition, these investors were granted Series A warrants to
purchase 938,275 shares of our common stock at an exercise price of $.01.These
Series A warrants vested immediately and were exercised immediately, upon grant.
The investors were also granted Series B-1 and B-2 warrants, which could be used
to purchase 542,989 and 469,138 shares of common stock at an exercise price of
$15.00 and $20.00 per share, respectively. These B-1 warrants were exercisable
beginning August 13, 2003 and expire seven years from the date of grant and the
B-2 warrants were exercisable beginning November 13, 2003 and expire seven years
from date of grant. We assigned values to the Series B preferred stock of
$9,382,742 and the Series A, B-1 and B-2 warrants issued to the investors of
$2,245,206, $694,447 and $539,390, or $3,479,043 in the aggregate, based upon
the relative fair market value of the stock at the date of issuance and the
estimated fair market value of the warrants, using the Black-Scholes option
pricing model.

The warrants issued with the second quarter and third quarter 2003 financings
were exchanged for B-1 warrants, issued in the fourth quarter of 2003.

The first year's dividends on the Series B preferred stock were paid in advance
in common shares at the rate of 12% upon issue of the preferred shares and were
to be paid semiannually in subsequent years, in either cash or common shares, at
our election, until the preferred stock is converted to common shares. For the
first year' dividends totaling $1,125,559, paid in common stock, the investors
were issued 375,315 shares of common stock, of which 293,489 shares were issued
in November 2002 and 81,826 shares in January 2003.

In addition, certain of the investors were given options to purchase, for one
year and for amounts ranging from 100% to 200% of their investments, additional
shares of the Series B convertible preferred stock at the price paid for such
stock by investors on November 13, 2002.

H.C. Wainwright & Company, Inc. (Wainwright) acted as placement agent in this
private placement. For its services as placement agent, we paid Wainwright
$601,490. Legal and other professional fees totaled $155,997. All but $136,046
of the $755,487 aggregate costs was amortized to interest expense when the
$5,908,000 convertible debentures and $1,200,000 of Series A preferred stock
were converted to Series B preferred stock. In connection with the Series B
conversion, we granted Wainwright and its agents warrants to purchase 800,000
and 500,000 shares of common stock, at an exercise price of $.01 and $15.00,
respectively, exercisable immediately upon issue and August 13, 2003,
respectively. These warrants expired on January 31, 2003 and will expire seven
years from issue, respectively. In December 2002, we issued 35,273 shares of
common stock upon exercise of the $.01 warrants granted to Wainwright. The fair
market value assigned to the Wainwright warrants was $280,000 and $24,615, or
$304,615 in the aggregate, for the $.01 warrants and the $15.00 warrants,
respectively. Total share issuance costs were $866,612 inclusive of professional
fees, the $136,046 referred to above fees paid to Wainwright, and the fair value
of the aforementioned warrants. Issuance costs for the Series B preferred stock
are reflected as a reduction of the proceeds from the sale of the preferred
stock.

Second Sale of Series B Convertible Preferred Stock: In February 2003, we
received gross proceeds of $2,000,000 from the sale of our Series B convertible
preferred stock. We issued to such investors 200 shares of Series B convertible
preferred stock, 292,308 shares of common stock (including 92,308 shares of
common stock constituting the first year's dividends on such 200 shares of
Series B convertible preferred stock, which dividends were paid in advance, and
200,000 shares of common stock, which were issued upon exercise of Series A
warrants, exercised at $.10 per share) and warrants to purchase an additional
200,000 shares of common stock, of which warrants to purchase 100,000 (the B-1
warrants) shares were exercisable at $15.00 per share and warrants to purchase
the other 100,000 (the B-2 warrants) shares were exercisable at $20.00 per
share. In May and June 2003, in conjunction with the conversion of virtually all
of the Series B preferred stock and our reverse stock split, these B-1 and B-2
warrants were amended and restated to provide for exercise prices of $4.00 and
$5.00, respectively. PRF did not convert its 50 shares of Series B preferred
stock on May 23, 2003 and, accordingly, the exercise price of its B-1 and B-2
Warrants were not amended and remained at their original exercise price of
$15.00 and $20.00, respectively.

Wainwright acted as placement agent in this private placement and in addition to
cash compensation, we granted warrants to purchase an aggregate of 37,692 shares
of common stock, exercisable at $0.01 per share, to employees of the placement
agent firm. The fair value of these warrants was $86,692. Total share issuance
costs were $393,488 inclusive of professional and investment banking fees and
the fair value of the aforementioned warrants. Issuance costs for the Series B
preferred stock are reflected as a reduction of the proceeds from the sale of
the preferred stock. During 2004 certain of these warrants to purchase 32,460
shares of our common stock were exercised. We received $325.00.

Dividends were payable in cash or common shares at our option, at the rate of
12% per annum. An accrued dividend of $50,000 at December 31, 2004 was provided
for within stockholders' deficit, as it was our intention to issue common shares
in payment of the dividend. These dividends were paid upon the conversion of the
Series B preferred on January 5, 2005 as described in Note 10.

Sale of Series C Convertible Preferred Stock: In May and July 2003, we received
gross proceeds of $5,690,000 from the sale of 948 shares of Series C convertible
preferred stock, issuing warrants to purchase 1,707,000 shares of our common
stock exercisable at $3.60 per share. Our Series C preferred stock had a stated
value of $6,000 per share and was convertible into 2,844,999 shares of common
stock at $2.00 per share. In addition, in connection with the Series C
financing, investors, other than Paul Royalty Fund, agreed to convert their
Series B preferred shares into common shares or their equivalent. As a result,
605.389 shares of Series B preferred stock were converted into 2,421,556 shares
of common stock and 482.885 shares of Series B preferred stock were converted
into an equal number of shares of Series D preferred stock (with a common stock
equivalent of 1,931,540 shares). The Series D convertible preferred stock is
non-redeemable and has a stated value of $10,000 per share. As part of the May
2003 Series C financing, employees of the investment-banking firm which arranged
the Series C financing were granted warrants to purchase 149,520 shares of our
common stock at an exercise price of $.01 as part of their compensation.
Accordingly, we recorded $269,000 in Series C preferred share issuance costs
related to the warrants issued. Total share issuance costs were $797,327
inclusive of professional and investment banking fees and the fair value of the
aforementioned warrants. Issuance costs for the Series C preferred stock are
reflected as a reduction of the proceeds from the sale of the preferred stock.

Dividends were payable in cash or common shares at our option, at the rate of
10% per annum. An accrued dividend of $563,805 and $336,550 at December 31, 2004
and 2003, respectively, was provided for within stockholders' deficit. In
January 2005 we issued common shares in payment of these dividends.

Deemed Dividend: In conjunction with these conversions, all Series B-1 and B-2
warrants were amended to provide for revised exercise prices of $4.00 and $5.00,
respectively. Paul Royalty Fund did not exercise its right to convert its 50
shares of Series B preferred stock into common stock or its equivalent and as
such, its B-1 and B-2 warrants were not amended and remained at their original
exercise prices of $15.00 and $20.00, respectively. As a result of the change in
the B-1 and B-2 warrants at May 23, 2003, we recognized a deemed dividend to
investors of $519,000.

Based on the relative fair market value of the preferred stock at the dates of
issuance and the estimated fair market value of the warrants, using the
Black-Scholes option pricing model, at December 31, 2003, we assigned values to
the Series C preferred stock and the Series C warrants of $4,464,368 and
$1,225,632, respectively. Similarly, we assigned values to the Series D
preferred stock, based on values previously assigned to the Series B preferred
stock.

Additionally, since the effective conversion price of the Series C preferred
stock on the date of issuance was lower than the market value of the common
shares on that date, we recognized $691,000 of additional discounts on the
preferred issuances. This conversion feature was charged to retained earnings as
accretion of discount.

In August 2003, holders of 483 shares of Series B convertible preferred stock
converted their shares into an equal number of shares of Series D convertible
preferred stock.

In June and October 2004, a holder of 35.624 shares of Series C preferred stock
with a value of $137,752, converted its shares into 106,872 shares of common
stock. Additionally we issued 13,743 shares of our common stock valued at
$30,099 as payment of dividends on the converted Series C preferred stock.






12 - STOCK OPTIONS

In April 1996, the Board of Directors and stockholders approved the adoption of
a stock option plan (the "Plan"). The Plan provided for the grant of options to
purchase up to 35,000 shares of our common stock. These options may be granted
to employees, our officers, our non-employee directors, consultants, and
advisors. The Plan provides for granting of options to purchase our common stock
at not less than the fair value of such shares on the date of the grant. Some of
the options generally vest ratably over a four-year period, while others vest
immediately. The options generally expire after seven years.

In August 1998, the stockholders and Board of Directors ratified and approved an
amended and restated 1996 Stock Option Plan increasing the maximum number of
shares of our common stock for which stock options may be granted from 35,000 to
155,000 shares. In August 2000, the stockholders and Board of Directors ratified
and approved the second amendment to our Amended and Restated 1996 Stock Option
Plan increasing the number of shares of our common stock for which options have
been or could be granted under the Plan from 155,000 to 300,000 shares.

In February 2003, the stockholders and Board of Directors ratified and approved
an amended and restated Stock Option Plan, increasing the maximum number of
shares of our common stock for which stock options may be granted from 300,000
to 450,000 shares. As of December 31, 2005, 15,458 options were available for
grant under the Plan.

In July 2005, the Board of Directors and stockholders approved the adoption of
the 2005 Stock Option Plan (the "2005 Plan"). The 2005 Plan provides for the
grant of options to purchase up to 1,000,000 shares of our common stock. These
options may be granted to employees, our officers, our non-employee directors,
consultants, and advisors. The 2005 Plan provides for granting of options to
purchase our common stock at not less than the fair value of such shares on the
date of the grant. As of December 31, 2005, all of the 1,000,000 options were
available for grant under the 2005 Plan.





Our Board of Directors or its Stock Option Committee has determined the exercise
price for all stock options awarded. The following table summarizes the stock
option activity through December 31, 2005:

                                                                                                                                     Weighted
                                                                                                                                     average
                                                                                                                                       exercise
                                                                                               Number                                price ($)
                                                                                               ------------------------------        ------------------------
                                                                                               ------------------------------        ------------------------
Granted - adoption of stock option plan                                                                             15,600                                   70.80
                                                                                               ------------------------------
                                                                                               ------------------------------
Balance, December 31, 1996                                                                                          15,600                                   70.80
Granted                                                                                                             12,300                                  119.40
Forfeited, expired                                                                                                   (300)                                   66.30
                                                                                               ------------------------------
                                                                                               ------------------------------
Balance, December 31, 1997                                                                                          27,600                                   92.50
Granted                                                                                                             68,975                                  121.00
Exercised                                                                                                            (675)                                   74.20
Forfeited, expired                                                                                                 (1,450)                                  111.90
                                                                                               ------------------------------
                                                                                               ------------------------------
Balance, December 31, 1998                                                                                          94,450                                  111.70
Granted                                                                                                             39,900                                  108.70
Forfeited, expired                                                                                                (22,100)                                  149.30
                                                                                               ------------------------------
                                                                                               ------------------------------
Balance, December 31, 1999                                                                                         112,250                                  103.30
Granted                                                                                                             44,996                                   79.60
Exercised                                                                                                            (350)                                   70.00
Forfeited, expired                                                                                                 (4,485)                                   82.70
                                                                                               ------------------------------
                                                                                               ------------------------------
Balance, December 31, 2000                                                                                         152,411                                  123.00
Granted                                                                                                             75,650                                   59.30
Forfeited, expired                                                                                                (24,730)                                   74.10
                                                                                               ------------------------------
                                                                                               ------------------------------
Balance, December 31, 2001                                                                                         203,331                                   85.40
Granted                                                                                                            115,511                                   12.90
Forfeited, expired                                                                                                (31,630)                                   76.80
                                                                                               ------------------------------
                                                                                               ------------------------------
Balance, December 31, 2002                                                                                         287,212                                   57.30
Granted                                                                                                            160,861                                    2.20
Forfeited, expired                                                                                                (99,874)                                   84.02
                                                                                               ------------------------------
                                                                                               ------------------------------
Balance, December 31, 2003                                                                                         348,199                                   24.16
Granted                                                                                                            129,500                                    1.92
Forfeited, expired                                                                                                (49,375)                                   20.32
                                                                                               ------------------------------
                                                                                               ------------------------------
Balance, December 31, 2004                                                                                         428,324                                   15.40
Granted                                                                                                    36,000                                             0.33
Forfeited, expired                                                                                                (29,782)                                   15.34
                                                                                               ------------------------------
                                                                                               ------------------------------
Balance, December 31, 2005                                                                                         434,542                                   14.16
                                                                                               ==============================
                                                                                               ==============================


The following data has been provided for exercisable options:

                                                                                                                    Year ended December 31,
                                                                                                                    -------------------------------------------------------------------------------------------
                                                                                                                    ----------------------------  -----------------------------  ------------------------------
                                                                                                                    2005                          2004                           2003
                                                                                                                    ----                          ----                           ----
Number of options                                                                                                                       347,267                        258,574                         250,508
Weighted average exercise price                                                                                                          $16.92                         $23.04                         $ 29.98
Weighted remaining contractual life                                                                                                  3.59 years                     4.18 years                      4.79 years






The following table summarizes option data as of December 31, 2005:

                                                                                                  Weighted
                                                                                                   Average              Weighted                                                              Weighted
                                                                                                  Remaining             Average                                                                Average
Range of                                          Number                                         Contractual            Exercise                   Number                                     Exercise
exercise prices                                   outstanding                         Life (years)                      Price                      Exercisable                                  Price
---------------                                   -----------                         ------------                      -----                      -----------                            -----------
$0.26 to $0.99                                                               64,500                              4.40                     $ 0.63                         60,000                          $ 0.62
$1.80 to $8.75                                                              285,736                              4.18                     $ 2.81                        204,611                          $ 3.07
$29.10 to $80.00                                                             67,630                              2.45                    $ 53.88                         65,980                         $ 53.74
$90.00 to $127.50                                                            16,676                              1.81                    $ 99.84                         16,676                         $ 99.84
                                                                             ------                                                                                      ------
                                                                            434,542                              3.85                    $ 14.16                        347,267                         $ 16.92
                                                                            =======                                                                                     =======

We recognized approximately $1,696,000 of compensation expense for options and
warrants issued to officers and our directors in 1998. Such options and warrants
were accounted for as variable option grants. Such options and warrants had
vested prematurely in December 1998, upon the exercise of warrants owned by one
of our directors, in accordance with the terms of certain compensation
provisions provided for and approved by our Board of Directors.

During the years ended December 31, 2005, 2003 and 2002, we issued 6,359,238
(see Note 10), 894,400, and 380,000 options, respectively, to senior executives,
which were not included in the Plan. During the year ended December 31, 2004 we
issued 100,000 options to a director which was not included in the Plan. These
options vested immediately and expire seven years from date of grant. The
following table provides the exercise price for options issued to the director
and senior management.

                                                               Remaining
   Number                           Exercise                   Contractual
Outstanding                         Price                      Life (years)
-----------                         -----                      ------------
                6,359,238                             $ 0.25                            6.81
                  460,000                             $ 1.80                            4.15
                  140,000                             $ 2.00                            3.96
                   74,000                             $ 2.10                            4.42
                  380,000                             $ 3.50                            3.89
                  320,400                             $ 3.60                            4.18
----------------------------------
                7,733,638
==================================

In addition, we recognized $7,189 and $94,393 in consulting expense in 2005 and
2004, respectively, for warrants granted to independent consultants for services
rendered to us.

13 - RELATED PARTY TRANSACTIONS

Due to Founder

Pursuant to an amended agreement, we had engaged the services of Dr. Mark
Eisenberg, one of our directors, who is also one of our founders, as a
consultant through August 31, 2005. During 2003, we terminated our agreement
with Dr. Eisenberg and discontinued research activities in Australia. For the
period from inception to December 31, 2003 production and laboratory costs
include compensation due to Dr. Eisenberg of approximately $1,029,000. In
accordance with the settlement agreement, we recorded consulting expense of
$194,656 for the remainder of the $304,478 of consulting fees due under the
consulting agreement with Dr. Eisenberg. Additionally, we recorded $28,881 in
rent expense that we owed Dr. Eisenberg for the space we occupied in the
Australian laboratory. The total amount due Dr. Eisenberg under the settlement
agreement aggregated $398,574 which represents unpaid consulting fees, the rent
for the Australian laboratory, and $65,215 of advances made by Dr. Eisenberg on
our behalf. We settled the balance due Dr. Eisenberg in 2004 by issuing 100,000
options to purchase our common stock at an exercise price of $2.00 per share. We
recorded the $398,574 settlement in 2004 as a contribution of capital given that
the settlement was with our director. These options will expire in five years.






Research Collaboration

On October 11, 2004 we entered into a collaboration with Hapto Biotech, Inc.,
for the purpose of further developing promising product leads identified through
a research collaboration established in September 2002 between us and Hapto
Biotech, utilizing each company's proprietary technologies. The activities of
the two entities has been conducted in a new entity, Hapto / Ortec
Collaboration, LLC. The agreement provides for a license agreement to us if the
collaboration is successful in developing other technology (as defined) which
can be used to treat hard to heal chronic wounds (as defined). See "Letter of
Intent' in Note 14.

Change of Control Agreements

In December 1998, our Board of Directors authorized agreements between us and
two of our executive officers and another employee, which state that in the
event of a "change of control" certain "special compensation arrangements" will
occur. A "change of control" is defined as a change in the ownership or
effective control of Ortec or in the ownership of a substantial portion of our
assets, but in any event if certain members of our Board of Directors no longer
constitute a majority of the Board of Directors. In the event that such change
of control occurs, the agreements provide these individuals additional
compensation, interest-free loans to exercise their stock options and warrants,
and extensions of the expiration dates of all of their then outstanding options
and warrants so that none will expire in less than three years from such
termination of employment. In addition, for all of the individuals, in the event
of a change of control, all unvested options and warrants will vest immediately
upon such change of control.

14 - COMMITMENTS AND CONTINGENCIES

Cell Therapy Manufacturing Agreement

In October 29, 2003 we entered into an agreement commencing November 1, 2003
with Cambrex Bio Science Walkersville, Inc., a subsidiary of Cambrex Corporation
(Cambrex), for Cambrex to manufacture ORCEL in Cambrex's Walkerville, Maryland
facilities. The Cambrex manufacturing facility is required to meet FDA's good
manufacturing processes standards. Cambrex is experienced in the manufacture of
cell-based medical products such as our ORCEL.

Our agreement with Cambrex requires us to currently pay Cambrex $132,613 per
month, or $1,591,350 per year, for the use of a production suite in their
facility located in Walkersville, Maryland. The payments we will make to Cambrex
will increase to $175,000 monthly, or $2,100,000 per year, if we require Cambrex
to build us a larger production facility to meet our requirements for the
production of ORCEL. In 2005 and 2004 we incurred charges of $1,552,725 and
$1,332,500, respectively, for the use of Cambrex's production facility. These
amounts are included in product and laboratory costs. Such annual payments
include some services and overhead expenses provided and paid for by Cambrex.
These annual payments we are required to make increase 3% per annum on the
anniversary of the commencement date. We are required to pay 50% of the cost of
the construction of that larger production facility up to $1,000,000 (up to
$2,500,000 if we terminate our Sales Agency Agreement with Cambrex). However,
the amount we contribute to the construction of that larger facility will be
repaid to us by credits against a portion of the future annual payments of
$2,100,000 and of certain other payments we are required to make to Cambrex
after the larger facility is in use. We are also required to pay specified
hourly charges for the Cambrex employees engaged in the production of ORCEL as
well as certain other charges. After construction of the larger production
facility we are required to acquire from Cambrex virtually all of our
requirements for ORCEL that Cambrex can produce. Prior to our election to have
Cambrex construct the larger production facility for us, either we or Cambrex
may terminate the agreement on six months notice by us and twelve months notice
by Cambrex. If we elect to have Cambrex construct the larger production facility
for us the agreement will continue for six years after the larger production
facility is constructed. However, even after such construction we and Cambrex
may elect to scale down over the following three years the portion of our
requirements for ORCEL that Cambrex will produce for us. We may elect the scale
down period at any time after one year after the larger production facility is
constructed and in operation in which event there are additional payments we
must make to Cambrex. If we elect the scale down period after one year we must
pay Cambrex $2,625,000 and if we elect the scale down period after two years we
must pay Cambrex $1,050,000. If we elect the scale down periods in either of
those two years, we forfeit our right to receive any further credits (up to the
amount of our contribution to the cost of the larger production facility)
against payments we are thereafter required to make to Cambrex. Either Cambrex
or we may elect the scale down period later than three years after that facility
is in operation and neither of us will be required to make any additional
payments to the other because of that election. If after the construction of the
larger production facility we breach a material term of our agreement with
Cambrex, or elect to terminate the agreement, we will have to pay Cambrex the
following amounts:

If termination occurs after the following                                                             Amount
anniversary of the construction of the                                                                of
larger production facility                                                                            Payment
-----------------------------------------------------------------------------------------------       ------------------------------
-----------------------------------------------------------------------------------------------       ------------------------------
6 years                                                                                                                  $1,050,000
5 years, but less than 6 years                                                                                            1,575,000
4 years, but less than 5 years                                                                                            2,625,000
3 years, but less than 4 years                                                                                            3,675,000
2 years, but less than 3 years                                                                                            5,250,000
1 year, but less than 2 years                                                                                             6,300,000

In addition, upon such termination we will forfeit our right to receive any
further credits (up to the amount of our contribution to the cost of the larger
production facility) against future payments we may have to make to Cambrex.

Sales & Marketing Agreements

License Agreement: In October 2003, we entered into an exclusive License
Agreement with Teva Medical Limited, a subsidiary of Teva Pharmaceutical
Industries Ltd. (Teva) for the sales and marketing of our ORCEL product in
Israel. This ten-year agreement, beginning on the date the product is launched
for marketing in Israel, requires Teva to seek regulatory and reimbursement
approval for ORCEL in Israel. We received an upfront payment of $50,000 in 2003
which we recorded as deferred income, see Note 6. We will receive an additional
$50,000 within thirty days of grant of reimbursement approval in Israel, and
another $100,000 within 30 days of attainment of aggregate net sales of
$3,000,000 in Israel within any period of twelve consecutive calendar months.
The agreement also provides for ORCEL pricing and terms of payment. Additionally
Teva will pay us royalties of 10% of net sales in Israel up to $5,000,000 per
annum. If sales are in excess of $5,000,000 annually Teva will pay us 10% on the
first $5,000,000 of sales in Israel and a 20% royalty on sales above $5,000,000
in Israel. As of December 31, 2005, regulatory and reimbursement approval have
not been achieved.

Sales Agency Agreement: On October 18, 2004 we entered into a Sales Agency
Agreement with Cambrex, providing for Cambrex to be the exclusive sales agent in
the United States for our ORCEL product or any other future bi-layered cellular
matrix product of ours for the treatment of venous stasis ulcers, diabetic foot
ulcers or any other therapeutic indication for dermatological chronic or acute
wound healing. The agreement is for a period of six years beginning sixty days
after we receive clearance from the FDA for the commercial sale of our ORCEL for
the treatment of venous stasis ulcers. The agreement requires us to pay
commissions to Cambrex ranging from initially at 40% of net sales and decreasing
to 27% of net sales as the amount of sales increases. The agreement requires
Cambrex to spend $4,000,000 for marketing efforts during the sixteen-month
period after the FDA clears our sale of ORCEL for the treatment of venous stasis
ulcers.

Cambrex had the right to terminate the agreement if we did not receive FDA
clearance for commercial sale of ORCEL for the treatment of venous stasis ulcers
by April 1, 2005, and has the right to terminate if for any period of six
consecutive months beginning in 2007, sales are less than 9,000 units. We may
terminate the agreement if sales of ORCEL are less in any twelve month period
than amounts targeted in the agreement for that period (ranging from 10,000
units in the first twelve month period to 100,000 units in the sixth twelve
month period).

Concurrent with the Sales Agency Agreement we entered into a License Agreement
pursuant to which we licensed certain intellectual property rights to Cambrex.
We also entered into a Security Agreement with Cambrex to secure the performance
of our obligations under the Manufacturing, License, and Sales Agreement. The
secured collateral consists of all accounts, cash, contract rights, payment
intangibles, and general intangibles arising out of or in connection with the
sale of products pursuant to the sales agreement and/or license agreement, and
all supporting obligations, guarantees and other security therefore, whether
secured or unsecured, whether now existing or hereafter created. The lien and
security interest under this security agreement is subordinate and junior in
priority to the perfected lien and security interest granted to Paul Royalty
Fund as secured party under the Paul Royalty Security Agreement.

In connection with the Sales Agency Agreement, our manufacturing agreement with
Cambrex was modified so that if Cambrex builds us a larger production facility
the maximum amount we could be required to contribute to that construction was
reduced from $2,500,000 to $1,000,000.





Supply Agreements

Cell supply agreement: In April 2004, we entered into a Material Supply
Agreement with ES Cell International Pte Ltd.(ESI). Under the terms of the
agreement, we provided ESI with human skin cells generated from cell lines
developed and manufactured by us for use in our ORCEL product. We received a
$50,000 up-front fee upon the signing of the agreement and we received an
additional $150,000 upon first delivery of certain specified cell lines. We have
recorded these amounts in interest and other income in 2004. We will receive
milestone payments of $150,000 within 30 days of an investigational new drug
filing for the ESI Focus Cell Therapy line and an additional $150,000 upon ESI's
receiving regulatory approval for marketing of the ESI Focus Cell Therapy
product. We will additionally receive royalties equivalent to .5% of product
sales revenue or license or distribution fees or other payments. The payment of
these additional amounts are wholly dependent on ESI achieving their milestones.
No additional payments were received in 2005.

Sponge supplier: We purchase bovine collagen sponges, a key component of ORCEL,
from one supplier who produces the sponges to our specifications. On December
30, 2004 we entered into a two-year supply agreement with this supplier. Under
such agreement we agreed to minimum purchase commitments. We agreed to purchase
a minimum of 3,500 units of finished collagen sponges within the first
twelve-month period. The value of such commitment is approximately $200,000.
Such commitment was not achieved in 2005 and we were released from any resulting
liability by the supplier. We also agreed that subsequent to a written
notification from the FDA allowing us to sell ORCEL commercially for treatment
of venous stasis ulcers we will provide such supplier projections for one or
more subsequent quarters and the parties will be obligated to purchase and sell
those projected amounts.

Government Regulation

We are subject to extensive government regulation. Products for human treatment
are subject to rigorous preclinical and clinical testing procedures as a
condition for clearance by the FDA and approval by similar authorities in
foreign countries prior to commercial sale. Presently, we are continuing our
clinical trials for the use of our product in the treatment of patients with
venous stasis ulcers and to submit the results of our human clinical trials to
the FDA; however, it is not possible for us to determine whether the results
achieved from the human clinical trials will be sufficient to obtain FDA
approval. If we are unable to obtain FDA approval, we may no longer be able to
continue our operations. It is not possible for us to determine whether the
results achieved from that human clinical trial will be sufficient to obtain FDA
clearance.

Letter of Intent

In December 2005 we executed a non-binding letter of intent to acquire Hapto
Biotech (Hapto), a privately-held company focused on the development of two
proprietary fibrin derived platform technologies: Fibrin Micro Beads (FMB's) and
Fibrin based peptides, (Haptides(TM)). Hapto's research indicates that FMB's
have the ability to optimize the recovery, potential delivery and therapeutic
value of adult stem cells. In October 2004, Ortec and Hapto initiated their
relationship by forming a joint venture to combine our proprietary collagen
biomaterial technology and Hapto's Haptide(TM) peptide technology to develop non
cellular, biologically active enhanced biomaterials to promote the attraction
and attachment of cells for application to the wound healing, reconstructive,
cosmetic, tissue regeneration and dental markets. We closed our acquisition of
Hapto on April 14, 2006. For such acquisition we issued a total of 30,860,000
shares of our common stock to the Hapto shareholders and granted them warrants
to purchase an additional 3,000,000 of our common shares at $0.30 per share. The
investment banking firm of Rodman & Renshaw, LLC acted as our advisor in this
acquisition.






15 - INCOME TAXES

We have deferred start-up costs for income tax purposes and intend to elect to
amortize such costs over a period of 60 months, under Section 195(b) of the
Internal Revenue Code, when we commence operations.

At December 31, 2005, we had net operating loss carry-forwards of approximately
$30,781,000 for Federal and New York State income tax purposes expiring through
2025. Due to the merger of Skin Group with and into Ortec in July 1992, the net
operating losses and other built-in deductions existing at that time were
subject to annual limitations pursuant to Internal Revenue Code Section 382. Our
ability to utilize net operating losses and other built-in deductions generated
after that date may be limited in the future due to additional issuances of our
common stock or other changes in control, as defined in the Internal Revenue
Code and related regulations.

For financial statement purposes, a valuation allowance of approximately
$56,795,000 at December 31, 2005 has been recognized to offset entirely our
deferred tax assets, which arose primarily from our operating loss
carry-forwards and the deferral of start-up expenses for tax purposes, as the
realization of such deferred tax assets is uncertain. Components of our deferred
tax asset are as follows:

Net operating loss carry-forwards                                                                     $                               12,928,000
Deferral of start-up costs                                                                                                            29,387,000
Interest                                                                                                                               8,381,000
Loss on settlement of promissory notes                                                                                                 5,494,000
Other                                                                                                                                    605,000
                                                                                                              ----------------------------------
                                                                                                              ----------------------------------
                                                                                                                                      56,795,000
Valuation allowance                                                                                                                 (56,795,000)
                                                                                                              ----------------------------------
Net deferred tax asset                                                                                $                 -
                                                                                                              ==================================
                                                                                                              ==================================

The following reconciles the income taxes computed at the federal statutory rate
to the amounts recorded in our statement of operations:

                                                                                                                                                                                                 Cumulative from
                                                                                                                                                                                                 March 12, 1991

(inception) to
                                                                                                                      Year ended December 31,                                                    December 31,
                                                                                                              --------------------------------------------------------------------------
                                                                                                                     2005                                    2004                                        2005
                                                                                                              --------------------------------        ----------------------------------         ------------------------------------
                                                                                                              --------------------------------        ----------------------------------         ------------------------------------
Income tax benefit at the
 Statutory rate                                                                                                              $   (10,327,000)                       $       (5,233,000)      $                          (48,400,000)
State and local income taxes,                                                                                                     (2,429,000)
 net of Federal benefit                                                                                                                                                     (1,231,000)                                  (9,563,000)
Permanent difference                                                                                                                    8,000                                     5,000                                    1,168,000
Effect of valuation allowance                                                                                                      12,748,000                                 6,459,000                                   56,795,000
                                                                                                              --------------------------------        ----------------------------------         ------------------------------------
                                                                                                              --------------------------------        ----------------------------------         ------------------------------------
                                                                                                     $                                       -                      $                  -      $                                     -
                                                                                                              ================================        ==================================         ====================================
                                                                                                              ================================        ==================================         ====================================









Our net operating loss tax carry-forwards expire as follows:

Year ending December 31,
2006                                                                 $                          76,000
2007                                                                                           233,000
2008                                                                                           511,000
2009                                                                                           597,000
2010                                                                                           440,000
2011                                                                                           677,000
2012                                                                                           839,000
2018                                                                                         1,189,000
2019                                                                                         2,602,000
2020                                                                                         3,535,000
2021                                                                                         4,014,000
2022                                                                                         3,311,000
2023                                                                                         3,054,000
2024                                                                                         5,448,000
2025                                                                                         4,255,000
                                                                             ---------------------------
                                                                             ---------------------------
                                                                     $                      30,781,000
                                                                             ===========================

16 - FAIR VALUE OF FINANCIAL INSTRUMENTS

Statement of Financial Accounting Standards No. 107, "Fair Value of Financial
Instruments," requires disclosure of the estimated fair value of an entity's
financial instrument assets and liabilities. For us, financial instruments
consist principally of cash and cash equivalents, loans payable and other
long-term obligations.

The following methods and assumptions were used to estimate the fair value of
each class of financial instrument for which it is practicable to estimate that
value.

Cash and Cash Equivalents

The carrying value reasonably approximates fair value because of the short-term
maturity of those instruments.

Loans Payable and Other Long-term Obligations

Based on borrowing rates currently available to us for other financings with
similar terms and maturities, the carrying value of our loans payable, capital
lease obligations and other long-term obligations approximate the fair value.

17 - RETIREMENT PLAN

The Company maintains a defined contribution 401(k) savings plan (401(k) plan)
for the benefit of eligible employees. Under the 401(k) plan, a participant may
elect to defer a portion of annual compensation. Contributions to the 401(k)
plan are immediately vested in plan participants' accounts. Plan expenses were
$4,485 and $3,255 for the years ended December 31, 2005 and 2004, respectively.
We do not match employee contributions.

18 - SUBSEQUENT EVENTS

Legal Challenge Withdrawn: In January 2006 we were informed that Advanced Tissue
Sciences withdrew its appeal against the grant of our European patent of ORCEL.
We were originally granted its European patent in December 1997 and received
notification in November 1998 that it was being challenged by Advanced Tissue
Sciences. In March 2002, we announced that we had successfully defended Advanced
Tissue Sciences' opposition filed with the European Patent office and,
subsequently, Advanced Tissue Sciences appealed the patent offices' decision,
but is now withdrawing that appeal. Withdrawal of the appeal by Advanced Tissue
Sciences concludes this litigation and our European patent remains as originally
issued.

Modification of Registration Rights Agreement. In October 2005 we closed a
private placement in which we sold our common stock and Series F warrants to a
group of accredited investors. In connection with such sales we entered into an
agreement with such investors whereby we undertook to register all of the shares
of our common stock they purchased, and the shares of our common stock issuable
upon exercise of our Series F warrants they acquired, in that private placement.
We agreed that if we did not file that registration statement by January 6,
2006, or have that registration statement declared effective by March 14, 2006,
we would pay liquidated damages to the purchasers. Our agreement with those
purchasers provided that the holders of a majority of the shares of our common
stock we were required to register pursuant to that agreement (the "majority
holders") could modify and/or waive our obligations under that agreement and
such modification and/or waiver would be binding on all the purchasers in that
private placement. On January 30, 2006 the majority holders (i) waived our
obligation to pay any liquidated damages for our failure to file the
registration statement by January 6, 2006; (ii) extended to June 7, 2006 the
time by which the registration statement had to be declared effective before we
had to pay any liquidated damages and (iii) permitted us to include in such
registration statement shares of our common stock we may issue, or that will be
issuable, in (x) a transaction in which we acquire by merger another
biotechnology company and/or (y) a new private placement of our securities in
which we raise up to $10,000,000. Such modification and waiver will enable us to
pursue such acquisition and private placement without incurring those liquidated
damages expenses.

Availability of Authorized Shares. On January 30 and 31, 2006, North Sound
Capital, LLC (North Sound) and SDS Capital Group SPC, Ltd. (SDS) entered into
agreements with us whereby they agreed not to convert any of the aggregate of
6,272.0156 shares of our Series D Convertible Preferred Stock owned by them, nor
exercise any of our Series F warrants held by them, until such time that we are
able to obtain approval from our stockholders to amend our certificate of
incorporation to increase the number of shares of our common stock we are
authorized to issue, or take such other corporate action, which will enable us
to have sufficient number of shares of our common stock which we are authorized
to issue, to issue in a private placement of our securities and in the
acquisition of a biotechnology company, which proposed transactions are both
referred to above. These agreements will provide us with the ability to use the
approximately 33,000,000 shares which North Sound and SDS have agreed not to
acquire, together with our available authorized shares, in such proposed private
placement and acquisition transactions. These agreements will be voided if we
are unable to complete the proposed private placement of our securities before
April 30, 2006. We have agreed that after the completion of the proposed private
placement and/or acquisition we will proceed promptly to file a proxy statement
for a meeting of our stockholders at which we expect to increase the number of
shares of our common stock we are authorized to issue, or take such other
corporate action, to have available for issuance enough shares of our common
stock upon conversion of North Sound's and SDS's Series D Convertible Preferred
Stock and upon exercise of their warrants.

Reduction of Liquidation Preference. All of the 6,272.0156 shares of our
outstanding Series D Convertible Preferred Stock are owned by North Sound and
SDS. On January 30 and 31, 2006 North Sound and SDS entered into agreements with
us agreeing to exchange all of their shares of our Series D Convertible
Preferred Stock into an equal number of shares of our new Series D-1 Convertible
Preferred Stock. The only difference between our Series D Preferred shares and
our Series D-1 Preferred shares is that the liquidation preference of the Series
D Preferred shares is $10,000 per share and that of the Series D-1 Preferred
shares is $10 per share. Each Series D-1 Preferred share will be convertible (as
is each Series D Preferred share) into 4,000 shares of our common stock.

Other than North Sound and SDS, and other of our shareholders and warrant
holders who signed the modification and waiver agreements referred to above,
being owners of our common stock, of our Series D Convertible Preferred Stock
and of our warrants to purchase shares of our common stock, we have no material
relationship with any such person.

Cambrex Suite Deal II: On February 13, 2006 we entered into an agreement with
our manufacturing and marketing partner, Cambrex, whereby for the six-month
period January 1 to June 30, 2006 the $132,612 monthly charges we incur for
rental of a production suite used to produce ORCEL at their Maryland facility,
Cambrex has agreed to accept 736,733 shares of our common stock monthly in lieu
of a cash payment. During the term of the agreement we will issue an aggregate
4,420,398 common shares for the aggregate amount of $795,672. We will also issue
a three-year warrant commencing July 1, 2006 to purchase 1,105,100 shares of our
common stock at $0.75 per share. Each of these securities will carry certain
registration rights.

Third Amendment of Lease: On March 16, 2006 we agreed to a two-year lease
extension at our 14,320 square foot New York City lab and office facility
location commencing January 1, 2006. We agreed to a monthly rental of $60,860 or
$730,320 per annum. We will have the option to renew for an additional two years
at the rate of $63,843 per month, or $766,120 annually

Vendor Settlement: On March 17, 2006, we settled a vendor liability of
approximately $102,000 for $35,000 cash payable in seven equal monthly
installments and a three-year warrant to purchase 285,000 shares of our common
stock at an exercise price of $0.25. The warrant has piggyback registration
rights.

Bridge Financing: In March 2006, we received $380,000 in short-term loans from
two entities. One loan for $130,000 was from one of our executive officers, is
non-interest bearing and is payable from the proceeds of the recent private
placement of our securities. The second loan for $250,000 bears interest at 8%
per annum and was from the investor who had a committed to provide us with
$1,058,000 by the later of the filing of our pre-market approval application for
our confirmatory venous leg ulcer trial, or March 31, 2006. This $250,000 loan
automatically converted into the equity securities we issued in our recent
private placement at 1.2 times the principle and accrued interest amount.
Additionally we agreed that since the investor provided us with the funds
earlier than was required, upon conversion of such $250,000 loan to our equity
securities, we would forego such investor's $808,000 remaining commitment and
that the earlier repricing (upon commitment) of our warrants held by such
investor would not be affected.

On March 31, 2006, we received $65,000 in a short-term loan from our executive
officers, of which $35,000 was repaid on April 6, 2006. On April 3, 2006 we
received another short-term loan of $45,000 from another of our executive
officers. Both of these loans will be repaid from the proceeds of our recent
private placement. On April 17, 2006, with the completion of our recent private
placement, we converted the $250,000 short-term loan with its then outstanding
loan balance of $301,333 into 301.33 shares of Series E Preferred Stock, and
issued a warrant to purchase 1,506,665 shares of our common stock at an exercise
price of $0.50 per share. On April 5, 2006 we received a $200,000 a short-term
loan due April 30, 2006 to be repaid at 110% of principal plus accrued interest
at 8% per annum on the original $200,000 principal balance. We issued a
three-year warrant to purchase 50,000 shares of our common stock at an exercise
price of $0.50 per share to the lender.

Private Placement: On April 17, 2006, we completed a private placement sale for
aggregate gross proceeds of $6,176,000 to accredited investors of our 6% Series
E Convertible Preferred Stock and warrants to purchase our common stock. The
Series E Convertible Preferred Stock is entitled to vote on an "as converted"
basis on all matters submitted to a vote by the holders of the common stock. At
any time these investors can convert their preferred stock into common stock at
a $0.20 conversion price. If we complete a reverse split of our outstanding
common stock by June 16, 2006, the investors are obligated to convert their
preferred stock on the 21st trading day following such reverse split by dividing
the amount they paid for such preferred shares plus dividends at 6% per annum,
by the lesser of $0.20, or 90% of the average of the volume weighted average
prices for our common stock for the twenty trading days following the effective
date of such reverse stock split. We issued five-year warrants to purchase our
common stock at $0.50 per share, for the number of common shares equal to the
purchase price paid for our convertible preferred shares divided by $0.20, or
warrants to purchase an aggregate of 30,880,000 of our common shares. The
warrants carry full ratchet price reset provisions should we sell our common
stock or our other securities convertible into, or exercisable for, our common
stock, at an effective price per common share less than the $0.50 exercise price
of the warrants. We are obligated to register, under the Securities Act of 1933,
all of the shares of our common stock issuable upon conversion of the 6% Series
E Convertible Preferred Stock, or upon exercise of such warrants. We will pay
investors 2% per month for any failure to timely file by June 18, 2006 or obtain
an effective registration statement by August 17, 2006.










                                      II-1
                PART II - INFORMATION NOT REQUIRED IN PROSPECTUS

ITEM 24.  INDEMNIFICATION OF DIRECTORS AND OFFICERS

The Registrant's Certificate of Incorporation provides that the personal
liability of the directors of the Registrant shall be limited to the fullest
extent permitted by the provisions of Section 102(b)(7) of the General
Corporation Law of the State of Delaware (DGCL). Section 102(b)(7) of the DGCL
generally provides that no director shall be liable personally to the Registrant
or its stockholders for monetary damages for breach of fiduciary duty as a
director, provided that the Certificate of Incorporation does not eliminate the
liability of a director for (1) any breach of the director's duty of loyalty to
the Registrant or its stockholders; (2) acts or omissions not in good faith or
that involve intentional misconduct or a knowing violation of law; (3) acts or
omissions in respect of certain unlawful dividend payments or stock redemptions
or repurchases; or (4) any transaction from which such director derives an
improper personal benefit. The effect of this provision is to eliminate the
rights of the Registrant and its stockholders to recover monetary damages
against a director for breach of her or his fiduciary duty of care as a director
(including breaches resulting from negligent or grossly negligent behavior)
except in the situations described in clauses (1) through (4) above. The
limitations summarized above, however, do not affect the ability of the
Registrant or its stockholders to seek nonmonetary remedies, such as an
injunction or rescission, against a director for breach of her or his fiduciary
duty.

In addition, the Certificate of Incorporation provides that the Registrant
shall, to the fullest extent permitted by Section 145 of the DGCL, indemnify all
persons whom it may indemnify pursuant to Section 145 of the DGCL. In general,
Section 145 of the DGCL permits the Registrant to indemnify a director, officer,
employee or agent of the Registrant or, when so serving at the Registrant's
request, another company who was or is a party or is threatened to be made a
party to any proceedings because of his or her position, if he or she acted in
good faith and in a manner reasonably believed to be in or not opposed to the
best interests of the Registrant and, with respect to any criminal action or
proceeding, has no reasonable cause to believe his or her conduct was unlawful.

The Registrant maintains a directors' and officers' liability insurance policy
covering certain liabilities that may be incurred by any director or officer in
connection with the performance of his or her duties and certain liabilities
that may be incurred by the Registrant, including the indemnification payable to
any director or officer. The entire premium for such insurance is paid by the
Registrant.

Insofar as indemnification for liabilities arising under the Securities Act of
1933, as amended (the "Securities Act"), may be permitted to directors,
officers, or persons controlling the Company pursuant to the foregoing
provisions, the Company has been informed that in the opinion of the Securities
and Exchange Commission, such indemnification is against public policy as
expressed in the Securities Act and is therefore unenforceable.

ITEM 25.  OTHER EXPENSES OF ISSUANCE AND DISTRIBUTION

It is expected that the following expenses will be incurred in connection with
the issuance and distribution of the Common Stock being registered. All such
expenses are being paid by the Issuer:

                  SEC Registration fee                                                                                                                                                                                         $  5,000
                  *Printing and Edgarization                                                                                                                                                                                      2,500
                  *Accountants' fees and expenses                                                                                                                                                                                12,500
                  *Attorneys' fees and expenses                                                                                                                                                                                  10,500
                  *Miscellaneous                                                                                                                                                                                         1,500
                                                                                                                                                                                                                     ---------
                  *Total                                                                                                                                                                                                        $32,000
                                                                                                                                                                                                                                =======
---------
*Estimated







ITEM 26.  RECENT SALES OF UNREGISTERED SECURITIES


                                                                                                                                                                   Total Cash or
                                                                                                                                                                 Other Consideration                              Fees paid to Placement
                    Date                                                  Name of Our Securities We Sold                                                          Paid by Investors                                                          Agents
----------------------------------------------  ------------------------------------------------------------------------------------  --------------------------------------------------------------------------  -------------------------------------------------------------
----------------------------------------------  ------------------------------------------------------------------------------------  --------------------------------------------------------------------------  -------------------------------------------------------------
July 20, 2003                                   58.33  shares  of  our  Series C  convertible  preferred  stock,  all  subsequently   $350,000                                                                    $35,000 and  warrants to purchase  149,520  shares
                                                exchanged  for  shares of our common  stock,  and  Series C  warrants  to  purchase                                                                               at $0.01 per share.
                                                105,000 shares of our common stock,  most of which were later exercised to purchase
                                                common stock or surrendered. (1)

----------------------------------------------  ------------------------------------------------------------------------------------  --------------------------------------------------------------------------  -------------------------------------------------------------
----------------------------------------------  ------------------------------------------------------------------------------------  --------------------------------------------------------------------------  -------------------------------------------------------------
August 2003                                     482.885 shares of our Series D convertible preferred stock. (3)                       None,  issued in exchange for 482.885 shares of our Series B  convertible   None.
                                                                                                                                      preferred stock.

----------------------------------------------  ------------------------------------------------------------------------------------  --------------------------------------------------------------------------  -------------------------------------------------------------
----------------------------------------------  ------------------------------------------------------------------------------------  --------------------------------------------------------------------------  -------------------------------------------------------------
2003 and 2004                                   Promissory  notes - $9,626,626  later  exchanged  for shares of common stock in the   $9,776,626                                                                  488,831 shares of our common stock.
                                                January 5, 2005 private placement described below. (1)

----------------------------------------------  ------------------------------------------------------------------------------------  --------------------------------------------------------------------------  -------------------------------------------------------------
----------------------------------------------  ------------------------------------------------------------------------------------  --------------------------------------------------------------------------  -------------------------------------------------------------
February 27, 2004                               Two year  warrants  to  purchase  14,052  shares of our  common  stock at $3.25 per   As part of the consideration for an equipment lease                         None.
                                                share. (1) (2)

----------------------------------------------  ------------------------------------------------------------------------------------  --------------------------------------------------------------------------  -------------------------------------------------------------
----------------------------------------------  ------------------------------------------------------------------------------------  --------------------------------------------------------------------------  -------------------------------------------------------------
October 27, 2004                                277,020  shares of our common stock and 34.31  shares of our  Series D  convertible   Extending due dates of $9,206,000 of such promissory notes.                 None.
                                                preferred stock. (1)

----------------------------------------------  ------------------------------------------------------------------------------------  --------------------------------------------------------------------------  -------------------------------------------------------------
----------------------------------------------  ------------------------------------------------------------------------------------  --------------------------------------------------------------------------  -------------------------------------------------------------
December 3, 2004                                496,481  shares of our common  stock,  233.8274  shares of our Series D convertible   $1,338,019 and forgiveness of a $100,000 promissory note obligation.        None.
                                                preferred  stock,  and our  Series E  warrants  to purchase  429,689  shares of our
                                                common stock at $1.80 per share. (1)

----------------------------------------------  ------------------------------------------------------------------------------------  --------------------------------------------------------------------------  -------------------------------------------------------------
----------------------------------------------  ------------------------------------------------------------------------------------  --------------------------------------------------------------------------  -------------------------------------------------------------
January 5, 2005 through February 20, 2005       17,994,030 shares of our common stock,  2,806.37 shares of our Series D convertible   $5,631,021,  exchange  of  913.2  shares  of  our  Series C  convertible    $563,102  plus  our  Series  E  P/A  warrants  to  purchase
                                                preferred  stock and our  Series E  warrants to purchase  22,026,621  shares of our   preferred stock and exchange of $9,626,626 of promissory notes.             2,746,376 shares of our common stock.
                                                common stock. (1)

----------------------------------------------  ------------------------------------------------------------------------------------  --------------------------------------------------------------------------  -------------------------------------------------------------
----------------------------------------------  ------------------------------------------------------------------------------------  --------------------------------------------------------------------------  -------------------------------------------------------------
May 27, 2005 through September 29, 2005         Promissory  notes and we reduced  exercise  prices of our  Series E  warrants  from   $3,486,000                                                                  $174,300
                                                $1.80 to $1.50,  and  reduced  exercise  prices of  lenders'  Series E  warrants to
                                                purchase  11,983,445  shares of our  common  stock  from $1.80 and $1.50 to $0.001,
                                                which the lenders exercised to purchase 3,817,157 shares of our common stock. (1)

----------------------------------------------  ------------------------------------------------------------------------------------  --------------------------------------------------------------------------  -------------------------------------------------------------
----------------------------------------------  ------------------------------------------------------------------------------------  --------------------------------------------------------------------------  -------------------------------------------------------------
July 12, 2005                                   1,030,000   shares  of  our  common  stock  and  3 year  warrants  to  purchase  an   Forgiveness  of  payment  of  $772,500  of  our   obligations   under  a    None.
                                                additional 1,545,000 shares of our common stock @ $1.80 per share. (1) (2)            manufacturing agreement.

----------------------------------------------  ------------------------------------------------------------------------------------  --------------------------------------------------------------------------  -------------------------------------------------------------
----------------------------------------------  ------------------------------------------------------------------------------------  --------------------------------------------------------------------------  -------------------------------------------------------------
                                                                                                                                                                   Total Cash or
                                                                                                                                                                 Other Consideration                              Fees paid to Placement
                    Date                                                  Name of Our Securities We Sold                                                          Paid by Investors                                                          Agents
----------------------------------------------  ------------------------------------------------------------------------------------  --------------------------------------------------------------------------  -------------------------------------------------------------
----------------------------------------------  ------------------------------------------------------------------------------------  --------------------------------------------------------------------------  -------------------------------------------------------------
July 18, 2005                                   Three year  warrants to  purchase  25,000  shares of our common  stock at $0.50 per   Financial advisory services.                                                None.
                                                share. (2)

----------------------------------------------  ------------------------------------------------------------------------------------  --------------------------------------------------------------------------  -------------------------------------------------------------
----------------------------------------------  ------------------------------------------------------------------------------------  --------------------------------------------------------------------------  -------------------------------------------------------------
October 2005                                    14,590,764  shares of our common  stock and our  Series F  warrants  to purchase an   $3,647,691                                                                  $539,069  (includes  5% on amount we received in May through
                                                aggregate  of  7,295,382  shares of our common  stock.  The  exercise  price of our                                                                               September 2005 for our promissory notes).
                                                Series E  warrants to purchase an aggregate of 5,881,079 held by purchasers in this
                                                private placement were reduced to $0.001 per share. (1)

----------------------------------------------  ------------------------------------------------------------------------------------  --------------------------------------------------------------------------  -------------------------------------------------------------
----------------------------------------------  ------------------------------------------------------------------------------------  --------------------------------------------------------------------------  -------------------------------------------------------------
October 2005                                    1,697,200 shares of our common stock and our Series F  warrants to purchase 848,600   In  satisfaction of $424,000 we owed to our placement  agent,  including    None.
                                                shares of our common stock.  We also reduced the exercise price of our  Series E-PA   $174,300 of the $539,069 amount referred to immediately above.
                                                warrants to purchase  2,746,376  shares of our common stock from $0.95 per share to
                                                $0.30 per share. (1) (2)

----------------------------------------------  ------------------------------------------------------------------------------------  --------------------------------------------------------------------------  -------------------------------------------------------------
----------------------------------------------  ------------------------------------------------------------------------------------  --------------------------------------------------------------------------  -------------------------------------------------------------
February 13 through June 2006                   4,420,000 shares of our common stock and three year warrants to purchase  1,105,100   Forgiveness  of  payment  of  $795,672  of  our   obligations   under  a    None.
                                                shares of our common stock at $0.75 per share. (1)                                    manufacturing agreement.

----------------------------------------------  ------------------------------------------------------------------------------------  --------------------------------------------------------------------------  -------------------------------------------------------------
----------------------------------------------  ------------------------------------------------------------------------------------  --------------------------------------------------------------------------  -------------------------------------------------------------
March 17, 2000                                  3 year  warrants  to  purchase  285,000  shares of our common  stock at an exercise   In satisfaction of a vendor's claim.                                        None.
                                                price of $0.25 per share. (2)

----------------------------------------------  ------------------------------------------------------------------------------------  --------------------------------------------------------------------------  -------------------------------------------------------------
----------------------------------------------  ------------------------------------------------------------------------------------  --------------------------------------------------------------------------  -------------------------------------------------------------
April 5, 2006                                   3 year warrants to purchase  50,000 shares of our common stock at an exercise price   Consideration for a $200,000 bridge loan.                                   None.
                                                of $0.50 per share. (1) (2).

----------------------------------------------  ------------------------------------------------------------------------------------  --------------------------------------------------------------------------  -------------------------------------------------------------
----------------------------------------------  ------------------------------------------------------------------------------------  --------------------------------------------------------------------------  -------------------------------------------------------------
April 2006                                      30,860,000  shares  of our  common  stock  and  three  year  warrants  to  purchase   Acquisition of Hapto Biotech, Inc.                                          Not applicable.
                                                3,000,000 shares of our common stock at $0.30 per share. (2)

----------------------------------------------  ------------------------------------------------------------------------------------  --------------------------------------------------------------------------  -------------------------------------------------------------
----------------------------------------------  ------------------------------------------------------------------------------------  --------------------------------------------------------------------------  -------------------------------------------------------------
April 1, 2006                                   Three year warrants to purchase  4,000,000  shares of our common stock at $0.30 per   Advisory services in the acquisition of Hapto Biotech, Inc.                 None.
                                                share. (2)
----------------------------------------------  ------------------------------------------------------------------------------------  --------------------------------------------------------------------------  -------------------------------------------------------------
----------------------------------------------  ------------------------------------------------------------------------------------  --------------------------------------------------------------------------  -------------------------------------------------------------
April 2006                                      6,477,333  shares of our  Series E  convertible  preferred  stock and our  Series H   $6,426,000  (including $250,000 received earlier in the year as a bridge    $608,200  and 5  year  warrants to purchase an  aggregate of
                                                warrants to purchase 32,386,665 shares of our common stock. (1)                       loan).                                                                      3,038,000  shares of our common  stock,  of which  2,888,000
                                                                                                                                                                                                                  may be  purchased at $0.40 per share and 150,000 @ $0.50 per
                                                                                                                                                                                                                  share
----------------------------------------------  ------------------------------------------------------------------------------------  --------------------------------------------------------------------------  -------------------------------------------------------------

                  (1)(2)(3)         The above sales were all exempt from the registration requirements of the Securities Act of 1933, as amended (the "Act"), for the following reasons:

(1)               Pursuant to Regulation D because all the purchasers were accredited investors.
(2)               Pursuant to Section 4(2) of the Act as transactions by an issuer not involving any public offering.
(3)               Pursuant to Section  3(a)(9) of the Act as a security  exchanged by the issuer with its existing  security  holders  exclusively  where no commission or other  remuneration is paid or given directly or indirectly for
                                             soliciting such exchange.

During the past 3 years we issued an aggregate of 1,635,000 shares of our common
stock to our four executive officers and 10,000 shares to one other employee.
These were restricted stock grants which these executive officers and employees
will lose if such person is no longer employed by us on January 1, 2007. During
the past 3 years we also granted options to our employees to purchase an
aggregate of 7,217,938 shares of our common stock, both pursuant to and outside
of our stock option plans. Of those options to purchase an aggregate of
6,966,438 shares were granted to our executive officers and 60,000 were granted
to our directors. Such restricted stock grants and the issuance of such options
were all exempt from the registration requirements of the Act because no sales
of securities were involved and also pursuant to Section 4(2) as transactions by
an issuer not involving any public offering.





ITEM 27.  EXHIBITS


                 Exhibit Number                    Description

4.1  Restated Certificate of Incorporation (Incorporated by reference to Exhibit
     3.2 of our quarterly report on Form 10-Q for the period ended September 30,
     2001, filed with the Commission on November 14, 2001, Commission File No.
     0-27368)

4.2  Amendment to Restated Certification of Incorporation (Incorporated by
     reference to Exhibit 3.2 of our annual report on Form 10-K for the period
     ended December 31, 2002, filed with the Commission on April 15, 2003,
     Commission File No. 0-27368)

4.3  Amendment to Certificate of Incorporation filed on August 19, 2003 being
     the Certificate of Designation of the Relative Rights and Preferences of
     the Series D convertible preferred stock (Incorporated by reference to
     Exhibit 3.6 of our quarterly report on Form 10-Q for the period ended
     September 30, 2003, filed with the Commission on November 14, 2003,
     Commission File No. 0-27368)

4.4  Amendment to Certificate of Incorporation filed on June 10, 2003 being a 1
     for 10 reverse split of our common stock (Incorporated, by reference to
     Exhibit 3.6 of our annual report on Form 10-K for the year ended December
     31, 2003, filed with the Commission on March 30, 2004).

4.5  * Amendment to Certificate of Incorporation filed April 6, 2006, being the
     Certificate of Designation of Preferences, Rights and Limitations of Series
     E 6% Convertible Preferred Stock.

4.6  * Amendment to Certificate of Incorporation filed June 9, 2006, being an
     authorization for the Board of Directors to effect prior to September 30,
     2006 a reverse split of the common stock in the range of from 1 for 5 to 1
     for 15.

4.7  By-Laws (Incorporated by reference to the Exhibit of our Registration
     Statement on Form SB-2, or Amendment 1 thereto, filed with the Commission,
     Commission File No. 33-96090)

5.1  * Opinion of Feder, Kaszovitz, Isaacson, Weber, Skala & Bass LLP, counsel
     for the Registrant

21   * List of Subsidiaries

23.1 * Consent of BDO Seidman, LLP, Independent Registered Public Accounting
     Firm

23.2 Consent of Grant Thornton LLP, Registered Independent Public Accounting
     Firm - To be filed by amendment

23.3 * Consent of Feder, Kaszovitz, Isaacson, Weber, Skala & Bass LLP (included
     in Exhibit 5.1)

     24.1* Power of Attorney - see signature page.

------------------
* filed herewith.









ITEM 28.  UNDERTAKINGS

The undersigned small business issuer hereby undertakes:

(1)  To file, during any period in which offers or sales are being made, a
     post-effective amendment to this registration statement:

     (i)  To include any prospectus required by Section 10(a)(3) of the
          Securities Act;

     (ii) To reflect in the prospectus any facts or events arising after the
          effective date of the registration statement (or the most recent
          post-effective amendment thereof) which, individually or in the
          aggregate, represent a fundamental change in the information set forth
          in the registration statement. Notwithstanding the foregoing, any
          increase or decrease in the volume of securities offered (if the total
          dollar value of securities offered would not exceed that which was
          registered) and any deviation from the low or high and of the
          estimated maximum offering range may be reflected in the form of
          prospectus filed with the Commission pursuant to Rule 424 (b) if, in
          the aggregate the changes in volume and price represent no more than
          20 percent change in the maximum aggregate offering price set forth in
          the "Calculation of Registration Fee" table in the effective
          registration statement.

     (iii) To include any material information with respect to the plan of
          distribution not previously disclosed in the registration statement or
          any material change to such information in the registration statement.

(2)  That, for the purpose of determining any liability under the Securities
     Act, each such post-effective amendment shall be deemed to be a new
     registration statement relating to the securities offered therein, and the
     offering of such securities at that time shall be deemed to be the initial
     bona fide offering thereof; and

(3)  To remove from registration by means of a post-effective amendment any of
     the securities being registered which remain unsold at the termination of
     the offering.

Insofar as indemnification for liabilities arising under the Securities Act of
1933 (the "Act") may be permitted to directors, officers and controlling persons
of the small business issuer pursuant to the foregoing provisions, or otherwise,
the small business issuer has been advised that in the opinion of the Securities
and Exchange Commission such indemnification is against public policy as
expressed in the Act and is, therefore, unenforceable. In the event that a claim
for indemnification against such liabilities (other than the payment by the
small business issuer of expenses incurred or paid by a director, officer, or
controlling person of the small business issuer in the successful defense of any
action, suit or proceeding) is asserted by such director, officer or controlling
person in connection with the securities being registered, the small business
issuer will, unless in the opinion of its counsel the matter has been settled by
controlling precedent, submit to a court of appropriate jurisdiction the
question whether such indemnification by it is against public policy as
expressed in the Securities Act and will be governed by the final adjudication
of such issue.







                                   SIGNATURES

Pursuant to the requirements of the Securities Act of 1933, the Registrant
certifies that it has reasonable grounds to believe that it meets all of the
requirements for filing on Form SB-2 and has duly caused this Registration
Statement to be signed on its behalf by the undersigned, thereunto duly
authorized, in the City of New York, State of New York, on June 19, 2006.

                                          ORTEC INTERNATIONAL, INC.

                                          By:               /s/ Ron Lipstein
                                          Ron Lipstein
                                          Chief Executive Officer (Principal Executive Officer)

Each of the undersigned hereby constitutes and appoints Ron Lipstein and Alan W.
Schoenbart and each of them, as his attorneys-in-fact, with full power of
substitution and resubstitution, to execute in his name, place and stead,
individually and in each capacity stated below, one or more amendments
(including without limitation post-effective amendments) to this registration
statement, to file the same (and any exhibit thereto) with the Commission and to
take any other action to effect the registration under the Securities Act of
1933 of common stock of the registrant subject thereto, as the attorney-in-fact
acting in the premises deems appropriate as fully for all intents and purposes
as he might or could do in person, hereby ratifying and confirming all that said
attorney-in-fact, or his substitute or substitutes, acting severally, may
lawfully do or cause to be done by virtue hereof. Pursuant to the requirements
of the Securities Act of 1933, this Registration Statement has been signed below
by the following persons in the capacities and dates indicated below:

Signature                                                                                                   Title                                                                    Date


/s/ Ron Lipstein                                                                        Vice Chairman, Board of Directors,                                                                             June 19, 2006
-----------------------------------------------------------
Ron Lipstein                                                                            Chief Executive Officer, Secretary and
                                                                                        Treasurer (Principal Executive Officer)

 /s/ Alan W. Schoenbart                                                                 Chief Financial Officer                                                      June 19, 2006
--------------------------------
Alan W. Schoenbart                                                                      (Principal Financial and Accounting Officer)


/s/ Steven Katz, Ph.D.                                                                  Chairman, Board of Directors                                                                                  June 19, 2006
-----------------------------------------------------------
Steven Katz, Ph.D.


                                                                                        Director                                                                                                     June 19, 2006
-------------------------------------------------------------
Dr. Mark Eisenberg


/s/ Steven Lilien                                                                       Director                                                                                                          June 19, 2006
-----------------------------------------------------------
Steven Lilien, Ph.D.


/s/ Allen Schiff                                                                        Director                                                                                                      June 19, 2006
-----------------------------------------------------------
Allen I. Schiff, Ph.D.


/s/ Gregory Brown                                                                       Director                                                                            June 19, 2006
-----------------------------------------------------------
Gregory B. Brown, M.D.


/s/ Raphael Hofstein                                                                    Director                                                                                              June 19, 2006
-----------------------------------------------------------
Raphael Hofstein, Ph.D.


/s/ Andreas Vogler                                                                      Director                                                                                                        June 19, 2006
-----------------------------------------------------------
Andreas Vogler